

06/29/00
10659 U.S. PTO

Docket No. 50950/JPW/EMW

June 29, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Wayne A. Hendrickson et al. for
Inventor(s)

CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL PROLIFERATION BY EFFECTING
DIMERIZATION OF THE RECEPTOR FOR STEM CELL FACTOR

Title of Invention

Also enclosed are:

☒ 85 sheet(s) of ☐ informal ☒ formal drawings.

☒ Oath or declaration of Applicant(s). (unsigned)

☒ A power of attorney

☐ An assignment of the invention to _____

☐ A Preliminary Amendment

☒ A verified statement to establish small entity status under 37 C.F.R.
§1.9 and §1.27. (unsigned)

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED	=	NUMBER EXTRA*		RATE		FEE		
					SMALL ENTITY	OTHER ENTITY	=	SMALL ENTITY	OTHER ENTITY
Total Claims	47 -20	=	27	X	\$ 9.00	\$18.00	=	\$ 243.00	\$
Independent Claims	4 -3	=	1	X	\$39.00	\$78.00	=	\$ 9.00	\$
Multiple Dependent Claims Presented: ___ Yes <u> X </u> No					\$130.00	\$260.00	=	\$ 0	\$
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE			\$ 345	\$ 690
					TOTAL FEE			\$ 627.00	\$

Applicants: Wayne A. Hendrickson et al.
U.S. Serial No.: Not Yet Known
Filed: June 29, 2000

June 29, 2000

Letter of Transmittal
Page 2

X A check in the amount of \$ 627.00 to cover the filing fee.

 Please charge Deposit Account No. in the amount of \$.

X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-31125:

 X Filing fees under 37 C.F.R. \$1.16.

 X Patent application processing fees under 37 C.F.R. \$1.17.


 The issue fee set in 37 C.F.R. \$1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. \$1.311(b).

X Three copies of this sheet are enclosed.

X A certified copy of previously filed foreign application No. filed in on . Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. \$119.

X Other (identify) Express Mail Certificate of Mailing bearing no. E1 807 507 584 US dated June 29, 2000, a loose set of figures (85 sheets), paper copy of Sequence Listing, CRF of Sequence Listing, and Statement in Accordance.

Respectfully submitted,


John E. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Applicant or Patentee: Wayne A. Hendrickson et al. Attorney's
Serial or Patent No.: Not Yet Known Docket No: 50950/JPW/EMW
Filed or Issued: Herewith
Title of Invention or Patent: CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL
PROLIFERATION BY EFFECTING DIMERIZATION OF THE RECEPTOR
FOR STEM CELL FACTOR

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. §1.9(f)
AND §1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Organization: The Trustees of Columbia University in the City of New York

Address of Organization: West 116th Street and Broadway
New York, New York 10027

TYPE OF ORGANIZATION:

X UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C. §§501(a) and
501(c)(3)
NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED
STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____
WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE 26 U.S.C.
§§501(a) and 501(c)(3) IF LOCATED IN THE UNITED STATES OF AMERICA
WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE
OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
NAME OF STATE: _____
CITATION OF STATUTE: _____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 C.F.R. §1.9(e)* for purposes of paying reduced fees under 35 U.S.C. §41(a) and 41(b), with regard to the invention entitled CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL PROLIFERATION BY EFFECTING DIMERIZATION OF THE RECEPTOR FOR STEM CELL FACTOR by inventor(s) Wayne A. Hendrickson et al.

described in:

X the specification filed herewith
application serial no. _____ filed _____
patent no. _____ issued _____

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive each individual, concern, or organization known to have rights to the invention is listed below^a and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. §1.9(d)* or a nonprofit organization under 37 C.F.R. 1.9(e)*

^a NOTE: Separate verified statements are required from each person, concern, or organization having rights to the invention averring to their status as small entities. 37 C.F.R. §1.27.

Name: N/A
Address: _____

Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. 37 C.F.R. §1.28(b)*.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: Mr. Jack M. Granowitz
Title In Organization: Executive Director, Columbia Innovation Enterprise
Address: Amsterdam & 120th Street - Suite 363 New York, New York 10027

Signature: _____
Date Of Signature: _____

07/03/00

A
Bar Seg

Dkt. 50950/JPW/EMW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wayne A. Hendrickson et al.
U.S. Serial No.: Not Yet Known
Filed : Herewith
For : CONJUGATED LIGANDS FOR THE STIMULATION OF
BLOOD CELL PROLIFERATION BY EFFECTING
DIMERIZATION OF THE RECEPTOR FOR STEM CELL
FACTOR

1185 Avenue of the Americas
New York, New York 10036
June 29, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

**EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION**

"Express Mail" mailing label number: EJ 807 507 584 US
Date of Deposit: June 29, 2000
I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 C.F.R. §1.10 on the date indicated
above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231.

Printed Name: _____

Elizabeth M. Wietkowski
ELIZABETH M. WIETKOWSKI

Respectfully submitted,

John P. White

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

**Application
for
United States Letters Patent**

To all whom it may concern:

Be it known that we, Wayne A. Hendrickson, Xuliang Jiang, Keith E. Langley, Rashid Syed and Yueh-Rong Ann Hsu

have invented certain new and useful improvements in

CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL PROLIFERATION BY
EFFECTING DIMERIZATION OF THE RECEPTOR FOR STEM CELL FACTOR

of which the following is a full, clear and exact description.

**CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL
PROLIFERATION BY EFFECTING DIMERIZATION OF THE RECEPTOR
FOR STEM CELL FACTOR**

Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of this application, preceding the claims.

Field of the Invention

This invention relates to stem cell factor (SCF) analogs, compositions containing such analogs, and related compositions. In another aspect, the present invention relates to nucleic acids encoding the present analogs or related nucleic acids, related host cells and vectors. In another aspect, the invention relates to computer programs and apparatuses for expressing the three dimensional structure of SCF and analogs thereof. In another aspect, the invention relates to methods for rationally designing SCF analogs and related compositions. In yet another aspect, the present invention relates to methods for treatment using the present SCF analogs.

BACKGROUND OF THE INVENTION

Stem cell factor (SCF) is an early-acting hematopoietic cytokine which elicits multiple biological effects. SCF is dimeric and occurs in soluble and membrane-bound forms. It transduces signals by ligand-mediated dimerization of its receptor, Kit. Kit is a receptor tyrosine kinase related to the receptors for platelet-derived growth factor (PDGF) and to those for vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), macrophage colony-stimulating factor (M-CSF) and Flt-3 ligand. The kinase portions of these receptors are closely related and their ligand-binding portions all comprise immunoglobulin-like (Ig) repeats, although these vary widely in sequence and also in number. Determined here is the crystal structure of selenomethionyl soluble human SCF at 2.2 Å resolution by multiwavelength anomalous diffraction (MAD) phasing. SCF has the characteristic helical cytokine topology, but the structure is unique apart from core portions. The SCF dimer has a symmetric 'head-to-head' association. Potential Kit-binding sites on the SCF dimer surface are located. A superposition of this dimer onto VEGF in its complex with the Flt-1 receptor places the binding sites on SCF in positions of topographical and electrostatic complementarity with the Kit counterparts of Flt-1. Similar models can be made for the complex of PDGF with its receptor and FGF-heparin.

INTRODUCTION

Stem cell factor (SCF) is an early-acting hematopoietic

cytokine that binds at the cell surface to its receptor, Kit, whereby it produces other biological effects in addition to those on hematopoiesis (see reviews by Galli et al., 1994; Lev et al., 1994; Besmer et al., 1997; Broudy, 1997). SCF, which is produced by various fibroblast-type cells including bone marrow stromal cells, has also been called Kit ligand (KL), mast-cell growth factor (MGF), and steel factor. The biochemistry and molecular biology that identified SCF and Kit as a ligand-receptor pair were preceded by an array of elegant animal biology studies that anticipated the underlying molecular mechanisms responsible for the genetics (Russell, 1979). Mice with mutations in the *Sl* locus (gene for SCF) or in the dominant-spotting *W* locus (*c-kit*, the gene for Kit) show complex phenotypes that include macrocytic anemia, sterility from a deficiency of germ cells, lack of coat pigmentation (white spotting of the skin from absences of pigment cells) and mast cell deficiency. Kit mutations in man are responsible for the autosomal dominant congenital pigmentation disorder, piebaldism. Consistent with these phenotypes, in the last 10 years, a host of *in vitro* and *in vivo* experiments have clearly established Kit-mediated roles for SCF in early stages of hematopoiesis, in gametogenesis, in melanocyte proliferation and function and in mast cell proliferation, maturation and activation; (Galli et al., 1994, Lev et al., 1994, Besmer et al., 1997; Broudy, 1997). SCF has potential therapeutic applications in the treatment of anemias, boosting the mobilization of hematopoietic stem/ progenitor cells to the peripheral blood for harvest and transplantation, and in increasing

the efficiency of gene transduction for gene therapy (Galli et al., 1994, McNiece and Briddell, 1995, Glaspy, 1996, Broudy, 1997).

SCF is expressed as membrane-associated forms of either 248 or 220 amino acid residues (Galli et al., 1994, Lev et al., 1994, Besmer et al., 1997, Broudy, 1997). The two forms are a consequence of alternative mRNA splicing that includes or excludes exon 6. Exon 6 encodes a proteolytic cleavage site such that soluble SCF¹⁻¹⁶⁵ is released from the 248 amino-acid precursor. Residues 166-189 represent a tether to the membrane, residues 190-221 represent a hydrophobic transmembrane segment, and residues 222-248 represent a cytoplasmic domain. The 220 amino acid residue form lacks the cleavage site and tends to remain membrane-bound. Soluble SCF exists as a non-covalently associated dimer (Arakawa et al., 1991). Each SCF monomer contains two intra-chain disulfide bridges, Cys4-Cys 89 and Cys43-Cys138 (Langley et al, 1992). The N-terminal 141 residues of SCF have been identified as a functional core, SCF¹⁻¹⁴¹, that includes the dimer interface and portions that bind and activate the receptor Kit (Langley et al., 1994).

It has been proposed that SCF is a member of the helical cytokine structural superfamily characterized by a double-crossover four-helix bundle topology (Bazan, 1991). Three-dimensional structures are known for many of the family members and, from a comparison of the structures and sequences, the members have been classified into three subgroups (Sprang and Bazan, 1993):

short-chain, long-chain and interferon-like.

5 The superfamily is highly divergent. Among five short-chain helical cytokines of known structure, sequence identity levels rarely exceed 20% and fewer than half of the residues constitute (41%-48%) a common framework of the fold with r.m.s. deviations ranging from 1.7 Å to 2.9Å for the 61 C α positions in common. Furthermore, many identical residues adopt different side chain conformations in the various structures. Nevertheless, sequence patterns do persist from the secondary structure and SCF has been proposed to be a short-chain helical cytokine (Bazan, 1991; Rozwarski et al., 1994).

10 Most helical cytokines signal through members of the hematopoietic cytokine receptor superfamily, which are without intrinsic kinase activity (Heldin, 1995). SCF, in contrast, signals through a class III receptor tyrosine kinase (i.e. Kit). This class of kinases also includes the receptors for platelet-derived growth factor (PDGF), macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and Flt-3 ligand, and it is related to class V receptor tyrosine kinases (Flt-1, Flt-1/KDR and Flt-4) for vascular endothelial growth factors (VEGFs) (Fantl et al., 1993; Heldin, 1995; Rousset et al., 1995). The receptors in these classes have 'split' kinase domains intracellularly and multiple immunoglobulin(Ig)-like domains extracellularly.

The structures of PDGF (Oefner et al., 1992), M-CSF (Pandit et al., 1992), and VEGF (Muller et al., 1997), have all been determined by X-ray crystallography, as has the complex of VEGF with domain 2 of its receptor, Flt-1 (Wiesmann et al., 1997).

The ligands for the class III and class V receptors are all dimeric. As is the case for other ligands, SCF initiates signal transduction by dimerization of its receptor, Kit and the two juxtaposed receptors undergo tyrosine autophosphorylation (Heldin, 1995; Broudy, 1997), which initiates downstream intracellular signaling.

Here reported is the crystal structure of the core fragment of recombinant human stem cell factor, SCF¹⁻¹⁴¹, as determined at 2.2 Å resolution from multiwavelength anomalous diffraction (MAD) measurements. Incorporating data from mutagenesis and other structure-function studies, located were putative receptor-binding sites on the surface of the symmetric SCF dimer. From a comparison of these results with the structural and functional data for the related ligand-receptor systems, the complex of SCF with the receptor Kit is modeled and suggests a similar mode of association between other class III and class V receptors and their ligands.

Human SCF can be obtained and purified from a number of sources. SCF has been isolated from the rat and the mouse. Using the amino acid sequence of SCF protein isolated from the rat, the nucleic acid sequence encoding

the rat protein sequence was obtained from a rat cDNA library and then was cloned. The cloned nucleic acid encoding rat SCF was used to isolate, by hybridization, the nucleic acid molecule encoding human SCF from a human cDNA library. The development of recombinant DNA technology, see, for instance, U.S. Patent 4,810,643 (Souza) incorporated herein by reference, has enabled the production of commercial scale quantities of SCF in glycosylated form as a product of eukaryotic host cell expression, and of SCF in non-glycosylated form as a product of prokaryotic host cell expression.

5

10

63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

SUMMARY OF THE INVENTION

The three dimensional structure of SCF has been determined herein to the atomic level. From this three-dimensional structure, one can now forecast with substantial certainty how changes in the composition of a SCF molecule may result in structural changes. These structural characteristics may be correlated with biological activity to design and produce SCF analogs.

This invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing an SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic.

This invention also provides an isolated SCF analog prepared according to the above-described computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF

molecule for a desired characteristic. In an embodiment the above-described SCF analog binds to SCF receptor, Kit. As used herein SCF receptor and "Kit" are used interchangeably to reflect the varied nomenclature used in the art.

This invention provides a composition comprising an isolated SCF analog prepared according to the above-described computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic, effective to treat a subject and a pharmaceutically acceptable carrier.

This invention provides a method of treating a subject comprising administration of an isolated SCF analog prepared by the above-described computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a

desired characteristic.

5 This invention provides a method for designing a compound (drug) capable of binding to the receptor of stem cell factor (SCF), Kit, comprising the steps of: a) determining a receptor binding site on the SCF based on the three dimensional structure of SCF or an SCF polypeptide **capable of binding the receptor; and b) designing a compound comprising an entity that binds the SCF receptor.** Accordingly, the designed compound is an SCF ligand analog, since a portion or part of the compound, "the entity", mimics the portion of SCF that binds to the SCF receptor, Kit. In step (a), and infra, the receptor binding site may be determined from atomic coordinates computed from X-ray diffraction data of a crystal comprising a polypeptide having an amino acid sequence portion of SCF capable of binding the receptor.

10
15
20 This invention provides a compound designed by the above-described method for designing a compound capable of binding to the receptor site of stem cell factor (SCF), Kit, comprising the steps of: a) determining a receptor binding site, on the SCF based on the atomic coordinates computed from X-ray diffraction data of a crystal comprising a polypeptide having an amino acid sequence portion of SCF capable of binding a ligand; and b) designing a **compound comprising an entity that binds the SCF receptor.** As used herein, the entity, i.e. the portion, of the designed compound fits the ligand binding site on the SCF receptor.

25
30

This invention provides a method of treating a subject comprising administration of a compound designed by the above-described method for designing a compound capable of binding to the SCF receptor site.

5

This invention also provides a method of stimulating the production of hematopoietic cells in a subject comprising administering an isolated stem cell factor (SCF) analog or SCF ligand analogs to the subject.

10

This invention provides an isolated stem cell factor (SCF) molecule, which is an altered SCF, comprising any portion of amino acids 1-165 of a human SCF polypeptide, optionally comprising an N-terminal methionine before amino acid residue 1, wherein the polypeptide has an amino acid sequence portion of SCF capable of binding to the SCF receptor, Kit. Amino acid residue 1 of SCF is E, glutamic acid.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500

BRIEF DESCRIPTION OF THE FIGURES

5 **Figures 1A-1C.** Representative electron-density distributions in SCF. (Fig. 1A) MAD-phased experimental map calculated at 2.3 Å resolution. (Fig. 1B) The experimental map after four-fold averaging. (Fig. 1C) The current $2F_o - F_c$ map superimposed with the model refined at 2.2 Å resolution. Each map is contoured at 1.0σ. Figures were drawn by the program O (Jones et al., 1991).

10 **Figures 2A-2B.** Overall structure of an SCF dimer. (Fig. 2A) Ribbon diagram. (Fig. 2B) C_α stereodiagram of the AB dimer. Figures were drawn using the program SETOR (Evans, 1993).

15 **Figure 3.** Structure-based sequence alignment of SCF with other short-chain helical cytokines of human species. The dots denote gaps. M-CSF, IL-4, GM-CSF, IL-2 and IL-5 were aligned with SCF structure through structural superposition using TOSS (Hendrickson, 1979) and O (Jones et al., 1991). C_α atoms were included if within 3.0 Å of their counterparts after superposition and at least three consecutive such residues are found in the fragment. The secondary structure

20

25

30

elements were assigned according to the output of the PROCHECK program (Laskowski *et al.*, 1993) except the helix assignment for residues 35-38, which was identified by inspection of the hydrogen-bond pattern. Secondary structures are shown in yellow with filled boxes referring to α -helices, half-filled boxes to 3_{10} -helices and arrows to β -strands. The solvent accessibility of the SCF dimer is indicated for each residue by an open circle if the fractional solvent accessibility is >0.4 , a half-filled circle if it is $0.1-0.4$, and a filled circle if it is <0.1 . Residues at the SCF dimer interface are identified by stars, and the N-linked glycosylation sites by red Ys above the Asn residues.

Figures 4A-4B. Comparison of SCF dimer (shades of green) and M-CSF dimer (shades of brown). (Fig. 4A) View as in Figure 2. (Fig. 4B) View perpendicular to Fig. 4A, along the diad axis of M-CSF. Symmetry axes are shown as lines in Fig. 4A and dots in Fig. 4B. When one subunit of SCF dimer is superimposed onto a subunit of the M-CSF dimer, the other subunits are translated by 3.8 \AA with a rotation of 4.7° to each other. Figures were generated using the program GRASP (Nicholls *et al.*, 1991).

Figure 5. Sequence alignments of SCF from human, mouse, rat and dog. (Anderson et al., 1990; Huang et al., 1990; Martin et al. 1990; Shull et al., 1992) The residues that are conserved in human and dog but different from rat and mouse are shadowed in yellow. Five regions of divergent sequence are identified (Roman numerals) Dots denote gaps, and dashes indicate residues identical to the human residues.

Figures 6A-6C. Ligand (worm structures)-receptor (yellow structures) models. (Fig. 6A) VEGF-Flt-1. (Fig. 6B) SCF-Kit. (Fig. 6C) PDGF-{DGF receptor. The used, without any modification, to approximate the receptor models. Receptor models are presented as yellow surfaces. The ligand models are presented as worm models. Background portions are colored light blue for one monomer and green for the other; receptor-interacting residues identified from site-directed mutagenesis experiments [VEGF (Muller et al., 1997), PDGF (Fenstermaker et al., 1993)] and other experimental data (SCF; see infra) are colored magenta. Figures were drawn by the program GRASP (Nicholls et al., 1991).

Figures 7A-7C. Electrostatic and carbohydrate surfaces of SCF and homology-modeled receptor Kit. (Fig. 7A) Electrostatic surface of SCF and worm of D2D3(Kit). (Fig. 7B) Electrostatic surface of Kit and worm of SCF. (Fig. 8C) Negative potential is colored red and positive potential, blue, with greatest saturations at -10 and +10kT, respectively. Carbohydrate moieties are represented by CPK models of a β -D-N-acetylglucose (green for SCF moieties and yellow for potential Kit moieties. Figures were drawn by the program GRASP (Nicholls et al., 1991).

Figure 8. X-ray crystallographic coordinates of truncated stem cell factor molecule comprising amino acids 1-141 of a human SCF polypeptide.

Figure 9. Suggested renaming of the waters of the X-ray crystallographic coordinates set forth in Figure 8.

Figure 10. Design for a double-headed SCF ligand analog. (10A) General model (10B) Embodiment of the ligand head as an oligopeptide. The compound is the conjugation of a linker molecule with two ligand-head molecules. Each ligand head

is composed of up to three functional moieties, F_1 , F_2 and F_3 , which serve to mimic receptor-binding sites on the surface of SCF. Each ligand head also contains a conjugation moiety, F_L , endowed with chemical reactivity for conjugation with a reactive group at the end of the linker molecule. The capping moiety, F_C , at each end of the linker molecule is endowed with chemical reactivity for conjugation with the conjugation moiety from the ligand head. Double-headed molecules of this structure can have the property of binding to the SCF receptor, Kit, in such a way as to dimerize the receptor molecules and thereby lead to Kit activation in a manner analogous to the natural activity of SCF.

Ligand heads can be designed in at least four ways. (1) Ligand heads can be synthesized as oligopeptides wherein the functional moieties (F_1 , F_2 , F_3) are sequence elements from the SCF polypeptide; (2) The functional moieties (F_1 , F_2 , F_3) on such a ligand head can be selected by bacteriophage display for optimal receptor binding; (3) Chemical mimetics of the functional moieties and connecting segments in an active oligopeptide can be substituted for the respective moieties and segments; or (4)

An appropriate chemical framework (scaffold) of connecting segments can be designed to present functional moieties (F_1 , F_2 , F_3) which can be selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF.

When an oligopeptide embodiment of a linker head is designed in accord with option (1) it can have a sequence wherein F_1 corresponds to a segment from within the N-terminal region of SCF, residues 1-10; F_2 corresponds to a segment from within residues 79-95 (mainly located on the α C helix); F_3 is a segment from the C-terminal end of α D, near residue 127; F_L is a cysteine residue; and X_n , X_m , and X_p are connecting-peptide segments, composed from appropriate linker residues such as alanine, glycine, serine or proline, and wherein $n=0-5$, $m=0-5$ and $p=3-8$ residues, respectively.

Linkers can be designed from an organic polymer such as polyethylene glycol $H[OCH_2CH_2]_nOH$, where $n=10-20$ may suffice to separate the heads appropriately, wherein a reactive capping moiety, F_c , is appended at each end. The capping moiety may be a thiol reactive group, such as N-ethyl

maleimide, designed to bond covalently to the conjugation moiety, F_L , on the ligand head, wherein F_L may be cysteine residue or another thiol-containing group.

20250727.062900

DETAILED DESCRIPTION OF THE INVENTION

5 The present determination of the three-dimensional structure to the atomic level is the most complete analysis to date, and provides important information to those wishing to design and prepare SCF analogs. For example, from the present three dimensional structural analysis, precise areas of hydrophobicity and hydrophilicity have been determined.

10 Relative hydrophobicity is important because it directly relates to the stability of the molecule. Generally, biological molecules, found in aqueous environments, are externally hydrophilic and internally hydrophobic; in accordance with the second law of thermodynamics provides, this is the lowest energy state and provides for stability. Although one could have speculated that SCF's internal core would be hydrophobic, and the outer areas would be hydrophilic, one would have had no way of knowing specific hydrophobic or hydrophilic areas. With the presently provided knowledge of areas of hydrophobicity/-philicity, one may forecast with substantial certainty which changes to the SCF molecule will affect the overall structure of the molecule.

25 As a general rule, one may use knowledge of the geography of the hydrophobic and hydrophilic regions to design analogs in which the overall SCF structure is not changed, but change does affect biological activity ("biological activity" being used here in its broadest sense to denote function). One may correlate biological

30

activity to structure. If the structure is not changed, and the mutation has no effect on biological activity, then the mutation has no biological function. If, however, the structure is not changed and the mutation does affect biological activity, then the residue (or atom) is essential to at least one biological function. Some of the present working examples were designed to provide no change in overall structure, yet have a change in biological function.

Based on the correlation of structure to biological activity, one aspect of the present invention relates to SCF analogs. These analogs are molecules which have more, fewer, different or modified amino acid residues from the SCF amino acid sequence. The modifications may be by addition, substitution, or deletion of one or more amino acid residues. The modification may include the addition or substitution of analogs of the amino acids themselves, such as peptidomimetics or amino acids with altered moieties such as altered side groups. The SCF used as a basis for comparison may be of human, animal or recombinant nucleic acid-technology origin (although the working examples disclosed herein are based on the recombinant production of the 141 amino acid species of human SCF, optionally having an extra N-terminal methionine residue). The analogs may possess functions different from natural human SCF molecule, or may exhibit the same functions, or varying degrees of the same functions. For example, the analogs may be designed to have a higher or lower biological activity, have a longer shelf-life or a decrease in stability, be easier to

formulate, or more difficult to combine with other ingredients. The analogs may bind receptor but elicit no biological activity and may therefore be useful as an antagonist against SCF effect (as, for example, in the overproduction of SCF). From time to time herein the present analogs are referred to as proteins or peptides for convenience, but contemplated herein are other types of molecules, such as peptidomimetics or chemically modified peptides.

In embodiment, the present invention relates to related compositions containing a SCF analog as an active ingredient. The term, "related composition," as used herein, is meant to denote a composition which may be obtained once the identity of the SCF analog is ascertained (such as a SCF analog labeled with a detectable label or pharmaceutical composition). Also considered a related composition are chemically modified versions of the SCF analog, such as those having attached at least one polyethylene glycol molecule.

For example, one may prepare a SCF analog to which a detectable label is attached, such as a fluorescent, chemiluminescent or radioactive molecule.

Another example is a pharmaceutical composition which may be formulated by known techniques using known materials, see, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pennsylvania 18042) pages 1435-1712, which are herein incorporated by reference. Generally, the formulation will depend on a

variety of factors such as administration, stability, production concerns and other factors. The SCF analog may be administered by injection or by pulmonary administration via inhalation. Enteric dosage forms may also be available for the present SCF analog compositions, and therefore oral administration may be effective. SCF analogs may be inserted into liposomes or other microcarriers for delivery, and may be formulated in gels or other compositions for sustained release. Although preferred compositions will vary depending on the use to which the composition will be put, generally, for SCF analogs having at least one of the biological activities of natural SCF, preferred pharmaceutical compositions are those prepared for subcutaneous injection or for pulmonary administration via inhalation, although the particular formulations for each type of administration will depend on the characteristics of the analog.

Another example of related composition is a receptor for the present analog. As used herein, the term "receptor" indicates a moiety which selectively binds to the present analog molecule. For example, antibodies, or fragments thereof, or "recombinant antibodies" (see Huse et al., Science 246:1275 (1989)) may be used as receptors. Selective binding does not mean only specific binding (although binding-specific receptors are encompassed herein), but rather that the binding is not a random event. Receptors may be on the cell surface or intra- or extra-cellular, and may act to effectuate, inhibit or localize the biological activity of the present analogs.

Receptor binding may also be a triggering mechanism for a cascade of activity indirectly related to the analog itself. Also contemplated herein are nucleic acids, vectors containing such nucleic acids and host cells containing such nucleic acids which encode such SCF analogs.

Another example of a related composition is a SCF analog with a chemical moiety attached. Generally, chemical modification may alter biological activity or antigenicity of a protein, or may alter other characteristics, and these factors will be taken into account by a skilled practitioner. As noted above, one example of such chemical moiety is polyethylene glycol. Modification may include the addition of one or more hydrophilic or hydrophobic polymer molecules, fatty acid molecules, or polysaccharide molecules. Examples of chemical modifiers include polyethylene glycol, alkylpolyethylene glycols, DI-poly(amino acids), polyvinylpyrrolidone, polyvinyl alcohol, pyran copolymer, acetic acid/acylation, propionic acid, palmitic acid, lecithin, stearic acid, dextran, carboxymethyl cellulose, pullulan, or agarose. See, Francis, *Focus on Growth Factors 3*: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20 0LD, UK). Also, chemical modification may include an additional protein or portion thereof, use of a cytotoxic agent, or an antibody.

In another embodiment, the present invention relates to nucleic acids encoding such analogs. The nucleic acids

may be DNAs or RNAs or derivatives thereof, and will typically be cloned and expressed on a vector, such as a phage or plasmid containing appropriate regulatory sequences. The nucleic acids may be labeled (such as using a radioactive, chemiluminescent, or fluorescent label) for diagnostic or prognostic purposes, for example. The nucleic acid sequence may be optimized for expression, such as including codons preferred for bacterial expression. The nucleic acid and its complementary strand, and modifications thereof which do not prevent encoding of the desired analog are here contemplated.

In another embodiment, the present invention relates to host cells containing the above nucleic acids encoding the present analogs. Host cells may be eukaryotic or prokaryotic, and expression systems may include extra steps relating to the attachment (or prevention) of sugar groups (glycosylation), proper folding of the molecule, the addition or deletion of leader sequences or other factors incident to recombinant expression.

In further embodiment the present invention relates to antisense nucleic acids which act to prevent or modify the type or amount of expression of such nucleic acid sequences. These may be prepared by known methods.

In another embodiment of the present invention, the nucleic acids encoding a present analog may be used for gene therapy purposes, for example, by placing a vector containing the analog-encoding sequence into a recipient

so the nucleic acid itself is expressed inside the recipient who is in need of the analog composition. The vector may first be placed in a carrier, such as a cell, and then the carrier placed into the recipient. Such expression may be localized or systemic. Other carriers include non-naturally occurring carriers, such as liposomes or other microcarriers or particles, which may act to mediate gene transfer into a recipient.

The present invention also provides for computer programs for the expression (such as visual display) of the SCF or analog three dimensional structure, and further, a computer program which expresses the identity of each constituent of an SCF molecule and the precise location within the overall structure of that constituent, down to the atomic level. Set forth below is one example of such program. There are many currently available computer programs for the expression of the three dimensional structure of a molecule. Generally, these programs provide for inputting of the coordinates for the three dimensional structure of a molecule (i.e., for example, a numerical assignment for each atom of an SCF molecule along an x, y, and z axis), means to express (such as visually display) such coordinates, means to alter such coordinates and means to express an image of a molecule having such altered coordinates. One may program crystallographic information, i.e., the coordinates of the location of the atoms of an SCF molecule in three dimensional space, wherein such coordinates have been obtained from crystallographic analysis of said SCF molecule, into such programs to generate a computer

program for the expression (such as visual display) of the SCF three dimensional structure. Also provided, therefore, is a computer program for the expression of SCF analog three dimensional structure. Preferred is the computer program Insight II, version 4, available from Biosym, San Diego, California, with the coordinates as set forth in Figure 8 input. Preferred expression means is on a Silicon Graphics 320 VGX computer, with Crystal Eyes glasses (also available from Silicon Graphics), which allows one to view the SCF molecule or its analog stereoscopically. The above-listed computer programs are only examples, and the use of such programs in the claimed methods is not limited thereto, as one of skill may use any other computer program that provides the desired three dimensional expression. Alternatively, the present SCF crystallographic coordinates and diffraction data are also deposited in the Protein Data Bank, Chemistry Department, Rutgers University, New Jersey, USA [formerly at Brookhaven National Laboratory, Upton, NY 11972]. One may use these data in preparing a different computer program for expression of the three dimensional structure of a SCF molecule or analog thereof. Therefore, another aspect of the present invention is a computer program for the expression of the three dimensional structure of a SCF molecule. Also provided is said computer program for visual display of the three dimensional structure of an SCF molecule; and further, said program having means for altering such visual display. Apparatus useful for expression of such computer program, particularly for the visual display of the computer image of said three dimensional structure of

an SCF molecule or analog thereof is also therefore here provided, as well as means for preparing said computer program and apparatus.

5 The computer program is useful for preparation of SCF analogs because one may select specific sites on the SCF molecule for alteration and readily ascertain the effect the alteration will have on the overall structure of the SCF molecule. Selection of said site for alteration will
10 depend on the desired biological characteristic of the SCF analog. If one were to randomly change said SCF molecule there would be substitutions, additions or deletions, and even more analogs having multiple changes. By viewing the three dimensional structure wherein said structure is correlated with the composition of the molecule, the selection for sites for alteration is no longer a random event, but sites for alteration may be determined rationally.

15
20 Identity of the three dimensional structure of SCF, including the placement of each constituent down to the atomic level has now yielded information regarding which moieties are necessary to maintain the overall structure of the SCF molecule. One may therefore select whether to maintain the overall structure of the SCF molecule when
25 preparing an SCF analog of the present invention, or whether (and how) to change the overall structure of the SCF molecule when preparing a SCF analog of the present invention. Optionally, once one has prepared such analog, one may test such analog for a desired
30 characteristic.

One may, for example, seek to maintain the overall structure possessed by a non-altered natural or recombinant SCF molecule. The overall structure is presented in Figures 2A-2B, and is described in more detail below. Maintenance of the overall structure may ensure receptor binding, a necessary characteristic for an analog possessing the biologic capabilities of natural SCF (if no receptor binding, signal transduction does not result from the presence of the analog). It is contemplated that one class of SCF analogs will possess the three dimensional core structure of a natural or recombinant (non-altered) SCF molecule, yet possess different characteristics, such as an increased ability to selectively stimulate neutrophils. Another class of SCF analogs are those with a different overall structure which diminishes the ability of an SCF analog molecule to bind to a SCF receptor, Kit, and possesses a diminished ability to selectively stimulate hematopoiesis, for example, as compared to non-altered natural or recombinant SCF.

For example, it is now known which moieties within the internal regions of the SCF molecule are hydrophobic, and, correspondingly, which moieties on the external portion of the SCF molecule are hydrophilic. Without knowledge of the overall three dimensional structure, preferably to the atomic level as provided herein, one could not forecast which alterations within this hydrophobic internal area would result in a change in the overall structural conformation of the molecule. An

overall structural change could result in a functional change, such as lack of receptor binding, for example, and therefore, diminishment of biological activity as found in non-altered SCF. Another class of SCF analogs is therefore SCF analogs which possess the same hydrophobicity as (non-altered) natural or recombinant SCF. More particularly, another class of SCF analogs possesses the same hydrophobic moieties within the four helical bundle of its internal core as those hydrophobic moieties possessed by (non-altered) natural or recombinant SCF yet have a composition different from said non-altered natural or recombinant SCF.

Another example relates to external loops which are structures which connect the internal core (helices) of the SCF molecule. From the three dimensional structure -- including information regarding the spatial location of the amino acid residues -- one may forecast that certain changes in certain loops will not result in overall conformational changes.

Therefore, another class of SCF analogs provided herein is that having an altered external loop but possessing the same overall structure as (non-altered) natural or recombinant SCF. More particularly, another class of SCF analogs provided herein are those having an altered external loop, said loop being selected from the loops discussed infra. More particularly, said loops, are altered to increase the half life of the molecule by stabilizing said loops. Such stabilization may be by connecting all or a portion of said loop(s) to a portion

of an alpha helical bundle found in the core of a SCF (or analog) molecule. Such connection may be via beta sheet, salt bridge, disulfide bonds, hydrophobic interaction or other connecting means available to those skilled in the art, wherein such connecting means serves to stabilize said external loop or loops.

Additionally, such external loops may be the site(s) for chemical modification because in (non-altered) natural or recombinant SCF such loops are relatively flexible and tend not to interfere with receptor binding. Thus, there would be additional room for a chemical moiety to be directly attached (or indirectly attached via another chemical moiety which serves as a chemical connecting means). The chemical moiety may be selected from a variety of moieties available for modification of one or more function of an SCF molecule. For example, an external loop may provide sites for the addition of one or more polymer which serves to increase serum half-life, such as a polyethylene glycol molecule. Such polyethylene glycol molecule(s) may be added wherein said loop is altered to include additional lysines which have reactive side groups to which polyethylene glycol moieties are capable of attaching. Other classes of chemical moieties may also be attached to one or more external loops, including but not limited to other biologically active molecules, such as receptors, other therapeutic proteins (such as other hematopoietic factors which would engender a hybrid molecule), or cytotoxic agents (such as diphtheria toxin). This list is of course not complete; one skilled in the art possessed of

the desired chemical moiety will have the means to effect attachment of said desired moiety to the desired external loop. Therefore, another class of the present SCF analogs includes those with at least one alteration in an external loop wherein said alteration provides for the addition of a chemical moiety such as at least one polyethylene glycol molecule.

Deletions, such as deletions of sites recognized by proteins for degradation of the molecule, may also be effectual in the external loops. This provides alternative means for increasing half-life of a molecule otherwise having the SCF receptor binding and signal transduction capabilities (e.g., the ability to selectively stimulate hematopoiesis). Therefore, another class of the present SCF analogs includes those with at least one alteration in an external loop wherein said alteration decreases the turnover of said analog by proteases. One may prepare an abbreviated SCF molecule by deleting a portion of the amino acid residues found in any of the the external loops (discussed infra), said abbreviated SCF molecule may have additional advantages in preparation or in biological function.

Another example relates to the relative charges between amino acid residues which are in proximity to each other. As noted above, the SCF molecule contains a relatively tightly packed four helical bundle. Some of the faces on the helices face other helices. At the point (such as a residue) where a helix faces another helix, the two amino acid moieties which face each other may have the same

charge, and thus tend to repel each other, which lends instability to the overall molecule. This may be eliminated by changing the charge (to an opposite charge or a neutral charge) of one or both of the amino acid moieties so that there is no repelling. Therefore, another class of SCF analogs includes those SCF analogs having been altered to modify instability due to surface interactions, such as electron charge location.

The present invention provides methods for designing SCF analogs and related compositions and the products of those methods. The end products of the methods may be the SCF analogs as defined above or related compositions. For instance, the examples disclosed herein demonstrate (a) the effects of changes in the constituents (i.e., chemical moieties) of the SCF molecule on the SCF structure and (b) the effects of changes in structure on biological function.

Accordingly, therefore, the present invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing an SCF molecule having an alteration at said one said selected site; and (d) optionally, testing the SCF molecule for a desired characteristic. The SCF molecule of step (a) may be naturally occurring wild type SCF or any portion or fragment thereof which is capable

of binding to SCF receptor.

In an embodiment of the above-described method the computer expression allows for display of the amino acids of the SCF molecule. In another embodiment of the method the computer expression allows for display of each atom of the SCF molecule. In a further embodiment of the method the SCF molecule is a native or a selenomethionyl SCF. In another embodiment of the method the site on the SCF molecule for alteration is a receptor binding site on the surface of the SCF molecule. In a further embodiment of the method the receptor binding site comprises amino acid residues 79-85. The SCF molecule may be a recombinant human SCF or a wild type naturally occurring human SCF. SCF wild type and recombinant may also be of other sources such as but not limited to rat or mouse. In an embodiment of the above-described method, the atomic coordinates of the crystal structure are set forth in Figure 8. In another embodiment the SCF analog comprises a polypeptide having an amino acid sequence portion of SCF capable of binding a receptor and having the overall three-dimensional conformation as shown in Figures 2A-2B, wherein the three-dimensional conformation is: a) anti-parallel, double-cross over 4-alpha helical bundle with a left hand twist; and b) overall dimensions of approximately 85 Å x 30 Å x 20 Å. In an embodiment the SCF analog comprises electron density distributions as set forth in Figures 1A, 1B, and 1C. In a further embodiment the SCF molecule is a native SCF or a selenomethionyl SCF.

In an embodiment the site on the SCF molecule for

alteration is a receptor binding site on the surface of the SCF molecule or a non-receptor site of the SCF.

Alteration of a non-receptor binding site will result in a designed SCF analog that binds to the SCF receptor but is less active such that such an analog may be used for blocking activity of the SCF.

In another embodiment the receptor binding site comprises approximately amino acid residues 79-95.

This invention provides an isolated SCF analog prepared according to the above-described method. In an embodiment the isolated SCF analog which binds to SCF receptor, Kit. In another embodiment the isolated SCF analog has an alteration in at least one atom of the atomic coordinates of the crystal structure set forth in Figure 8. In a further embodiment the SCF analog comprises a polypeptide having an amino acid sequence portion of SCF capable of binding a receptor and having the overall three-dimensional conformation as shown in Figures 2A-2B, wherein the three-dimensional conformation is: a) anti-parallel, double-cross over 4-alpha helical bundle with a left hand twist; and b) overall dimensions of approximately 85 Å x 30 Å x 20 Å. In an embodiment the SCF analog comprises electron density distributions altered from those set forth in Figures 1A, 1B, and 1C.

This invention provides a composition comprising an isolated SCF analog prepared according to the above-described method effective to treat a subject and a

pharmaceutically acceptable carrier. In an embodiment of the composition, the isolated SCF analog has an alteration in at least one atom of the atomic coordinates of the crystal structure set forth in Figure 8. In another embodiment the isolated SCF analog comprises a polypeptide having an amino acid sequence portion of SCF capable of binding a receptor and having the overall three-dimensional conformation as shown in Figures 2A-2B, or an alteration thereof, wherein the three-dimensional conformation is: a) anti-parallel, double-cross over 4-alpha helical bundle with a left hand twist; and b) overall dimensions of approximately 85 Å x 30 Å x 20 Å. In a further embodiment the isolated SCF analog comprises electron density distributions as set forth in Figures 1A, 1B, and 1C. In an embodiment the isolated SCF analog comprises a native SCF1-165, a recombinant selenomethionyl SCF1-141, or a recombinant selenomethionyl SCF1-165.

Any of the aforementioned SCF analogs may optionally have before the first N-terminal amino acid residue a methionine at position"-1".

In an embodiment of the composition the site on the isolated SCF molecule for alteration is a receptor binding site on the surface of the SCF molecule. In a further embodiment the receptor binding site comprises approximately amino acid residues 79-95.

This invention provides a method of treating a subject having a disorder requiring SCF comprising administration

of a composition comprising an isolated SCF analog prepared by the method of preparing a SCF analog or a compound designed by the method of designing a compound capable of binding to the SCF receptor as described infra. In an embodiment the subject has a blood disorder. In another embodiment the disorder which the subject has is anemia, myeloproliferative disorder, neoplasia, nerve damage, infertility, intestinal damage, a pigmentation disorder, or immunodeficiency. In an embodiment the administration of the isolated SCF analog is for ex vivo or in vitro production of peripheral blood progenitors, ex vivo or in vitro stem cell expansion, ex vivo or in vitro growth of epithelial cells, ex vivo or in vitro growth of stromal cells, ex vivo or in vitro dendritic cell stimulation, and in vivo cell mobilization. In an embodiment the isolated SCF analog is administered orally or by any other routes described infra. In an embodiment the isolated SCF analog has an alteration in at least one atom of the atomic coordinates of the crystal structure set forth in Figure 8. In a further embodiment the isolated SCF analog comprises a native SCF1-165 or a recombinant selenomethionyl SCF1-141. In another embodiment the site on the isolated SCF molecule for alteration is a receptor binding site on the surface of the SCF molecule. In a further embodiment the receptor binding site comprises approximately amino acid residues 79-95. In an embodiment the isolated SCF analog comprises a native or recombinant SCF1-165 or a recombinant selenomethionyl SCF1-141. As used herein throughout SCF receptor is Kit.

This invention provides a method for designing a compound capable of binding to the stem cell factor (SCF) receptor site of comprising the steps of: a) determining a binding site for the SCF receptor on the SCF based on the three-dimensional structure of SCF or an SCF polypeptide or portion/fragment thereof, atomic coordinates computed from X-ray diffraction data of a crystal comprising a polypeptide having an amino acid sequence portion of SCF capable of binding the receptor; and b) designing a compound comprising an entity that binds the SCF receptor. The designed compound mimics, i.e. is a copy or simulation of the overall portion of SCF that binds to SCF receptor, Kit.

In an embodiment the design of the compound of step (b) is determined by shape complementarity or by estimated interaction energy. In another embodiment the designed compound fits an SCF receptor binding site on SCF receptor as shown in Figure 6. In a further embodiment the designed compound fits an SCF receptor binding site on SCF receptor as shown in Figures 7A or 7B. In an embodiment the designed compound has an alteration in at least one atom of the atomic coordinates of the crystal structure set forth in Figure 8. In yet another embodiment the designed compound is a double-headed SCF ligand analog having the structure set forth in Figure 10A. In a still further embodiment each ligand head of the double-headed SCF ligand analog is an oligopeptide having the structure set forth in Figure 10B. The designed compound comprises two conjugated ligands having a linker between the two ligands.

In an embodiment, the oligopeptide comprises a sequence, wherein functional moiety F_1 corresponds to a segment of amino acid residues from within N-terminal residues 1-10 of SCF, functional moiety F_2 corresponds to a segment of amino acid residues from within residues 79-95 of SCF, and functional moiety F_3 corresponds to a segment of amino acid residues located within three amino acid residues of amino acid residue 127, wherein F_1 , F_2 , and F_3 are connected by connecting peptide segments X_n , X_m , and X_p , respectively, wherein $n=0-5$, $m=0-5$ and $p=3-8$ amino acid residues, respectively, and the conjugation moiety F_L is a cysteine residue.

A functional moiety is defined as an entity that has a particular binding property, i.e. it mimics receptor-binding sites on the surface of SCF, i.e. the ligand portion of SCF.

The amino acid residues located within 3 amino acid residues of amino acid residue 127 may be located within 3 residues in either direction of residue 127. In further embodiments the amino acid residues may be from 4 to 10 amino acid residues in either direction of amino acid residue 127.

In another embodiment of the above-described method the functional moieties F_1 , F_2 , and F_3 on the ligand heads have been selected by bacterial phage display for optimal receptor binding. In an embodiment the functional moieties and connecting peptide segments of an active oligopeptide ligand head are replaced by chemical

mimetics. In another embodiment an appropriate chemical scaffold of connecting segments has been designed to comprise (present) functional moieties F_1 , F_2 , and F_3 , which have been selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF. In an embodiment the linker comprises an organic polymer having two ends capped at each end by a reactive capping moiety, F_c , which react covalently with the conjugation moiety, F_L , on the ligand head. In an embodiment the organic polymer is polyethyleneglycol (PEG) comprising the structure $H[OCH_2CH_2]_nOH$, wherein n is 10-20. In an embodiment the capping moiety, F_c , is a thiol-reactive group such as N-ethyl maleimide. In an embodiment the conjugating moiety, F_L , is a thiol containing group such as cysteine.

This invention provides a compound designed by the method of claim 32.

A composition comprising the compound designed by the above described method and a pharmaceutically acceptable carrier. In an embodiment the compound comprises an isolated SCF analog, whose alteration site is a receptor-binding site on the surface of the altered SCF molecule. In another embodiment the composition comprises a double-headed receptor SCF ligand analog having the structure set forth in Figure 10A. In an embodiment each ligand head of the double-headed SCF ligand analog is an oligopeptide having the structure set forth in Figure 10B.

In another embodiment the oligopeptide comprises a sequence, wherein functional moiety F_1 corresponds to a segment of amino acid residues from within N-terminal residues 1-10 of SCF, functional moiety F_2 corresponds to a segment of amino acid residues from within residues 79-95 of SCF, and functional moiety F_3 corresponds to a segment of amino acid residues located within three amino acid residues of amino acid residue 127, wherein F_1 , F_2 , and F_3 are connected by connecting peptide segments X_n , X_m , and X_p , respectively, wherein $n=0-5$, $m=0-5$ and $p=3-8$ amino acid residues, respectively, and the conjugation moiety F_L is a cysteine residue. In a further embodiment the functional moieties F_1 , F_2 , and F_3 on the ligand heads have been selected by bacterial phage display for optimal receptor binding. In an embodiment the functional moieties and connecting peptide segments of an active oligopeptide ligand head are replaced by chemical mimetics. In another embodiment an appropriate chemical scaffold of connecting segments has been designed to comprise (present) functional moieties F_1 , F_2 , and F_3 , which have been selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF. In another embodiment the linker comprises an organic polymer having two ends capped at each end by a reactive capping moiety, F_c , which react covalently with the conjugation moiety, F_L , on the ligand head. In a further embodiment the organic polymer is polyethyleneglycol (PEG) comprising the structure $H[OCH_2CH_2]_nOH$, wherein n is 10-20. In another embodiment the capping moiety, F_c , is a thiol-reactive group such as

N-ethyl maleimide. In an embodiment the conjugating moiety, F_L , is a thiol containing group such as cysteine.

This invention provides a method of treating a subject comprising administration of a compound designed by the above described method. In an embodiment the subject has a blood disorder. In a further embodiment the blood disorder is anemia or immunodeficiency. In an embodiment the compound is administered orally or any other routes. In an embodiment the compound is an isolated SCF analog. In another embodiment the compound comprises an isolated SCF analog, whose alteration site is a receptor binding site on the surface of the altered SCF molecule. In another embodiment of the method the composition comprises a double-headed receptor SCF ligand analog having the structure set forth in Figure 10A. In an embodiment each ligand head of the double-headed SCF ligand analog is an oligopeptide having the structure set forth in Figure 10B. In another embodiment the oligopeptide comprises a sequence, wherein functional moiety F_1 corresponds to a segment of amino acid residues from within N-terminal residues 1-10 of SCF, functional moiety F_2 corresponds to a segment of amino acid residues from within residues 79-95 of SCF, and functional moiety F_3 corresponds to a segment of amino acid residues located within three amino acid residues of amino acid residue 127, wherein F_1 , F_2 , and F_3 are connected by connecting peptide segments X_n , X_m , and X_p , respectively, wherein $n=0-5$, $m=0-5$ and $p=3-8$ amino acid residues, respectively, and the conjugation moiety F_L is a cysteine residue. In a further embodiment the functional moieties F_1 , F_2 , and F_3

on the ligand heads have been selected by bacterial phage display for optimal receptor binding. In an embodiment the functional moieties and connecting peptide segments of an active oligopeptide ligand head are replaced by chemical mimetics. In another embodiment an appropriate chemical scaffold of connecting segments has been designed to comprise (present) functional moieties F_1 , F_2 , and F_3 , which have been selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF. In another embodiment the linker comprises an organic polymer having two ends capped at each end by a reactive capping moiety, F_c , which react covalently with the conjugation moiety, F_L , on the ligand head. In a further embodiment the organic polymer is polyethyleneglycol (PEG) comprising the structure $H[OCH_2CH_2]_nOH$, wherein n is 10-20. In another embodiment the capping moiety, F_c , is a thiol-reactive group such as N-ethyl maleimide. In an embodiment the conjugating moiety, F_L , is a thiol containing group such as cysteine.

This invention provides a method of stimulating the production of hematopoietic cells in a subject comprising administering an isolated stem cell factor (SCF) analog. In an embodiment isolated stem cell factor (SCF) analog is prepared by the method of claim 1 or designed by the above described method. In another embodiment the administration is oral or any other route. In an embodiment the isolated SCF analog has an alteration in at least one atom of the atomic coordinates of the crystal structure as set forth in Figure 8. In another

embodiment the isolated SCF analog comprises amino acid residues of native or recombinant SCF1-165 or amino acid residues of a recombinant selenomethionyl SCF1-141. In an embodiment of this method the isolated SCF analog, comprises an isolated altered SCF molecule, whose alteration site is a receptor binding site on the surface of the altered SCF molecule. In another embodiment of the above-described the compound comprises an isolated SCF analog, whose alteration site is a receptor-binding site on the surface of the altered SCF molecule. In another embodiment of said method the composition comprises a double-headed receptor SCF ligand analog having the structure set forth in Figure 10A. In an embodiment each ligand head of the double-headed SCF ligand analog is an oligopeptide having the structure set forth in Figure 10B. In another embodiment the oligopeptide comprises a sequence, wherein functional moiety F_1 corresponds to a segment of amino acid residues from within N-terminal residues 1-10 of SCF, functional moiety F_2 corresponds to a segment of amino acid residues from within residues 79-95 of SCF, and functional moiety F_3 corresponds to a segment of amino acid residues located within three amino acid residues of amino acid residue 127, wherein F_1 , F_2 , and F_3 are connected by connecting peptide segments X_n , X_m , and X_p , respectively, wherein $n=0-5$, $m=0-5$ and $p=3-8$ amino acid residues, respectively, and the conjugation moiety F_L is a cysteine residue. In a further embodiment the functional moieties F_1 , F_2 , and F_3 on the ligand heads have been selected by bacterial phage display for optimal receptor binding. In an embodiment the functional moieties

and connecting peptide segments of an active oligopeptide ligand head are replaced by chemical mimetics. In another embodiment an appropriate chemical scaffold of connecting segments has been designed to comprise (present) functional moieties F_1 , F_2 , and F , which have been selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF. In another embodiment the linker comprises an organic polymer having two ends capped at each end by a reactive capping moiety, F_c , which react covalently with the conjugation moiety, F_L , on the ligand head. In a further embodiment the organic polymer is polyethyleneglycol (PEG) comprising the structure $H[OCH_2CH_2]_nOH$, wherein n is 10-20. In another embodiment the capping moiety, F_c , is a thiol-reactive group such as N-ethyl maleimide. In an embodiment the conjugating moiety, F_L , is a thiol containing group such as cysteine.

This invention provides an isolated stem cell factor (SCF) molecule, which is an altered SCF, comprising any portion of amino acids 1-165 of a human SCF polypeptide, optionally comprising an N-terminal methionine before amino acid residue 1, wherein the polypeptide has an amino acid sequence portion of SCF capable of binding to the SCF receptor. In an embodiment of the altered isolated stem cell factor molecule an alteration is selected from the group consisting of deletion, insertion and substitution of at least one amino acid residue from the naturally occurring amino acid sequence of SCF.

In a further embodiment an alteration is a truncated SCF comprising amino acids 1-141 of a human SCF polypeptide, optionally comprising an N-terminal methionine before amino acid residue 1, E. In another embodiment the three-dimensional structure is altered from the atomic coordinates are set forth in Figure 8. In yet another embodiment the electron density distribution map is altered from the atomic coordinates are set forth in Figures 1A, 1B, or 1C. In a still further embodiment the substitution of at least one amino acid residue is selected from the group consisting of SCF(Y26C) disulfide-linked dimer, SCF(D25C), SCF(K62C), SCF(K78N, N81K), SCF(R117A, I118A), SCF(E92A, S95A), and SCF(D124A, K127D). In another embodiment the overall three-dimensional conformation of the stem cell factor molecule has an altered three-dimensional structure of the α C- β 2 loop.

This invention provides a pharmaceutical composition comprising the above described altered isolated SCF molecule and a pharmaceutically acceptable carrier. In an embodiment the altered SCF molecule molecule is a hybrid molecule of the altered stem cell factor molecule and a second protein or fragment thereof. As used herein, an SCF hybrid molecule is defined as a molecule wherein analog SCF is combined with with part or all of another protein such as another cytokine or another protein, which for example, effects signal transduction via entry through the cell through a SCF-SCF receptor transport mechanism. In an embodiment the alteration of the α C- β 2 loop is a change in length of the amino acid sequence of

the α C- β 2 loop by a deletion or an insertion of at least one amino acid residue or a change in at least one amino acid residue from the naturally occurring amino acid residue(s) of the α C- β 2 loop. In another embodiment the change in said at least one amino acid residue from the naturally occurring amino acid residue(s) is selected from the group consisting of SCF(Y26C) disulfide-linked dimer, SCF(D25C), SCF(K62C), SCF(K78N, N81K), SCF(R117A, I118A), SCF(E92A, S95A), and SCF(D124A, K127D).

Generally, for design of drugs as described in the above-described methods, certain changes are known to have certain structural effects. For example, deleting one cysteine could result in the unfolding of a molecule which is, in its unaltered state, is normally folded via a disulfide bridge. There are other known methods for adding, deleting or substituting amino acids in order to change the function of a protein.

The atomic coordinates may be determined in the above-described method by multiwave anomalous diffraction (MAD) measurements, but is not limited hereto, since any means determined suitable by one of skill in the art may also be used.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS

MATERIALS AND METHODS

SCF Expression, purification and analyses

Human SCF¹⁻¹⁴¹ was expressed recombinantly in *E. coli* as described previously (Langley et al., 1994). For expression of SeMet SCF¹⁻¹⁴¹, the expression vector was transfected into the methionine auxotrophic *E. coli* strain FM5. Fermentation was carried out at 30°C in 8 liters of minimal medium consisting of ammonium sulfate (10 g/liter), glucose (5 g/liter), methionine (0.125 g/liter), phosphate salts, magnesium, citric acid, trace metals, and vitamins. When an OD₆₀₀ of 3-5 was reached, a feed medium was added that consisted of the following components in a total volume of 1 liter: 100 g of ammonium sulfate, 450 g of glucose, 2 g of methionine, magnesium, trace metals, and vitamins. At an OD₆₀₀ of 12.4, induction medium (one liter containing 100 g of ammonium sulfate, 300 g of glucose, and 1 g of selenomethionine) was added and fermentation proceeded at 30°C. Five hours later (at an OD₆₀₀ of approximately 16), the temperature was raised to 42°C to induce SCF expression and additional selenomethionine (1 g) was added. Cells were harvested 4 hours after the temperature shift (OD₆₀₀ of approximately 16). SeMet SCF¹⁻¹⁴¹ expression was estimated as 0.5 g/liter. Both SCF¹⁻¹⁴¹ and SeMetSCF¹⁻¹⁴¹ were purified with minor modifications to previously described procedures (Langley et al., 1992, 1994). Both retain the initiating

methionine (or SeMet) residue [position (-1)] (Langley et al., 1994). N-terminal amino acid sequencing was performed as described (Lu et al., 1991). About 90% SeMet was present in SeMetSCF¹⁻¹⁴¹ at each of the Met positions, based on amino acid analysis and N-terminal sequencing results (i.e. lack of recovery of Met residues for SeMetSCF¹⁻¹⁴¹ in comparison with SCF¹⁻¹⁴¹; data not shown).

Crystallization

Crystals were obtained by the use of hanging drop vapor diffusion method under aerobic conditions. The initial crystals were grown by mixing 1 μ l of protein solution [44 mg/ml for SCF¹⁻¹⁴¹ or 38 mg/ml for SeMet SCF¹⁻¹⁴¹] in 10 mM sodium phosphate pH 6.5, 80 mM NaCl] with 1 μ l crystallization reservoir solution. The crystallization reservoir solution included 25% (w/w) PEG 400, 240 mM CaCl₂, 100 mM HEPES pH 7.4 for SCF¹⁻¹⁴¹, and 22% PEG400, 220 mM CaCl₂, 100 mM HEPES pH 7.2 and 5-10 mM dithiothreitol (DTT) for SeMetSCF¹⁻¹⁴¹. Crystallization trays were incubated at 20° C and crystals reached full size in approximately 3 days with typical dimensions of 0.5 x 0.2 x 0.2 mm. Microseeding and lower concentrations of DTT solution (2 mM) were needed to reproduce SeMetSCF¹⁻¹⁴¹ crystals subsequently. An extant SeMetSCF¹⁻¹⁴¹ crystal was washed with its reservoir solution and then crushed to produce microseeds, which were stored in 50 μ l of a stabilizing solution of 32% (w/w)PEG400, 260 mM CaCl₂, 100 mM HEPES (pH 7.4) at room temperature. For microseeding experiments, the seed stock was diluted by 10-10,000-fold with crystallization reservoir solution. A 1 μ l aliquot of this prepared precipitant was mixed with 1 μ l of the

protein solution to make the droplet. The crystal for MAD phasing was grown from a crystallization reservoir solution containing 2 mM DTT concentration.

Diffraction measurements

X-ray diffraction data from SCF¹⁻¹⁴¹ crystals were recorded on two Hamlin-Xuong area detectors at 293K at a home source. The data were integrated using the UCSD software package and scaled using AGROVATA and ROTAVATA as implemented in CCP4 suite (CCP4, 1994). The MAD experiments for SeMetSCF¹⁻¹⁴¹ were conducted at the X4A synchrotron beam line of Brookhaven National Laboratory using Fuji image plates. A single crystal was frozen at 110K using paratone-N (Exxon) as a cryoprotectant. The MAD data were collected at four wavelengths (before the edge, at the SeK edge, at the peak and after the peak) in oscillations of 1.3-1.5° without overlap. The SeMetSCF¹⁻¹⁴¹ crystal was oriented such that b-axis was parallel to the oscillation axis and a mirror geometry was used during data collection. The MAD data were processed using DENZO and Scalepack (Otwinowski, 1993; Gewirth, 1995) (Table I).

Table I. MAD data collection and phasing statistics.

	Data collection (25 - 2.0 Å) ^a		Unique reflections	Completeness (%)	Signal(I/σ) R _{sym} (%)
	Wavelength(Å)				
5	λ1=0.9919 (pre-edge)	65,810	95.1	18.4	6.7
	λ2=0.9793 (inflection)	65,759	95.0	16.7	5.8
	λ3=0.9791 (peak)	65,665	94.9	15.2	6.7
	λ4=0.9686 (remote)	65,689	94.9	16.0	5.6
Anomalous diffraction ratios (20 - 2.6 Å) ^b					
15	λ1	λ1	λ2	λ3	λ4
		0.035 (0.030)	0.051	0.042	0.035
20	λ2		0.052 (0.029)	0.033	0.051
	λ3			0.070 (0.031)	0.041
25	λ4				0.055 (0.030)

MAD phasing (25 - 2.6 Å)^c
 $R(\sigma|F_r) = 0.044$ $R(\sigma|F_a) = 0.39$ $\langle \Delta(\Delta\phi) \rangle = 41.6^\circ$ $\langle \sigma(\Delta\phi) \rangle = 18.7^\circ$

Table I continued. MAD data collection and phasing statistics.

^a	Unique reflections are determined by point group 222 (not mmm) to distinguish Bijvoet-related reflections. Rsym = 100 x $\sum_{hkl} F_o - \langle I \rangle / \sum_{hkl} \sum_i I_i$, where I_i is the i th measurement of reflection hkl and $\langle I \rangle$ is the weighted mean of all measurements of I .
^b	Anomalous diffraction ratios = $\langle \Delta F ^2 \rangle / \langle F ^2 \rangle$, where $\Delta F $ is the absolute value of the Bijvoet (diagonal elements) or dispersive difference (off-diagonal elements), respectively. Values in parentheses are for centric data.
^c	$R = \sum_{hkl} F_o - \langle F \rangle / \sum F $. oP_s is the structure factor due to normal scattering from all the atoms. oP_A is the structure factor due to normal scattering from the anomalous scatterers only, and $\Delta\phi$ is the phase difference between oP_s and oP_A . $\Delta(\Delta\phi)$ is the difference between two independent determinations of $\Delta\phi$.

Molecular replacement attempts

Structure determination by the molecular replacement method was attempted for the home source data set. The MERLOT (Fitzgerald, 1988) and AmoRe (CCP4, 1994) programs were used with various four-helix bundle structures as search models, and a good rotation solution was obtained. The rotation solution agreed well with the orientation of helical bundles (approximately along the *b*-axis of unit cell) that was deduced from native Patterson maps. Dissimilarities among the helical cytokines and the multiplicity of subunits (four) hampered detection of any significant translational function peaks.

Phase evaluation

The processed MAD data were passed through the MADSYS programs (Hendrickson, 1985). Algebraic and probabilistic MAD phasing procedures (Hendrickson, 1985; Pahler et al., 1990) were applied for phase determination (Table II). Selenium sites were located by HASSP program (CCP4, 1994) in F_o Patterson and difference Fourier maps and refined by MADSYS programs. The choice of enantiomer was determined by comparison of the electron density maps computed from the two enantiomorphic selenium structures to maximum Bragg spacings of 2.6 Å. The phases were improved by 4-fold non-crystallographic symmetry (NCS) averaging. The rotation-translation matrices of the NCS axes were determined by TOSS (Hendrickson, 1979) from the selenium sites and subsequently refined by LSQRHO (W.A. Hendrickson, unpublished) and RAVE (Kleywegt and Jones, 1994), and the averaging procedure by DM (CCP4, 1994).

Model building and refinement

The initial model of SeMetSCF¹⁻¹⁴¹ was built into the averaged map at 2.3 Å by using program O (Jones et al., 1991). The model includes 98 core residues for each of the four molecules in an asymmetric unit. The remote wavelength after the SeK peak was used for the refinement with the Bijvoet difference applied to Se scattering factors. The R-value for this model, before any refinement, was 42.1% in the resolution range of 10.0 - 2.3 Å. NCS restraints were applied during the initial rounds of refinements. After several iterations of least square and simulated annealing refinement with X-PLOR (Brünger et al., 1987) and manual rebuilding against SIGMAA (Read, 1986) and $2|F_o| - |F_c|$ maps, the crystallographic R-value is 19.9% for the current model (Table III). The sites of Ca²⁺ ions, a component of the crystallization medium, were located from a Bijvoet difference Patterson map at the remote wavelength before the SeK edge. The SCF¹⁻¹⁴¹ model was obtained by subjecting the refined SeMetSCF¹⁻¹⁴¹ model to refinement against the area-detector data set from the SCF¹⁻¹⁴¹ crystal using the XPLOR program (Brünger et al., 1987). The atomic coordinates have been deposited in the Brookhaven Protein Data Bank with accession code 1scf.

Table II. Lattice and Refinement Statistics

	SeMetSCF ¹⁻³⁴¹ (Å)	Native
Lattice		
Space group	P2 ₁ 2 ₁ 2 ₁	P2 ₁ 2 ₁ 2 ₁
Cell constants (a,b,c) (Å)	71.8, 82.6, 88.2	73.0, 84.7, 88.8
Z ^a	4	4
Refinement ^b		
Resolution range (Å)	20.0 - 2.2	8.0 - 3.3
Completeness (%)	96.6	98.6
Unique reflections ^c	49851	7990
R-value ^d (F >2σ) (%)	19.9	20.8
R _{free} ^e (%)	24.2	27.3
R _{sym} ^f (%)	5.6	15.2
Model parameter		
Total non-H atoms	3804	3502
Total residues	448	447
Total water molecules	264	0
Total metal ions	3	0
rms bond length/angle	0.016/2.5°	0.017 / 3.0°
Average B-factor (Å ²)	32.1	18.7
main-chain rms B (bond, angle) (Å ²)	1.2/1.6	1.9/2.2
side-chain rms B (bond, angle) (Å ²)	2.1/2.4	3.0/3.3

^aZ: number of molecules in the asymmetric unit.^bThe reflection data higher than the resolution range were not included in the refinement due to poor R_{sym} in these resolution shells.^cUnique reflections are determined by point group 222 for the SeMetSCF¹⁻³⁴¹ dataset to distinguish Bijvoet-related reflections and by point group mmm for native dataset.^dR-value = $\sum_{hkl} ||F_o| - |F_c|| / \sum_{hkl} |F_o|$.

Table II. continued Lattice and Refinement Statistics

5

^aA subset of the data (6%) was excluded from the refinement and used for the free R-value calculation.

^f R_{SPM} for SeMetSCP¹⁻¹⁴¹ data set was calculated in the resolution range of 25-2.2 Å and for the SCP¹⁻¹⁴¹ data set in the resolution range of 13-3.3 Å.

10

Structure analysis

Solvent accessibilities were defined as compared with the corresponding Gly-X-Gly peptide (Shrake and Rupley, 1973) as calculated by XPLOR (Brunger et al., 1987). Structural superimpositions were performed based on α -carbon atoms alone. The coordinates were taken from the Brookhaven Data Bank with entry codes: M-CSF, 1hmc (Pandit et al., 1992); IL-4, 1rcb (Wlodawer et al., 1992); GM-CSF, 1gmf (Diederichs et al., 1991) IL-2, 3ink (McKay, 1992); IL-5, 1hul (Milburn et al., 1993). Initial segments of equivalence between two structures were defined according to equivalent secondary structure elements. These structures were then superimposed using program TOSS (Hendrickson, 1979) and the number of equivalent atoms were extended using Lsq_imp command in program O (Jones et al., 1991). A cutoff distance of 3.0 Å and at least three residues in a consecutive fragment were used as the criteria of defining equivalent atom sets. Different initial equivalent segments did give different results in the structural alignment, as Rozwarski et al observed in their study (Rozwarski et al., 1994). In this study, several initial sets of equivalent segments for each alignment were tried and the one that generated in the greatest number of equivalent atoms after the Lsq_imp extension was retained.

RESULTS AND DISCUSSION

Structure determination

Both native and selenomethionyl (SeMet) human SCF¹⁻¹⁴¹ were expressed as recombinant proteins in *E. coli* (Langley et al., 1994). Crystals grew in space group P2₁2₁2₁ with four SCF subunits and 39% solvent in the asymmetric unit. The attempts to solve the crystal structure of SCF¹⁻¹⁴¹ by molecular replacement from other cytokine models gave good rotation solutions, but no significant translation function peaks. Experimental phases for SeMetSCF¹⁻¹⁴¹ were then evaluated in a multiwavelength anomalous diffraction (MAD) experiment. Four-wavelength data were measured from a single, frozen SeMetSCF¹⁻¹⁴¹ crystal and analyzed with MADSYS (Hendrickson, 1985). Twelve selenium sites were found in four congruent sets that proved to be associated with the respective SCF subunits in the crystal. A MAD-phased electron-density map was calculated at 2.3Å resolution (**Figure 1A**) and improved by molecular averaging (**Figure 1B**) and refinement (**Figure 1C**).

An atomic model was fitted to the experimental maps and refined at 2.2Å resolution to an R-value of 0.199 ($|F| > 2\sigma$) with stereochemical ideality typified by the r.m.s. deviation from bond ideality of 0.016Å. There are no residues in energetically disfavored regions of the Ramachandran plot. This model for SeMetSCF¹⁻¹⁴¹ has 3804 non-hydrogen atoms from 448 amino acid residues, 264 water molecules, three Ca²⁺ ions and one polyethylene glycol (PEG) moiety. All four polypeptide chains

(designated A, B, C, and D) are sufficiently disordered before residue 11 to preclude modeling of this portion, and none of them is fully ordered through to the end. Specifically, A92-103, B130-136, B139-141, C92-103, C127-141, and D91-103 and D128-141 are all disordered. This disorder is such that, of the eight disulfide bridges, only two are seen. To test whether the reducing agent used to crystallize SeMetSCF¹⁻¹⁴¹ (see Materials and Methods) might have broken these bonds and caused the disorder, the native SCF¹⁻¹⁴¹ structure which was crystallized without reducing agent was also refined. The two crystals are nearly isomorphous (differences are due to temperature at data collection), and the two structures show the same pattern of order-disorder.

Structure of SCF

The four independent SCF subunits in the crystal are similar but distinctive, and identification of the AB and CD pairs as the molecular dimers is unmistakable. None of the SCF monomer copies is complete, but each flexible portion except for the N-terminus is stabilized by lattice contacts to another monomer. Thus, through the combination of chains A and B there are images for all but residues 1-10, and the position of Cys89 to which Cys 4 must bridge, determines the approximate course of this disordered segment. The overall structure of this composite SCF dimer is shown in **Figure 2A** and the C_α backbone for the actual AB dimer is drawn in stereo in **Figure 2B**. Topologically, SCF structure is similar to other short-chain helical cytokines (Rozwarski et al.,

1994) with a core of four helices (αA , αB , αC and αD) and two beta strands, $\beta 1$ between αA and αB and $\beta 2$ between αC and αD . Apart from the tight $\beta 2$ - αD connection, however, the segments outside these core elements are unique in conformation if not in length. In particular, there is an additional one-turn helix, $\alpha B'$, between $\beta 1$ and αB , there is an exceptional hairpin loop between αB and αC at the dimer interface, and there is another extra one-turn helix, $\alpha D'$, in the C-terminal extension. The bounds of secondary-structure elements are given in **Figure 3**.

The core SCF dimer has its subunits arranged in a head-to-head manner with the opposed four-helix bundle axes nearly coincident (**Figure 2**). This gives the molecule an elongated shape, $\sim 85\text{\AA} \times 30\text{\AA} \times 20\text{\AA}$. Approximately 855\AA^2 of surface area is buried from each protomer into the dimer interface. The interface is dominated by contacts from the C-terminal end of αA and the αA - $\beta 1$ connection of one monomer to the αB - αC loop of the other monomer (**Figure 2**), and the reciprocal pair is related by an approximate dyad axis of symmetry. The actual symmetry operators have rotational and translational components of 176.3° and 0.33° , respectively, for the AB dimer and 177.4° and 0.04° for the CD dimer. The two dimers thereby deviate significantly and similarly (with A matched to C and B matched to D) from true 2-fold symmetry. Nevertheless, since interatomic contacts at the interface are symmetric, it is presumed that these deviations reflect flexibility rather than inherent asymmetry.

Then the r.m.s. deviation for the C_α positions in common between the two dimers is 0.80 Å (208 C_α atoms) is comparable to that of pairwise comparisons among the four independent molecules (from 0.57 Å to 0.94 Å for 103 C_α atoms). If D alone is superimposed onto B, a rotation of 2.1° brings A and C into optimal superposition. In the contrary match-up, with D onto A, a rotation of 6.7° is needed to superimpose B and C.

The crystal structure is compatible with solution biochemistry. Consistent with the relative rates of *in vitro* oxidation of methionyl residues (Hsu et al. 1996), Met36 and Met48 are buried in the hydrophobic core whereas Met27 is solvent accessible. Furthermore, as predicted on the basis of fluorescence spectroscopy studies (Arakawa et al., 1991), Trp41 is buried within the hydrophobic core.

Natural SCF and Chinese hamster ovary(CHO) cell-expressed recombinant SCF are heavily glycosylated by both N-linked and O-linked carbohydrates. All four potential N-linked sites are in the SCF¹⁻¹⁶⁵ are in the SCF¹⁻¹⁴¹ portion that has been crystallized (Langley et al., 1992; Lu et al., 1992). Although the recombinant proteins expressed in bacteria are non-glycosylated, both human and rat SCF expressed in *E. coli* and then refolded *in vitro* have native structures, as judged by biophysical methods and *in vitro* biopotency assays (Arakawa et al., 1991; Langley et al., 1992). The crystal structure of the recombinant SCF in this study is compatible with the glycosylation pattern found for SCF expressed from mammalian cells.

Thus, the potential site at Asn72, which is unglycosylated in both human and rat natural SCF expressed from mammalian cells, is buried in the dimer interface, whereas the site at Asn120, which is fully glycosylated in both species, is accessible in the atomic model. Other sites (Asn65 in both human and rat, human Asn93 and rat Asn109) are glycosylated in some molecules but not others. These sites are also accessible in the atomic model. Asn93 is located in the highly flexible region between α C and β 2, and its side chain is disordered.

Although natural SCF is a noncovalently associated dimer, recombinant human SCF produced in *E. coli* can fold alternatively *in vitro* into a covalently-linked dimer. These dimers have Cys4-Cys89' and Cys43-Cys138' intermolecular disulfide bonds (Lu et al., 1996). The disulfide-linked and natural non-covalently associated SCF dimers are similar with regard to biochemical and biophysical properties, biopotency and receptor-binding affinity. The disulfide-linked SCF is also biologically active with higher biopotency in supporting growth of hematopoietic cell line and stimulating hematopoietic cell colony formation but slightly lower binding affinity to c-Kit than the noncovalently associated dimer. It was proposed that the disulfide-linked dimer arises from a double-swap of α A and α D helices between the monomers (Lu et al., 1996). The crystal structure of SCF, however, suggests that a single-swap at the α B- α C loop near residue 68 is more likely.

Comparison with other short-chain helical cytokines

Although SCF has the characteristic features of short-chain helical cytokines, as among other members, both sequence and structure are highly divergent. If anything, SCF resembles the others less than they resemble one another (**Table III**). The comparison in this study of SCF with other short-chain helical cytokine structures [granulocyte-macrophage colony-stimulating factor (GM-CSF) (Diederichs et al., 1991), , M-CSF (Pandit et al., 1992), interleukin (IL)-2 (McKay, 1992), IL-4 (Wlodaver et al., 1992) , and IL-5 (Milburn et al., 1993)] shows greatest structural similarity with M-CSF or IL-4, but even here fewer than half of the residues can be superimposed (**Table III**). Sequence similarities are essentially random. A structure-based sequence alignment (**Figure 3**) of SCF with other short-chain helical cytokines has pairwise identities ranging from 6.7% to 18.8% (**Table III**) and not even a single residue in SCF is conserved in all the others. Moreover, the best alignment presented in Figure 3 is only valid for the specified criteria herein, and it differs somewhat from that given by Rozwarski et al. (Rozwarski et al., 1994). Indeed, because of variability in the core structures in this divergent superfamily, a self-consistent pairwise alignment of the family members has not been able to be achieved. Nevertheless, the core elements are remarkably similar in structure.

Table III. Structural and sequence comparisons of short-chain helical cytokines.

	SCF	M-CSF	IL-4	GM-CSF	IL-2	IL-5
SCF		14.1 (13.0)	12.7 (12.3)	12.5 (23.5)	18.8 (16.4)	6.7 (21.1)
M-CSF	64 (1.755)		14.8 (18.9)	13.8 (18.3)	17.5 (17.1)	10.5 (18.6)
IL-4	63 (1.578)	54 (1.820)		26.6 (25.0)	14.5 (22.2)	18.9 (18.9)
GM-CSF	48 (1.632)	58 (1.814)	64 (1.559)		9.8 (26.0)	20.4 (14.7)
IL-2	48 (1.700)	57 (1.581)	69 (1.330)	61 (1.482)		14.5 (22.2)
IL-5	45 (1.695)	38 (1.721)	53 (1.324)	49 (1.334)	62 (1.371)	

Structural comparisons and sequence comparisons between the short-chain helical cytokines are given in the lower and upper triangles, respectively. Structural comparisons are given as the maximum number of equivalent α -carbon atoms between two short-chain helical cytokines, and the r.m.s. deviation (\AA), (in parentheses). Sequence comparisons are given as the percentage of sequence identity from sequence alignment based on structural superimposition, and that based on the sequence alignment from BESTFIT program of the GCG package (in

Table III. continued Structural and sequence comparisons of short-chain helical cytokines.

parentheses). The latter alignment is based only on maximizing the percentage of identity, similarities and length of the matching sequences, and the sequences submitted to the BESTFIT program were restricted within the region as defined in the PDB files, including the disordered residues. With the advantage of the relatively large number of independent data points (15 pairs), the correlation between sequence similarity and structural deviation was analyzed. Without any restriction of structural alignment, the correlation coefficient (C) between structural deviation and sequence identity is -0.21 and the student's t probability (P) is 0.44, suggesting little correlation between a specific sequence and the tertiary fold. With the restriction of structural alignment, however, C is -0.30 and P 0.28, indicating that the structure-based sequence identity and structural deviation are weakly connected (as also observed in another highly diverged protein family, hemoglobin; Aronson et al., 1994).

Core portions aside, SCF differs markedly from other short-chain helical cytokines, as indeed they differ from one another (Figure 3; Rozwarski et al., 1994)). First, helix α A of SCF is unusually shortened at its N-terminus. Its disordered extension must deviate toward α C, as in M-CSF but not in the others, by virtue of the Cys4-Cys89' disulfide bridge in common with M-CSF. Secondly, the conformation of the α A- β 1 connection is distinctive as required for the dimer interface, and the β 1- α B connection uniquely has α B'. Again at the dimer interface, the α B- α C loop extends out distinctively along the dyad axis. Thirdly, the unusually long α C- β 2 loop of SCF is both highly flexible (only one ordered copy) and with a path of its own when ordered. Finally, the C-terminal extension after α D compares only to that of M-CSF, and then only in its general direction of exit out past α B and the β - strands.

Among the short-chain helical cytokines, SCF is most closely related to M-CSF. These two have similarities in gene structure, alternative splicing, proteolytic maturation, disulfide bridging, dimer assembly, and receptor type (these similarities also extend to the Flt-3 ligand; Lyman and Jacobsen, 1998). Despite negligible sequence identity, an alignment and secondary structure prediction prompted by these relationships (Bazan, 1991) fits the actual

structure amazingly well, except for shifts in α B and in the α C- β 2 loop. Here reality confounds logic; unexpectedly, comparable glycosylation sites (Asn120 in SCF and Asn122 in M-CSF) are displaced by one helical turn and comparable disulfide bridges (Cys43-Cys138' in SCF and Cys48-Cys139' in M-CSF) are not superimposable structurally (**Figure 4**).

Both were roughly correct in secondary-structure prediction for helices α A and α C, but substantial misplacements were made for helices α B and α D and strand β 2. In the study of Rozwarski et al. (Rozwarski et al., 1994), the alignment for α B is incorrect by a shift of 14 residues and that for β 2 and α D by a shift of 7 residues. Bazan's earlier sequence alignment (Bazan, 1991) fits to the structural alignment herein amazingly well, except for a shift of one residue for α B and a three-residue gap in the α C- β 2 loop.

Comparison with other cytokine dimers

Helical cytokines dimerize in various ways (Sprang and Bazan, 1993). Among the five dimeric helical cytokines for which crystal structures have been described [M-CSF, IL-5, ciliary neurotrophic factor (CNTF), interferon- γ (IFN- γ) and IL-10], only IFN- γ and IL-10 are similar dimers. These latter two have a 'tip-to-tip' packing with helix axes approximately perpendicular. Otherwise, the only salient

feature in common is having the subunits oriented with bundle axes aligned in parallel and helix dipoles positioned to compensate. There is 'head-to-head' packing of the four-helix bundles in M-CSF, 'tail-to-tail' packing in IL-5, and 'side-to-side' packing in CNTF. Moreover, IFN- γ , IL-10 and IL-5 are all interdigitated dimers with helices swapped between subunits. Thus, although SCF relates most closely to M-CSF, the dimer structure could not be deduced readily beforehand.

SCF in keeping with its relationship to M-CSF, is a non-interdigitated 'head-to-head' dimer (**Figure 4**). The two interfaces between promoters are completely different, however. One α A- β 1 loop of M-CSF is situated between the α A- β 1 and α B- α C loops of the other protomer, whereas in SCF each α A- β 1 loop interacts only with α B- α C loop of the partner. This staggered mode of M-CSF dimerization (**Figure 4B**) is dictated by the position of the Cys31-Cys31' intermolecular disulfide bond in M-CSF. The dyad axes are similarly oriented in the two cases (perpendicular to the bundle axis and parallel to the α A- α D and α B- α C helix planes), but whereas the dyad axis in SCF nearly intersects the bundle axis, that in M-CSF is offset toward the α A- α D helix pair (**Figure 4**). Thus, when one protomer of an SCF dimer is superimposed onto one from M-CSF, the superimposition of the two mates requires a translation of 3.8 Å but a rotation of only 4.7°.

Location of the binding site for the receptor Kit
SCF binds with high affinity (nM range) to its
receptor (Philo et al., 1996; Broudy, 1997)).
Various structure-function studies and analyses
help to define residues of SCF that may be involved
in this binding. These studies include mutagenesis
experiments, immunochemical mapping, comparative
analyses of inter-species ligand-receptor
interactions, and analyses of glycosylation.
Residues thereby implicated in receptor binding can
then be mapped onto the surface of SCF as defined
by the crystal structure. Although a precise
definition of the receptor-binding site on SCF will
require direct structural information on the
complex of SCF with the Kit receptor, this mapping
of the binding site provides a crude picture that
is useful when coupled with information on Kit and
related receptors.

From studies of truncation and point mutants,
Langley et al (1994) demonstrated that the
N-terminal residues 1-4 and 1-10 and the Cys4-Cys89
disulfide bond are required for receptor binding
and bioactivity, and that the Cys43-Cys138
disulfide bond and C-terminal residues past 127 are
not required for receptor binding but may have some
roles in cell proliferation activity. Moreover,
alterations at Asn10 and Asn11 brought about by
chemical isomerization or by mutagenesis have
positive or negative effects depending on the
substitution (Hsu et al., 1998). A quadruple

mutant of SCF (Arg121Asn, Asp124Asn, Lys127Asp and Asp128Lys) was found to be defective in bioactivity (Matous et al., 1996). The molecular cause of this deficiency may be specific to Lys127 or due to indirect electrostatic effects. Arg121 and Asp124 are adjacent to the main N-linked glycosylation site, which is not involved in binding (see infra), and Asp128 is absent in the 1-127 truncation mutant that retains full receptor-binding activity (Langley et al., 1994). Moreover, a study of human-murine SCF chimeras narrowed the important receptor recognition epitopes to within residues 1 to 35 and 79 to 97 (Matous et al., 1996), and the epitope of a neutralizing antibody was mapped to the region of residues 60-95 (Mendez et al., 1996) and 79-97 (Matous et al., 1996).

Although SCF molecules from different mammalian species are very similar (>75% identity), there are substantial differences in inter-species receptor activation. Human SCF activates murine Kit very poorly, rodent SCF has only slightly lower potency than human SCF in binding/activating human Kit (Martin et al., 1990; Lev et al., 1992), and canine SCF activates human Kit slightly better than human SCF does itself (K.E. Lang, unpublished data). It is likely that the receptor-binding regions involve residues that are different between man and mouse but conserved between man and dog. These residues can be classified into five groups in the sequence (Figure 5). Most residues in group III are buried

and those in group II are close to the dimer interface. The residues in groups III (45-58) are buried and those in group II (24-34) are close to the dimer interface. The results in groups I (1-15), IV (80-117) and and V (130-140) are more likely to be involved in direct receptor binding.

The heavy glycosylation of natural and CHO cell-derived recombinant SCFs sheds light on the question whether residues in vicinity of α D, the equivalent of the major receptor binding site in GH, are involved in receptor binding. Human SCF expressed in CHO cells is approximately 30% by weight (Arakawa et al., 1991). The main glycosylation site is at Asn120 (Langley et al., 1992). Glycosylation at this site, which is near the center of the α D helix, does not appear to influence biological activity; therefore, the area around this residue cannot be involved in receptor binding. Glycosylation of human SCF at either Asn65 or Asn93 lowers the biological activity approximately 10-fold; therefore, these residues may be near but not directly at the binding site.

Taken together, these observations indicate that the receptor-binding site may include residues from the first few N-terminal residues, the 79-95 region (mainly located on α C helix) and the C-terminal end of α D (around 127). These regions are contiguous on the SCF surface in the atomic model provided herein. The putative receptor-binding site of M-CSF

was mapped to a similar region (Taylor et al., 1994).

Structural characteristics of SCF-Kit and related ligand-receptor complexes

Kit, the receptor for SCF, is a class III receptor tyrosine kinase. This class, which includes the receptors for PDGF and M-CSF, is also closely related to the class IV receptors for FGF and the class V receptors for VEGF, Flt-3 ligand and KDR (Pantl et al., 1993). The ligand-binding portions of these receptors are all composed of immunoglobulin(Ig)-like domains and the kinase domains all include kinase insert sequences. The three classes are distinguished by the number of Ig repeats (five for class III, three for class IV and seven for class V) and by the length of kinase insert, which corresponds to an excursion between two helices of the kinase structure. These Ig-like receptors share similar signal transduction pathways, chromosomal localization and gene organization (Rousset et al., 1995), but their ligands come with completely unrelated topologies as typified by VEGF (cystine knot) on the one hand, versus M-CSF, SCF and Flt-3 ligand (helical cytokine) on the other. Even receptors of the same class have unrelated ligands; thus both SCF and PDGF use class III receptors and VEGF and Flt-3 ligand use class V receptors. The amino acid sequences of the ligands are extremely dissimilar

even when the fold is the same, as for PDGF vs. VEGF (25% identity) and M-CSF vs SCF (14% identity).

Although Ig-like receptors have very similar kinase portions (70% amino acid sequence identity between III and V) and about 50% identity for III or V with IV) their Ig-like domains are dissimilar in sequence both between repeats within a molecule and also at comparable positions between different receptors. (Rousset et al., 1995) Nevertheless, there are features of the receptor-ligand interaction that the class III and class V receptors have in common. First, for every studied example, the ligand binding function has been localized to the first three Ig-like domains and, where defined, to domains D2 and D3 specifically (Heidaran et al., 1990; Blechman et al., 1993; Lev et al., 1993; Wang et al., 1993; Davis-Smyth et al., 1996; Barleon et al., 1997). Secondly, the ligands for all of these receptors are functional as dimers; M-CSF, VEGF and PDGF are covalently dimers, while SCF and Flt-3 ligand are non-covalently linked dimers. In each case, signaling occurs through ligand-mediated receptor oligomerization (Heldin, 1995). For SCF-Kit, it has been shown directly by biophysical methods that complexes containing toe SCF subunits and two Kit extracellular domain molecules can form in solution (Philo et al., 1996). The genetic organization of these receptor genes has the placements and phases

of introns in common (Agnes et al., 1997) and the extracellular domains can be recognized from sequence motifs as telokin-like, I-set members of the Ig superfamily (Bateman and Chothia, 1995; Harpaz and Chothia, 1994).

The structure of domain D2 of Flt-1 receptor in complex with VEGF (Wiesmann et al., 1997) provides a template for ligand interactions with PDGF-related receptors. Wiesmann et al. (1997) modeled the interaction of VEGF with D1D2D3D4(Flt-1) and discussed the likelihood that other ligand complexes with class III and class V receptors may be similar. In light of the structure of SCF and the identified location of receptor-binding sites, the SCF-Kit complex is modeled herein.

The D2(Flt-1) domain is similar in structure to telokin, as predicted (Harpaz and Chothia, 1994), and thereby also to both domains in the structure of vascular cell adhesion molecule (VCAM)-1 (Jones et al., 1995). To test the validity of VCAM-1 as a model for D2D3(Flt-1) and D2D3 (Kit), used herein was a prediction-based threading program (Fisher and Eisenberg, 1996) to thread the sequences of the Ig-like domains of Flt-1 and Kit into the telokin and VCAM-1 structures. Fits were achieved with moderate to very high confidence of similarity. The resulting structure-based sequence alignment of D2D3(Kit) with the VCAM-1 template (five gaps) has a continuous domain boundary, and residues Cys151

and Cys183 in D2(Kit) are positioned properly to make an additional disulfide bridge between strands C and F.

5 **Characteristics of the SCF-Kit interaction**

Although it has been suggested (Matous *et al.*, 1996; Mendiaz *et al.*, 1996) that SCF may interact with its receptor in a manner analogous to the ligand-receptor interactions of another helical cytokine, growth hormone (de Vos *et al.*, 1992), an alternative mode of interaction can be contemplated given the similarities among Ig-like tyrosine-kinase receptors described above. If these similarities extend to the signaling interaction, the structure of the complex of VEGF with domain D2 of Flt-1 (Wiesmann *et al.*, 1997) should provide a template for the interaction despite the disparate structures of the ligands.

To test this hypothesis next constructed was a model of the VEGF-D2D3(Flt-1) receptor complex from a rigid-body superposition of VEGF (Muller *et al.*, 1997) and VCAM-1 such as to mimic the reported VEGF- D2(Flt-1) structure (Wiesmann *et al.*, 1997). Then, keeping the dyad-symmetric receptor pair fixed, VEGF was successively replaced with the other Ig-like receptors ligands of known three-dimensional structure: PDGF (Oefner *et al.*, 1992), M-CSF (Pandit *et al.*, 1992), and SCF (this work). Each was placed on the dyad axis and

positioned to optimize contacts between the VEGF-binding site on the receptor and the putative receptor-binding regions of the ligands. Remarkably, these disparate dimeric ligands have similar spacings between binding sites and a satisfactory fit is possible for each (Figure 6). Also constructed were simple homology models of the various receptors with changes in the backbone only to accommodate insertions and deletions. The model for SCF with D2D3(Kit) shows a striking electrostatic complementarity between a highly negative binding surface on SCF and a positive surface on Kit (Figures 7A and 7B). The glycosylation sites on both molecules are also compatible with unimpeded interaction.

The Kit receptor is activated by both soluble and membrane-bound forms of SCF, and signaling from the membrane-bound form appears to be have *in vivo* roles (se Lyman and Jacobsen, 1998). Moreover, as in the case of Flt-1 (Barleon et al., 1997), the D4(Kit) may be involved in inter-receptor contacts in the signaling dimer (Blechman et al., 1995) [although this proposal for Kit has been questioned (Philo et al., 1996; Lemmon et al., 1997)]. The model constructed herein for the SCF-Kit complex is compatible with these properties (Figure 7A and 7B). The C-termini of the SCF dimer are directed oppositely from those of Kit, as would be appropriate for a cell-cell contact, and the receptor units cross naturally at D4. It is

noteworthy that the ligands of other Ig-like receptors also have membrane-bound forms (M-CSF and Flt-3 ligand) or are typically complexed to the extracellular matrix (Kawasaki and Ladner, 1990; Lyman and Jacobsen, 1998).

The ligand-receptor structures that are suggested herein for the Ig-like kinase receptors are remarkable. Despite marked differences in ligand structure as typified by VEGF (cystine knot), SCF (helical cytokine) and FGF (beta trefoil), the geometrical configurations of receptor binding sites on these ligands are alike. Coupled with features in common among the receptors and in their biology, a similar mode of ligand-receptor interaction across the Ig-like subfamily of receptor tyrosine kinases seems plausible.

SECOND SERIES OF EXPERIMENTS

Based on the X-ray crystallographic structure of SCF, several analogs were made and their biological activities were measured and compared to that of SCF wild type.

<u>Analogs</u>	<u>Biological Activity</u> (Approximate, compared to wild type SCF)
SCF(Y26C) disulfide linker	2 to 3 fold higher
SCF(D25C)	100 fold lower
SCF(K62C)	7 fold lower

These analogs were designed based on the structure of the dimer interface of SCF, which is a non-covalent dimer. Leu22, Pro23, Lys24, Asp25, Tyr26, Lys62 and Phe63 are in the dimer surface. The side chains of Leu22, Pro23, Tyr26, and Phe63 reside in the buried center of the dimerization site and are involved in hydrophobic interactions. The hydrophilic side chains of Lys24, Asp25 and Lys62 from each monomer residue in the solvent accessible surface, and are involved in ionic interactions. By replacing Tyr26 with Cys, [SCF(Y26C)], it was anticipated that a dimer covalently linked by a disulfide bond between the C26 residue of each monomer would form because the distance between the β carbons of the two Cys26 residues would be less than 3Å.

<u>Analogs</u>	<u>Biological Activity</u> (Approximate, compared to wild type SCF)
SCF(K78N, N81K)	3 fold lower
SCF(R117A, I118A)	10 fold lower
SCF(E92A, S95A)	no change
SCF(D124A, K127D)	no change

These analogs were designed based on the assumption that there may be two distinct receptor binding sites, per monomer, as with growth hormone. One site would be on the face between helix A and helix C, and the other site would be on the face between helix A and helix D.

References

Agnes, F., et al. (1997) Genomic organization of the extracellular coding region of the human FGFR4 and FLT4 genes: Evolution of the genes encoding receptor tyrosine kinases with immunoglobulin-like domains. *J. Mol. Evol.*, **45**, 45-49.

Anderson, D. M., et al. (1990) Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. *Cell*, **63**, 235-243.

Andre, C., et al. (1992) Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III. *Oncogene*, **7**, 685-691.

Arakawa, T., et al. (1992) Molecular weights of glycosylated and nonglycosylated forms of recombinant human stem cell factor determined by low-angle laser scattering. *Analytical Biochem.*, **203**, 52-57.

Arakawa, T., et al. (1991) Glycosylated and unglycosylated recombinant-derived human stem cell factor are dimeric and have extensive regular secondary structure. *J. Biol. Chem.*, **266**, 18942-18948.

Aronson, H.-E. G., et al. (1994) Quantification of tertiary structural conservation despite primary

sequence drift in the globin fold. *Prot. Sci.*, **3**,
1706-1711.

Barleon, B., et al. (1997) Mapping of the sites for
ligand binding and receptor dimerization at the
extracellular domain of the vascular endothelial
growth factor receptor flt-1. *J. Biol. Chem.*, **272**,
10382-10388.

Bateman, A. and Chothia, C. (1995) Outline
structures for the extracellular domains of the
fibroblast growth factor receptors. *Nature
Structural Biology*, **2**, 1068-1074.

Bazan, J. F. (1991) Genetic and structural homology
of stem cell factor and macrophage colony-
stimulating factor. *Cell*, **65**, 9-10.

Bella, J., et al. (1998) The structure of the two
amino-terminal domains of human ICAM-1 suggests how
it functions as a rhinovirus receptor and as an
LFA-1 integrin ligand. *Proc. Natl. Acad. Sci. USA*,
95, 4140-4145.

Besmer, P. (1997) Kit-ligand-stem cell factor. In
Garland, J.M., Quesenberry, P.J. and Hilton, D.J.
(eds), *Colony-Stimulating Factors: Molecular and
Cellular Biology*, 2nd edn., Marcel Dekker, Inc., New
York, NY, PP. 369-404.

Blechman, J. M., et al. (1993) Soluble c-kit

proteins and antireceptor monoclonal antibodies
confine the binding site of the stem cell factor.
J. Biol. Chem., **268**, 4399-4406.

Blechman, J. M., et al. (1995) The fourth
immunoglobulin domain of the stem cell factor
receptor couples ligand binding to signal
transduction. *Cell*, **80**, 103-113.

Broudy, V. C. (1997) Stem cell factor and
hematopoiesis. *Blood*, **90**, 1345-1364.

Brünger, A. T., et al. (1987) Crystallographic
R-factor refinement by molecular dynamics. *Science*,
235, 458-460.

Casasnovas, J. M., et al. (1997) Crystal structure
of ICAM-2 reveals a distinctive integrin
recognition surface. *Nature*, **387**, 312-315.

Casasnovas, J. M., et al. (1998) A dimeric crystal
structure for the N-terminal two domains of
intercellular adhesion molecule-1. *Proc. Natl.
Acad. Sci. USA*, **95**, 4134-4139.

Collaborative Computational Project Number 4 (1994)
The CCP4 suite: programs for protein
crystallography. *Acta Crystallogr., D*, **50**, 252-270.

Davis-Smyth, T., et al. (1996) The second
immunoglobulin-like domain of the VEGF tyrosine

kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. *EMBO J.*, **15**, 4919-4927.

5 de Vos, A. M., et al. (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science*, **255**, 306-312.

10 Diederichs, K., et al. (1991) Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor. *Science*, **254**, 1779-1782.

15 DiGabriele, A. D., et al. (1998) Structure of a heparin-linked biologically active dimer of fibroblast growth factor. *Nature*, **393**, 812-817.

20 DiMario, J., et al. (1989) Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. *Science*, **244**, 688-690.

25 Ealick, S. E., et al. (1991) Three-dimensional structure of recombinant human interferon-gamma. *Science*, **252**, 698-702.

30 Evans, S. V. (1993) SETOR: Hardware lighted three dimensional solid model representations of macromolecules. *J. Mol. Graphics*, **11**, 134-138.

Fantl, W. J., et al. (1993) Signalling by receptor tyrosine kinases. *Annu. Rev. Biochem.*, **62**, 453-481.

Fenstermaker et al., (1993) A cationic region of the platelet-derived growth factor (PDGF) A-chain (Arg159-Lys160nLys161) is required for receptor binding and mitogenic activity of the PDGF-AA homodimer., *J. Biol. Chem.*, **268**, 10482-10489.

Fisher, D. and Eisenberg, D. (1996) Fold recognition using sequence-derived predictions. *Prot. Sci.*, **5**, 947-955.

Fitzgerald, P. M. D. (1988) MERLOT, an integrated package of computer programs for the determination of crystal structures by molecular replacement. *J. Appl. Crystallogr.*, **21**, 273-278.

Flanagan, J. G. and Leder, P. (1990) The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. *Cell*, **63**, 185-194.

Fukuda, N., et al. (1997) Role of long-form PDGF A-chain in the growth of vascular smooth muscle cells from spontaneously hypertensive rats. *Am. J. Hypertens.*, **10(10 Pt 1)**, 1117-1124.

Galli, S. J., et al. (1994) The kit ligand, stem cell factor. *Adv. Immunol.*, **55**, 1-96.

Gewirth, D. (1995) *The HKL Manual*. Yale University, New Haven, Connecticut.

Glaspy, J. (1996) Clinical applications of stem

cell factor. *Curr. Opin. Hematol.*, **3**, 223-229.

Harpaz, Y. and Chothia, C. (1994) Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. *J. Mol. Biol.*, **238**, 528-539.

Heidaran, M. A., et al. (1990) Chimeric alpha- and beta-platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the alpha-PDGF receptor that determine PDGF-AA binding specificity. *J. Biol. Chem.*, **265**, 18741-18744.

Heldin, C.-H. (1995) Dimerization of cell surface receptors in signal transduction. *Cell*, **80**, 213-223.

Hendrickson, W. A. (1979) Transformations to optimize the superposition of similar structures. *Acta Cryst, A*, **35**, 158-163.

Hendrickson, W. A. et al. (1985) Direct phase determination based on anomalous scattering. *Methods Enzymology*, **115**, 41-55.

Houck, K. A., et al. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol. Endocrinol.*, **5**,

1806-1814.

Hsu, Y.-R., et al. (1996) *In vitro* methionine oxidation of Escherichia coli-derived human stem cell factor: effects on molecular structure, biological activity, and dimerization. *Protein Sci.*, **5**, 1165-1173.

Hsu, Y.-R., et al. (1998) Selective deamidation of recombinant human stem cell factor during *in vitro* aging: isolation and characterization of the aspartyl and isoaspartyl homodimers and heterodimers. *Biochemistry*, **37**, 2251-2262.

Huang, E., et al. (1990) The hematopoietic growth factor KL is encoded by the *SL* locus and is the ligand of the c-kit receptor, the product of the *W* locus, *Cell*, **63**, 225-233.

Jones, D. T., et al. (1992) A new approach to protein fold recognition. *Nature*, **358**, 86-89.

Jones, E. Y., et al. (1995) Crystal structure of integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 angstroms resolution. *Nature*, **373**, 539-544.

Jones, T. A. (1992) a, yaap, asap, @#*? A set of averaging programs, In S. Bailey, Hubbard, R. & Waller, D. (ed.) *Molecular Replacement, Proceedings*

of the CCP4 Study Weekend, Daresbury Laboratory,
Warrington, UK, pp. 92-105.

Jones, T. A., et al. (1991) Improved methods for
building protein models in electron density maps
and the location of errors in these models. *Acta
Crystallogr., A*, **47**, 110-119.

Kawasaki, E. S. and Ladner, M. B. (1990) Molecular
biology of macrophage colony-stimulating factor.
Immunol. Ser., **49**, 155-176.

Kelvenbach, C. G., et al. (1991) Densimetric
determination of carbohydrate content in
glycoproteins. *J. Biochem. Biophys Methods*, **23**,
295-300.

Kleywegt, G. J. and Jones, T. A. (1994) Halloween
...masks and bones. In Bailey, S. Hubbard, R., and
Waller, D. (eds), From First Map to Final Model,
Proceedings of the CCP4 Study Weekend. Daresbury
Laboratory, Warrington, UK, pp 59-66.

Koths, K. (1997) Structure-function studies on
human macrophage colony-stimulating factor. *Mol.
Reprod. Dev.*, **46**, 31-37.

Langley, K. E., et al. (1992) Purification and
characterization of soluble forms of human and rat
stem cell factor recombinantly expressed by
Escherichia Coli and by Chinese hamster ovary

cells. *Arch. Biochem. Biophys.*, **295**, 21-28.

Langley, K. E., et al. (1994) Properties of variant forms of human stem cell factor recombinantly expressed in *Escherichia coli*. *Arch. Biochem. Biophys.*, **311**, 55-61.

Laskowski, R. A., et al. (1993) PROCHECK: a program to check stereochemical quality of protein structures. *J. Appl. Crystallogr.*, **26**, 283-291.

Lemmon, M.A., et al. (1997) Kit receptor dimerization is driven by bivalent of stem cell factor, *J. Biol. Chem.*, **272**, 6311-6317.

Lev, S., et al., (1992) Dimerization and activation of the Kit receptor by monovalent and bivalent binding of the stem cell factor. *J. Biol. Chem.*, **267**, 15970-15977.

Lev, S., et al., (1993) Interspecies molecular chimeras of Kit help define the binding site of the stem cell factor. *Mol. Cell. Biol.*, **13**, 2224-2234.

Lev, S., et al., (1994) Steel factor and *c-kit* protooncogene: genetic lessons in signal transduction, *Crit. Rev. Oncog.*, **5**, 141-168.

Lu, H. S., et al., (1991) Amino acid sequence and post-translational modification of stem cell factor isolated from buffalo rat liver cell-conditioned

medium. *J. Biol. Chem.*, **266**, 8102-8107.

Lu, H. S., et al., (1992) Post-translational processing of membrane-associated recombinant human stem cell factor expressed in Chinese hamster ovary cells. *Arch. Biochem. Biophys.*, **298**, 150-158.

Lu, H. S., et al., (1996) Isolation and characterization of a disulfide-linked human stem cell factor dimer. *J. Biol. Chem.*, **271**, 11309-11316.

Lyman, S.D, and Jacobsen, S.E.W. (1998) c-Kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities, *Blood*, **91**, 1101-1134.

Martin, F. H., et al., (1990) Primary structure and functional expression of rat and human stem cell factor DNAs. *Cell*, **63**, 203-211.

Matous, J. V., et al., (1996) Structure-function relationships of stem cell factor: an analysis based on a series of human-murine SCF chimera and the mapping of a neutralizing monoclonal antibody. *Blood*, **88**, 437-444.

McDonald, N. Q., et al., (1995) Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. *EMBO J.*, **14**, 2689-2699.

McKay, D.B. (1992) Unraveling the structure of IL-2, *Science*, **257**, 412-413.

McNiece, I. K. and Briddell, R. A. (1995) Stem cell factor. *J. Leukoc. Biol.*, **57**, 14-22.

Mendiaz, E. A., et al. (1996) Epitope mapping and immunoneutralization of recombinant human stem cell factor. *Eur. J. Biochem.*, **239**, 842-849.

Milburn, M. V., et al. (1993) A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5. *Nature*, **363**, 172-176.

Muller, Y. A., et al. (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. *Proc. Natl. Acad. Sci. USA*, **94**, 7192-7197.

Neufeld, G., et al. (1994) Vascular endothelial growth factor and its receptors. *Prog. Growth Factor Res.*, **5**, 89-97.

Nicholls, A., et al. (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins*, **11**, 281-296.

Oefner, C., et al. (1992) Crystal structure of human platelet-derived growth factor BB. *EMBO J.*,

11, 3921-3926.

Otwinowski, Z. (1993) Oscillation data reduction program, In N.I.L. Sawyer, and S. Bailey (eds.) *Data Collection and Processing*, Science and Engineering Research Council, Warrington, UK, Vol. pp. 55-62.

Pähler, A., et al., (1990) A probability representation for phase information from multiwavelength anomalous dispersion. *Acta Cryst. A*, **46**, 537-540.

Pandit, J., et al., (1992) Three-dimensional structure of dimeric huam recombinant macrophage colony-stimulating factor. *Science*, **258**, 1358-1362.

Philo, J. S., et al., (1996) Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit. *J. Biol. Chem.*, **271**, 6895-6902.

Qiu, F., et al., (1988) Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. *EMBO J.*, **7**, 1003-1011.

Raines, E.W. and Ross, R. (1992) Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded

sequences. *J. Cell Biol.*, **116**, 533-543.

Read, R. J. (1986) Improved Fourier coefficients
for maps using phases from partial structures with
errors. *Acta Crystallogr, A*, **42**, 140-149.

Rousset, D., et al., (1995) Molecular evolution of
the genes encoding receptor tyrosine kinase with
immunoglobulinlike domains. *J. Mol. Evol.*, **41**,
421-430.

Rozwarski, D. A., et al., (1994) Structural
comparisons among the short-chain helical
cytokines. *Structure*, **2**, 159-173.

Russell, E.S. (1979) Hereditary anemias of the
mouse: a review for geneticists. *Adv. Genet.*, **20**,
357-459.

Shrake, A. and Rupley, J. A. (1973) Environment and
exposure to solvent of protein atoms: lysozyme and
insulin. *J. Mol. Biol.*, **79**, 351-371.

Shull, R.M. et al., (1992) Canine stem cell factor
(c-kit ligand) supports the survival of
hematopoietic progenitors in long-term canine marro

Stanley, E. R. and Guilbert, L. J. (1981) Methods
for the purification, assay, characterization and
target cell binding of a colony stimulating factor
(CSF-1). *J. Immunol. Methods*, **42**, 253-284.

Sprang, S.R. and Bazan J.F. (1993) Cytokine structural taxonomy and mechanisms of receptor engagement, *Curr. Opin. Struct. Biol.*, **3**, 815-827.

Stein, J., et al. (1990) Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. *Blood*, **76**, 1308-1314.

Tan, K., et al., (1998) The structure of immunoglobulin superfamily domains 1 and 2 of MAdCAM-1 reveals novel features important for integrin recognition. *Structure*, **6**, 793-801.

Taylor, E. W., et al., (1994) Structure-function studies on recombinant human macrophage colony-stimulating factor (M-CSF). *J. Biol. Chem.*, **269**, 31171-31177.

Toksoz, D., et al., (1992) Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. *Proc. Natl. Acad. Sci. USA*, **89**, 7350-7354.

Wang, J. H., et al., (1995) The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): a cyclic peptide based on the domain 1 C-D loop can inhibit

VCAM-1-alpha 4 integrin interaction. *Proc. Natl. Acad. Sci. USA*, **92**, 5714-5718.

5 Wang, Z., et al., (1993) Identification of the ligand-binding regions in the macrophage colony-stimulating factor receptor extracellular domain. *Mol. Cell. Biol.*, **13**, 5348-5359.

10 Wiesmann, C., et al., (1997) Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. *Cell*, **91**, 695-704.

15 Wlodawer, A., et al., (1992) Crystal structure of human recombinant interleukin-4 at 2.25 Å, *FEBS Lett.*, **309**, 59-64.

20 Zdanov, A., et al., (1995) Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. *Structure*, **3**, 591-601.

25 Zimmer, Y., et al., (1993) Multiple structural elements determine ligand binding of fibroblast growth factor receptors: Evidence that both Ig domain 2 and 3 define receptor specificity. *J. Biol. Chem.*, **268**, 7899-7903.

What is claimed is:

1. A computer based method for preparing a stem cell factor (SCF) analog comprising the steps of:
 - (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure;
 - (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration;
 - (c) preparing a SCF molecule having an alteration at said at least one selected site; and
 - (d) optionally, testing the SCF molecule for a desired characteristic.
2. The method of claim 1, wherein the SCF analog comprises a polypeptide having an amino acid sequence portion of SCF capable of binding a receptor and having the overall three-dimensional conformation as shown in Figures 2A-2B, wherein the three-dimensional conformation is:
 - a) anti-parallel, double-cross over 4-alpha helical bundle with a left hand twist; and
 - b) overall dimensions of approximately 85 Å x 30 Å x 20 Å.
3. The method of claim 1, wherein the SCF analog

comprises electron density distributions as set forth in Figures 1A, 1B, and 1C.

4. The method of claim 1 wherein the SCF molecule is a native SCF or a selenomethionyl SCF.
5. The method of claim 1 wherein the site on the SCF molecule for alteration is a receptor binding site on the surface of the SCF molecule or a non-receptor site of the SCF.
6. The method of claim 5, wherein the receptor binding site comprises approximately amino acid residues 79-95.
7. An isolated SCF analog prepared according to the method of claim 1.
8. The isolated SCF analog of claim 7, wherein the SCF analog comprises a polypeptide having an amino acid sequence portion of SCF capable of binding a receptor and having the overall three-dimensional conformation as shown in Figures 2A-2B, wherein the three-dimensional conformation is:
 - a) anti-parallel, double-cross over 4-alpha helical bundle with a left hand twist; and
 - b) overall dimensions of approximately 85 Å x 30 Å x 20 Å..

9. The isolated SCF analog of claim 10, wherein the SCF analog comprises electron density distributions altered from those set forth in Figures 1A, 1B, and 1C.
10. A composition comprising an isolated SCF analog prepared according to the method of claim 1 effective to treat a subject and a pharmaceutically acceptable carrier.
11. A method of treating a subject having a disorder requiring SCF comprising administration of a composition comprising an isolated SCF analog prepared by the method of claim 1 or a compound designed by the method of claim 32.
12. The method of claim 11, wherein the subject has a blood disorder.
13. The method of claim 12, wherein the disorder which the subject has is anemia, myeloproliferative disorder, neoplasia, nerve damage, infertility, intestinal damage, a pigmentation disorder, or immunodeficiency.
14. The method of claim 11, wherein the administration of the isolated SCF analog is for ex vivo or in vitro production of peripheral blood progenitors, ex vivo or in vitro stem cell expansion, ex vivo or in vitro

growth of epithelial cells, ex vivo or in vitro growth of stromal cells, ex vivo or in vitro dendritic cell stimulation, and in vivo cell mobilization.

- 5
15. A method for designing a compound capable of binding to the stem cell factor (SCF) receptor site of comprising the steps of:
- 10
- a) determining a binding site for the SCF receptor on the SCF based on the three-dimensional structure of SCF or an SCF polypeptide or portion/fragment thereof, atomic coordinates computed from X-ray diffraction data of a crystal comprising a polypeptide having an amino acid sequence portion of SCF capable of binding the receptor; and
- 15
- b) designing a compound comprising an entity that binds the SCF receptor.
- 20
16. The method of claim 15, wherein the design of the compound of step (b) is determined by shape complementarity or by estimated interaction energy.
- 25
17. The method of claim 15, wherein the designed compound fits an SCF receptor binding site on SCF receptor as shown in Figure 6.
- 30
18. The method of claim 15, wherein the designed compound fits an SCF receptor binding site on

SCF receptor as shown in Figures 7A or 7B.

19. The method of claim 15, wherein the designed compound is a double-headed SCF ligand analog having the structure set forth in Figure 10A.
20. The method of claim 19, wherein each ligand head of the double-headed SCF ligand analog is an oligopeptide having the structure set forth in Figure 10B.
21. The method of claim 20, wherein the oligopeptide comprises a sequence, wherein functional moiety F_1 corresponds to a segment of amino acid residues from within N-terminal residues 1-10 of SCF, functional moiety F_2 corresponds to a segment of amino acid residues from within residues 79-95 of SCF, and functional moiety F_3 corresponds to a segment of amino acid residues located within three amino acid residues of amino acid residue 127, wherein F_1 , F_2 , and F_3 are connected by connecting peptide segments X_n , X_m , and X_p , respectively, wherein $n=0-5$, $m=0-5$ and $p=3-8$ amino acid residues, respectively, and the conjugation moiety F_L is a cysteine residue.
22. The method of claim 21, wherein the functional moieties F_1 , F_2 , and F_3 on the ligand heads have been selected by bacterial phage display

for optimal receptor binding.

23. The method of claim 21, wherein the functional moieties and connecting peptide segments of an active oligopeptide ligand head are replaced by chemical mimetics.
24. The method of claim 15, wherein an appropriate chemical scaffold of connecting segments has been designed to comprise (present) functional moieties F_1 , F_2 , and F_3 , which have been selected by combinatorial chemistry for optimal receptor binding from a library of chemical moieties complementary to receptor-binding sites on the surface of SCF.
25. The method of claim 15, wherein the linker comprises an organic polymer having two ends capped at each end by a reactive capping moiety, F_c , which react covalently with the conjugation moiety, F_L , on the ligand head.
26. The method of claim 25, wherein the organic polymer is polyethyleneglycol (PEG) comprising the structure $H[OCH_2CH_2]_nOH$, wherein n is 10-20.
27. The method of claim 25, wherein the capping moiety, F_c , is a thiol-reactive group such as N-ethyl maleimide.

28. The method of claim 15, wherein the conjugating moiety, F_L, is a thiol containing group such as cysteine.
29. A compound designed by the method of claim 15.
30. A composition comprising the compound designed by the method of claim 15 and a pharmaceutically acceptable carrier.
31. The compound of claim 30, wherein the compound comprises an isolated SCF analog, whose alteration site is a receptor-binding site on the surface of the altered SCF molecule.
32. A method of treating a subject comprising administration of a compound designed by the method of claim 32.
33. The method of claim 32, wherein the subject has a blood disorder.
34. The method of claim 33, wherein the blood disorder is anemia or immunodeficiency.
35. The method of claim 32, wherein the compound is an isolated SCF analog.
36. A method of stimulating the production of hematopoietic cells in a subject comprising administering an isolated stem cell factor

(SCF) analog.

37. The method of claim 36, wherein isolated stem cell factor (SCF) analog is prepared by the method of claim 1 or designed by the method of claim 32.
38. The method of claim 37, wherein the isolated SCF analog comprises amino acid residues of native or recombinant SCF1-165 or amino acid residues of a recombinant selenomethionyl SCF1-141.
39. An isolated stem cell factor (SCF) molecule, which is an altered SCF, comprising any portion of amino acids 1-165 of a human SCF polypeptide, optionally comprising an N-terminal methionine before amino acid residue 1, wherein the polypeptide has an amino acid sequence portion of SCF capable of binding to the SCF receptor.
40. The altered isolated stem cell factor molecule of claim 39, wherein an alteration is selected from the group consisting of deletion, insertion and substitution of at least one amino acid residue from the naturally occurring amino acid sequence of SCF.
41. The altered isolated stem cell factor molecule of claim 40, wherein an alteration is a

truncated SCF comprising amino acids 1-141 of a human SCF polypeptide, optionally comprising an N-terminal methionine before amino acid residue 1.

- 5
42. The altered isolated stem cell factor molecule of claim 40, wherein the substitution of at least one amino acid residue is selected from the group consisting of SCF(Y26C) disulfide-linked dimer, SCF(D25C), SCF(K62C), SCF(K78N, N81K), SCF(R117A, I118A), SCF(E92A, S95A), and SCF(D124A, K127D).
- 10
43. A stem cell factor molecule of claim 40, wherein the overall three-dimensional conformation of the stem cell factor molecule has an altered three-dimensional structure of the α C- β 2 loop.
- 15
44. A pharmaceutical composition comprising the altered isolated SCF molecule of claim 39 and a pharmaceutically acceptable carrier.
- 20
45. A stem cell factor molecule of claim 39, wherein the molecule is a hybrid molecule of the altered stem cell factor molecule and a second protein or fragment thereof.
- 25
46. A stem cell factor molecule of claim 39, wherein the alteration of the α C- β 2 loop is a change in length of the amino acid sequence of
- 30

the α C- β 2 loop by a deletion or an insertion of at least one amino acid residue or a change in at least one amino acid residue from the naturally occurring amino acid residue(s) of the α C- β 2 loop.

47. The altered isolated stem cell factor molecule of claim 46, wherein the change in said at least one amino acid residue from the naturally occurring amino acid residue(s) is selected from the group consisting of SCF(Y26C) disulfide-linked dimer, SCF(D25C), SCF(K62C), SCF(K78N, N81K), SCF(R117A, I118A), SCF(E92A, S95A), and SCF(D124A, K127D).

CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD
CELL PROLIFERATION BY EFFECTING DIMERIZATION OF THE
RECEPTOR FOR STEM CELL FACTOR

5 ABSTRACT OF THE DISCLOSURE

10

15

20

25

30

This invention provides a computer based method for preparing a stem cell factor (SCF) analog comprising the steps of: (a) providing computer expression of the three dimensional structure of an SCF molecule using its crystal structure; (b) selecting from the computer expression of step (a) at least one site on the SCF molecule for alteration; (c) preparing a SCF molecule having an alteration at said at least one selected site; and (d) optionally, testing the SCF molecule for a desired characteristic. This invention also provides SCF analogs and SCF ligand analogs prepared according to the above-described method. Compositions comprising SCF analogs or SCF ligand analogs prepared according to the above-described method effective to treat a subject and a pharmaceutically acceptable carrier are provided, as are methods of treating a subject comprising administration of pharmaceutical compositions comprising the prepared SCF analogs and SCF ligand analogs prepared by the described methods. This invention also provides methods for designing compounds capable of binding to the SCF receptor site and compounds designed by the above-described methods.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7

Figure 8-1

```

HEADER      GROWTH FACTOR
TITLE       HUMAN RECOMBINANT STEM CELL FACTOR
COMPND      MOL ID: 1;
COMPND      2 MOLECULE: STEM CELL FACTOR;
COMPND      3 CHAIN: A, B, C, D;
COMPND      4 SYNONYM: SCF, SL, MGF, MAST CELL GROWTH FACTOR;
COMPND      5 ENGINEERED: YES;
COMPND      6 BIOLOGICAL_UNIT: DIMER
SOURCE      MOL ID: 1;
SOURCE      2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE      3 ORGANISM_COMMON: HUMAN;
SOURCE      4 EXPRESSION_SYSTEM: NULL
KEYWDS      HUMAN STEM CELL FACTOR, STEEL FACTOR, KIT LIGAND, MAST CELL
KEYWDS      2 GROWTH FACTOR
EXPDTA      X-RAY DIFFRACTION
AUTHOR      X.JIANG,O.GUREL,K.E.LANGLEY,W.A.HENDRICKSON
JRNL        AUTH X.JIANG,O.GUREL,K.E.LANGLEY,W.A.HENDRICKSON
JRNL        TITL CRYSTAL STRUCTURE OF RECOMBINANT HUMAN STEM CELL
JRNL        TITL 2 FACTOR
JRNL        REF TO BE PUBLISHED
JRNL        REFN
REMARK      1
REMARK      2
REMARK      2 RESOLUTION. 2.2  ANGSTROMS.
REMARK      3
REMARK      3 REFINEMENT.
REMARK      3 PROGRAM : X-PLOR 3.1
REMARK      3 AUTHORS : BRUNGER
REMARK      3
REMARK      3 DATA USED IN REFINEMENT.
REMARK      3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.2
REMARK      3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.0
REMARK      3 DATA CUTOFF (SIGMA(F)) : 2
REMARK      3 DATA CUTOFF HIGH (ABS(F)) : 100000
REMARK      3 DATA CUTOFF LOW (ABS(F)) : 0.1
REMARK      3 COMPLETENESS (WORKING+TEST) (%) : 96.6
REMARK      3 NUMBER OF REFLECTIONS : 49851
REMARK      3
REMARK      3 FIT TO DATA USED IN REFINEMENT.
REMARK      3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK      3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK      3 R VALUE (WORKING SET) : 0.199
REMARK      3 FREE R VALUE : 0.242
REMARK      3 FREE R VALUE TEST SET SIZE (%) : 6.0
REMARK      3 FREE R VALUE TEST SET COUNT : 3016
REMARK      3 ESTIMATED ERROR OF FREE R VALUE : 0.0044
REMARK      3
REMARK      3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK      3 TOTAL NUMBER OF BINS USED : 10
REMARK      3 BIN RESOLUTION RANGE HIGH (A) : 2.0
REMARK      3 BIN RESOLUTION RANGE LOW (A) : 2.28
REMARK      3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.0
REMARK      3 REFLECTIONS IN BIN (WORKING SET) : 4349
REMARK      3 BIN R VALUE (WORKING SET) : 0.3159
REMARK      3 BIN FREE R VALUE : 0.3450
REMARK      3 BIN FREE R VALUE TEST SET SIZE (%) : 6.4
REMARK      3 BIN FREE R VALUE TEST SET COUNT : 302
REMARK      3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.0198
REMARK      3
REMARK      3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.

```

1SCF

0353

03509027.062000

Figure 8-2

```

REMARK 3 PROTEIN ATOMS : 3517
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 19
REMARK 3 SOLVENT ATOMS : 264
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : 38.5
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 32.1
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : NULL
REMARK 3 B22 (A**2) : NULL
REMARK 3 B33 (A**2) : NULL
REMARK 3 B12 (A**2) : NULL
REMARK 3 B13 (A**2) : NULL
REMARK 3 B23 (A**2) : NULL
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM SIGMAA (A) : NULL
REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL
REMARK 3
REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL
REMARK 3 ESD FROM C-V SIGMAA (A) : NULL
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.016
REMARK 3 BOND ANGLES (DEGREES) : 2.5
REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.8
REMARK 3 IMPROPER ANGLES (DEGREES) : 2.05
REMARK 3
REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA
REMARK 3 MAIN-CHAIN BOND (A**2) : 1.2 ; 1.5
REMARK 3 MAIN-CHAIN ANGLE (A**2) : 1.6 ; 2.0
REMARK 3 SIDE-CHAIN BOND (A**2) : 2.1 ; 2.0
REMARK 3 SIDE-CHAIN ANGLE (A**2) : 2.4 ; 2.5
REMARK 3
REMARK 3 NCS MODEL : RESTRAINTS
REMARK 3
REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT
REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL
REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL
REMARK 3
REMARK 3 PARAMETER FILE 1 : PARAM19_MOD.PRO
REMARK 3 PARAMETER FILE 2 : PARAM19.SOL
REMARK 3 PARAMETER FILE 3 : HETEROPARAM19.PAR
REMARK 3 TOPOLOGY FILE 1 : TOPH19_MOD.PRO
REMARK 3 TOPOLOGY FILE 2 : TOPH19.SOL
REMARK 3 TOPOLOGY FILE 3 : HETERO.TOP
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT WAS PERFORMED WITH
REMARK 3 ANOMALOUS ON; PARAM19_MOD.PRO AND TOPH19_MOD.PRO ARE
REMARK 3 MODIFIED PARAMETER AND TOPOLOGY FILES OF PARAM19.PRO AND
REMARK 3 TOPH19.PRO, RESPECTIVELY, FOR SELENOMETHIONYL PROTEINS.
REMARK 3 NCS RESTRAINTS WERE APPLIED ONLY DURING THE INITIAL
REMARK 3 REFINEMENT.
REMARK 4
REMARK 4 1SCF COMPLIES WITH FORMAT V. 2.3,

```

0060027-062900

[illegible]

5

```

REMARK 6
REMARK 6 THE FOLLOWING RESIDUES ARE DISORDERED IN THE STRUCTURE:
REMARK 6 A1-10; A92-103; B1-10; B130-136; B139-141; C1-10; C92-103;
REMARK 6 C127-141; D1-10; D91-103; D128-141
REMARK 7
REMARK 7 THE SIDE CHAINS OF THE FOLLOWING RESIDUES ARE DISORDERED IN
REMARK 7 THE STRUCTURE: A11-13,A91,A127,A133,B11,B13,B93,B96-97,
REMARK 7 B103,B128,B137,C11,C13,C39,D11,D13,D90,D106,D127
REMARK 8
REMARK 8 LYS A 91 IS LAST RESIDUE BEFORE GAP, PHE B 129 IS LAST
REMARK 8 RESIDUE BEFORE GAP, LYS C 91 IS LAST RESIDUE BEFORE GAP,
REMARK 8 PHE C 126 IS LAST RESIDUE BEFORE GAP, VAL D 90 IS LAST
REMARK 8 RESIDUE BEFORE GAP.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION :
REMARK 200 TEMPERATURE (KELVIN) : 110
REMARK 200 PH : 7.4
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : NSLS
REMARK 200 BEAMLINE : X4A
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 0.986
REMARK 200 MONOCHROMATOR : SILICON CRYSTAL
REMARK 200 OPTICS : MIRRORS
REMARK 200
REMARK 200 DETECTOR TYPE : IMAGE PLATE
REMARK 200 DETECTOR MANUFACTURER : FUJI
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENSO
REMARK 200 DATA SCALING SOFTWARE : SCALEPACK
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 65689
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.0
REMARK 200 RESOLUTION RANGE LOW (A) : 25
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3
REMARK 200
REMARK 200 OVERALL:
REMARK 200 COMPLETENESS FOR RANGE (%) : 94.9
REMARK 200 DATA REDUNDANCY : 2.75
REMARK 200 R MERGE (I) : NULL
REMARK 200 R SYM (I) : 0.056
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 15.3
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.0
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07
REMARK 200 COMPLETENESS FOR SHELL (%) : 72
REMARK 200 DATA REDUNDANCY IN SHELL : 2.23
REMARK 200 R MERGE FOR SHELL (I) : NULL
REMARK 200 R SYM FOR SHELL (I) : 0.581
REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.6
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: NULL
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MAD
REMARK 200 SOFTWARE USED: MADLSQ
REMARK 200 STARTING MODEL: NULL

```


11/85

Figure 8-4

```

REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): NULL
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS*3/DA): NULL
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: PROTEIN WAS CRYSTALLIZED FROM
REMARK 280 22% PEG 400, 220 MM CACL2, 100 MM HEPES, PH 7.4 AND 5MM
REMARK 280 DTT IN 20 DEGREE ROOM
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21
REMARK 290
REMARK 290      SYMOP      SYMMETRY
REMARK 290      NNNMMM      OPERATOR
REMARK 290      1555      X,Y,Z
REMARK 290      2555      1/2-X,-Y,1/2+Z
REMARK 290      3555      -X,1/2+Y,1/2-Z
REMARK 290      4555      1/2+X,1/2-Y,-Z
REMARK 290
REMARK 290      WHERE NNN -> OPERATOR NUMBER
REMARK 290      MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY2 2 -1.000000 0.000000 0.000000 35.90922
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 44.09560
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 41.27456
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 44.09560
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 35.90922
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 41.27456
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 295
REMARK 295 NON-CRYSTALLOGRAPHIC SYMMETRY
REMARK 295 THE TRANSFORMATIONS PRESENTED ON THE MTRIX RECORDS BELOW
REMARK 295 DESCRIBE NON-CRYSTALLOGRAPHIC RELATIONSHIPS AMONG ATOMS
REMARK 295 IN THIS ENTRY. APPLYING THE APPROPRIATE MTRIX
REMARK 295 TRANSFORMATION TO THE RESIDUES LISTED FIRST WILL YIELD
REMARK 295 APPROXIMATE COORDINATES FOR THE RESIDUES LISTED SECOND.
REMARK 295 CHAIN IDENTIFIERS GIVEN AS "?" REFER TO CHAINS FOR WHICH
REMARK 295 ATOMS ARE NOT FOUND IN THIS ENTRY.
REMARK 295
REMARK 295      APPLIED TO      TRANSFORMED TO
REMARK 295      TRANSFORM CHAIN RESIDUES      CHAIN RESIDUES      RMSD
REMARK 295      SSS
REMARK 295      M 1      B 11 .. 91      A 11 .. 91      1.020
REMARK 295      M 2      A 11 .. 91      C 11 .. 91      1.677
REMARK 295      M 3      D 11 .. 91      A 11 .. 91      1.926
REMARK 295      M 4      C 11 .. 91      B 11 .. 91      0.620
REMARK 295      M 5      D 11 .. 91      B 11 .. 91      1.764

```

00603027.062900

Figure 8-5

```

REMARK 295      M 6      D 11 .. 91      C 11 .. 91      1.810
REMARK 295      M 7      D 11 .. 91      A 11 .. 91      0.898
REMARK 295
REMARK 295      WHERE SSS -> COLUMNS 8-10 OF MTRIX RECORDS
REMARK 295
REMARK 295      REMARK:
REMARK 295      TRANSFORMATION RELATES CHAIN B TO CHAIN A; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN C TO CHAIN A; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN D TO CHAIN A; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN C TO CHAIN B; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN D TO CHAIN B; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN D TO CHAIN C; INCLUDING
REMARK 295      RESIDUES 11-90 AND 104-126.
REMARK 295      TRANSFORMATION RELATES CHAIN CD DIMER TO CHAIN AB DIMER;
REMARK 295      INCLUDING RESIDUES A11-91,A104-126,B11-B90,B104-127,
REMARK 295      C11-91,C104-126,D11-90,D104-127
REMARK 470
REMARK 470      MISSING ATOM
REMARK 470      THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470      RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470      I=INSERTION CODE):
REMARK 470      M RES CSSEQI ATOMS
REMARK 470      ASN A 11 CG OD1 ND2
REMARK 470      VAL A 12 CG1 CG2
REMARK 470      LYS A 13 CG CD CE NZ
REMARK 470      LYS A 91 CG CD CE NZ
REMARK 470      LYS A 127 CG CD CE NZ
REMARK 470      SER A 133 OG
REMARK 470      ASN B 11 CG OD1 ND2
REMARK 470      LYS B 13 CG CD CE NZ
REMARK 470      ASN B 93 CG OD1 ND2
REMARK 470      LYS B 96 CG CD CE NZ
REMARK 470      ASP B 97 CG OD1 OD2
REMARK 470      LYS B 103 CG CD CE NZ
REMARK 470      ASP B 128 CG OD1 OD2
REMARK 470      ASP B 137 CG OD1 OD2
REMARK 470      ASN C 11 CG OD1 ND2
REMARK 470      LYS C 13 CG CD CE NZ
REMARK 470      LEU C 39 CG OD1 CD2
REMARK 470      ASN D 11 CG OD1 ND2
REMARK 470      LYS D 13 CG CD CE NZ
REMARK 470      VAL D 90 CG1 CG2
REMARK 470      GLU D 106 CG CD OE1 OE2
REMARK 470      LYS D 127 CG CD CE NZ
REMARK 500
REMARK 500      GEOMETRY AND STEREOCHEMISTRY
REMARK 500      SUBTOPIC: CLOSE CONTACTS
REMARK 500
REMARK 500      THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC
REMARK 500      SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15
REMARK 500      ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A
REMARK 500      SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375
REMARK 500      INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE
REMARK 500      LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS.

```

13/85

Figure 8-6

```

REMARK 500 DISTANCE CUTOFF:
REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS
REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMP DISTANCE
REMARK 500 CA CA 1021 O VAL A 139 3655 2.18
REMARK 500
REMARK 500 REMARK: NULL
REMARK 600
REMARK 600 HETEROGEN
REMARK 600 1PE: ONLY PART OF THE PEG400 CHAIN IS ORDERED IN THE
REMARK 600 STRUCTURE.
REMARK 999
REMARK 999 SEQUENCE
REMARK 999 1SCF A SWS P21583 1 - 35 NOT IN ATOMS LIST
REMARK 999 1SCF A SWS P21583 167 - 273 NOT IN ATOMS LIST
REMARK 999 1SCF B SWS P21583 1 - 35 NOT IN ATOMS LIST
REMARK 999 1SCF B SWS P21583 164 - 273 NOT IN ATOMS LIST
REMARK 999 1SCF C SWS P21583 1 - 35 NOT IN ATOMS LIST
REMARK 999 1SCF C SWS P21583 152 - 273 NOT IN ATOMS LIST
REMARK 999 1SCF D SWS P21583 1 - 35 NOT IN ATOMS LIST
REMARK 999 1SCF D SWS P21583 153 - 273 NOT IN ATOMS LIST
DBREF 1SCF A 11 91 SWS P21583 SCF_HUMAN 36 116
DBREF 1SCF A 104 141 SWS P21583 SCF_HUMAN 129 166
DBREF 1SCF B 11 129 SWS P21583 SCF_HUMAN 36 154
DBREF 1SCF B 137 138 SWS P21583 SCF_HUMAN 162 163
DBREF 1SCF C 11 91 SWS P21583 SCF_HUMAN 36 116
DBREF 1SCF C 104 126 SWS P21583 SCF_HUMAN 129 151
DBREF 1SCF D 11 90 SWS P21583 SCF_HUMAN 36 115
DBREF 1SCF D 104 127 SWS P21583 SCF_HUMAN 129 152
SEQADV 1SCF MSE A 27 SWS P21583 MET 52 MODIFIED
SEQADV 1SCF MSE A 36 SWS P21583 MET 61 MODIFIED
SEQADV 1SCF MSE A 48 SWS P21583 MET 73 MODIFIED
SEQADV 1SCF A SWS P21583 GLU 117 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 ASN 118 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 SER 119 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 SER 120 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 LYS 121 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 ASP 122 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 LEU 123 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 LYS 124 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 LYS 125 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 SER 126 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 PHE 127 GAP IN PDB ENTRY
SEQADV 1SCF A SWS P21583 LYS 128 GAP IN PDB ENTRY
SEQADV 1SCF MSE B 27 SWS P21583 MET 52 MODIFIED
SEQADV 1SCF MSE B 36 SWS P21583 MET 61 MODIFIED
SEQADV 1SCF MSE B 48 SWS P21583 MET 73 MODIFIED
SEQADV 1SCF B SWS P21583 VAL 155 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 VAL 156 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 ALA 157 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 SER 158 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 GLU 159 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 THR 160 GAP IN PDB ENTRY
SEQADV 1SCF B SWS P21583 SER 161 GAP IN PDB ENTRY
SEQADV 1SCF MSE C 27 SWS P21583 MET 52 MODIFIED
SEQADV 1SCF MSE C 36 SWS P21583 MET 61 MODIFIED
SEQADV 1SCF MSE C 48 SWS P21583 MET 73 MODIFIED
SEQADV 1SCF C SWS P21583 GLU 117 GAP IN PDB ENTRY
SEQADV 1SCF C SWS P21583 ASN 118 GAP IN PDB ENTRY

```

09600027-062900

SEQUES	14	B	273	SER	PRO	GLU	LYS	ASP	SER	ARG	VAL	SER	VAL	THR	LYS	PRO
SEQUES	15	B	273	PHE	MET	LEU	PRO	ASP	PRO	VAL	ALA	VAL	SER	LEU	ARG	ASN
SEQUES	16	B	273	ASP	SER	SER	SER	SER	ASN	ARG	LYS	ALA	LYS	ASN	PRO	PRO
SEQUES	17	B	273	GLY	ASP	SER	SER	LEU	HIS	TRP	ALA	ALA	MET	ALA	LEU	PRO
SEQUES	18	B	273	ALA	LEU	PHE	SER	LEU	ILE	ILE	GLY	PHE	ALA	PHE	GLY	ALA
SEQUES	19	B	273	LEU	TYR	TRP	LYS	LYS	ARG	GLN	PRO	SER	LEU	THR	ARG	ALA
SEQUES	20	B	273	VAL	GLU	ASN	ILE	GLN	ILE	ASN	GLU	GLU	ASP	ASN	GLU	ILE
SEQUES	21	B	273	SER	MET	LEU	GLN	GLU	LYS	GLU	ARG	GLU	PHE	GLN	GLU	VAL
SEQUES	1	C	273	MET	LYS	LYS	THR	GLN	THR	TRP	ILE	LEU	THR	CYS	ILE	TYR
SEQUES	2	C	273	LEU	GLN	LEU	LEU	LEU	PHE	ASN	PRO	LEU	VAL	LYS	THR	GLU
SEQUES	3	C	273	GLY	ILE	CYS	ARG	ASN	ARG	VAL	THR	ASN	ASN	VAL	LYS	ASP
SEQUES	4	C	273	VAL	THR	LYS	LEU	ALA	ASN	LEU	PRO	LYS	LYS	ASP	TYR	MSE
SEQUES	5	C	273	VAL	TRP	PRO	VAL	TRP	VAL	PRO	GLY	MSE	ASP	VAL	LEU	PRO
SEQUES	6	C	273	SER	HIS	CYS	TRP	ILE	ILE	SER	GLU	MSE	VAL	PHE	GLN	LEU
SEQUES	7	C	273	ASP	SER	LEU	THR	ASP	LEU	LEU	ASP	LYS	PHE	SER	ASN	ILE
SEQUES	8	C	273	SER	GLU	GLY	LEU	SER	ASN	TYR	SER	ILE	ILE	ASP	LYS	LEU
SEQUES	9	C	273	VAL	ASN	ILE	VAL	ASP	ASP	LEU	VAL	GLU	CYS	VAL	LYS	GLU
SEQUES	10	C	273	ASN	SER	SER	LYS	ASP	LEU	LYS	LYS	SER	PHE	LYS	SER	PRO
SEQUES	11	C	273	GLU	PRO	ARG	LEU	PHE	THR	PRO	GLY	GLU	PHE	PHE	ARG	ILE
SEQUES	12	C	273	PHE	ASN	ARG	SER	ILE	ASP	ALA	PHE	LYS	ASP	PHE	VAL	VAL
SEQUES	13	C	273	ALA	SER	GLU	THR	SER	ASP	CYS	VAL	VAL	SER	SER	THR	LEU
SEQUES	14	C	273	SER	PRO	GLU	LYS	ASP	SER	ARG	VAL	SER	VAL	THR	LYS	PRO
SEQUES	15	C	273	PHE	MET	LEU	PRO	PRO	VAL	ALA	ALA	SER	SER	LEU	ARG	ASN
SEQUES	16	C	273	ASP	SER	SER	SER	SER	ASN	ARG	LYS	ALA	LYS	ASN	PRO	PRO
SEQUES	17	C	273	GLY	ASP	SER	SER	LEU	HIS	TRP	ALA	ALA	MET	ALA	LEU	PRO
SEQUES	18	C	273	ALA	LEU	PHE	SER	LEU	ILE	ILE	GLY	PHE	ALA	PHE	GLY	ALA
SEQUES	19	C	273	LEU	TYR	TRP	LYS	LYS	ARG	GLN	PRO	SER	LEU	THR	ARG	ALA
SEQUES	20	C	273	VAL	GLU	ASN	ILE	GLN	ILE	ASN	GLU	GLU	ASP	ASN	GLU	ILE
SEQUES	21	C	273	SER	MET	LEU	GLN	GLU	LYS	GLU	ARG	GLU	PHE	GLN	GLU	VAL
MODRES	18CF	MSE	A	27	MET	SELENOMETHIONINE										
MODRES	18CF	MSE	A	36	MET	SELENOMETHIONINE										
MODRES	18CF	MSE	A	48	MET	SELENOMETHIONINE										
MODRES	18CF	MSE	B	27	MET	SELENOMETHIONINE										
MODRES	18CF	MSE	B	36	MET	SELENOMETHIONINE										
MODRES	18CF	MSE	B	48	MET	SELENOMETHIONINE										

Figure 8-9

```

MODRES 1SCF MSE D 36 MET SELENOMETHIONINE
MODRES 1SCF MSE D 48 MET SELENOMETHIONINE
HET MSE A 27 8
HET MSE A 36 8
HET MSE A 48 8
HET MSE B 27 8
HET MSE B 36 8
HET MSE B 48 8
HET MSE C 27 8
HET MSE C 36 8
HET MSE C 48 8
HET MSE D 27 8
HET MSE D 36 8
HET MSE D 48 8
HET CA 1021 1
HET CA 1022 1
HET CA 1023 1
HET 1PE 1 16
HETNAM MSE SELENOMETHIONINE
HETNAM CA CALCIUM ION
HETNAM 1PE POLYETHYLENE GLYCOL
HETSYN 1PE PEG400
FORMUL 1 MSE 3(CS H11 N1 O2 SE1)
FORMUL 2 MSE 3(CS H11 N1 O2 SE1)
FORMUL 3 MSE 3(CS H11 N1 O2 SE1)
FORMUL 4 MSE 3(CS H11 N1 O2 SE1)
FORMUL 5 CA 3(CAL 2+)
FORMUL 6 1PE C10 H22 O6
FORMUL 7 HOH *264 (H2 O1)
HELIX 1 1 VAL A 12 ASN A 21 1
HELIX 2 2 SER A 41 CYS A 43 5
HELIX 3 3 SER A 46 LYS A 62 5
HELIX 4 4 ASN A 72 CYS A 89 1
HELIX 5 5 PRO A 112 LYS A 127 1
HELIX 6 6 VAL B 12 ASN B 21 1
HELIX 7 7 SER B 41 CYS B 43 5
HELIX 8 8 SER B 46 LYS B 62 5
HELIX 9 9 ASN B 72 GLU B 92 1
HELIX 10 10 PRO B 112 LYS B 127 1
HELIX 11 11 VAL C 12 ASN C 21 1
HELIX 12 12 SER C 41 LYS C 62 1
HELIX 13 13 ASN C 72 VAL C 90 1
HELIX 14 14 PRO C 112 ASP C 124 1
HELIX 15 15 VAL D 12 ASN D 21 1
HELIX 16 16 SER D 41 CYS D 43 5
HELIX 17 17 SER D 46 LYS D 62 5
HELIX 18 18 ASN D 72 CYS D 89 1
HELIX 19 19 PRO D 112 ALA D 125 1
SHEET 1 A 2 THR A 29 LYS A 31 0
SHEET 2 A 2 PRO A 107 LEU A 109 -1 N ARG A 108 O LEU A 30
SHEET 1 B 2 THR B 29 LYS B 31 0
SHEET 2 B 2 PRO B 107 LEU B 109 -1 N ARG B 108 O LEU B 30
SHEET 1 C 2 THR C 29 LYS C 31 0
SHEET 2 C 2 PRO C 107 LEU C 109 -1 N ARG C 108 O LEU C 30
SHEET 1 D 2 THR D 29 LYS D 31 0
SHEET 2 D 2 PRO D 107 LEU D 109 -1 N ARG D 108 O LEU D 30
SSBOND 1 CYS A 43 CYS A 138
SSBOND 2 CYS B 43 CYS B 138
LINK N MSE A 27 C TYR A 26
LINK C MSE A 27 N ILE A 28

```

[illegible]

Figure 8-11

ATOM	5	CB	ASN	A	11	8.113	4.228	21.038	1.00	60.46	C
ATOM	6	N	VAL	A	12	10.013	5.143	18.009	1.00	57.40	C
ATOM	7	CA	VAL	A	12	10.715	6.225	17.309	1.00	53.71	C
ATOM	8	C	VAL	A	12	9.844	7.387	16.820	1.00	50.84	C
ATOM	9	O	VAL	A	12	10.343	8.268	16.130	1.00	51.46	C
ATOM	10	CB	VAL	A	12	11.541	5.657	16.126	1.00	53.25	C
ATOM	11	N	LYS	A	13	8.543	7.490	17.147	1.00	49.07	C
ATOM	12	CA	LYS	A	13	7.721	8.640	16.756	1.00	44.35	C
ATOM	13	C	LYS	A	13	8.114	9.879	17.542	1.00	42.88	C
ATOM	14	O	LYS	A	13	8.271	10.995	17.007	1.00	41.79	C
ATOM	15	CB	LYS	A	13	6.258	8.378	17.093	1.00	44.76	C
ATOM	16	N	ASP	A	14	8.283	9.557	18.839	1.00	38.29	C
ATOM	17	CA	ASP	A	14	8.609	10.545	19.818	1.00	35.56	C
ATOM	18	C	ASP	A	14	10.068	10.894	19.718	1.00	32.01	C
ATOM	19	O	ASP	A	14	10.389	12.060	19.896	1.00	30.80	C
ATOM	20	CB	ASP	A	14	8.151	10.072	21.200	1.00	38.77	C
ATOM	21	CG	ASP	A	14	6.725	10.518	21.630	1.00	43.77	C
ATOM	22	OD1	ASP	A	14	6.046	11.324	20.969	1.00	45.53	C
ATOM	23	OD2	ASP	A	14	6.269	10.057	22.680	1.00	47.33	C
ATOM	24	N	VAL	A	15	10.939	9.938	19.360	1.00	28.31	C
ATOM	25	CA	VAL	A	15	12.335	10.224	19.089	1.00	27.35	C
ATOM	26	C	VAL	A	15	12.510	11.219	17.959	1.00	29.06	C
ATOM	27	O	VAL	A	15	13.265	12.166	18.138	1.00	32.49	C
ATOM	28	CB	VAL	A	15	13.191	8.976	18.792	1.00	26.33	C
ATOM	29	CG1	VAL	A	15	14.623	9.347	18.405	1.00	20.32	C
ATOM	30	CG2	VAL	A	15	13.215	8.064	20.008	1.00	24.37	C
ATOM	31	N	THR	A	16	11.858	11.085	16.807	1.00	28.42	C
ATOM	32	CA	THR	A	16	11.968	12.085	15.758	1.00	27.97	C
ATOM	33	C	THR	A	16	11.386	13.413	16.208	1.00	25.43	C
ATOM	34	O	THR	A	16	12.020	14.418	15.905	1.00	25.82	C
ATOM	35	CB	THR	A	16	11.357	11.646	14.385	1.00	27.70	C
ATOM	36	OG1	THR	A	16	9.959	11.529	14.588	1.00	32.27	C
ATOM	37	CG2	THR	A	16	11.931	10.335	13.912	1.00	25.71	C
ATOM	38	N	LYS	A	17	10.243	13.459	16.928	1.00	24.83	C
ATOM	39	CA	LYS	A	17	9.701	14.698	17.482	1.00	23.60	C
ATOM	40	C	LYS	A	17	10.659	15.401	18.410	1.00	21.54	C
ATOM	41	O	LYS	A	17	10.756	16.624	18.373	1.00	23.88	C
ATOM	42	CB	LYS	A	17	8.365	14.488	18.206	1.00	27.08	C
ATOM	43	CG	LYS	A	17	7.291	14.120	17.198	1.00	34.84	C
ATOM	44	CD	LYS	A	17	5.881	14.040	17.781	1.00	40.64	C
ATOM	45	CE	LYS	A	17	4.800	13.911	16.665	1.00	45.98	C
ATOM	46	NZ	LYS	A	17	4.607	12.559	16.140	1.00	48.58	C
ATOM	47	N	LEU	A	18	11.417	14.646	19.212	1.00	19.73	C
ATOM	48	CA	LEU	A	18	12.377	15.207	20.151	1.00	17.98	C
ATOM	49	C	LEU	A	18	13.544	15.778	19.401	1.00	17.55	C
ATOM	50	O	LEU	A	18	13.813	16.959	19.523	1.00	17.68	C
ATOM	51	CB	LEU	A	18	12.875	14.144	21.121	1.00	17.63	C
ATOM	52	CG	LEU	A	18	13.850	14.582	22.216	1.00	15.34	C
ATOM	53	CD1	LEU	A	18	13.278	15.668	23.080	1.00	15.28	C
ATOM	54	CD2	LEU	A	18	14.253	13.389	23.032	1.00	14.40	C
ATOM	55	N	VAL	A	19	14.189	14.952	18.577	1.00	18.35	C
ATOM	56	CA	VAL	A	19	15.187	15.421	17.628	1.00	19.40	C
ATOM	57	C	VAL	A	19	14.757	16.628	16.824	1.00	18.97	C
ATOM	58	O	VAL	A	19	15.533	17.562	16.711	1.00	22.36	C
ATOM	59	CB	VAL	A	19	15.668	14.325	16.729	1.00	18.19	C
ATOM	60	CG1	VAL	A	19	16.675	14.817	15.708	1.00	20.68	C
ATOM	61	CG2	VAL	A	19	16.422	13.390	17.612	1.00	19.91	C
ATOM	62	N	ALA	A	20	13.530	16.732	16.366	1.00	18.27	C
ATOM	63	CA	ALA	A	20	13.105	17.946	15.719	1.00	17.82	C
ATOM	64	C	ALA	A	20	12.923	19.074	16.711	1.00	18.90	C

00669027.052000

Figure 8-12

ATOM	65	O	ALA	A	20	12.977	20.244	16.352	1.00	20.70	O
ATOM	66	CB	ALA	A	20	11.777	17.661	15.059	1.00	17.70	C
ATOM	67	N	ASN	A	21	12.677	18.787	17.979	1.00	20.04	N
ATOM	68	CA	ASN	A	21	12.450	19.852	18.933	1.00	20.73	C
ATOM	69	C	ASN	A	21	13.695	20.161	19.771	1.00	20.34	C
ATOM	70	O	ASN	A	21	13.627	20.909	20.741	1.00	21.05	O
ATOM	71	CB	ASN	A	21	11.235	19.456	19.751	1.00	20.84	C
ATOM	72	CG	ASN	A	21	10.409	20.664	20.103	1.00	20.51	C
ATOM	73	OD1	ASN	A	21	10.157	21.501	19.250	1.00	25.03	O
ATOM	74	ND2	ASN	A	21	9.983	20.853	21.359	1.00	25.03	N
ATOM	75	N	LEU	A	22	14.851	19.615	19.399	1.00	18.22	N
ATOM	76	CA	LEU	A	22	16.129	19.924	20.000	1.00	17.27	C
ATOM	77	C	LEU	A	22	17.023	20.733	19.051	1.00	19.37	C
ATOM	78	O	LEU	A	22	17.001	20.468	17.851	1.00	19.69	O
ATOM	79	CB	LEU	A	22	16.856	18.631	20.432	1.00	16.17	C
ATOM	80	CG	LEU	A	22	16.342	17.790	21.598	1.00	14.77	C
ATOM	81	CD1	LEU	A	22	17.058	16.447	21.768	1.00	14.07	C
ATOM	82	CD2	LEU	A	22	16.463	18.606	22.862	1.00	11.82	C
ATOM	83	N	PRO	A	23	17.833	21.728	19.457	1.00	19.42	N
ATOM	84	CA	PRO	A	23	18.655	22.511	18.537	1.00	19.17	C
ATOM	85	C	PRO	A	23	19.694	21.621	17.878	1.00	20.53	C
ATOM	86	O	PRO	A	23	20.318	20.832	18.575	1.00	21.23	O
ATOM	87	CB	PRO	A	23	19.341	23.488	19.459	1.00	18.21	C
ATOM	88	CG	PRO	A	23	18.549	23.480	20.755	1.00	16.10	C
ATOM	89	CD	PRO	A	23	18.206	22.015	20.846	1.00	17.73	C
ATOM	90	N	LYS	A	24	19.959	21.716	16.571	1.00	23.65	N
ATOM	91	CA	LYS	A	24	20.937	20.852	15.866	1.00	27.23	C
ATOM	92	C	LYS	A	24	22.388	20.847	16.370	1.00	25.36	C
ATOM	93	O	LYS	A	24	23.179	19.918	16.149	1.00	25.16	O
ATOM	94	CB	LYS	A	24	20.931	21.150	14.332	1.00	29.02	C
ATOM	95	CG	LYS	A	24	19.550	20.939	13.680	1.00	36.19	C
ATOM	96	CD	LYS	A	24	19.557	21.512	12.245	1.00	43.22	C
ATOM	97	CE	LYS	A	24	18.207	21.800	11.585	1.00	42.88	C
ATOM	98	NZ	LYS	A	24	18.433	22.694	10.448	1.00	48.02	N
ATOM	99	N	ASP	A	25	22.712	21.900	17.110	1.00	26.32	N
ATOM	100	CA	ASP	A	25	24.060	22.087	17.653	1.00	28.70	C
ATOM	101	C	ASP	A	25	24.209	22.024	19.180	1.00	26.91	C
ATOM	102	O	ASP	A	25	25.225	22.386	19.785	1.00	27.43	O
ATOM	103	CB	ASP	A	25	24.551	23.433	17.144	1.00	30.59	C
ATOM	104	CG	ASP	A	25	23.780	24.615	17.684	1.00	33.09	C
ATOM	105	OD1	ASP	A	25	22.556	24.529	17.847	1.00	34.74	O
ATOM	106	OD2	ASP	A	25	24.421	25.638	17.933	1.00	37.53	C
ATOM	107	N	TYR	A	26	23.122	21.605	19.808	1.00	24.09	N
ATOM	108	CA	TYR	A	26	23.165	21.289	21.189	1.00	20.96	C
ATOM	109	C	TYR	A	26	23.821	19.937	21.246	1.00	20.04	C
ATOM	110	O	TYR	A	26	23.282	18.951	20.780	1.00	22.61	O
ATOM	111	CB	TYR	A	26	21.759	21.239	21.710	1.00	20.00	C
ATOM	112	CG	TYR	A	26	21.728	20.927	23.199	1.00	23.05	C
ATOM	113	CD1	TYR	A	26	22.430	21.764	24.039	1.00	20.56	C
ATOM	114	CD2	TYR	A	26	21.015	19.843	23.683	1.00	22.87	C
ATOM	115	CE1	TYR	A	26	22.421	21.541	25.376	1.00	23.76	C
ATOM	116	CE2	TYR	A	26	20.993	19.629	25.047	1.00	22.41	C
ATOM	117	CZ	TYR	A	26	21.693	20.493	25.877	1.00	23.68	C
ATOM	118	OH	TYR	A	26	21.661	20.353	27.259	1.00	22.67	O
HETATM	119	N	MSE	A	27	25.003	19.890	21.809	1.00	21.07	N
HETATM	120	CA	MSE	A	27	25.716	18.643	22.008	1.00	21.95	C
HETATM	121	C	MSE	A	27	25.325	17.906	23.296	1.00	23.63	C
HETATM	122	O	MSE	A	27	25.089	18.481	24.371	1.00	22.77	O
HETATM	123	CB	MSE	A	27	27.201	18.955	22.055	1.00	27.32	C
HETATM	124	CG	MSE	A	27	27.695	19.788	20.866	1.00	28.96	C

00509027.062900

HETATM	125	SE	MS	A	27	27.207	18.877	19.234	1.00	37.24	SE
HETATM	126	CE	MSE	A	27	28.489	17.511	19.371	1.00	26.83	SE
ATOM	127	N	ILE	A	28	25.250	16.576	23.165	1.00	22.91	N
ATOM	128	CA	ILE	A	28	24.860	15.666	24.240	1.00	21.29	CA
ATOM	129	C	ILE	A	28	26.030	14.713	24.494	1.00	21.02	C
ATOM	130	O	ILE	A	28	26.530	14.075	23.571	1.00	20.97	O
ATOM	131	CB	ILE	A	28	23.550	14.901	23.870	1.00	19.78	CB
ATOM	132	CG1	ILE	A	28	22.372	15.818	23.534	1.00	17.37	CG1
ATOM	133	CG2	ILE	A	28	23.147	14.006	25.006	1.00	18.93	CG2
ATOM	134	CD1	ILE	A	28	21.207	15.120	22.805	1.00	16.08	CD1
ATOM	135	N	THR	A	29	26.492	14.597	25.744	1.00	20.17	N
ATOM	136	CA	THR	A	29	27.592	13.727	26.087	1.00	20.16	CA
ATOM	137	C	THR	A	29	27.065	12.315	26.315	1.00	20.21	C
ATOM	138	O	THR	A	29	26.051	12.085	26.918	1.00	19.29	O
ATOM	139	CB	THR	A	29	28.269	14.295	27.333	1.00	20.02	CB
ATOM	140	OG1	THR	A	29	28.515	15.655	27.048	1.00	24.08	OG1
ATOM	141	CG2	THR	A	29	29.593	13.644	27.634	1.00	23.19	CG2
ATOM	142	N	LEU	A	30	27.767	11.369	25.708	1.00	18.56	N
ATOM	143	CA	LEU	A	30	27.462	9.976	25.862	1.00	17.76	CA
ATOM	144	C	LEU	A	30	28.824	9.351	25.959	1.00	18.41	C
ATOM	145	O	LEU	A	30	29.738	9.774	25.283	1.00	20.72	O
ATOM	146	CB	LEU	A	30	26.649	9.396	24.642	1.00	19.78	CB
ATOM	147	CG	LEU	A	30	26.350	7.884	24.473	1.00	14.53	CG
ATOM	148	CD1	LEU	A	30	25.475	7.478	25.601	1.00	18.04	CD1
ATOM	149	CD2	LEU	A	30	25.629	7.525	23.205	1.00	14.92	CD2
ATOM	150	N	LYS	A	31	28.984	8.378	26.833	1.00	18.64	N
ATOM	151	CA	LYS	A	31	30.176	7.575	26.918	1.00	20.71	CA
ATOM	152	C	LYS	A	31	28.978	6.417	26.918	1.00	23.02	C
ATOM	153	O	LYS	A	31	28.966	5.701	26.170	1.00	23.02	O
ATOM	154	CB	LYS	A	31	30.411	7.009	28.295	1.00	19.63	CB
ATOM	155	CG	LYS	A	31	30.788	8.066	29.309	1.00	25.85	CG
ATOM	156	CD	LYS	A	31	31.154	7.355	30.605	1.00	29.83	CD
ATOM	157	CE	LYS	A	31	31.652	8.305	31.675	1.00	32.89	CE
ATOM	158	NZ	LYS	A	31	32.116	7.506	32.799	1.00	39.63	NZ
ATOM	159	N	TYR	A	32	30.845	6.219	25.034	1.00	24.83	N
ATOM	160	CA	TYR	A	32	30.565	5.424	23.844	1.00	22.31	CA
ATOM	161	C	TYR	A	32	31.607	4.359	23.967	1.00	19.55	C
ATOM	162	O	TYR	A	32	32.759	4.667	23.746	1.00	22.18	O
ATOM	163	CB	TYR	A	32	30.569	6.367	22.640	1.00	25.12	CB
ATOM	164	CG	TYR	A	32	30.557	5.725	21.262	1.00	27.46	CG
ATOM	165	CD1	TYR	A	32	29.890	5.4				

ATOM	185	N	GLY	A	35	34.312	1.550	18.666	1.00	28.92	N
ATOM	186	CA	GLY	A	35	34.175	0.517	17.650	1.00	28.59	C
ATOM	187	C	GLY	A	35	32.886	-0.277	17.715	1.00	28.76	C
ATOM	188	O	GLY	A	35	32.743	-1.224	16.957	1.00	29.41	O
HETATM	189	N	MSE	A	36	31.923	0.064	18.569	1.00	27.95	N
HETATM	190	CA	MSE	A	36	30.612	-0.561	18.587	1.00	28.65	C
HETATM	191	C	MSE	A	36	29.809	-0.477	17.276	1.00	28.45	C
HETATM	192	O	MSE	A	36	28.824	-1.189	17.098	1.00	26.26	O
HETATM	193	CB	MSE	A	36	29.774	0.036	19.739	1.00	32.71	C
HETATM	194	CG	MSE	A	36	29.232	1.427	19.485	1.00	34.05	C
HETATM	195	SE	MSE	A	36	27.946	2.252	20.676	1.00	36.59	SE
HETATM	196	CE	MSE	A	36	26.309	1.728	19.841	1.00	26.94	C
ATOM	197	N	ASP	A	37	30.212	0.393	16.338	1.00	30.42	N
ATOM	198	CA	ASP	A	37	30.736	0.413	14.335	1.00	30.74	C
ATOM	199	C	ASP	A	37	30.053	-0.794	14.038	1.00	29.32	C
ATOM	200	O	ASP	A	37	29.344	-1.054	13.064	1.00	28.97	O
ATOM	201	CB	ASP	A	37	30.200	1.716	14.234	1.00	33.15	C
ATOM	202	CG	ASP	A	37	31.706	1.960	14.294	1.00	35.22	C
ATOM	203	OD1	ASP	A	37	32.230	2.247	15.374	1.00	42.04	O
ATOM	204	OD2	ASP	A	37	32.369	1.875	13.275	1.00	34.84	O
ATOM	205	N	VAL	A	38	31.054	-1.584	14.381	1.00	23.11	N
ATOM	206	CA	VAL	A	38	31.471	-2.713	13.566	1.00	23.69	C
ATOM	207	C	VAL	A	38	31.568	-4.045	14.389	1.00	26.12	C
ATOM	208	O	VAL	A	38	31.649	-5.172	13.882	1.00	27.25	O
ATOM	209	CB	VAL	A	38	32.741	-2.089	12.936	1.00	19.85	C
ATOM	210	CG1	VAL	A	38	34.023	-2.366	13.647	1.00	16.55	C
ATOM	211	CG2	VAL	A	38	32.825	-2.379	11.512	1.00	19.54	C
ATOM	212	N	LEU	A	39	31.464	-3.968	16.728	1.00	26.26	N
ATOM	213	CA	LEU	A	39	31.505	-5.113	16.008	1.00	26.77	C
ATOM	214	C	LEU	A	39	30.149	-5.788	16.888	1.00	25.48	C
ATOM	215	O	LEU	A	39	29.130	-5.109	16.842	1.00	23.47	O
ATOM	216	CB	LEU	A	39	32.061	-4.671	18.014	1.00	25.49	C
ATOM	217	CG	LEU	A	39	33.515	-4.307	18.156	1.00	27.97	C
ATOM	218	CD1	LEU	A	39	33.729	-3.645	19.510	1.00	30.79	C
ATOM	219	CD2	LEU	A	39	34.399	-5.522	17.940	1.00	23.69	C
ATOM	220	N	PRO	A	40	30.017	-7.086	17.192	1.00	25.65	N
ATOM	221	CA	PRO	A	40	28.764	-7.665	17.563	1.00	27.77	C
ATOM	222	C	PRO	A	40	28.031	-7.004	18.792	1.00	27.59	C
ATOM	223	O	PRO	A	40	28.710	-6.411	19.658	1.00	26.55	O
ATOM	224	CB	PRO	A	40	29.102	-9.122	17.683	1.00	27.41	C
ATOM	225	CG	PRO	A	40	30.584	-9.150	18.263	1.00	29.35	C
ATOM	226	CD	PRO	A	40	30.076	-8.082</				

Figure 8-15

ATOM	245	C	CYS	A	43	29.916	-5.341	23.766	1.00	29.31	C
ATOM	246	O	CYS	A	43	30.779	-4.912	24.512	1.00	31.36	O
ATOM	247	CB	CYS	A	43	31.140	-6.395	21.915	1.00	31.15	C
ATOM	248	SG	CYS	A	43	31.674	-7.929	21.120	1.00	35.60	S
ATOM	249	N	TRP	A	44	28.833	-4.637	23.555	1.00	28.24	N
ATOM	250	CA	TRP	A	44	28.704	-3.240	23.952	1.00	25.54	C
ATOM	251	C	TRP	A	44	27.331	-2.947	24.498	1.00	25.35	C
ATOM	252	O	TRP	A	44	27.173	-1.924	25.113	1.00	28.50	O
ATOM	253	CB	TRP	A	44	28.965	-2.299	22.746	1.00	22.52	C
ATOM	254	CG	TRP	A	44	28.207	-2.626	21.450	1.00	20.09	C
ATOM	255	CD1	TRP	A	44	28.851	-3.316	20.455	1.00	19.03	C
ATOM	256	CD2	TRP	A	44	26.890	-2.326	21.142	1.00	20.02	C
ATOM	257	NE1	TRP	A	44	27.948	-3.464	19.527	1.00	20.48	N
ATOM	258	CE2	TRP	A	44	26.791	-2.877	19.882	1.00	19.41	C
ATOM	259	CE3	TRP	A	44	25.841	-1.609	21.652	1.00	18.83	C
ATOM	260	CZ2	TRP	A	44	25.665	-2.678	19.127	1.00	16.33	C
ATOM	261	CZ3	TRP	A	44	24.711	-1.431	20.910	1.00	16.81	C
ATOM	262	CH2	TRP	A	44	24.617	-1.962	19.653	1.00	17.88	C
ATOM	263	N	ILE	A	45	26.328	-3.786	24.275	1.00	27.39	N
ATOM	264	CA	ILE	A	45	24.934	-3.500	24.540	1.00	28.48	C
ATOM	265	C	ILE	A	45	24.666	-3.370	26.025	1.00	29.97	C
ATOM	266	O	ILE	A	45	23.770	-2.622	26.389	1.00	31.30	O
ATOM	267	CB	ILE	A	45	24.055	-4.601	23.904	1.00	28.39	C
ATOM	268	CG1	ILE	A	45	22.603	-4.220	23.795	1.00	28.24	C
ATOM	269	CG2	ILE	A	45	24.152	-5.926	24.668	1.00	28.54	C
ATOM	270	CD1	ILE	A	45	22.371	-2.868	23.098	1.00	30.38	C
ATOM	271	N	SER	A	46	25.408	-4.044	26.900	1.00	30.95	N
ATOM	272	CA	SER	A	46	25.200	-3.897	28.337	1.00	32.47	C
ATOM	273	C	SER	A	46	25.677	-2.546	28.844	1.00	30.61	C
ATOM	274	O	SER	A	46	24.974	-1.880	29.597	1.00	30.88	O
ATOM	275	CB	SER	A	46	25.899	-5.016	29.106	1.00	35.61	C
ATOM	276	OG	SER	A	46	25.387	-6.311	28.746	1.00	43.59	O
ATOM	277	N	GLU	A	47	26.840	-2.123	28.370	1.00	28.57	N
ATOM	278	CA	GLU	A	47	27.355	-0.823	28.680	1.00	28.90	C
ATOM	279	C	GLU	A	47	26.567	0.306	28.090	1.00	27.44	C
ATOM	280	O	GLU	A	47	26.383	1.323	28.735	1.00	28.17	O
ATOM	281	CB	GLU	A	47	28.791	-0.702	28.244	1.00	30.74	C
ATOM	282	CG	GLU	A	47	29.439	0.554	28.818	1.00	34.60	C
ATOM	283	CD	GLU	A	47	29.550	0.665	30.351	1.00	37.52	C
ATOM	284	OE1	GLU	A	47	28.998	-0.153	31.107	1.00	37.54	O
ATOM	285	OE2	GLU	A	47	30.208	1.607	30.800	1.00	38.33	C
HETATM	286	N	MSE	A	48	26.073	0.098	26.879	1.00	27.89	N
HETATM	287	CA	MSE	A	48	25.327	1.113	26.154	1.00	28.18	C
HETATM	288	C	MSE	A	48	23.945	1.421	26.667	1.00	26.21	C
HETATM	289	O	MSE	A	48	23.580	2.578	26.606	1.00	27.02	O
HETATM	290	CB	MSE	A	48	25.309	0.882	24.637	1.00	29.23	C
HETATM	291	CG	MSE	A	48	26.739	1.048	24.095	1.00	28.12	C
HETATM	292	SE	MSE	A	48	27.685	2.655	24.690	1.00	35.61	SE
HETATM	293	CE	MSE	A	48	26.476	3.857	23.743	1.00	22.58	C
ATOM	294	N	VAL	A	49	23.147	0.491	27.195	1.00	27.65	N
ATOM	295	CA	VAL	A	49	21.882	0.875	27.814	1.00	27.43	C
ATOM	296	C	VAL	A	49	22.037	1.680	29.115	1.00	27.42	C
ATOM	297	O	VAL	A	49	21.224	2.595	29.394	1.00	27.48	O
ATOM	298	CB	VAL	A	49	20.884	-0.284	27.907	1.00	27.18	C
ATOM	299	CG1	VAL	A	49	20.438	-0.478	26.452	1.00	27.08	C
ATOM	300	CG2	VAL	A	49	21.421	-1.534	28.610	1.00	23.66	C
ATOM	301	N	VAL	A	50	23.100	1.370	29.847	1.00	26.26	N
ATOM	302	CA	VAL	A	50	23.469	2.060	31.068	1.00	24.75	C
ATOM	303	C	VAL	A	50	23.964	3.431	30.716	1.00	25.57	C
ATOM	304	O	VAL	A	50	23.485	4.384	31.320	1.00	28.77	O

00000027.0029000

[illegible]

ATOM	305	CB	VAL	A	50	24.545	1.307	31.812	1.00	24.44	C
ATOM	306	CG1	VAL	A	50	25.062	2.106	32.969	1.00	23.79	N
ATOM	307	CG2	VAL	A	50	23.952	0.040	32.382	1.00	24.17	C
ATOM	308	N	GLN	A	51	24.888	3.551	29.758	1.00	22.88	N
ATOM	309	CA	GLN	A	51	25.315	4.841	29.294	1.00	18.59	C
ATOM	310	C	GLN	A	51	24.226	5.698	28.700	1.00	18.17	C
ATOM	311	O	GLN	A	51	24.223	6.904	28.948	1.00	20.05	C
ATOM	312	CB	GLN	A	51	26.474	4.707	28.320	1.00	21.19	C
ATOM	313	CG	GLN	A	51	27.676	4.059	28.934	1.00	17.37	C
ATOM	314	CD	GLN	A	51	28.072	4.720	30.240	1.00	21.56	C
ATOM	315	OE1	GLN	A	51	27.879	5.913	30.476	1.00	23.67	C
ATOM	316	NE2	GLN	A	51	28.662	3.969	31.152	1.00	22.77	C
ATOM	317	LEU	A	52	23.291	5.106	27.959	1.00	15.38	N	
ATOM	318	CA	LEU	A	52	23.217	5.850	27.979	1.00	16.72	C
ATOM	319	C	LEU	A	52	21.199	6.284	28.411	1.00	18.34	C
ATOM	320	O	LEU	A	52	20.676	7.387	28.382	1.00	18.73	C
ATOM	321	CB	LEU	A	52	21.533	5.006	26.309	1.00	15.91	C
ATOM	322	CG	LEU	A	52	22.207	5.059	24.928	1.00	17.11	C
ATOM	323	CD1	LEU	A	52	21.807	3.849	24.155	1.00	14.42	C
ATOM	324	CD2	LEU	A	52	21.886	6.330	24.184	1.00	12.26	C
ATOM	325	N	SER	A	53	20.932	5.433	29.378	1.00	20.83	N
ATOM	326	CA	SER	A	53	20.098	5.806	30.505	1.00	23.79	C
ATOM	327	C	SER	A	53	20.716	6.966	31.295	1.00	24.20	C
ATOM	328	O	SER	A	53	19.977	7.897	31.624	1.00	26.42	C
ATOM	329	CB	SER	A	53	19.917	4.605	31.403	1.00	23.71	C
ATOM	330	OG	SER	A	53	19.285	5.024	32.601	1.00	30.23	C
ATOM	331	N	ASP	A	54	22.043	6.977	31.553	1.00	23.25	N
ATOM	332	CA	ASP	A	54	22.687	8.036	30.349	1.00	20.61	C
ATOM	333	C	ASP	A	54	22.359	9.325	31.572	1.00	17.82	C
ATOM	334	O	ASP	A	54	22.303	10.358	32.142	1.00	20.41	C
ATOM	335	CB	ASP	A	54	24.114	7.682	32.740	1.00	25.54	C
ATOM	336	CG	ASP	A	54	24.207	6.579	33.815	1.00	31.33	C
ATOM	337	OD1	ASP	A	54	23.185	5.965	34.178	1.00	36.02	C
ATOM	338	OD2	ASP	A	54	25.318	6.318	34.307	1.00	32.62	C
ATOM	339	N	SER	A	55	22.962	9.286	30.291	1.00	16.79	N
ATOM	340	CA	SER	A	55	22.857	10.514	29.541	1.00	17.42	C
ATOM	341	C	SER	A	55	21.454	11.096	29.425	1.00	16.81	C
ATOM	342	O	SER	A	55	21.293	12.318	29.474	1.00	17.95	C
ATOM	343	CB	SER	A	55	23.511	10.378	28.150	1.00	18.91	C
ATOM	344	OG	SER	A	55	24.863	9.936	28.237	1.00	22.06	C
ATOM	345	LEU	A	56	22.439	10.243	29.379	1.00	17.01	C	
ATOM	346	CA	LEU	A	56	19.073	10.726	29.162	1.00	17.99	C
ATOM	347	C	LEU	A	56	18.518	11.188	30.514	1.00	18.27	C
ATOM	348	O	LEU	A	56	17.800	12.186	30.575	1.00	18.82	C
ATOM	349	CB	LEU	A	56	18.130	9.712	28.505	1.00	17.68	C
ATOM	350	CG	LEU	A	56	18.061	9.584	26.983	1.00	18.44	C
ATOM	351	CD1	LEU	A	56	17.381	8.280	26.613	1.00	19.03	C
ATOM	352	CD2	LEU	A	56	17.392	10.764	26.321	1.00	16.39	C
ATOM	353	N	THR	A	57	18.835	10.532	31.616	1.00	18.45	N
ATOM	354	CA	THR	A	57	18.376	11.005	32.911	1.00	21.42	C
ATOM	355	C	THR	A	57	18.975	12.383	33.205	1.00	21.42	C
ATOM	356	O	THR	A	57	18.263	13.287	33.640	1.00	21.53	C
ATOM	357	CB	THR	A	57	18.680	9.942	33.948	1.00	18.39	C
ATOM	358	OG1	THR	A	57	18.055	8.793	33.418	1.00	20.01	C
ATOM	359	CG2	THR	A	57	18.982	10.190	30.349	1.00	23.58	C
ATOM	360	N	ASP	A	58	20.245	12.587	32.819	1.00	22.66	N
ATOM	361	CA	ASP	A	58	20.908	13.867	32.971	1.00	24.69	C
ATOM	362	C	ASP	A	58	20.269	14.969	32.162	1.00	23.11	C
ATOM	363	O	ASP	A	58	20.243	16.133	32.567	1.00	22.89	C
ATOM	364	CB	ASP	A	58	22.410	13.766	32.646	1.00	33.60	C

24/85

Figure 8-17

ATOM	365	CG	ASP	A	58	23.101	15.151	32.595	1.00	41.66	C
ATOM	366	OD1	ASP	A	58	23.500	15.636	33.666	1.00	45.37	O
ATOM	367	OD2	ASP	A	58	23.204	15.764	31.502	1.00	43.30	O
ATOM	368	N	LEU	A	59	19.762	14.614	30.994	1.00	21.38	N
ATOM	369	CA	LEU	A	59	19.106	15.568	30.124	1.00	19.63	C
ATOM	370	C	LEU	A	59	17.857	16.179	30.719	1.00	20.35	C
ATOM	371	O	LEU	A	59	17.522	17.321	30.413	1.00	19.57	O
ATOM	372	CB	LEU	A	59	18.751	14.826	28.859	1.00	19.31	C
ATOM	373	CG	LEU	A	59	19.006	15.498	27.551	1.00	18.41	C
ATOM	374	CD1	LEU	A	59	20.161	16.496	27.615	1.00	16.32	C
ATOM	375	CD2	LEU	A	59	19.225	14.401	26.555	1.00	17.59	C
ATOM	376	N	LEU	A	60	17.163	15.410	31.587	1.00	21.63	N
ATOM	377	CA	LEU	A	60	15.930	15.857	32.216	1.00	20.55	C
ATOM	378	C	LEU	A	60	16.133	17.147	32.974	1.00	22.32	C
ATOM	379	O	LEU	A	60	15.264	18.016	32.929	1.00	23.28	O
ATOM	380	CB	LEU	A	60	15.389	14.796	33.145	1.00	17.67	C
ATOM	381	CG	LEU	A	60	14.680	13.601	32.538	1.00	14.57	C
ATOM	382	CD1	LEU	A	60	14.293	12.641	33.643	1.00	12.83	C
ATOM	383	CD2	LEU	A	60	13.462	14.048	31.847	1.00	8.22	C
ATOM	384	N	ASP	A	61	17.338	17.285	33.558	1.00	22.42	N
ATOM	385	CA	ASP	A	61	17.805	18.483	34.247	1.00	22.10	C
ATOM	386	C	ASP	A	61	17.810	19.768	33.433	1.00	20.08	C
ATOM	387	O	ASP	A	61	17.841	20.870	33.974	1.00	20.02	O
ATOM	388	CB	ASP	A	61	19.203	18.169	34.753	1.00	28.60	C
ATOM	389	CG	ASP	A	61	19.803	19.159	35.750	1.00	34.29	C
ATOM	390	OD1	ASP	A	61	19.459	19.073	36.931	1.00	40.97	O
ATOM	391	OD2	ASP	A	61	20.616	20.006	35.356	1.00	37.85	O
ATOM	392	N	LYS	A	62	17.721	19.693	32.105	1.00	19.76	N
ATOM	393	CA	LYS	A	62	17.839	20.862	31.245	1.00	16.53	C
ATOM	394	C	LYS	A	62	16.485	21.335	30.770	1.00	16.75	C
ATOM	395	O	LYS	A	62	16.388	22.383	30.130	1.00	17.62	O
ATOM	396	CB	LYS	A	62	18.684	20.529	30.020	1.00	18.65	C
ATOM	397	CG	LYS	A	62	19.986	19.755	30.233	1.00	16.80	C
ATOM	398	CD	LYS	A	62	20.808	20.483	31.276	1.00	18.07	C
ATOM	399	CE	LYS	A	62	22.135	19.776	31.535	1.00	23.34	C
ATOM	400	NZ	LYS	A	62	22.088	18.331	31.330	1.00	28.06	N
ATOM	401	N	PHE	A	63	15.400	20.605	31.068	1.00	16.40	N
ATOM	402	CA	PHE	A	63	14.086	20.979	30.586	1.00	16.93	C
ATOM	403	C	PHE	A	63	13.110	21.140	31.730	1.00	17.40	C
ATOM	404	O	PHE	A	63	13.294	20.626	32.626	1.00	17.50	O
ATOM	405	CB	PHE	A	63	13.576	19.942	29.574	1.00	15.08	C
ATOM	406	CG	PHE	A	63	14.424	19.850	28.325	1.00	13.39	C
ATOM	407	CD1	PHE	A	63	14.261	20.767	27.317	1.00	13.60	C
ATOM	408	CD2	PHE	A	63	15.410	18.888	28.252	1.00	14.95	C
ATOM	409	CE1	PHE	A	63	15.126	20.740	26.266	1.00	10.99	C
ATOM	410	CE2	PHE	A	63	16.305	18.889	27.207	1.00	14.45	C
ATOM	411	CZ	PHE	A	63	16.150	19.832	26.229	1.00	10.95	C
ATOM	412	N	SER	A	64	12.031	21.843	31.444	1.00	19.14	N
ATOM	413	CA	SER	A	64	10.993	22.080	32.407	1.00	21.71	C
ATOM	414	C	SER	A	64	9.832	21.125	32.198	1.00	22.87	C
ATOM	415	O	SER	A	64	9.431	20.758	31.098	1.00	24.09	O
ATOM	416	CB	SER	A	64	10.533	23.508	32.261	1.00	22.47	C
ATOM	417	OG	SER	A	64	9.408	23.881	33.049	1.00	29.46	O
ATOM	418	N	ASN	A	65	9.298	20.809	33.363	1.00	23.97	N
ATOM	419	CA	ASN	A	65	8.233	19.855	33.608	1.00	29.13	C
ATOM	420	C	ASN	A	65	6.899	20.539	33.390	1.00	31.34	C
ATOM	421	O	ASN	A	65	5.883	19.858	33.203	1.00	35.27	O
ATOM	422	CB	ASN	A	65	8.309	19.551	35.119	1.00	30.43	C
ATOM	423	CG	ASN	A	65	8.097	18.117	35.514	1.00	33.16	C
ATOM	424	OD1	ASN	A	65	7.488	17.258	34.873	1.00	41.60	O

00609027.062900

ATOM	425	ND2	ASN	A	65	8.641	17.823	36.656	1.00	34.77	N
ATOM	426	N	ILE	A	66	6.892	21.862	33.561	1.00	32.62	N
ATOM	427	CA	ILE	A	66	5.708	22.691	33.384	1.00	33.83	C
ATOM	428	C	ILE	A	66	5.681	23.071	31.918	1.00	35.58	C
ATOM	429	O	ILE	A	66	6.450	23.910	31.431	1.00	36.08	O
ATOM	430	CB	ILE	A	66	5.752	24.000	34.223	1.00	33.21	C
ATOM	431	CG1	ILE	A	66	6.162	23.831	35.672	1.00	33.50	C
ATOM	432	CG2	ILE	A	66	4.416	24.708	34.158	1.00	31.21	C
ATOM	433	CD1	ILE	A	66	5.330	22.784	36.415	1.00	32.37	C
ATOM	434	N	SER	A	67	4.782	22.424	31.201	1.00	37.23	N
ATOM	435	CA	SER	A	67	4.669	22.650	29.771	1.00	40.50	C
ATOM	436	C	SER	A	67	3.358	22.008	29.327	1.00	42.07	C
ATOM	437	O	SER	A	67	3.073	20.841	29.822	1.00	43.65	O
ATOM	438	CB	SER	A	67	5.992	21.985	29.075	1.00	40.62	C
ATOM	439	CG	SER	A	67	6.244	22.539	27.815	1.00	36.76	C
ATOM	440	N	GLU	A	68	2.502	22.765	28.648	1.00	44.40	N
ATOM	441	CA	GLU	A	68	1.317	22.183	28.023	1.00	46.43	C
ATOM	442	C	GLU	A	68	1.777	21.448	26.758	1.00	46.20	C
ATOM	443	O	GLU	A	68	2.874	21.690	26.234	1.00	47.39	O
ATOM	444	CB	GLU	A	68	0.364	23.301	27.637	1.00	49.01	C
ATOM	445	CG	GLU	A	68	-1.051	22.858	27.256	1.00	53.42	C
ATOM	446	CD	GLU	A	68	-2.066	23.229	28.324	1.00	56.12	C
ATOM	447	OE1	GLU	A	68	-2.255	22.391	29.223	1.00	58.37	O
ATOM	448	OE2	GLU	A	68	-2.634	24.342	28.250	1.00	56.09	O
ATOM	449	N	GLY	A	69	0.957	20.523	26.282	1.00	45.44	N
ATOM	450	CA	GLY	A	69	1.228	19.834	25.221	1.00	43.62	C
ATOM	451	C	GLY	A	69	2.552	19.130	24.029	1.00	42.83	C
ATOM	452	CG	GLY	A	69	2.944	18.429	25.963	1.00	43.42	C
ATOM	453	N	LEU	A	70	3.245	19.412	23.927	1.00	42.01	N
ATOM	454	CA	LEU	A	70	4.567	18.856	23.634	1.00	40.66	C
ATOM	455	C	LEU	A	70	5.570	19.283	24.688	1.00	37.48	C
ATOM	456	O	LEU	A	70	5.769	20.477	24.916	1.00	39.56	O
ATOM	457	CB	LEU	A	70	5.069	19.339	22.221	1.00	42.73	C
ATOM	458	CG	LEU	A	70	6.365	18.753	21.553	1.00	43.68	C
ATOM	459	CD1	LEU	A	70	6.429	17.212	21.539	1.00	40.99	C
ATOM	460	CD2	LEU	A	70	6.506	19.318	20.134	1.00	42.81	C
ATOM	461	N	SER	A	71	6.203	18.289	25.301	1.00	32.14	N
ATOM	462	CA	SER	A	71	7.187	18.514	26.330	1.00	24.30	C
ATOM	463	C	SER	A	71	8.394	17.653	26.032	1.00	20.56	C
ATOM	464	O	SER	A	71	6.282	16.449	25.900	1.00	21.53	O
ATOM	465	CB	SER	A	71	6.619	18.160	27.653	1.00	21.80	C
ATOM	466	CG	SER	A	71	7.393	18.171	2			

Figure 8-19

ATOM	485	CZ	TYR	A	73	11.592	15.891	34.491	1.00	14.02	C
ATOM	486	OH	TYR	A	73	12.042	15.429	35.703	1.00	14.54	O
ATOM	487	N	SER	A	74	8.682	15.323	29.087	1.00	18.48	N
ATOM	488	CA	SER	A	74	7.947	14.076	29.034	1.00	18.74	C
ATOM	489	C	SER	A	74	8.429	13.074	28.017	1.00	18.80	C
ATOM	490	O	SER	A	74	8.430	11.882	28.327	1.00	18.69	O
ATOM	491	CB	SER	A	74	6.434	14.228	29.002	1.00	21.96	C
ATOM	492	OG	SER	A	74	5.847	15.278	28.253	1.00	30.65	O
ATOM	493	N	ILE	A	75	8.928	13.522	26.849	1.00	18.95	N
ATOM	494	CA	ILE	A	75	9.481	12.602	25.855	1.00	17.82	C
ATOM	495	C	ILE	A	75	10.689	11.896	26.422	1.00	17.12	C
ATOM	496	O	ILE	A	75	10.679	10.688	26.557	1.00	18.03	O
ATOM	497	CB	ILE	A	75	9.750	13.298	24.460	1.00	20.42	C
ATOM	498	CG1	ILE	A	75	8.440	13.885	23.860	1.00	19.63	C
ATOM	499	CG2	ILE	A	75	10.327	12.283	23.471	1.00	17.30	C
ATOM	500	CD1	ILE	A	75	8.582	14.604	22.508	1.00	23.08	C
ATOM	501	N	ILE	A	76	11.698	12.625	26.857	1.00	18.46	N
ATOM	502	CA	ILE	A	76	12.916	12.070	27.436	1.00	19.33	C
ATOM	503	C	ILE	A	76	12.622	11.116	28.592	1.00	19.01	O
ATOM	504	O	ILE	A	76	13.199	10.040	28.714	1.00	20.65	O
ATOM	505	CB	ILE	A	76	13.816	13.253	27.900	1.00	18.88	C
ATOM	506	CG1	ILE	A	76	14.239	14.216	26.789	1.00	17.98	C
ATOM	507	CG2	ILE	A	76	15.057	12.732	28.600	1.00	20.53	C
ATOM	508	CD1	ILE	A	76	14.950	15.500	27.300	1.00	15.54	C
ATOM	509	N	ASP	A	77	11.643	11.474	29.412	1.00	19.90	N
ATOM	510	CA	ASP	A	77	11.226	10.682	30.562	1.00	19.93	C
ATOM	511	C	ASP	A	77	10.627	9.341	30.177	1.00	21.32	C
ATOM	512	O	ASP	A	77	10.832	8.318	30.830	1.00	21.41	O
ATOM	513	CB	ASP	A	77	10.189	11.524	31.263	1.00	21.00	C
ATOM	514	CG	ASP	A	77	9.506	10.808	32.390	1.00	23.32	C
ATOM	515	OD1	ASP	A	77	10.211	10.249	33.204	1.00	26.02	O
ATOM	516	OD2	ASP	A	77	8.283	10.750	32.419	1.00	24.74	C
ATOM	517	N	LYS	A	78	9.835	9.312	29.101	1.00	23.41	N
ATOM	518	CA	LYS	A	78	9.385	8.038	28.606	1.00	23.09	C
ATOM	519	C	LYS	A	78	10.529	7.247	27.975	1.00	24.61	C
ATOM	520	O	LYS	A	78	10.518	6.000	28.021	1.00	26.85	O
ATOM	521	CB	LYS	A	78	8.267	8.237	27.656	1.00	25.84	C
ATOM	522	CG	LYS	A	78	7.024	8.643	28.403	1.00	29.26	C
ATOM	523	CD	LYS	A	78	5.882	8.766	27.362	1.00	40.97	C
ATOM	524	CE	LYS	A	78	6.119	9.815	26.221	1.00	43.91	C
ATOM	525	NZ	LYS	A	78	5.056	9.792	25.229	1.00	48.24	N
ATOM	526	N	LEU	A	79	11.559	7.936	27.437	1.00	22.19	N
ATOM	527	CA	LEU	A	79	12.718	7.253	26.865	1.00	18.09	C
ATOM	528	C	LEU	A	79	13.577	6.757	27.968	1.00	16.82	C
ATOM	529	O	LEU	A	79	14.146	5.692	27.806	1.00	17.74	O
ATOM	530	CB	LEU	A	79	13.580	8.147	25.986	1.00	16.97	C
ATOM	531	CG	LEU	A	79	12.928	8.748	24.768	1.00	15.98	C
ATOM	532	CD1	LEU	A	79	13.984	9.540	24.058	1.00	16.93	C
ATOM	533	CD2	LEU	A	79	12.264	7.721	23.857	1.00	14.76	C
ATOM	534	N	VAL	A	80	13.609	7.460	29.101	1.00	16.48	N
ATOM	535	CA	VAL	A	80	14.352	6.994	30.249	1.00	13.79	C
ATOM	536	C	VAL	A	80	13.697	5.725	30.731	1.00	14.44	C
ATOM	537	O	VAL	A	80	14.385	4.763	31.022	1.00	14.81	O
ATOM	538	CB	VAL	A	80	14.382	8.054	31.331	1.00	17.12	C
ATOM	539	CG1	VAL	A	80	14.937	7.490	32.631	1.00	17.65	C
ATOM	540	CG2	VAL	A	80	15.307	9.189	30.910	1.00	13.43	C
ATOM	541	N	ASN	A	81	12.383	5.633	30.743	1.00	16.27	N
ATOM	542	CA	ASN	A	81	11.696	4.398	31.081	1.00	18.71	C
ATOM	543	C	ASN	A	81	11.852	3.174	30.176	1.00	21.49	C
ATOM	544	O	ASN	A	81	11.945	2.060	30.691	1.00	22.57	O

ATOM	545	CB	ASN	A	81	10.244	4.707	31.191	1.00	20.64	C
ATOM	546	CG	ASN	A	81	9.968	5.574	32.402	1.00	22.06	C
ATOM	547	OD1	ASN	A	81	10.652	5.475	33.422	1.00	22.22	C
ATOM	548	ND2	ASN	A	81	8.941	6.409	32.322	1.00	21.76	N
ATOM	549	N	ILE	A	82	11.898	3.339	28.846	1.00	21.86	N
ATOM	550	CA	ILE	A	82	12.226	2.270	27.917	1.00	23.02	C
ATOM	551	C	ILE	A	82	13.602	1.742	28.112	1.00	23.67	C
ATOM	552	O	ILE	A	82	13.728	0.536	28.067	1.00	26.85	O
ATOM	553	CB	ILE	A	82	12.089	2.768	26.497	1.00	22.79	C
ATOM	554	CG1	ILE	A	82	10.613	2.757	26.220	1.00	23.80	C
ATOM	555	CG2	ILE	A	82	12.854	1.951	25.474	1.00	21.98	C
ATOM	556	CD1	ILE	A	82	10.321	3.659	25.020	1.00	27.18	C
ATOM	557	N	VAL	A	83	14.619	2.586	28.254	1.00	25.82	N
ATOM	558	CA	VAL	A	83	12.996	2.104	28.338	1.00	27.82	C
ATOM	559	O	VAL	A	83	16.212	1.471	29.706	1.00	30.01	O
ATOM	560	CB	VAL	A	83	16.995	0.522	29.796	1.00	32.08	C
ATOM	561	CG	VAL	A	83	17.139	3.137	28.252	1.00	26.25	C
ATOM	562	CG1	VAL	A	83	18.343	2.445	27.683	1.00	28.68	C
ATOM	563	CG2	VAL	A	83	16.883	4.437	27.569	1.00	28.99	C
ATOM	564	N	ASP	A	84	15.602	1.983	30.789	1.00	30.99	N
ATOM	565	CA	ASP	A	84	15.711	1.384	32.123	1.00	34.08	C
ATOM	566	C	ASP	A	84	15.125	-0.013	32.275	1.00	34.30	C
ATOM	567	O	ASP	A	84	15.666	-0.816	33.035	1.00	35.01	O
ATOM	568	CB	ASP	A	84	15.148	2.331	33.189	1.00	37.32	C
ATOM	569	CG	ASP	A	84	15.909	3.664	33.316	1.00	42.03	C
ATOM	570	OD1	ASP	A	84	16.907	3.865	32.621	1.00	43.39	C
ATOM	571	OD2	ASP	A	84	15.496	4.523	34.107	1.00	44.86	C
ATOM	572	N	ASP	A	85	14.555	-0.335	31.524	1.00	35.79	N
ATOM	573	CA	ASP	A	85	13.554	-1.707	31.332	1.00	37.15	C
ATOM	574	C	ASP	A	85	14.655	-2.665	30.860	1.00	34.71	C
ATOM	575	O	ASP	A	85	14.777	-3.800	31.308	1.00	33.69	O
ATOM	576	CB	ASP	A	85	12.434	-1.780	30.233	1.00	42.27	C
ATOM	577	CG	ASP	A	85	11.023	-1.216	30.474	1.00	46.16	C
ATOM	578	OD1	ASP	A	85	10.747	-0.756	31.587	1.00	46.14	C
ATOM	579	OD2	ASP	A	85	10.197	-1.234	29.539	1.00	50.79	C
ATOM	580	N	LEU	A	86	15.437	-2.164	29.904	1.00	33.83	N
ATOM	581	CA	LEU	A	86	16.527	-2.886	29.288	1.00	33.71	C
ATOM	582	C	LEU	A	86	17.747	-2.955	30.177	1.00	34.12	C
ATOM	583	O	LEU	A	86	18.440	-3.965	29.883	1.00	34.66	O
ATOM	584	CE	LEU	A	86	16.907	-2.260	27.948	1.00	31.87	C
ATOM	585	CG	LEU	A	86	15.878	-2.198	26.829	1.00	30.75	C
ATOM	586	CD1	LEU	A	86	16.383	-1.351	25.699			

Figure 8-21

ATOM	605	CA	CYS	A	89	16.489	-7.244	31.503	1.00	54.51	C
ATOM	606	C	CYS	A	89	17.952	-7.703	31.459	1.00	55.09	C
ATOM	607	O	CYS	A	89	18.231	-8.791	31.961	1.00	57.42	O
ATOM	608	CB	CYS	A	89	15.903	-6.972	30.078	1.00	57.17	C
ATOM	609	SG	CYS	A	89	15.060	-8.280	29.096	1.00	64.80	S
ATOM	610	N	VAL	A	90	18.890	-6.838	31.002	1.00	55.69	N
ATOM	611	CA	VAL	A	90	20.357	-7.027	31.060	1.00	55.91	C
ATOM	612	C	VAL	A	90	20.906	-7.397	32.450	1.00	57.84	C
ATOM	613	O	VAL	A	90	22.014	-7.924	32.546	1.00	58.27	O
ATOM	614	CB	VAL	A	90	21.074	-5.738	30.480	1.00	53.45	C
ATOM	615	CG1	VAL	A	90	22.542	-5.564	30.824	1.00	52.76	C
ATOM	616	CG2	VAL	A	90	20.965	-5.689	28.978	1.00	50.05	C
ATOM	617	N	LYS	A	91	20.212	-7.128	33.558	1.00	59.29	N
ATOM	618	CA	LYS	A	91	20.556	-7.785	34.810	1.00	62.11	C
ATOM	619	C	LYS	A	91	19.865	-9.163	34.996	1.00	63.85	C
ATOM	620	O	LYS	A	91	20.517	-10.061	35.533	1.00	66.48	O
ATOM	621	CB	LYS	A	91	20.305	-6.837	35.993	1.00	61.39	C
ATOM	622	N	SER	A	104	36.757	4.074	31.300	1.00	64.71	N
ATOM	623	CA	SER	A	104	36.147	4.043	29.974	1.00	64.00	C
ATOM	624	C	SER	A	104	34.723	3.416	29.904	1.00	61.57	C
ATOM	625	O	SER	A	104	34.321	2.749	30.871	1.00	62.78	O
ATOM	626	CB	SER	A	104	37.147	3.441	28.919	1.00	65.90	C
ATOM	627	OG	SER	A	104	38.150	4.399	28.533	1.00	67.30	C
ATOM	628	N	PRO	A	105	33.891	3.576	28.842	1.00	57.26	N
ATOM	629	CA	PRO	A	105	34.173	4.332	27.635	1.00	53.19	C
ATOM	630	C	PRO	A	105	34.452	5.801	27.827	1.00	51.76	C
ATOM	631	O	PRO	A	105	34.107	6.397	28.848	1.00	53.30	O
ATOM	632	CB	PRO	A	105	32.968	4.091	26.813	1.00	51.85	C
ATOM	633	CG	PRO	A	105	31.869	3.765	27.755	1.00	53.45	C
ATOM	634	CD	PRO	A	105	32.618	2.880	28.698	1.00	55.74	C
ATOM	635	N	GLU	A	106	35.242	6.296	26.875	1.00	50.80	N
ATOM	636	CA	GLU	A	106	35.584	7.700	26.790	1.00	47.97	C
ATOM	637	C	GLU	A	106	34.332	8.435	26.350	1.00	44.14	C
ATOM	638	O	GLU	A	106	33.684	8.006	25.400	1.00	42.91	O
ATOM	639	CB	GLU	A	106	36.796	7.970	25.858	1.00	51.71	C
ATOM	640	CG	GLU	A	106	36.873	7.196	24.509	1.00	57.13	C
ATOM	641	CD	GLU	A	106	38.045	6.192	24.389	1.00	60.78	C
ATOM	642	OE1	GLU	A	106	38.141	5.251	25.189	1.00	61.59	O
ATOM	643	OE2	GLU	A	106	38.874	6.338	23.482	1.00	63.52	C
ATOM	644	N	PRO	A	107	33.936	9.481	27.092	1.00	41.02	N
ATOM	645	CA	PRO	A	107	32.846	10.386	26.770	1.00	38.74	C
ATOM	646	C	PRO	A	107	33.069	11.190	25.517	1.00	37.93	C
ATOM	647	O	PRO	A	107	34.148	11.749	25.271	1.00	40.00	O
ATOM	648	CB	PRO	A	107	32.764	11.292	27.970	1.00	39.85	C
ATOM	649	CG	PRO	A	107	34.162	11.290	28.542	1.00	40.91	C
ATOM	650	CD	PRO	A	107	34.522	9.832	28.384	1.00	41.30	C
ATOM	651	N	ARG	A	108	32.000	11.208	24.724	1.00	35.40	N
ATOM	652	CA	ARG	A	108	32.006	11.864	23.436	1.00	33.34	C
ATOM	653	C	ARG	A	108	30.766	12.722	23.318	1.00	29.75	C
ATOM	654	O	ARG	A	108	29.727	12.347	23.867	1.00	29.55	O
ATOM	655	CB	ARG	A	108	32.102	10.859	22.297	1.00	35.14	C
ATOM	656	CG	ARG	A	108	33.480	10.219	22.313	1.00	39.55	C
ATOM	657	CD	ARG	A	108	33.734	9.386	21.057	1.00	44.05	C
ATOM	658	NE	ARG	A	108	34.715	8.324	22.284	1.00	45.36	N
ATOM	659	CZ	ARG	A	108	34.965	7.376	20.373	1.00	45.18	C
ATOM	660	NH1	ARG	A	108	34.481	7.446	19.142	1.00	46.89	N
ATOM	661	NH2	ARG	A	108	35.679	6.306	20.712	1.00	46.89	N
ATOM	662	N	LEU	A	109	30.932	13.877	22.650	1.00	26.42	N
ATOM	663	CA	LEU	A	109	29.833	14.770	22.334	1.00	25.17	C
ATOM	664	C	LEU	A	109	29.126	14.453	21.020	1.00	25.96	C

00600027.002900

ATOM	665	O	LEU	A	109	29.774	14.229	20.002	1.00	26.43	C
ATOM	666	CB	LEU	A	109	30.316	16.182	22.280	1.00	24.30	C
ATOM	667	CG	LEU	A	109	31.003	16.770	23.483	1.00	25.72	C
ATOM	668	CD1	LEU	A	109	31.426	18.185	23.137	1.00	26.28	C
ATOM	669	CD2	LEU	A	109	30.097	16.820	24.677	1.00	25.67	C
ATOM	670	N	PHE	A	110	27.794	14.427	20.988	1.00	24.52	N
ATOM	671	CA	PHE	A	110	27.019	14.004	19.822	1.00	22.36	C
ATOM	672	C	PHE	A	110	25.996	15.079	19.586	1.00	21.47	C
ATOM	673	O	PHE	A	110	25.618	15.777	20.525	1.00	21.05	O
ATOM	674	CB	PHE	A	110	26.227	12.725	20.075	1.00	21.69	C
ATOM	675	CG	PHE	A	110	27.133	11.561	20.318	1.00	23.01	C
ATOM	676	CD1	PHE	A	110	27.676	10.892	19.238	1.00	24.43	C
ATOM	677	CD2	PHE	A	110	27.506	11.243	20.297	1.00	23.68	C
ATOM	678	CE1	PHE	A	110	26.614	9.897	19.463	1.00	24.61	C
ATOM	679	CE2	PHE	A	110	28.460	10.282	21.798	1.00	22.08	C
ATOM	680	CZ	PHE	A	110	29.017	9.597	20.746	1.00	23.51	C
ATOM	681	N	THR	A	111	25.557	15.239	18.339	1.00	20.40	N
ATOM	682	CA	THR	A	111	24.422	16.102	18.047	1.00	19.58	C
ATOM	683	C	THR	A	111	23.175	15.367	18.473	1.00	15.81	C
ATOM	684	O	THR	A	111	23.239	14.150	18.603	1.00	18.63	O
ATOM	685	CB	THR	A	111	24.305	16.421	16.578	1.00	19.96	C
ATOM	686	CG1	THR	A	111	24.145	15.178	15.907	1.00	21.91	C
ATOM	687	CG2	THR	A	111	25.487	17.252	16.118	1.00	23.08	C
ATOM	688	N	PRO	A	112	22.030	15.982	18.688	1.00	15.89	N
ATOM	689	CA	PRO	A	112	20.783	15.254	18.984	1.00	16.41	C
ATOM	690	C	PRO	A	112	20.500	14.085	18.025	1.00	17.10	C
ATOM	691	O	PRO	A	112	20.329	12.954	18.313	1.00	18.12	O
ATOM	692	CB	PRO	A	112	21.999	16.375	18.870	1.00	17.89	C
ATOM	693	CG	PRO	A	112	20.581	17.559	19.386	1.00	14.36	C
ATOM	694	CD	PRO	A	112	21.876	17.424	18.685	1.00	12.46	C
ATOM	695	N	GLU	A	113	20.564	14.321	16.728	1.00	20.22	N
ATOM	696	CA	GLU	A	113	20.393	13.303	15.737	1.00	24.11	C
ATOM	697	C	GLU	A	113	21.371	12.143	15.864	1.00	24.55	C
ATOM	698	O	GLU	A	113	20.963	10.982	15.866	1.00	25.38	O
ATOM	699	CB	GLU	A	113	20.539	13.991	14.420	1.00	29.66	C
ATOM	700	CG	GLU	A	113	20.432	13.029	13.250	1.00	41.26	C
ATOM	701	CD	GLU	A	113	21.253	13.476	12.042	1.00	49.84	C
ATOM	702	OE1	GLU	A	113	22.475	13.694	12.197	1.00	52.84	O
ATOM	703	OE2	GLU	A	113	20.662	13.586	10.949	1.00	55.78	C
ATOM	704	N	GLU	A	114	22.663	12.384	16.033	1.00	24.48	N
ATOM	705	CA	GLU	A	114	22.695	11.991	16.198	1.00		

ATOM	725	CA	PHE	A	116	19.401	9.327	18.860	1.00	18.51	C
ATOM	726	C	PHE	A	116	19.510	8.196	17.854	1.00	22.03	C
ATOM	727	O	PHE	A	116	18.768	7.213	17.892	1.00	22.83	O
ATOM	728	CB	PHE	A	116	18.204	10.195	18.687	1.00	19.13	C
ATOM	729	CG	PHE	A	116	17.735	10.764	20.021	1.00	19.41	C
ATOM	730	CD1	PHE	A	116	17.159	9.924	20.952	1.00	19.08	C
ATOM	731	CD2	PHE	A	116	17.991	12.079	20.343	1.00	19.60	C
ATOM	732	CE1	PHE	A	116	16.911	10.381	22.214	1.00	18.67	C
ATOM	733	CE2	PHE	A	116	17.747	12.528	21.619	1.00	21.95	C
ATOM	734	CZ	PHE	A	116	17.218	11.674	22.550	1.00	19.99	C
ATOM	735	N	ARG	A	117	20.510	8.249	16.986	1.00	22.43	N
ATOM	736	CA	ARG	A	117	20.822	7.134	16.123	1.00	21.98	C
ATOM	737	C	ARG	A	117	21.453	6.076	16.971	1.00	19.70	C
ATOM	738	O	ARG	A	117	21.339	4.946	16.841	1.00	22.56	O
ATOM	739	CB	ARG	A	117	21.769	7.623	15.052	1.00	27.63	C
ATOM	740	CG	ARG	A	117	22.329	6.596	14.082	1.00	36.33	C
ATOM	741	CD	ARG	A	117	23.135	7.255	12.971	1.00	43.02	C
ATOM	742	NE	ARG	A	117	22.296	8.207	12.239	1.00	49.61	N
ATOM	743	CZ	ARG	A	117	22.704	9.468	12.008	1.00	54.02	C
ATOM	744	NH1	ARG	A	117	23.915	9.867	12.474	1.00	53.58	N
ATOM	745	NH2	ARG	A	117	21.899	10.314	11.313	1.00	53.56	N
ATOM	746	N	ILE	A	118	22.394	6.348	17.874	1.00	19.56	C
ATOM	747	CA	ILE	A	118	22.944	5.328	18.746	1.00	18.66	C
ATOM	748	C	ILE	A	118	21.888	4.776	19.673	1.00	19.62	C
ATOM	749	O	ILE	A	118	21.887	3.579	19.933	1.00	21.23	O
ATOM	750	CB	ILE	A	118	24.054	5.970	20.230	1.00	22.00	C
ATOM	751	CG1	ILE	A	118	25.121	6.479	18.593	1.00	22.63	C
ATOM	752	CG2	ILE	A	118	24.665	5.002	20.534	1.00	22.20	C
ATOM	753	CD1	ILE	A	118	26.178	7.330	19.285	1.00	23.90	C
ATOM	754	N	PHE	A	119	20.971	5.619	20.180	1.00	20.06	N
ATOM	755	CA	PHE	A	119	19.827	5.124	20.943	1.00	21.07	C
ATOM	756	C	PHE	A	119	18.940	4.182	20.141	1.00	21.06	C
ATOM	757	O	PHE	A	119	18.720	3.075	20.600	1.00	22.31	O
ATOM	758	CB	PHE	A	119	19.001	6.253	21.590	1.00	18.55	C
ATOM	759	CG	PHE	A	119	17.726	5.856	22.342	1.00	18.55	C
ATOM	760	CD1	PHE	A	119	16.517	5.708	21.673	1.00	17.37	C
ATOM	761	CD2	PHE	A	119	17.346	5.719	23.718	1.00	21.29	C
ATOM	762	CE1	PHE	A	119	15.738	5.435	22.351	1.00	19.37	C
ATOM	763	CE2	PHE	A	119	16.555	5.444	24.004	1.00	19.97	C
ATOM	764	CZ	PHE	A	119	15.969	5.311	23.721	1.00	19.81	C
ATOM	765	N	ASN	A	120	18.426	4.507	18.957	1.00	22.51	N
ATOM	766	CA	ASN								

[illegible]

ATOM	785	CA	SER	A	122	20.981	-0.077	20.908	1.00	27.73	C
ATOM	786	C	SER	A	122	19.643	-0.555	21.201	1.00	27.23	C
ATOM	787	O	SER	A	122	19.603	-1.652	21.716	1.00	28.27	C
ATOM	788	CB	SER	A	122	21.388	0.942	22.071	1.00	25.31	O
ATOM	789	OG	SER	A	122	22.619	1.543	21.726	1.00	25.19	O
ATOM	790	N	ILE	A	123	18.530	0.087	20.884	1.00	29.27	N
ATOM	791	CA	ILE	A	123	17.210	-0.453	21.140	1.00	31.25	C
ATOM	792	C	ILE	A	123	16.972	-1.618	20.207	1.00	32.43	C
ATOM	793	O	ILE	A	123	16.522	-2.672	20.637	1.00	32.75	O
ATOM	794	CB	ILE	A	123	16.129	0.661	20.973	1.00	33.20	O
ATOM	795	CG1	ILE	A	123	16.103	1.685	22.130	1.00	35.29	C
ATOM	796	CG2	ILE	A	123	14.739	0.181	20.629	1.00	33.87	C
ATOM	797	CD1	ILE	A	123	16.243	1.313	22.271	1.00	32.81	C
ATOM	798	N	ASP	A	124	17.225	-1.466	18.937	1.00	35.41	N
ATOM	799	C	ASP	A	124	17.064	-2.502	17.973	1.00	38.41	C
ATOM	800	O	ASP	A	124	17.902	-3.728	18.170	1.00	38.55	O
ATOM	801	O	ASP	A	124	17.386	-4.820	17.960	1.00	39.71	O
ATOM	802	CB	ASP	A	124	17.074	-1.951	16.562	1.00	43.19	C
ATOM	803	CG	ASP	A	124	15.763	-1.179	16.387	1.00	51.27	C
ATOM	804	OD1	ASP	A	124	14.700	-1.790	16.620	1.00	56.07	O
ATOM	805	OD2	ASP	A	124	15.784	0.020	16.039	1.00	54.65	O
ATOM	806	N	ALA	A	125	19.102	-3.546	18.739	1.00	37.63	N
ATOM	807	CA	ALA	A	125	20.039	-4.621	18.983	1.00	37.10	C
ATOM	808	C	ALA	A	125	19.555	-5.682	19.944	1.00	39.02	C
ATOM	809	O	ALA	A	125	20.250	-6.667	20.150	1.00	40.94	O
ATOM	810	CB	ALA	A	125	21.321	-4.035	19.500	1.00	35.16	C
ATOM	811	N	PHE	A	126	18.374	-5.538	20.499	1.00	41.45	N
ATOM	812	CA	PHE	A	126	17.774	-6.599	21.363	1.00	45.13	C
ATOM	813	O	PHE	A	126	16.837	-7.482	20.578	1.00	47.39	O
ATOM	814	C	PHE	A	126	16.711	-8.660	20.900	1.00	48.19	C
ATOM	815	CB	PHE	A	126	16.971	-6.099	22.571	1.00	45.19	C
ATOM	816	CG	PHE	A	126	17.791	-5.456	23.683	1.00	44.53	C
ATOM	817	CD1	PHE	A	126	18.239	-4.150	23.568	1.00	43.63	C
ATOM	818	CD2	PHE	A	126	18.073	-6.184	24.815	1.00	44.69	C
ATOM	819	CE1	PHE	A	126	18.960	-3.565	24.576	1.00	41.80	C
ATOM	820	CE2	PHE	A	126	18.800	-5.597	25.822	1.00	43.70	C
ATOM	821	CZ	PHE	A	126	19.238	-4.295	25.670	1.00	43.96	C
ATOM	822	N	LYS	A	127	16.128	-6.898	19.600	1.00	50.61	N
ATOM	823	CA	LYS	A	127	15.283	-7.655	18.679	1.00	53.75	C
ATOM	824	C	LYS	A	127	16.349	-8.640	17.856	1.00	55.45	C
ATOM	825	O	LYS	A	127	17.038	-9.876	17.922	1.00	57.14	O
ATOM	826	CB	LYS	A	127	14.546	-6.638	17.764	1.00	51.56	C
ATOM	827	N	ASP	A	128	17.077	-8.036	17.105	1.00	57.96	N
ATOM	828	CA	ASP	A	128	18.105	-8.734	16.356	1.00	59.25	C
ATOM	829	C	ASP	A	128	19.292	-9.249	17.190	1.00	59.16	C
ATOM	830	O	ASP	A	128	20.461	-8.894	17.008	1.00	58.89	O
ATOM	831	CB	ASP	A	128	18.492	-7.915	15.062	1.00	61.00	C
ATOM	832	CG	ASP	A	128	18.868	-6.421	15.036	1.00	61.70	C
ATOM	833	OD1	ASP	A	128	20.024	-6.078	15.330	1.00	63.63	C
ATOM	834	OD2	ASP	A	128	18.015	-5.603	14.667	1.00	61.66	C
ATOM	835	N	PHE	A	129	18.967	-10.151	18.118	1.00	59.49	N
ATOM	836	CA	PHE	A	129	19.969	-10.719	19.002	1.00	60.40	C
ATOM	837	C	PHE	A	129	20.411	-12.101	18.003	1.00	61.55	C
ATOM	838	O	PHE	A	129	19.596	-12.979	18.179	1.00	61.67	O
ATOM	839	CB	PHE	A	129	19.410	-10.801	20.440	1.00	64.40	C
ATOM	840	CG	PHE	A	129	20.326	-10.282	21.561	1.00	67.62	C
ATOM	841	CD1	PHE	A	129	21.642	-10.721	21.686	1.00	68.55	C
ATOM	842	CD2	PHE	A	129	19.847	-9.338	22.473	1.00	69.51	C
ATOM	843	CE1	PHE	A	129	22.664	-10.192	22.672	1.00	68.84	C
ATOM	844	CE2	PHE	A	129	20.665	-8.823	23.472	1.00	68.79	C

Figure 8-25

ATOM	845	CZ	PHE	A	129	21.976	-9.245	23.561	1.00	69.80	C
ATOM	846	N	VAL	A	130	21.737	-12.294	18.417	1.00	60.68	N
ATOM	847	CA	VAL	A	130	22.337	-13.577	18.041	1.00	60.72	C
ATOM	848	C	VAL	A	130	23.459	-13.949	19.040	1.00	59.57	C
ATOM	849	O	VAL	A	130	24.157	-13.076	19.597	1.00	58.08	O
ATOM	850	CB	VAL	A	130	22.937	-13.560	16.582	1.00	60.98	C
ATOM	851	CG1	VAL	A	130	23.051	-15.001	16.068	1.00	60.93	C
ATOM	852	CG2	VAL	A	130	22.229	-12.635	15.579	1.00	58.32	C
ATOM	853	N	VAL	A	131	23.635	-15.277	19.213	1.00	57.03	N
ATOM	854	CA	VAL	A	131	24.634	-15.872	20.101	1.00	54.98	C
ATOM	855	C	VAL	A	131	26.059	-15.336	19.950	1.00	53.17	C
ATOM	856	O	VAL	A	131	26.547	-15.173	18.839	1.00	51.72	O
ATOM	857	CB	VAL	A	131	24.563	-17.411	19.950	1.00	55.34	C
ATOM	858	CG1	VAL	A	131	25.611	-18.162	20.780	1.00	55.30	C
ATOM	859	CG2	VAL	A	131	23.145	-17.893	20.297	1.00	54.41	C
ATOM	860	N	ALA	A	132	26.660	-15.027	21.117	1.00	52.91	N
ATOM	861	CA	ALA	A	132	28.022	-14.512	21.293	1.00	52.69	C
ATOM	862	C	ALA	A	132	29.161	-15.433	20.860	1.00	53.47	C
ATOM	863	O	ALA	A	132	30.250	-15.019	20.445	1.00	52.96	O
ATOM	864	CB	ALA	A	132	28.268	-14.176	22.771	1.00	48.84	C
ATOM	865	N	SER	A	133	28.899	-16.725	21.000	1.00	55.81	N
ATOM	866	CA	SER	A	133	29.812	-17.748	20.533	1.00	58.09	C
ATOM	867	C	SER	A	133	29.744	-17.881	19.005	1.00	59.46	C
ATOM	868	O	SER	A	133	30.726	-18.259	18.343	1.00	61.98	O
ATOM	869	CB	SER	A	133	29.348	-19.047	21.161	1.00	59.31	C
ATOM	870	N	GLU	A	134	28.556	-17.536	18.469	1.00	58.64	N
ATOM	871	CA	GLU	A	134	28.251	-17.530	17.031	1.00	57.10	C
ATOM	872	C	GLU	A	134	28.550	-16.218	16.298	1.00	54.08	C
ATOM	873	O	GLU	A	134	28.319	-16.114	15.094	1.00	50.66	O
ATOM	874	CB	GLU	A	134	26.768	-17.808	16.761	1.00	58.33	C
ATOM	875	CG	GLU	A	134	26.269	-19.189	17.121	1.00	61.93	C
ATOM	876	CD	GLU	A	134	24.955	-19.558	16.436	1.00	65.28	C
ATOM	877	OE1	GLU	A	134	24.056	-18.711	16.294	1.00	64.83	O
ATOM	878	OE2	GLU	A	134	24.853	-20.726	16.034	1.00	68.18	C
ATOM	879	N	THR	A	135	28.999	-15.169	16.988	1.00	52.70	N
ATOM	880	CA	THR	A	135	29.366	-13.953	16.291	1.00	51.61	C
ATOM	881	C	THR	A	135	30.896	-13.856	16.192	1.00	51.35	C
ATOM	882	O	THR	A	135	31.549	-14.721	15.580	1.00	52.93	O
ATOM	883	CB	THR	A	135	28.621	-12.683	16.830	1.00	49.31	C
ATOM	884	OG1	THR	A	135	29.039	-12.534	18.171	1.00	49.65	O
ATOM	885	CG2	THR	A	135	27.108	-12.772	16.767	1.00	48.16	C
ATOM	886	N	SER	A	136	31.473	-12.828	16.825	1.00	50.88	N
ATOM	887	CA	SER	A	136	32.885	-12.502	16.714	1.00	49.48	C
ATOM	888	C	SER	A	136	33.422	-12.163	18.121	1.00	47.44	C
ATOM	889	O	SER	A	136	32.624	-12.000	19.056	1.00	46.14	O
ATOM	890	CB	SER	A	136	32.966	-11.306	15.767	1.00	50.00	C
ATOM	891	OG	SER	A	136	32.146	-11.504	14.615	1.00	52.41	O
ATOM	892	N	ASP	A	137	34.760	-12.051	18.314	1.00	44.90	N
ATOM	893	CA	ASP	A	137	35.366	-11.578	19.566	1.00	40.01	C
ATOM	894	C	ASP	A	137	35.037	-10.093	19.850	1.00	36.45	C
ATOM	895	O	ASP	A	137	34.105	-9.570	19.228	1.00	35.34	O
ATOM	896	CB	ASP	A	137	36.879	-11.949	19.641	1.00	40.10	C
ATOM	897	CG	ASP	A	137	37.915	-11.197	18.783	1.00	44.69	C
ATOM	898	OD1	ASP	A	137	37.617	-10.121	18.252	1.00	46.41	O
ATOM	899	OD2	ASP	A	137	39.056	-11.661	18.648	1.00	46.87	O
ATOM	900	N	CYS	A	138	35.702	-9.337	20.741	1.00	32.95	N
ATOM	901	CA	CYS	A	138	35.263	-7.982	21.014	1.00	31.28	C
ATOM	902	C	CYS	A	138	36.311	-6.919	20.838	1.00	30.73	C
ATOM	903	O	CYS	A	138	36.233	-5.825	21.414	1.00	31.32	O
ATOM	904	CB	CYS	A	138	34.557	-7.854	22.361	1.00	32.08	C

ATOM	905	SG	CYS	A	138	32.988	-8.777	22.463	1.00	37.40	S
ATOM	906	N	VAL	A	139	37.258	-7.242	19.954	1.00	30.63	N
ATOM	907	CA	VAL	A	139	38.333	-6.318	19.599	1.00	29.74	C
ATOM	908	C	VAL	A	139	38.151	-5.898	18.168	1.00	28.81	C
ATOM	909	O	VAL	A	139	37.830	-6.734	17.342	1.00	27.95	O
ATOM	910	CB	VAL	A	139	39.769	-6.915	19.600	1.00	28.99	C
ATOM	911	CG1	VAL	A	139	40.717	-5.884	20.195	1.00	29.64	C
ATOM	912	CG2	VAL	A	139	39.889	-8.307	20.143	1.00	26.32	C
ATOM	913	N	VAL	A	140	38.424	-4.646	17.840	1.00	31.00	N
ATOM	914	CA	VAL	A	140	38.442	-4.247	16.459	1.00	34.50	C
ATOM	915	C	VAL	A	140	39.899	-4.167	16.020	1.00	36.64	C
ATOM	916	O	VAL	A	140	40.406	-5.059	15.323	1.00	39.48	O
ATOM	917	CB	VAL	A	140	37.758	-2.914	16.217	1.00	36.55	C
ATOM	918	CG1	VAL	A	140	37.417	-2.900	14.747	1.00	36.42	C
ATOM	919	CG2	VAL	A	140	36.594	-2.569	17.119	1.00	34.81	C
ATOM	920	N	SER	A	141	40.566	-3.136	16.529	1.00	37.83	N
ATOM	921	CA	SER	A	141	41.905	-2.682	16.123	1.00	41.81	C
ATOM	922	C	SER	A	141	41.936	-1.563	15.056	1.00	42.37	C
ATOM	923	O	SER	A	141	43.035	-1.174	14.685	1.00	43.60	O
ATOM	924	CB	SER	A	141	42.986	-3.811	15.889	1.00	42.08	C
ATOM	925	OG	SER	A	141	43.175	-4.693	17.008	1.00	38.01	C
TER	927		SER	A	141						
ATOM	928	N	ASN	B	11	2.666	37.382	21.946	1.00	65.93	N
ATOM	929	CA	ASN	B	11	1.945	36.256	22.556	1.00	66.50	C
ATOM	930	C	ASN	B	11	2.726	35.510	22.658	1.00	66.17	C
ATOM	931	O	ASN	B	11	3.559	34.641	23.372	1.00	66.24	O
ATOM	932	CB	ASN	B	11	1.888	35.204	21.515	1.00	66.50	C
ATOM	933	N	VAL	B	12	2.404	35.814	24.934	1.00	65.43	N
ATOM	934	C	VAL	B	12	3.197	35.450	26.131	1.00	62.92	C
ATOM	935	O	VAL	B	12	3.195	33.985	26.631	1.00	60.27	O
ATOM	936	CA	VAL	B	12	4.143	33.547	27.294	1.00	59.00	C
ATOM	937	CB	VAL	B	12	2.780	36.430	27.299	1.00	64.35	C
ATOM	938	CG1	VAL	B	12	1.408	36.086	27.935	1.00	63.94	C
ATOM	939	CG2	VAL	B	12	3.908	36.621	28.318	1.00	63.41	C
ATOM	940	N	LYS	B	13	2.125	33.208	26.374	1.00	56.82	N
ATOM	941	CA	LYS	B	13	2.071	31.821	26.800	1.00	51.85	C
ATOM	942	C	LYS	B	13	3.021	31.001	25.927	1.00	48.88	C
ATOM	943	O	LYS	B	13	3.595	30.003	26.380	1.00	49.33	O
ATOM	944	CB	LYS	B	13	0.640	31.283	26.675	1.00	52.25	C
ATOM	945	N	ASP	B	14	3.258	31.456	24.684	1.00	44.12	N
ATOM	946	CA	ASP	B	14	4.169	30.783	23.770	1.00	37.71	C
ATOM	947	C	ASP	B	14	5.662	30.978	24.040	1.00	31.42	C

[illegible]

ATOM	966	CG2	THR	B	16	5.605	29.577	30.304	1.00	29.47
ATOM	967	N	LYS	B	17	6.385	28.387	26.979	1.00	24.02
ATOM	968	CA	LYS	B	17	6.508	27.042	26.455	1.00	25.48
ATOM	969	C	LYS	B	17	7.776	26.845	25.607	1.00	22.72
ATOM	970	O	LYS	B	17	8.397	25.806	25.690	1.00	22.89
ATOM	971	CB	LYS	B	17	5.235	26.851	25.662	1.00	29.47
ATOM	972	CG	LYS	B	17	5.047	25.479	25.076	1.00	36.80
ATOM	973	CD	LYS	B	17	3.820	25.460	24.129	1.00	40.47
ATOM	974	CE	LYS	B	17	3.432	24.008	23.742	1.00	42.23
ATOM	975	NZ	LYS	B	17	4.518	23.260	23.099	1.00	40.28
ATOM	976	N	LEU	B	18	8.223	27.840	24.836	1.00	21.80
ATOM	977	CA	LEU	B	18	9.489	27.797	24.148	1.00	19.84
ATOM	978	C	LEU	B	18	10.608	27.577	23.161	1.00	19.53
ATOM	979	O	LEU	B	18	11.425	26.868	24.985	1.00	22.71
ATOM	980	CB	LEU	B	18	9.650	28.989	23.206	1.00	17.63
ATOM	981	CG	LEU	B	18	10.954	29.148	22.479	1.00	13.25
ATOM	982	CD1	LEU	B	18	11.216	27.956	21.627	1.00	16.15
ATOM	983	CD2	LEU	B	18	10.895	30.338	21.606	1.00	13.19
ATOM	984	N	VAL	B	19	10.670	28.606	26.187	1.00	17.49
ATOM	985	CA	VAL	B	19	11.713	28.547	27.193	1.00	15.59
ATOM	986	C	VAL	B	19	11.708	27.199	27.912	1.00	16.76
ATOM	987	O	VAL	B	19	12.763	26.598	28.121	1.00	18.54
ATOM	988	CB	VAL	B	19	11.587	29.741	28.170	1.00	15.79
ATOM	989	CG1	VAL	B	19	12.566	29.662	29.308	1.00	13.19
ATOM	990	CG2	VAL	B	19	11.922	31.014	27.489	1.00	12.62
ATOM	991	N	ALA	B	20	10.533	26.655	25.289	1.00	12.22
ATOM	992	CA	ALA	B	20	10.155	25.844	24.918	1.00	17.20
ATOM	993	C	ALA	B	20	11.856	24.235	28.075	1.00	20.20
ATOM	994	O	ALA	B	20	11.185	23.166	28.578	1.00	22.02
ATOM	995	CB	ALA	B	20	8.972	25.064	29.185	1.00	18.25
ATOM	996	N	ASN	B	21	10.854	24.390	26.763	1.00	22.32
ATOM	997	CA	ASN	B	21	11.373	23.351	25.920	1.00	21.93
ATOM	998	C	ASN	B	21	12.711	23.661	25.314	1.00	21.34
ATOM	999	O	ASN	B	21	13.114	22.930	24.441	1.00	23.28
ATOM	1000	CB	ASN	B	21	10.378	23.022	24.573	1.00	26.17
ATOM	1001	CG	ASN	B	21	9.256	22.250	25.831	1.00	31.77
ATOM	1002	ND1	ASN	B	21	9.352	21.054	25.313	1.00	30.13
ATOM	1003	ND2	ASN	B	21	8.168	22.985	25.820	1.00	34.22
ATOM	1004	N	LEU	B	22	13.455	22.675	25.727	1.00	20.84
ATOM	1005	CA	LEU	B	22	14.225	24.880	25.285	1.00	18.95
ATOM	1006	C	LEU	B	22	15.754	24.358	26.359	1.00	19.14
ATOM	1007	O	LEU	B	22	15.428	24.560	27.526	1.00	19.71
ATOM	1008	CB	LEU	B	22	15.097	26.380	25.022	1.00	17.41
ATOM	1009	CG	LEU	B	22	14.510	27.035	23.750	1.00	15.79
ATOM	1010	CD1	LEU	B	22	14.718	28.544	23.724	1.00	13.61
ATOM	1011	CD2	LEU	B	22	15.120	26.381	22.517	1.00	14.80
ATOM	1012	N	PRO	B	23	16.903	23.701	26.091	1.00	18.35
ATOM	1013	CA	PRO	B	23	17.831	23.260	27.130	1.00	17.51
ATOM	1014	C	PRO	B	23	18.329	24.418	28.008	1.00	17.87
ATOM	1015	O	PRO	B	23	18.703	25.449	27.421	1.00	18.87
ATOM	1016	CB	PRO	B	23	18.908	22.653	26.007	1.00	13.87
ATOM	1017	CG	PRO	B	23	17.299	22.223	25.002	1.00	12.84
ATOM	1018	CD	PRO	B	23	17.357	23.421	24.762	1.00	14.01
ATOM	1019	N	LYS	B	24	18.327	23.440	29.347	1.00	18.87
ATOM	1020	C	LYS	B	24	18.756	25.441	30.226	1.00	21.96
ATOM	1021	CA	LYS	B	24	20.207	25.930	30.039	1.00	21.00
ATOM	1022	O	LYS	B	24	20.567	27.081	30.304	1.00	21.61
ATOM	1023	CB	LYS	B	24	18.456	25.044	31.703	1.00	23.68
ATOM	1024	CG	LYS	B	24	16.956	25.097	32.077	1.00	29.69
ATOM	1025	CD	LYS	B	24	16.544	24.007	33.429	1.00	34.88

Figure 8-28

ATOM	1026	CE	LYS	B	24	15.010	24.526	33.777	1.00	39.45	C
ATOM	1027	NZ	LYS	B	24	14.493	23.773	34.927	1.00	41.87	C
ATOM	1028	N	ASP	B	25	21.040	25.044	29.503	1.00	19.08	N
ATOM	1029	CA	ASP	B	25	22.440	25.350	29.263	1.00	20.79	C
ATOM	1030	C	ASP	B	25	22.758	25.601	27.789	1.00	19.77	C
ATOM	1031	O	ASP	B	25	23.907	25.469	27.373	1.00	20.06	O
ATOM	1032	CB	ASP	B	25	23.305	24.190	29.796	1.00	17.87	C
ATOM	1033	CG	ASP	B	25	23.063	22.836	29.175	1.00	20.81	C
ATOM	1034	OD1	ASP	B	25	21.975	22.598	28.651	1.00	22.64	O
ATOM	1035	OD2	ASP	B	25	23.964	21.991	29.214	1.00	24.79	C
ATOM	1036	N	TYR	B	26	21.753	25.866	26.950	1.00	19.06	N
ATOM	1037	CA	TYR	B	26	21.990	26.130	25.542	1.00	18.77	C
ATOM	1038	C	TYR	B	26	22.027	27.652	25.358	1.00	18.82	C
ATOM	1039	O	TYR	B	26	21.066	28.358	25.655	1.00	19.57	C
ATOM	1040	CB	TYR	B	26	20.900	25.477	24.712	1.00	16.23	C
ATOM	1041	CG	TYR	B	26	21.007	25.766	23.228	1.00	19.16	C
ATOM	1042	CD1	TYR	B	26	22.034	25.216	22.492	1.00	20.33	C
ATOM	1043	CD2	TYR	B	26	20.097	26.629	22.632	1.00	19.21	C
ATOM	1044	CE1	TYR	B	26	22.125	25.531	21.150	1.00	19.71	C
ATOM	1045	CE2	TYR	B	26	20.180	26.936	21.294	1.00	18.86	C
ATOM	1046	CZ	TYR	B	26	21.184	26.356	20.565	1.00	21.21	C
ATOM	1047	OH	TYR	B	26	21.209	26.560	19.204	1.00	23.57	O
HETATM	1048	N	MSE	B	27	23.136	28.207	24.891	1.00	18.02	N
HETATM	1049	CA	MSE	B	27	23.249	29.645	24.886	1.00	20.01	C
HETATM	1050	C	MSE	B	27	22.894	30.253	23.553	1.00	20.43	C
HETATM	1051	O	MSE	B	27	23.319	29.791	22.493	1.00	22.74	O
HETATM	1052	CB	MSE	B	27	24.648	30.070	25.309	1.00	21.80	C
HETATM	1053	CG	MSE	B	27	25.179	29.494	26.646	1.00	24.25	C
HETATM	1054	SE	MSE	B	27	24.219	29.995	28.260	1.00	30.76	SE
HETATM	1055	CE	MSE	B	27	24.936	31.691	28.317	1.00	17.91	C
ATOM	1056	N	ILE	B	28	22.071	31.294	23.642	1.00	21.17	N
ATOM	1057	CA	ILE	B	28	21.690	32.092	22.507	1.00	20.03	C
ATOM	1058	C	ILE	B	28	22.501	33.383	22.470	1.00	20.64	C
ATOM	1059	O	ILE	B	28	22.545	34.162	23.403	1.00	19.83	O
ATOM	1060	CB	ILE	B	28	20.168	32.289	22.522	1.00	19.56	C
ATOM	1061	CG1	ILE	B	28	19.489	30.935	22.719	1.00	14.81	C
ATOM	1062	CG2	ILE	B	28	19.653	32.893	21.195	1.00	17.30	C
ATOM	1063	CD1	ILE	B	28	17.993	31.054	22.978	1.00	14.38	C
ATOM	1064	N	THR	B	29	23.235	33.585	21.364	1.00	22.56	N
ATOM	1065	CA	THR	B	29	24.048	34.777	21.117	1.00	21.92	C
ATOM	1066	C	THR	B	29	23.167	35.926	20.723	1.00	21.18	C
ATOM	1067	O	THR	B	29	22.235	35.744	19.926	1.00	24.05	O
ATOM	1068	CB	THR	B	29	25.003	34.540	19.949	1.00	24.32	C
ATOM	1069	OG1	THR	B	29	25.751	33.393	20.310	1.00	26.19	O
ATOM	1070	CG2	THR	B	29	25.901	35.743	19.657	1.00	23.45	C
ATOM	1071	N	LEU	B	30	23.485	37.110	21.229	1.00	19.18	N
ATOM	1072	CA	LEU	B	30	22.694	38.278	20.928	1.00	19.42	C
ATOM	1073	C	LEU	B	30	23.612	39.444	21.123	1.00	20.84	C
ATOM	1074	O	LEU	B	30	24.251	39.604	22.155	1.00	22.59	O
ATOM	1075	CB	LEU	B	30	21.486	38.458	21.822	1.00	16.57	C
ATOM	1076	CG	LEU	B	30	20.712	39.739	21.692	1.00	17.65	C
ATOM	1077	CD1	LEU	B	30	19.907	39.690	20.405	1.00	15.54	C
ATOM	1078	CD2	LEU	B	30	19.875	40.004	22.946	1.00	14.12	C
ATOM	1079	N	LYS	B	31	23.641	40.271	20.085	1.00	21.41	N
ATOM	1080	CA	LYS	B	31	24.340	41.533	20.142	1.00	22.33	C
ATOM	1081	C	LYS	B	31	23.462	42.478	20.918	1.00	21.90	C
ATOM	1082	O	LYS	B	31	22.714	43.295	20.370	1.00	24.57	O
ATOM	1083	CB	LYS	B	31	24.642	42.093	18.754	1.00	21.18	C
ATOM	1084	CG	LYS	B	31	25.844	41.479	18.111	1.00	21.89	C
ATOM	1085	CD	LYS	B	31	25.551	41.360	16.647	1.00	29.30	C

0960027.062000

Figure 8-29

ATOM	1086	CE	LYS	B	31	26.741	40.957	15.808	1.00	31.29	C
ATOM	1087	NZ	LYS	B	31	27.628	42.105	15.688	1.00	39.41	N
ATOM	1088	N	TYR	B	32	23.572	42.299	22.227	1.00	21.32	N
ATOM	1089	CA	TYR	B	32	22.800	43.101	23.138	1.00	19.60	C
ATOM	1090	C	TYR	B	32	23.198	44.586	22.981	1.00	19.96	C
ATOM	1091	O	TYR	B	32	24.384	44.940	22.977	1.00	20.37	O
ATOM	1092	CB	TYR	B	32	23.094	42.513	24.532	1.00	17.35	C
ATOM	1093	CG	TYR	B	32	22.621	43.373	25.710	1.00	17.26	C
ATOM	1094	CD1	TYR	B	32	21.298	43.297	26.107	1.00	15.20	C
ATOM	1095	CD2	TYR	B	32	23.490	44.280	26.299	1.00	14.00	C
ATOM	1096	CE1	TYR	B	32	20.851	44.149	27.086	1.00	13.12	C
ATOM	1097	CE2	TYR	B	32	23.013	45.166	27.227	1.00	14.39	C
ATOM	1098	CZ	TYR	B	32	21.702	45.070	27.606	1.00	13.82	C
ATOM	1099	OH	TYR	B	32	21.213	45.916	28.560	1.00	18.31	O
ATOM	1100	N	VAL	B	33	22.179	45.455	22.873	1.00	19.13	N
ATOM	1101	CA	VAL	B	33	22.376	46.889	22.818	1.00	19.34	C
ATOM	1102	C	VAL	B	33	22.478	47.489	24.223	1.00	22.86	C
ATOM	1103	O	VAL	B	33	21.487	47.535	24.979	1.00	23.26	O
ATOM	1104	CB	VAL	B	33	21.220	47.609	22.071	1.00	18.33	C
ATOM	1105	CG1	VAL	B	33	21.607	49.014	21.732	1.00	17.72	C
ATOM	1106	CG2	VAL	B	33	20.868	46.933	20.772	1.00	18.88	C
ATOM	1107	N	PRO	B	34	23.669	48.022	24.556	1.00	23.14	N
ATOM	1108	CA	PRO	B	34	23.950	48.685	25.814	1.00	25.98	C
ATOM	1109	C	PRO	B	34	22.991	49.844	26.052	1.00	27.87	C
ATOM	1110	O	PRO	B	34	22.782	50.697	25.173	1.00	28.20	O
ATOM	1111	CB	PRO	B	34	25.355	49.247	25.629	1.00	24.52	C
ATOM	1112	CG	PRO	B	34	25.947	48.454	24.514	1.00	23.81	C
ATOM	1113	CD	PRO	B	34	24.761	48.256	23.617	1.00	23.96	C
ATOM	1114	N	GLY	B	35	22.428	49.854	27.265	1.00	27.60	N
ATOM	1115	CA	GLY	B	35	21.544	50.919	27.694	1.00	26.85	C
ATOM	1116	C	GLY	B	35	20.103	50.509	27.809	1.00	26.95	C
ATOM	1117	O	GLY	B	35	19.314	51.234	28.392	1.00	27.06	O
HETATM	1118	N	MSE	B	36	19.736	49.361	27.277	1.00	27.66	N
HETATM	1119	CA	MSE	B	36	18.444	48.762	27.502	1.00	31.16	C
HETATM	1120	C	MSE	B	36	17.873	48.948	28.920	1.00	33.96	C
HETATM	1121	O	MSE	B	36	16.708	49.315	29.138	1.00	34.27	O
HETATM	1122	CB	MSE	B	36	18.679	47.299	27.225	1.00	34.63	C
HETATM	1123	CG	MSE	B	36	17.921	46.622	26.126	1.00	37.69	C
HETATM	1124	SE	MSE	B	36	16.954	45.030	26.682	1.00	48.87	SE
HETATM	1125	CE	MSE	B	36	16.692	45.161	28.580	1.00	40.22	C
ATOM	1126	N	ASP	B	37	18.753	48.712	29.902	1.00	35.95	N
ATOM	1127	CA	ASP	B	37	18.421	48.828	31.303	1.00	37.28	C
ATOM	1128	C	ASP	B	37	18.228	50.272	31.758	1.00	38.57	C
ATOM	1129	O	ASP	B	37	17.189	50.545	32.368	1.00	42.23	O
ATOM	1130	CB	ASP	B	37	19.407	48.058	32.203	1.00	38.21	C
ATOM	1131	CG	ASP	B	37	20.907	48.280	32.005	1.00	42.18	C
ATOM	1132	OD1	ASP	B	37	21.288	49.092	31.150	1.00	44.69	O
ATOM	1133	OD2	ASP	B	37	21.709	47.641	32.708	1.00	43.60	O
ATOM	1134	N	VAL	B	38	19.111	51.237	31.458	1.00	36.46	N
ATOM	1135	CA	VAL	B	38	18.974	52.585	32.008	1.00	34.42	C
ATOM	1136	C	VAL	B	38	18.360	53.701	31.150	1.00	35.48	C
ATOM	1137	O	VAL	B	38	17.844	54.706	31.662	1.00	35.46	O
ATOM	1138	CB	VAL	B	38	20.314	53.047	32.623	1.00	33.96	C
ATOM	1139	CG1	VAL	B	38	20.656	52.110	33.757	1.00	33.39	C
ATOM	1140	CG2	VAL	B	38	21.452	53.127	31.638	1.00	30.40	C
ATOM	1141	N	LEU	B	39	18.466	53.536	29.826	1.00	34.58	N
ATOM	1142	CA	LEU	B	39	18.173	54.590	28.859	1.00	33.84	C
ATOM	1143	C	LEU	B	39	16.770	54.521	28.304	1.00	34.39	C
ATOM	1144	O	LEU	B	39	16.234	53.407	28.274	1.00	37.21	O
ATOM	1145	CB	LEU	B	39	19.106	54.513	27.672	1.00	31.59	C

0060967 062900

Figure 8-30

ATOM	1146	CG	LEU	B	39	20.516	54.934	27.836	1.00	30.49	C
ATOM	1147	CD1	LEU	B	39	21.233	54.571	26.544	1.00	30.11	C
ATOM	1148	CD2	LEU	B	39	20.556	56.416	28.187	1.00	28.81	C
ATOM	1149	N	PRO	B	40	16.124	55.613	27.821	1.00	33.22	N
ATOM	1150	CA	PRO	B	40	14.743	55.564	27.336	1.00	32.18	C
ATOM	1151	C	PRO	B	40	14.595	54.656	26.104	1.00	31.61	C
ATOM	1152	O	PRO	B	40	15.515	54.575	25.295	1.00	32.07	O
ATOM	1153	CB	PRO	B	40	14.498	57.028	27.054	1.00	31.41	C
ATOM	1154	CG	PRO	B	40	15.395	57.749	28.027	1.00	32.72	C
ATOM	1155	CD	PRO	B	40	16.655	56.977	27.813	1.00	33.34	C
ATOM	1156	N	SER	B	41	13.487	53.949	25.885	1.00	31.04	C
ATOM	1157	CA	SER	B	41	13.422	52.973	24.819	1.00	32.48	C
ATOM	1158	C	SER	B	41	13.785	53.436	23.428	1.00	32.31	C
ATOM	1159	O	SER	B	41	14.301	52.651	22.638	1.00	30.86	O
ATOM	1160	CB	SER	B	41	12.119	52.197	24.820	1.00	34.06	C
ATOM	1161	OG	SER	B	41	10.984	53.037	24.872	1.00	39.11	O
ATOM	1162	N	HIS	B	42	13.622	54.747	23.191	1.00	34.63	N
ATOM	1163	CA	HIS	B	42	13.911	55.363	21.888	1.00	36.02	C
ATOM	1164	C	HIS	B	42	15.396	55.300	21.511	1.00	36.52	C
ATOM	1165	O	HIS	B	42	15.780	55.228	20.327	1.00	34.40	O
ATOM	1166	CB	HIS	B	42	13.316	56.805	21.755	1.00	34.27	C
ATOM	1167	CG	HIS	B	42	13.946	57.935	22.576	1.00	34.59	C
ATOM	1168	ND1	HIS	B	42	13.588	58.408	23.772	1.00	36.14	N
ATOM	1169	CD2	HIS	B	42	15.013	58.687	22.154	1.00	32.00	C
ATOM	1170	CE1	HIS	B	42	14.381	59.396	24.117	1.00	32.43	C
ATOM	1171	NE2	HIS	B	42	15.227	59.539	23.124	1.00	35.02	N
ATOM	1172	N	CYS	B	43	16.177	55.249	22.615	1.00	35.96	N
ATOM	1173	CA	CYS	B	43	17.627	55.122	22.565	1.00	35.90	C
ATOM	1174	C	CYS	B	43	18.176	53.799	22.054	1.00	32.86	C
ATOM	1175	O	CYS	B	43	19.347	53.782	21.649	1.00	33.40	O
ATOM	1176	CB	CYS	B	43	18.339	55.448	23.910	1.00	40.38	C
ATOM	1177	SG	CYS	B	43	18.099	57.127	24.542	1.00	45.68	S
ATOM	1178	N	TRP	B	44	17.380	52.707	22.075	1.00	29.25	N
ATOM	1179	CA	TRP	B	44	17.913	51.374	21.831	1.00	25.51	C
ATOM	1180	C	TRP	B	44	17.009	50.463	21.066	1.00	24.22	C
ATOM	1181	O	TRP	B	44	17.544	49.594	20.406	1.00	26.02	O
ATOM	1182	CB	TRP	B	44	18.375	50.661	23.113	1.00	21.99	C
ATOM	1183	CG	TRP	B	44	17.351	50.644	24.234	1.00	20.34	C
ATOM	1184	CD1	TRP	B	44	17.361	51.632	25.183	1.00	18.11	C
ATOM	1185	CD2	TRP	B	44	16.297	49.745	24.363	1.00	19.23	C
ATOM	1186	NE1	TRP	B	44	16.293	51.390	25.908	1.00	19.12	N
ATOM	1187	CE2	TRP	B	44	15.635	50.281	25.471	1.00	18.20	C
ATOM	1188	CE3	TRP	B	44	15.892	48.551	23.795	1.00	15.22	C
ATOM	1189	CZ2	TRP	B	44	14.532	49.622	26.000	1.00	14.99	C
ATOM	1190	CZ3	TRP	B	44	14.805	47.897	24.324	1.00	13.45	C
ATOM	1191	CH2	TRP	B	44	14.130	48.434	25.405	1.00	15.50	C
ATOM	1192	N	ILE	B	45	15.680	50.626	21.096	1.00	24.85	N
ATOM	1193	CA	ILE	B	45	14.726	49.656	20.539	1.00	25.50	C
ATOM	1194	C	ILE	B	45	14.926	49.254	19.094	1.00	26.34	C
ATOM	1195	O	ILE	B	45	14.724	48.086	18.762	1.00	28.11	O
ATOM	1196	CB	ILE	B	45	13.231	50.055	20.773	1.00	26.28	C
ATOM	1197	CG1	ILE	B	45	12.358	48.838	20.592	1.00	24.31	C
ATOM	1198	CG2	ILE	B	45	12.716	51.206	19.885	1.00	25.51	C
ATOM	1199	CD1	ILE	B	45	12.688	47.633	21.486	1.00	19.41	C
ATOM	1200	N	SER	B	46	15.336	50.233	18.274	1.00	28.06	N
ATOM	1201	CA	SER	B	46	15.623	50.071	16.851	1.00	28.67	C
ATOM	1202	C	SER	B	46	16.739	49.059	16.553	1.00	27.51	C
ATOM	1203	O	SER	B	46	16.558	48.113	15.773	1.00	26.90	O
ATOM	1204	CB	SER	B	46	15.933	51.472	16.250	1.00	28.71	C
ATOM	1205	OG	SER	B	46	16.259	51.414	14.871	1.00	31.35	O

D:\000027\062900

Figure 8-31

ATOM	1206	N	GLU	B	47	17.902	49.210	17.203	1.00	26.77	N
ATOM	1207	CA	GLU	B	47	18.910	48.173	17.142	1.00	27.22	C
ATOM	1208	C	GLU	B	47	18.555	46.912	17.906	1.00	23.80	C
ATOM	1209	O	GLU	B	47	19.011	45.850	17.513	1.00	24.85	O
ATOM	1210	CB	GLU	B	47	20.209	48.703	17.683	1.00	30.36	C
ATOM	1211	CG	GLU	B	47	21.460	47.909	17.269	1.00	31.64	C
ATOM	1212	CD	GLU	B	47	21.718	47.840	15.774	1.00	31.93	C
ATOM	1213	OE1	GLU	B	47	21.267	48.726	15.034	1.00	32.82	O
ATOM	1214	OE2	GLU	B	47	22.391	46.892	15.366	1.00	31.60	O
HETATM	1215	N	MSE	B	48	17.739	46.958	18.958	1.00	23.65	N
HETATM	1216	CA	MSE	B	48	17.401	45.755	19.709	1.00	21.94	C
HETATM	1217	C	MSE	B	48	16.511	44.916	18.837	1.00	22.24	C
HETATM	1218	O	MSE	B	48	16.819	43.732	18.731	1.00	24.91	O
HETATM	1219	CB	MSE	B	48	16.783	46.061	21.080	1.00	22.86	C
HETATM	1220	CG	MSE	B	48	16.875	44.981	22.173	1.00	24.51	C
HETATM	1221	SE	MSE	B	48	18.597	44.203	22.615	1.00	30.61	SE
HETATM	1222	CE	MSE	B	48	17.982	42.661	21.922	1.00	26.74	C
ATOM	1223	N	VAL	B	49	15.506	45.445	18.110	1.00	21.88	N
ATOM	1224	CA	VAL	B	49	14.661	44.597	17.276	1.00	20.25	C
ATOM	1225	C	VAL	B	49	15.387	43.973	16.098	1.00	20.18	C
ATOM	1226	O	VAL	B	49	15.120	42.815	15.780	1.00	22.62	O
ATOM	1227	CB	VAL	B	49	13.351	45.252	16.813	1.00	23.22	C
ATOM	1228	CG1	VAL	B	49	12.455	45.562	17.992	1.00	24.62	C
ATOM	1229	CG2	VAL	B	49	13.551	46.527	16.025	1.00	23.30	C
ATOM	1230	N	VAL	B	50	16.363	44.655	15.484	1.00	19.52	N
ATOM	1231	CA	VAL	B	50	17.179	44.087	14.408	1.00	19.02	C
ATOM	1232	C	VAL	B	50	18.005	42.916	14.897	1.00	19.73	C
ATOM	1233	O	VAL	B	50	18.091	41.872	14.232	1.00	19.76	O
ATOM	1234	CB	VAL	B	50	18.110	45.171	13.808	1.00	18.29	C
ATOM	1235	CG1	VAL	B	50	19.181	44.607	12.925	1.00	16.52	C
ATOM	1236	CG2	VAL	B	50	17.290	46.136	13.024	1.00	18.74	C
ATOM	1237	N	GLN	B	51	18.617	43.151	16.064	1.00	17.95	N
ATOM	1238	CA	GLN	B	51	19.447	42.130	16.677	1.00	18.39	C
ATOM	1239	C	GLN	B	51	18.645	40.938	17.084	1.00	16.66	C
ATOM	1240	O	GLN	B	51	19.056	39.827	16.830	1.00	18.39	O
ATOM	1241	CB	GLN	B	51	20.264	42.655	17.851	1.00	18.87	C
ATOM	1242	CG	GLN	B	51	21.265	43.713	17.440	1.00	18.55	C
ATOM	1243	CD	GLN	B	51	22.253	43.283	16.370	1.00	23.83	C
ATOM	1244	OE1	GLN	B	51	22.400	42.141	15.918	1.00	23.92	O
ATOM	1245	NE2	GLN	B	51	23.019	44.265	15.958	1.00	27.04	N
ATOM	1246	N	LEU	B	52	17.481	41.149	17.652	1.00	16.16	N
ATOM	1247	CA	LEU	B	52	16.615	40.053	18.010	1.00	17.66	C
ATOM	1248	C	LEU	B	52	16.106	39.302	16.810	1.00	18.23	C
ATOM	1249	O	LEU	B	52	16.012	38.080	16.844	1.00	18.09	O
ATOM	1250	CB	LEU	B	52	15.412	40.576	18.771	1.00	19.12	C
ATOM	1251	CG	LEU	B	52	15.665	40.840	20.232	1.00	20.87	C
ATOM	1252	CD1	LEU	B	52	14.609	41.767	20.734	1.00	20.47	C
ATOM	1253	CD2	LEU	B	52	15.692	39.553	21.037	1.00	21.69	C
ATOM	1254	N	SER	B	53	15.797	40.014	15.717	1.00	20.42	N
ATOM	1255	CA	SER	B	53	15.410	39.376	14.469	1.00	18.47	C
ATOM	1256	C	SER	B	53	16.491	38.428	13.973	1.00	18.27	C
ATOM	1257	O	SER	B	53	16.259	37.257	13.692	1.00	17.53	O
ATOM	1258	CB	SER	B	53	15.188	40.496	13.523	1.00	21.19	C
ATOM	1259	OG	SER	B	53	14.858	39.866	12.317	1.00	22.45	O
ATOM	1260	N	ASP	B	54	17.729	38.892	13.962	1.00	21.01	N
ATOM	1261	CA	ASP	B	54	18.811	38.060	13.483	1.00	25.15	C
ATOM	1262	C	ASP	B	54	19.040	36.841	14.339	1.00	24.43	C
ATOM	1263	O	ASP	B	54	19.279	35.764	13.782	1.00	24.72	O
ATOM	1264	CB	ASP	B	54	20.170	38.731	13.462	1.00	32.20	C
ATOM	1265	CG	ASP	B	54	20.366	40.017	12.671	1.00	44.10	C

05670627.056660

Figure 8-32

ATOM	1266	OD1	ASP	B	54	19.508	40.411	11.838	1.00	48.06	O
ATOM	1267	OD2	ASP	B	54	21.429	40.630	12.924	1.00	50.40	O
ATOM	1268	N	SER	B	55	19.025	37.009	15.674	1.00	21.94	N
ATOM	1269	CA	SER	B	55	19.197	35.872	16.589	1.00	21.29	C
ATOM	1270	C	SER	B	55	18.036	34.884	16.516	1.00	19.86	C
ATOM	1271	O	SER	B	55	18.259	33.675	16.567	1.00	20.94	O
ATOM	1272	CB	SER	B	55	19.356	36.295	18.052	1.00	18.68	C
ATOM	1273	OG	SER	B	55	20.384	37.208	18.406	1.00	18.26	O
ATOM	1274	N	LEU	B	56	16.789	35.362	16.374	1.00	20.32	N
ATOM	1275	CA	LEU	B	56	15.647	34.453	16.343	1.00	20.44	C
ATOM	1276	C	LEU	B	56	15.628	33.735	15.025	1.00	21.16	C
ATOM	1277	O	LEU	B	56	15.299	32.552	14.968	1.00	20.64	O
ATOM	1278	CB	LEU	B	56	14.335	35.169	16.568	1.00	19.08	C
ATOM	1279	CG	LEU	B	56	13.967	35.545	17.993	1.00	19.76	C
ATOM	1280	CD1	LEU	B	56	12.809	36.497	18.033	1.00	18.12	C
ATOM	1281	CD2	LEU	B	56	13.621	34.308	18.773	1.00	17.63	C
ATOM	1282	N	THR	B	57	16.081	34.451	13.984	1.00	22.55	N
ATOM	1283	CA	THR	B	57	16.144	33.901	12.624	1.00	23.77	C
ATOM	1284	C	THR	B	57	17.169	32.775	12.599	1.00	25.31	C
ATOM	1285	O	THR	B	57	16.904	31.674	12.109	1.00	28.36	O
ATOM	1286	CB	THR	B	57	16.420	35.019	11.581	1.00	22.83	C
ATOM	1287	OG1	THR	B	57	15.245	35.800	11.520	1.00	20.28	O
ATOM	1288	CG2	THR	B	57	16.608	34.496	10.209	1.00	22.98	C
ATOM	1289	N	ASP	B	58	18.331	32.975	13.229	1.00	27.29	N
ATOM	1290	CA	ASP	B	58	19.328	31.934	13.394	1.00	25.16	C
ATOM	1291	C	ASP	B	58	18.874	30.781	14.238	1.00	22.74	C
ATOM	1292	O	ASP	B	58	19.128	29.640	13.909	1.00	20.50	O
ATOM	1293	CB	ASP	B	58	20.510	32.549	14.059	1.00	32.90	C
ATOM	1294	CG	ASP	B	58	21.367	33.343	13.098	1.00	40.22	C
ATOM	1295	OD1	ASP	B	58	21.635	32.807	11.999	1.00	47.28	O
ATOM	1296	OD2	ASP	B	58	21.780	34.468	13.458	1.00	42.79	O
ATOM	1297	N	LEU	B	59	18.174	31.090	15.328	1.00	22.88	N
ATOM	1298	CA	LEU	B	59	17.597	30.066	16.166	1.00	22.01	C
ATOM	1299	C	LEU	B	59	16.596	29.206	15.391	1.00	22.75	C
ATOM	1300	O	LEU	B	59	16.642	27.981	15.498	1.00	24.25	O
ATOM	1301	CB	LEU	B	59	16.984	30.711	17.389	1.00	21.26	C
ATOM	1302	CG	LEU	B	59	16.544	29.703	18.408	1.00	21.05	C
ATOM	1303	CD1	LEU	B	59	17.733	28.955	19.020	1.00	20.13	C
ATOM	1304	CD2	LEU	B	59	15.718	30.419	19.413	1.00	20.68	C
ATOM	1305	N	LEU	B	60	15.729	29.754	14.537	1.00	22.30	N
ATOM	1306	CA	LEU	B	60	14.838	28.912	13.776	1.00	21.18	C
ATOM	1307	C	LEU	B	60	15.559	27.884	12.897	1.00	24.69	C
ATOM	1308	O	LEU	B	60	15.084	26.761	12.702	1.00	27.59	O
ATOM	1309	CB	LEU	B	60	13.949	29.829	12.982	1.00	20.34	C
ATOM	1310	CG	LEU	B	60	12.805	29.256	12.208	1.00	15.11	C
ATOM	1311	CD1	LEU	B	60	11.775	28.689	13.124	1.00	14.00	C
ATOM	1312	CD2	LEU	B	60	12.216	30.351	11.405	1.00	15.62	C
ATOM	1313	N	ASP	B	61	16.768	28.142	12.405	1.00	28.19	N
ATOM	1314	CA	ASP	B	61	17.425	27.134	11.587	1.00	31.01	C
ATOM	1315	C	ASP	B	61	17.898	25.925	12.380	1.00	30.42	C
ATOM	1316	O	ASP	B	61	18.293	24.903	11.836	1.00	30.78	O
ATOM	1317	CB	ASP	B	61	18.486	27.766	10.638	1.00	40.38	C
ATOM	1318	CG	ASP	B	61	20.011	27.910	10.913	1.00	49.60	C
ATOM	1319	OD1	ASP	B	61	20.632	27.086	11.630	1.00	52.10	O
ATOM	1320	OD2	ASP	B	61	20.602	28.852	10.340	1.00	54.11	O
ATOM	1321	N	LYS	B	62	17.841	26.023	13.706	1.00	29.72	N
ATOM	1322	CA	LYS	B	62	18.282	24.972	14.586	1.00	26.53	C
ATOM	1323	C	LYS	B	62	17.227	23.920	14.754	1.00	26.40	C
ATOM	1324	O	LYS	B	62	17.553	22.835	15.224	1.00	28.09	O
ATOM	1325	CB	LYS	B	62	18.655	25.534	15.953	1.00	25.89	C

09000027 060900

ATOM	1326	CG	LYS	B	62	21.0653	26.451	15.996	1.00	24.99	C
ATOM	1327	CD	LYS	B	62	19.8525	25.810	15.308	1.00	26.66	C
ATOM	1328	CE	LYS	B	62	22.198	26.806	15.251	1.00	28.58	C
ATOM	1329	NZ	LYS	B	62	21.868	27.957	14.431	1.00	34.52	C
ATOM	1330	N	PHE	B	63	15.986	24.225	14.389	1.00	26.48	C
ATOM	1331	CA	PHE	B	63	14.862	23.316	14.568	1.00	29.27	C
ATOM	1332	C	PHE	B	63	14.293	22.916	13.220	1.00	31.78	C
ATOM	1333	O	PHE	B	63	14.573	23.581	12.227	1.00	34.39	O
ATOM	1334	CB	PHE	B	63	13.744	23.920	15.427	1.00	24.13	C
ATOM	1335	CG	PHE	B	63	14.261	24.236	16.809	1.00	23.83	C
ATOM	1336	CD1	PHE	B	63	14.269	23.263	17.761	1.00	20.94	C
ATOM	1337	CD2	PHE	B	63	14.811	25.488	17.066	1.00	25.66	C
ATOM	1338	CE1	PHE	B	63	14.872	23.535	18.964	1.00	23.54	C
ATOM	1339	CE2	PHE	B	63	15.444	25.741	18.263	1.00	22.33	C
ATOM	1340	CZ	PHE	B	63	15.467	24.752	19.211	1.00	21.46	C
ATOM	1341	N	SER	B	64	13.565	21.791	13.203	1.00	35.96	C
ATOM	1342	CA	SER	B	64	12.847	21.251	12.047	1.00	41.24	C
ATOM	1343	C	SER	B	64	11.362	21.237	12.401	1.00	44.87	C
ATOM	1344	O	SER	B	64	11.045	21.210	13.593	1.00	45.47	O
ATOM	1345	CB	SER	B	64	13.299	19.810	11.723	1.00	39.81	C
ATOM	1346	CG	SER	B	64	14.690	19.659	11.441	1.00	41.15	C
ATOM	1347	N	ASN	B	65	10.393	21.257	11.464	1.00	50.28	C
ATOM	1348	CA	ASN	B	65	8.980	21.293	11.878	1.00	53.31	C
ATOM	1349	C	ASN	B	65	8.304	19.970	12.291	1.00	53.88	C
ATOM	1350	O	ASN	B	65	8.619	18.877	11.815	1.00	53.27	O
ATOM	1351	CB	ASN	B	65	8.137	22.123	10.899	1.00	55.21	C
ATOM	1352	CG	ASN	B	65	7.847	22.674	10.585	1.00	55.25	C
ATOM	1353	OD1	ASN	B	65	5.829	22.845	10.846	1.00	62.80	C
ATOM	1354	ND2	ASN	B	65	6.802	22.997	12.821	1.00	58.83	C
ATOM	1355	N	ILE	B	66	7.402	20.111	13.274	1.00	55.78	N
ATOM	1356	CA	ILE	B	66	6.604	19.028	13.857	1.00	58.20	C
ATOM	1357	C	ILE	B	66	5.128	19.413	13.732	1.00	59.99	C
ATOM	1358	O	ILE	B	66	4.679	20.439	14.266	1.00	59.98	C
ATOM	1359	CB	ILE	B	66	6.916	18.864	15.373	1.00	58.00	C
ATOM	1360	CG1	ILE	B	66	8.393	18.635	15.973	1.00	56.77	C
ATOM	1361	CG2	ILE	B	66	6.119	17.713	15.650	1.00	58.43	C
ATOM	1362	CD1	ILE	B	66	8.729	18.733	17.169	1.00	53.61	C
ATOM	1363	N	SER	B	67	4.387	18.545	13.027	1.00	62.59	N
ATOM	1364	CA	SER	B	67	2.945	18.687	12.803	1.00	65.18	C
ATOM	1365	C	SER	B	67	2.049	18.114	13.335	1.00	66.89	C
ATOM	1366	O	SER	B	67	1.110	17.339	13.725	1.00	68.18	O
ATOM	136										

Figure 8-34

ATOM	1386	CB	LEU	B	70	3.243	25.033	20.295	1.00	52.74	C
ATOM	1387	CG	LEU	B	70	2.243	26.184	20.332	1.00	54.01	C
ATOM	1388	CD1	LEU	B	70	2.326	26.991	19.014	1.00	54.05	C
ATOM	1389	CD2	LEU	B	70	0.834	25.683	20.698	1.00	55.75	C
ATOM	1390	N	SER	B	71	5.437	23.543	18.271	1.00	43.22	N
ATOM	1391	CA	SER	B	71	6.788	23.107	18.347	1.00	37.10	C
ATOM	1392	C	SER	B	71	7.676	24.348	18.452	1.00	35.41	C
ATOM	1393	O	SER	B	71	7.223	25.469	18.195	1.00	34.32	C
ATOM	1394	CB	SER	B	71	7.030	22.242	17.147	1.00	36.36	C
ATOM	1395	OG	SER	B	71	6.753	22.899	15.934	1.00	36.82	C
ATOM	1396	N	ASN	B	72	8.946	24.206	18.876	1.00	33.26	C
ATOM	1397	CA	ASN	B	72	9.888	25.327	18.974	1.00	28.70	C
ATOM	1398	C	ASN	B	72	10.013	26.017	17.631	1.00	25.92	C
ATOM	1399	ASN	ASN	B	72	10.086	27.234	17.401	1.00	25.46	C
ATOM	1400	CB	ASN	B	72	11.281	24.862	19.462	1.00	28.81	C
ATOM	1401	CG	ASN	B	72	11.365	24.292	20.880	1.00	26.47	C
ATOM	1402	OD1	ASN	B	72	10.592	24.638	21.764	1.00	25.38	C
ATOM	1403	ND2	ASN	B	72	12.284	23.373	21.160	1.00	26.66	N
ATOM	1404	N	TYR	B	73	9.968	25.221	16.547	1.00	26.29	N
ATOM	1405	CA	TYR	B	73	9.940	25.723	15.179	1.00	26.54	C
ATOM	1406	C	TYR	B	73	8.760	26.639	14.993	1.00	23.80	C
ATOM	1407	O	TYR	B	73	8.967	27.809	14.726	1.00	27.19	C
ATOM	1408	CB	TYR	B	73	9.881	24.631	14.075	1.00	28.15	C
ATOM	1409	CG	TYR	B	73	10.162	25.129	12.647	1.00	28.60	C
ATOM	1410	OD	TYR	B	73	9.210	25.828	11.901	1.00	29.58	C
ATOM	1411	CD2	TYR	B	73	11.426	24.929	12.122	1.00	30.26	C
ATOM	1412	CE1	TYR	B	73	9.566	26.391	10.690	1.00	29.50	C
ATOM	1413	CE2	TYR	B	73	11.783	25.467	11.898	1.00	31.02	C
ATOM	1414	CZ	TYR	B	73	16.955	26.215	10.209	1.00	32.98	C
ATOM	1415	OH	TYR	B	73	11.245	26.802	9.014	1.00	36.91	C
ATOM	1416	N	SER	B	74	7.535	26.185	15.145	1.00	23.20	N
ATOM	1417	CA	SER	B	74	6.402	27.077	15.028	1.00	24.27	C
ATOM	1418	C	SER	B	74	6.449	28.270	15.935	1.00	23.26	C
ATOM	1419	O	SER	B	74	6.039	29.360	15.572	1.00	25.85	C
ATOM	1420	CB	SER	B	74	5.156	26.342	15.357	1.00	25.27	C
ATOM	1421	OG	SER	B	74	5.173	25.254	14.460	1.00	32.42	C
ATOM	1422	N	ILE	B	75	6.958	28.120	17.146	1.00	25.08	N
ATOM	1423	CA	ILE	B	75	6.913	29.248	18.057	1.00	23.59	C
ATOM	1424	C	ILE	B	75	7.908	30.294	17.620	1.00	21.89	C
ATOM	1425	O	ILE	B	75	7.509	31.437	17.519	1.00	21.91	C
ATOM	1426	CB	ILE	B	75	7.150	28.785	16.812	1.00	23.07	C
ATOM	1427	CG1	ILE	B	75	5.984	27.956	19.962	1.00	23.49	C
ATOM	1428	CG2	ILE	B	75	7.272	29.985	20.397	1.00	22.81	C
ATOM	1429	CD1	ILE	B	75	6.254	27.309	21.343	1.00	21.59	C
ATOM	1430	N	ILE	B	76	9.149	29.881	17.347	1.00	21.79	N
ATOM	1431	CA	ILE	B	76	10.226	30.789	16.994	1.00	22.16	C
ATOM	1432	C	ILE	B	76	9.830	31.465	15.705	1.00	23.36	C
ATOM	1433	O	ILE	B	76	9.898	32.679	15.673	1.00	26.09	C
ATOM	1434	CB	ILE	B	76	11.611	30.123	16.831	1.00	21.17	C
ATOM	1435	CG1	ILE	B	76	12.075	29.444	18.092	1.00	19.74	C
ATOM	1436	CG2	ILE	B	76	12.661	31.169	16.489	1.00	18.62	C
ATOM	1437	CD1	ILE	B	76	13.143	28.388	17.846	1.00	17.66	C
ATOM	1438	N	ASP	B	77	9.353	30.734	14.702	1.00	23.97	N
ATOM	1439	CA	ASP	B	77	8.866	31.293	13.562	1.00	25.97	C
ATOM	1440	C	ASP	B	77	7.856	32.413	13.657	1.00	26.70	C
ATOM	1441	O	ASP	B	77	7.065	33.525	13.187	1.00	28.84	O
ATOM	1442	CB	ASP	B	77	8.223	30.179	12.680	1.00	28.57	C
ATOM	1443	CG	ASP	B	77	8.018	30.507	11.212	1.00	32.25	C
ATOM	1444	OD1	ASP	B	77	8.957	31.036	10.598	1.00	34.07	C
ATOM	1445	OD2	ASP	B	77	6.927	30.224	10.794	1.00	32.50	C

ATOM	1446	N	LYS	B	78	6.797	32.211	14.443	1.00	28.77	N
ATOM	1447	CA	LYS	B	78	5.891	33.285	14.868	1.00	28.31	C
ATOM	1448	C	LYS	B	78	6.596	34.463	15.571	1.00	26.90	C
ATOM	1449	O	LYS	B	78	6.221	35.629	15.449	1.00	26.22	O
ATOM	1450	CB	LYS	B	78	4.861	32.589	15.792	1.00	32.30	C
ATOM	1451	CG	LYS	B	78	3.767	33.491	16.260	1.00	41.29	C
ATOM	1452	CD	LYS	B	78	2.746	32.676	17.100	1.00	49.72	C
ATOM	1453	CE	LYS	B	78	1.564	33.546	17.666	1.00	53.37	C
ATOM	1454	NZ	LYS	B	78	0.551	32.773	18.406	1.00	54.23	N
ATOM	1455	N	LEU	B	79	7.663	34.218	16.330	1.00	25.35	N
ATOM	1456	CA	LEU	B	79	8.352	35.299	17.007	1.00	23.52	C
ATOM	1457	C	LEU	B	79	9.151	36.141	16.063	1.00	22.42	C
ATOM	1458	O	LEU	B	79	9.249	37.348	16.219	1.00	20.72	O
ATOM	1459	CB	LEU	B	79	9.292	34.752	18.074	1.00	23.66	C
ATOM	1460	CG	LEU	B	79	7.739	33.927	18.397	1.00	21.39	C
ATOM	1461	CD1	LEU	B	79	9.823	33.698	20.260	1.00	17.84	C
ATOM	1462	CD2	LEU	B	79	7.579	34.608	19.911	1.00	21.67	C
ATOM	1463	N	VAL	B	80	9.727	35.426	15.094	1.00	25.43	N
ATOM	1464	CA	VAL	B	80	10.474	35.983	13.952	1.00	25.77	C
ATOM	1465	C	VAL	B	80	9.566	36.918	13.200	1.00	25.42	C
ATOM	1466	O	VAL	B	80	9.948	38.052	12.971	1.00	26.43	O
ATOM	1467	CB	VAL	B	80	10.989	34.920	12.949	1.00	24.61	C
ATOM	1468	CG1	VAL	B	80	11.693	35.588	11.801	1.00	26.74	C
ATOM	1469	CG2	VAL	B	80	12.018	33.999	13.521	1.00	24.19	C
ATOM	1470	N	ASN	B	81	8.352	36.466	12.893	1.00	27.82	N
ATOM	1471	CA	ASN	B	81	7.420	37.299	12.163	1.00	29.77	C
ATOM	1472	C	ASN	B	81	6.999	38.527	12.964	1.00	29.38	C
ATOM	1473	O	ASN	B	81	6.937	39.593	12.277	1.00	32.14	O
ATOM	1474	CB	ASN	B	81	7.221	36.505	15.562	1.00	31.24	C
ATOM	1475	CG	ASN	B	81	6.543	35.379	10.564	1.00	33.72	C
ATOM	1476	OD1	ASN	B	81	7.608	35.271	9.962	1.00	34.16	C
ATOM	1477	ND2	ASN	B	81	5.614	34.454	10.332	1.00	37.55	N
ATOM	1478	N	ILE	B	82	6.761	38.515	14.283	1.00	30.06	N
ATOM	1479	CA	ILE	B	82	6.418	39.713	15.057	1.00	27.77	C
ATOM	1480	C	ILE	B	82	7.591	40.672	15.019	1.00	28.50	C
ATOM	1481	O	ILE	B	82	7.388	41.866	14.826	1.00	30.63	O
ATOM	1482	CB	ILE	B	82	6.164	39.318	16.534	1.00	27.91	C
ATOM	1483	CG1	ILE	B	82	4.880	38.557	16.625	1.00	29.24	C
ATOM	1484	CG2	ILE	B	82	6.192	40.458	17.555	1.00	23.22	C
ATOM	1485	CD1	ILE	B	82	4.796	37.771	17.958	1.00	33.77	C
ATOM	1486	N	VAL	B	83	8.833	40.218	15.222	1.00	28.54	N
ATOM	1487	CA									

ATOM	1506	CG	ASN	B	85	4.984	42.012	11.146	1.00	36.50	C
ATOM	1507	OD1	ASP	B	85	5.491	41.708	10.065	1.00	34.52	C
ATOM	1508	OD2	ASP	B	85	3.945	41.485	11.574	1.00	37.36	C
ATOM	1509	N	LEU	B	86	8.151	44.567	13.473	1.00	31.94	O
ATOM	1510	CA	LEU	B	86	8.695	45.686	14.241	1.00	29.00	C
ATOM	1511	C	LEU	B	86	9.945	46.335	13.646	1.00	27.01	C
ATOM	1512	O	LEU	B	86	10.158	47.536	13.788	1.00	25.07	O
ATOM	1513	CB	LEU	B	86	8.888	45.242	15.703	1.00	29.72	C
ATOM	1514	CG	LEU	B	86	7.630	44.973	16.544	1.00	29.69	C
ATOM	1515	CD1	LEU	B	86	7.934	44.246	17.825	1.00	29.68	C
ATOM	1516	CD2	LEU	B	86	6.938	46.265	16.914	1.00	29.39	C
ATOM	1517	N	VAL	B	87	10.774	45.550	12.962	1.00	26.28	N
ATOM	1518	CA	VAL	B	87	11.895	46.068	12.214	1.00	29.27	C
ATOM	1519	C	VAL	B	87	11.333	47.009	13.763	1.00	32.65	C
ATOM	1520	O	VAL	B	87	11.721	48.175	11.164	1.00	38.93	O
ATOM	1521	CB	VAL	B	87	12.725	44.966	11.523	1.00	28.93	C
ATOM	1522	CG1	VAL	B	87	13.789	45.570	10.630	1.00	25.59	C
ATOM	1523	CG2	VAL	B	87	13.417	44.036	12.521	1.00	30.50	C
ATOM	1524	N	GLU	B	88	10.392	46.534	10.325	1.00	34.28	N
ATOM	1525	CA	GLU	B	88	9.820	47.291	9.217	1.00	34.18	C
ATOM	1526	C	GLU	B	88	9.201	48.582	9.702	1.00	34.90	C
ATOM	1527	O	GLU	B	88	9.505	49.640	9.178	1.00	35.08	O
ATOM	1528	CB	GLU	B	88	8.789	46.446	8.468	1.00	34.62	C
ATOM	1529	CG	GLU	B	88	9.361	45.233	7.725	1.00	35.13	C
ATOM	1530	CD	GLU	B	88	8.360	44.218	7.145	1.00	37.81	C
ATOM	1531	OE1	GLU	B	88	7.241	44.088	7.653	1.00	39.42	C
ATOM	1532	OE2	GLU	B	88	8.696	43.539	6.176	1.00	38.59	C
ATOM	1533	N	CYS	B	89	12.402	44.520	10.384	1.00	38.74	N
ATOM	1534	CA	CYS	B	89	7.802	49.680	11.378	1.00	41.73	C
ATOM	1535	C	CYS	B	89	8.798	50.685	11.934	1.00	43.62	C
ATOM	1536	O	CYS	B	89	8.578	51.896	11.896	1.00	44.63	O
ATOM	1537	CB	CYS	B	89	6.875	49.166	12.472	1.00	43.51	C
ATOM	1538	SG	CYS	B	89	6.538	50.326	13.821	1.00	52.54	S
ATOM	1539	N	VAL	B	90	9.907	50.205	12.473	1.00	45.45	N
ATOM	1540	CA	VAL	B	90	10.919	51.096	13.007	1.00	48.36	C
ATOM	1541	C	VAL	B	90	11.787	51.723	11.909	1.00	49.57	C
ATOM	1542	O	VAL	B	90	12.399	52.768	12.121	1.00	50.61	O
ATOM	1543	CB	VAL	B	90	11.681	50.331	14.107	1.00	48.77	C
ATOM	1544	CG1	VAL	B	90	12.903	51.039	14.582	1.00	51.24	C
ATOM	1545	CG2	VAL	B	90	10.793	50.256	15.316	1.00	48.76	C
ATOM	1546	N	LYS	B	91	11.834	51.181	10.659	1.00	50.46	N
ATOM	1547										

Figure 8-37

ATOM	1566	C	ASN	B	93	10.247	56.971	11.593	1.00	65.46	C
ATOM	1567	O	ASN	B	93	11.368	56.721	12.018	1.00	65.03	O
ATOM	1568	CB	ASN	B	93	9.069	55.511	13.153	1.00	63.55	C
ATOM	1569	N	SER	B	94	9.868	58.041	10.904	1.00	68.52	N
ATOM	1570	CA	SER	B	94	10.773	58.985	10.254	1.00	70.87	C
ATOM	1571	C	SER	B	94	11.391	60.076	11.141	1.00	71.17	C
ATOM	1572	O	SER	B	94	12.292	60.821	10.689	1.00	72.46	O
ATOM	1573	CB	SER	B	94	10.028	59.573	9.039	1.00	71.38	C
ATOM	1574	OG	SER	B	94	8.711	60.001	9.407	1.00	73.36	O
ATOM	1575	N	SER	B	95	10.923	60.135	12.415	1.00	68.97	N
ATOM	1576	CA	SER	B	95	11.564	60.953	13.424	1.00	68.06	C
ATOM	1577	C	SER	B	95	13.040	60.572	13.473	1.00	67.28	C
ATOM	1578	O	SER	B	95	13.457	59.458	13.839	1.00	64.89	O
ATOM	1579	CB	SER	B	95	10.932	60.795	14.794	1.00	68.06	C
ATOM	1580	OG	SER	B	95	11.441	61.800	15.670	1.00	69.36	O
ATOM	1581	N	LYS	B	96	13.755	61.565	12.916	1.00	66.92	N
ATOM	1582	CA	LYS	B	96	15.199	61.518	12.771	1.00	67.27	C
ATOM	1583	C	LYS	B	96	15.848	60.974	14.056	1.00	66.10	C
ATOM	1584	O	LYS	B	96	16.615	59.996	14.014	1.00	64.46	O
ATOM	1585	CB	LYS	B	96	15.699	62.948	12.478	1.00	67.07	C
ATOM	1586	N	ASP	B	97	15.289	61.560	15.147	1.00	64.54	N
ATOM	1587	CA	ASP	B	97	15.657	61.369	16.562	1.00	62.82	C
ATOM	1588	C	ASP	B	97	15.739	59.968	17.239	1.00	60.00	C
ATOM	1589	O	ASP	B	97	16.792	59.674	17.852	1.00	59.90	O
ATOM	1590	CB	ASP	B	97	14.689	62.230	17.394	1.00	63.85	C
ATOM	1591	N	LEU	B	98	14.638	59.137	17.174	1.00	53.67	N
ATOM	1592	CA	LEU	B	98	14.641	57.690	17.447	1.00	44.35	C
ATOM	1593	C	LEU	B	98	15.837	57.135	16.728	1.00	40.32	C
ATOM	1594	O	LEU	B	98	15.868	57.109	15.497	1.00	40.10	O
ATOM	1595	CB	LEU	B	98	13.389	56.996	16.916	1.00	41.21	C
ATOM	1596	CG	LEU	B	98	13.251	55.479	17.095	1.00	40.48	C
ATOM	1597	CD1	LEU	B	98	11.904	55.030	17.695	1.00	39.61	C
ATOM	1598	CD2	LEU	B	98	13.519	54.787	15.784	1.00	37.90	C
ATOM	1599	N	LYS	B	99	16.815	56.840	17.593	1.00	36.84	N
ATOM	1600	CA	LYS	B	99	18.171	56.457	17.229	1.00	35.08	C
ATOM	1601	C	LYS	B	99	18.141	55.218	16.365	1.00	34.40	C
ATOM	1602	O	LYS	B	99	17.600	54.164	16.712	1.00	34.91	O
ATOM	1603	CB	LYS	B	99	19.028	56.193	18.485	1.00	35.16	C
ATOM	1604	CG	LYS	B	99	20.550	56.058	18.286	1.00	37.24	C
ATOM	1605	CD	LYS	B	99	21.314	55.641	19.556	1.00	36.33	C
ATOM	1606	CE	LYS	B	99	22.817	55.994	19.594	1.00	38.98	C
ATOM	1607	NZ	LYS	B	99	23.617	55.657	18.428	1.00	38.67	N
ATOM	1608	N	LYS	B	100	18.689	55.387	15.174	1.00	34.28	N
ATOM	1609	CA	LYS	B	100	18.726	54.285	14.232	1.00	34.35	C
ATOM	1610	C	LYS	B	100	20.147	53.964	13.811	1.00	31.26	C
ATOM	1611	O	LYS	B	100	20.368	52.917	13.224	1.00	32.09	O
ATOM	1612	CB	LYS	B	100	17.832	54.592	13.044	1.00	36.01	C
ATOM	1613	CG	LYS	B	100	16.335	54.635	13.349	1.00	38.72	C
ATOM	1614	CD	LYS	B	100	15.782	55.851	12.617	1.00	43.22	C
ATOM	1615	CE	LYS	B	100	14.290	55.723	12.370	1.00	43.50	C
ATOM	1616	NZ	LYS	B	100	13.982	55.990	10.969	1.00	43.57	N
ATOM	1617	N	SER	B	101	21.120	54.814	14.159	1.00	29.00	N
ATOM	1618	CA	SER	B	101	22.529	54.614	13.871	1.00	28.55	C
ATOM	1619	C	SER	B	101	23.351	54.047	15.032	1.00	28.24	C
ATOM	1620	O	SER	B	101	23.732	54.783	15.943	1.00	31.98	O
ATOM	1621	CB	SER	B	101	23.049	55.977	13.473	1.00	27.88	C
ATOM	1622	OG	SER	B	101	24.459	55.979	13.457	1.00	27.09	O
ATOM	1623	N	PHE	B	102	23.680	52.766	15.077	1.00	27.56	N
ATOM	1624	CA	PHE	B	102	24.364	52.184	16.230	1.00	27.12	C
ATOM	1625	C	PHE	B	102	25.620	51.495	15.755	1.00	28.99	C

00600027.062900

Figure 8-38

ATOM	1626	O	PHE	B	102	25.613	51.001	14.627	1.00	28.31	O
ATOM	1627	CB	PHE	B	102	23.538	51.127	16.945	1.00	22.35	C
ATOM	1628	CG	PHE	B	102	22.247	51.672	17.462	1.00	20.73	C
ATOM	1629	CD1	PHE	B	102	21.206	51.877	16.608	1.00	22.70	C
ATOM	1630	CD2	PHE	B	102	22.105	51.932	18.801	1.00	24.01	C
ATOM	1631	CE1	PHE	B	102	20.007	52.325	17.098	1.00	23.86	C
ATOM	1632	CE2	PHE	B	102	20.892	52.343	19.295	1.00	23.54	C
ATOM	1633	CZ	PHE	B	102	19.837	52.536	18.435	1.00	23.17	C
ATOM	1634	N	LYS	B	103	26.691	51.459	16.575	1.00	30.21	N
ATOM	1635	CA	LYS	B	103	27.823	50.595	16.284	1.00	30.86	C
ATOM	1636	C	LYS	B	103	27.374	49.171	16.550	1.00	32.14	C
ATOM	1637	O	LYS	B	103	26.583	48.957	17.472	1.00	33.74	O
ATOM	1638	CB	LYS	B	103	28.965	50.952	17.200	1.00	32.77	C
ATOM	1639	N	SER	B	104	27.788	48.202	15.720	1.00	32.95	N
ATOM	1640	CA	SER	B	104	27.284	46.825	15.805	1.00	33.85	C
ATOM	1641	C	SER	B	104	27.695	46.249	17.145	1.00	31.14	C
ATOM	1642	O	SER	B	104	28.891	46.121	17.418	1.00	32.16	O
ATOM	1643	CB	SER	B	104	27.812	45.908	14.692	1.00	36.29	C
ATOM	1644	OG	SER	B	104	28.690	46.589	13.784	1.00	44.97	O
ATOM	1645	N	PRO	B	105	26.737	45.950	18.023	1.00	28.62	N
ATOM	1646	CA	PRO	B	105	27.026	45.601	19.393	1.00	27.39	C
ATOM	1647	C	PRO	B	105	27.816	44.315	19.472	1.00	26.85	C
ATOM	1648	O	PRO	B	105	27.947	43.532	18.527	1.00	29.04	O
ATOM	1649	CB	PRO	B	105	25.668	45.476	19.922	1.00	26.67	C
ATOM	1650	CG	PRO	B	105	24.803	46.313	19.104	1.00	27.85	C
ATOM	1651	CD	PRO	B	105	25.308	45.910	17.747	1.00	26.48	C
ATOM	1652	N	GLU	B	106	28.426	44.160	20.628	1.00	27.12	N
ATOM	1653	CA	GLU	B	106	29.240	42.982	20.897	1.00	27.97	C
ATOM	1654	C	GLU	B	106	28.299	41.806	21.172	1.00	25.13	C
ATOM	1655	O	GLU	B	106	27.294	41.966	21.870	1.00	21.99	O
ATOM	1656	CB	GLU	B	106	30.140	43.258	22.105	1.00	30.05	C
ATOM	1657	CG	GLU	B	106	31.418	42.451	22.220	1.00	35.47	C
ATOM	1658	CD	GLU	B	106	32.045	42.483	23.613	1.00	40.01	C
ATOM	1659	OE1	GLU	B	106	32.162	43.570	24.198	1.00	41.10	O
ATOM	1660	OE2	GLU	B	106	32.431	41.409	24.102	1.00	42.35	O
ATOM	1661	N	PRO	B	107	28.564	40.640	20.578	1.00	23.74	N
ATOM	1662	CA	PRO	B	107	27.806	39.423	20.817	1.00	24.07	C
ATOM	1663	C	PRO	B	107	27.906	38.967	22.264	1.00	22.95	C
ATOM	1664	O	PRO	B	107	28.989	38.920	22.832	1.00	24.47	O
ATOM	1665	CB	PRO	B	107	28.437	38.439	19.837	1.00	24.75	C
ATOM	1666	CG	PRO	B	107	28.949	39.309	18.715	1.00	25.17	C
ATOM	1667	CD	PRO	B	107	29.556	40.448	19.512	1.00	24.46	C
ATOM	1668	N	ARG	B	108	26.765	38.677	22.884	1.00	22.39	N
ATOM	1669	CA	ARG	B	108	26.684	38.164	24.239	1.00	20.57	C
ATOM	1670	C	ARG	B	108	25.904	36.865	24.227	1.00	17.43	C
ATOM	1671	O	ARG	B	108	24.954	36.685	23.488	1.00	17.22	O
ATOM	1672	CB	ARG	B	108	26.064	39.155	25.256	1.00	20.10	C
ATOM	1673	CG	ARG	B	108	27.007	40.157	25.848	1.00	21.68	C
ATOM	1674	CD	ARG	B	108	26.321	41.144	26.778	1.00	25.69	C
ATOM	1675	NE	ARG	B	108	25.859	40.576	28.047	1.00	27.65	N
ATOM	1676	CZ	ARG	B	108	25.517	41.345	29.084	1.00	26.15	C
ATOM	1677	NH1	ARG	B	108	25.637	42.653	29.004	1.00	26.98	N
ATOM	1678	NH2	ARG	B	108	25.031	40.819	30.217	1.00	27.28	N
ATOM	1679	N	LEU	B	109	26.320	35.964	25.078	1.00	16.44	N
ATOM	1680	CA	LEU	B	109	25.649	34.700	25.242	1.00	19.58	C
ATOM	1681	C	LEU	B	109	24.667	34.827	26.384	1.00	19.57	C
ATOM	1682	O	LEU	B	109	24.963	35.423	27.418	1.00	21.90	O
ATOM	1683	CB	LEU	B	109	26.626	33.555	25.533	1.00	18.89	C
ATOM	1684	CG	LEU	B	109	27.661	33.129	24.491	1.00	20.14	C
ATOM	1685	CD1	LEU	B	109	28.673	32.188	25.119	1.00	18.71	C

00000027.000000

Figure 8-39

ATOM	1686	CD2	LEU	B	109	26.985	32.436	23.316	1.00	22.74	C
ATOM	1687	N	PHE	B	110	23.477	34.293	26.119	1.00	19.30	N
ATOM	1688	CA	PHE	B	110	22.372	34.322	27.050	1.00	18.85	C
ATOM	1689	C	PHE	B	110	21.748	32.939	27.188	1.00	19.38	C
ATOM	1690	O	PHE	B	110	21.676	32.205	26.207	1.00	18.43	O
ATOM	1691	CB	PHE	B	110	21.312	35.298	26.553	1.00	17.38	C
ATOM	1692	CG	PHE	B	110	21.743	36.756	26.567	1.00	19.20	C
ATOM	1693	CD1	PHE	B	110	21.733	37.487	27.744	1.00	20.10	C
ATOM	1694	CD2	PHE	B	110	22.198	37.350	25.408	1.00	19.07	C
ATOM	1695	CE1	PHE	B	110	22.211	38.788	27.755	1.00	19.86	C
ATOM	1696	CE2	PHE	B	110	22.643	38.650	25.436	1.00	15.79	C
ATOM	1697	CZ	PHE	B	110	22.659	39.367	26.596	1.00	17.86	C
ATOM	1698	N	THR	B	111	21.246	32.547	28.376	1.00	18.40	N
ATOM	1699	CA	THR	B	111	20.431	31.336	28.505	1.00	14.95	C
ATOM	1700	C	THR	B	111	19.077	31.537	27.823	1.00	14.86	C
ATOM	1701	CB	THR	B	111	18.720	32.705	27.696	1.00	18.62	C
ATOM	1702	CG	THR	B	111	20.254	30.986	30.016	1.00	10.83	C
ATOM	1703	OG1	THR	B	111	19.440	32.008	30.536	1.00	14.68	O
ATOM	1704	CG2	THR	B	111	21.520	31.006	30.845	1.00	11.33	C
ATOM	1705	N	PRO	B	112	18.205	30.602	27.418	1.00	14.14	N
ATOM	1706	CA	PRO	B	112	16.903	30.899	26.832	1.00	12.85	C
ATOM	1707	C	PRO	B	112	16.055	31.789	27.714	1.00	15.00	C
ATOM	1708	O	PRO	B	112	15.351	32.679	27.268	1.00	16.67	O
ATOM	1709	CB	PRO	B	112	16.297	29.536	26.730	1.00	13.18	C
ATOM	1710	CG	PRO	B	112	17.459	28.689	26.406	1.00	11.71	C
ATOM	1711	CD	PRO	B	112	18.482	29.179	27.402	1.00	12.63	C
ATOM	1712	N	GLU	B	113	16.103	31.597	29.015	1.00	17.42	N
ATOM	1713	CA	GLU	B	113	15.375	32.431	29.945	1.00	19.68	C
ATOM	1714	C	GLU	B	113	15.802	33.888	29.901	1.00	18.59	C
ATOM	1715	O	GLU	B	113	14.931	34.751	29.885	1.00	21.48	O
ATOM	1716	CB	GLU	B	113	15.546	31.841	31.328	1.00	22.92	C
ATOM	1717	CG	GLU	B	113	14.984	32.707	32.439	1.00	32.95	C
ATOM	1718	CD	GLU	B	113	15.763	32.704	33.770	1.00	39.93	C
ATOM	1719	OE1	GLU	B	113	16.869	33.281	33.900	1.00	41.39	O
ATOM	1720	OE2	GLU	B	113	15.193	32.144	34.712	1.00	44.90	O
ATOM	1721	N	GLU	B	114	17.096	34.210	29.885	1.00	18.49	N
ATOM	1722	CA	GLU	B	114	17.601	35.576	29.760	1.00	17.43	C
ATOM	1723	C	GLU	B	114	17.321	36.289	28.451	1.00	16.60	C
ATOM	1724	O	GLU	B	114	16.910	37.449	28.404	1.00	19.48	O
ATOM	1725	CB	GLU	B	114	19.090	35.543	29.960	1.00	19.55	C
ATOM	1726	CG	GLU	B	114	19.486	35.319	31.442	1.00	23.40	C
ATOM	1727	CD	GLU	B	114	20.962	35.034	31.718	1.00	25.98	C
ATOM	1728	OE1	GLU	B	114	21.730	34.826	30.765	1.00	25.41	O
ATOM	1729	OE2	GLU	B	114	21.322	34.982	32.906	1.00	28.77	O
ATOM	1730	N	PHE	B	115	17.507	35.551	27.379	1.00	14.86	N
ATOM	1731	CA	PHE	B	115	17.212	35.998	26.023	1.00	15.76	C
ATOM	1732	C	PHE	B	115	15.776	36.422	25.843	1.00	14.74	C
ATOM	1733	O	PHE	B	115	15.474	37.469	25.295	1.00	16.04	O
ATOM	1734	CB	PHE	B	115	17.513	34.865	25.012	1.00	14.37	C
ATOM	1735	CG	PHE	B	115	17.384	35.323	23.572	1.00	16.76	C
ATOM	1736	CD1	PHE	B	115	18.400	36.062	22.990	1.00	15.08	C
ATOM	1737	CD2	PHE	B	115	16.217	35.063	22.881	1.00	16.51	C
ATOM	1738	CE1	PHE	B	115	18.169	36.611	21.755	1.00	15.92	C
ATOM	1739	CE2	PHE	B	115	16.024	35.579	21.619	1.00	13.36	C
ATOM	1740	CZ	PHE	B	115	16.994	36.364	21.079	1.00	14.28	C
ATOM	1741	N	PHE	B	116	14.897	35.549	26.284	1.00	15.61	N
ATOM	1742	CA	PHE	B	116	13.497	35.810	26.150	1.00	15.94	C
ATOM	1743	C	PHE	B	116	12.918	36.798	27.125	1.00	16.92	C
ATOM	1744	O	PHE	B	116	11.842	37.326	26.862	1.00	18.97	O
ATOM	1745	CB	PHE	B	116	12.759	34.499	26.111	1.00	16.90	C

09609027 062900

Figure 8-40

ATOM	1746	CG	PHE	B	116	12.962	33.796	24.776	1.00	16.87	C
ATOM	1747	CD1	PHE	B	116	12.315	34.278	23.639	1.00	16.00	C
ATOM	1748	CD2	PHE	B	116	13.830	32.714	24.689	1.00	17.13	C
ATOM	1749	CE1	PHE	B	116	12.558	33.654	22.429	1.00	17.64	C
ATOM	1750	CE2	PHE	B	116	14.079	32.114	23.482	1.00	16.31	C
ATOM	1751	CZ	PHE	B	116	13.427	32.582	22.349	1.00	17.77	C
ATOM	1752	N	ARG	B	117	13.629	37.094	28.208	1.00	17.01	N
ATOM	1753	CA	ARG	B	117	13.292	38.189	29.085	1.00	18.94	C
ATOM	1754	C	ARG	B	117	13.636	39.492	28.388	1.00	20.76	C
ATOM	1755	O	ARG	B	117	12.988	40.526	28.561	1.00	21.80	O
ATOM	1756	CB	ARG	B	117	14.124	38.043	30.361	1.00	22.28	C
ATOM	1757	CG	ARG	B	117	13.889	39.003	31.538	1.00	29.21	C
ATOM	1758	CD	ARG	B	117	13.292	38.359	32.834	1.00	35.23	C
ATOM	1759	NE	ARG	B	117	14.094	37.253	33.357	1.00	37.19	N
ATOM	1760	CZ	ARG	B	117	15.408	37.373	33.616	1.00	42.10	C
ATOM	1761	NH1	ARG	B	117	16.023	38.568	33.647	1.00	45.58	N
ATOM	1762	NH2	ARG	B	117	16.151	36.268	33.794	1.00	43.18	N
ATOM	1763	N	ILE	B	118	14.709	39.453	27.596	1.00	20.97	N
ATOM	1764	CA	ILE	B	118	15.078	40.588	26.807	1.00	18.77	C
ATOM	1765	C	ILE	B	118	14.103	40.799	25.662	1.00	20.54	C
ATOM	1766	O	ILE	B	118	13.592	41.896	25.487	1.00	20.49	C
ATOM	1767	CB	ILE	B	118	16.498	40.364	26.385	1.00	16.96	C
ATOM	1768	CG1	ILE	B	118	17.377	40.515	27.587	1.00	21.82	C
ATOM	1769	CG2	ILE	B	118	16.892	41.347	25.310	1.00	15.77	C
ATOM	1770	CD1	ILE	B	118	18.851	40.271	27.253	1.00	14.00	C
ATOM	1771	N	PHE	B	119	13.817	39.736	24.922	1.00	22.16	N
ATOM	1772	CA	PHE	B	119	12.840	39.717	23.864	1.00	23.96	C
ATOM	1773	C	PHE	B	119	11.528	40.271	24.356	1.00	26.51	C
ATOM	1774	O	PHE	B	119	10.934	41.093	23.674	1.00	29.24	O
ATOM	1775	CB	PHE	B	119	12.660	38.299	23.364	1.00	22.84	C
ATOM	1776	CG	PHE	B	119	11.555	38.173	22.327	1.00	24.88	C
ATOM	1777	CD1	PHE	B	119	11.811	38.512	21.006	1.00	25.69	C
ATOM	1778	CD2	PHE	B	119	10.271	37.803	22.727	1.00	24.94	C
ATOM	1779	CE1	PHE	B	119	10.748	38.539	20.122	1.00	25.07	C
ATOM	1780	CE2	PHE	B	119	9.216	37.831	21.844	1.00	24.69	C
ATOM	1781	CZ	PHE	B	119	9.465	38.212	20.539	1.00	25.22	C
ATOM	1782	N	ASN	B	120	11.076	39.898	25.540	1.00	29.22	N
ATOM	1783	CA	ASN	B	120	9.863	40.470	26.094	1.00	31.04	C
ATOM	1784	C	ASN	B	120	9.953	41.939	26.499	1.00	32.79	C
ATOM	1785	O	ASN	B	120	9.018	42.684	26.204	1.00	34.41	O
ATOM	1786	CB	ASN	B	120	9.343	39.640	27.253	1.00	29.44	C
ATOM	1787	CG	ASN	B	120	8.856	38.301	26.738	1.00	33.04	C
ATOM	1788	OD1	ASN	B	120	8.264	38.216	25.651	1.00	32.93	C
ATOM	1789	ND2	ASN	B	120	9.110	37.237	27.508	1.00	31.91	N
ATOM	1790	N	ARG	B	121	11.018	42.436	27.140	1.00	32.47	N
ATOM	1791	CA	ARG	B	121	11.117	43.849	27.465	1.00	30.92	C
ATOM	1792	C	ARG	B	121	11.067	44.709	26.204	1.00	29.78	C
ATOM	1793	O	ARG	B	121	10.444	45.760	26.207	1.00	28.95	O
ATOM	1794	CB	ARG	B	121	12.391	44.075	28.271	1.00	33.61	C
ATOM	1795	CG	ARG	B	121	12.655	45.523	28.664	1.00	41.90	C
ATOM	1796	CD	ARG	B	121	11.463	46.261	29.336	1.00	48.78	C
ATOM	1797	NE	ARG	B	121	11.048	47.453	28.567	1.00	55.93	N
ATOM	1798	CZ	ARG	B	121	11.568	48.694	28.762	1.00	59.13	C
ATOM	1799	NH1	ARG	B	121	12.543	48.894	29.659	1.00	60.86	N
ATOM	1800	NH2	ARG	B	121	11.124	49.767	28.074	1.00	60.62	N
ATOM	1801	N	SER	B	122	11.680	44.225	25.121	1.00	29.04	N
ATOM	1802	CA	SER	B	122	11.818	44.920	23.854	1.00	27.66	C
ATOM	1803	C	SER	B	122	10.512	45.006	23.126	1.00	29.01	C
ATOM	1804	O	SER	B	122	10.198	46.085	22.634	1.00	30.77	O
ATOM	1805	CB	SER	B	122	12.808	44.195	22.954	1.00	24.91	C

09609027 062000

Figure 8-41

ATOM	1806	OG	SER	B	122	14.125	44.237	23.464	1.00	21.03	O
ATOM	1807	N	ILE	B	123	9.765	43.896	23.061	1.00	30.73	N
ATOM	1808	CA	ILE	B	123	8.427	43.886	22.488	1.00	33.96	C
ATOM	1809	C	ILE	B	123	7.513	44.857	23.232	1.00	38.09	C
ATOM	1810	O	ILE	B	123	6.743	45.579	22.610	1.00	38.61	O
ATOM	1811	CB	ILE	B	123	7.863	42.445	22.513	1.00	33.36	C
ATOM	1812	CG1	ILE	B	123	8.567	41.492	21.559	1.00	33.77	C
ATOM	1813	CG2	ILE	B	123	6.385	42.334	22.276	1.00	35.01	C
ATOM	1814	CD1	ILE	B	123	8.539	41.729	20.058	1.00	31.14	C
ATOM	1815	N	ASP	B	124	7.638	44.925	24.562	1.00	42.48	N
ATOM	1816	CA	ASP	B	124	6.868	45.809	25.424	1.00	45.69	C
ATOM	1817	C	ASP	B	124	7.347	47.237	25.404	1.00	45.68	C
ATOM	1818	O	ASP	B	124	6.592	48.118	25.836	1.00	46.88	O
ATOM	1819	CB	ASP	B	124	6.915	45.381	26.932	1.00	50.45	C
ATOM	1820	CG	ASP	B	124	6.483	43.950	27.274	1.00	56.00	C
ATOM	1821	OD1	ASP	B	124	5.766	43.310	26.481	1.00	61.21	O
ATOM	1822	OD2	ASP	B	124	6.883	43.461	28.344	1.00	56.72	O
ATOM	1823	N	ALA	B	125	8.599	47.461	24.970	1.00	46.60	N
ATOM	1824	CA	ALA	B	125	9.190	48.801	24.903	1.00	47.64	C
ATOM	1825	C	ALA	B	125	8.420	49.664	23.926	1.00	48.60	C
ATOM	1826	O	ALA	B	125	8.412	50.882	24.081	1.00	48.65	O
ATOM	1827	CB	ALA	B	125	10.643	48.781	24.422	1.00	46.01	C
ATOM	1828	N	PHE	B	126	7.752	49.014	22.960	1.00	50.56	N
ATOM	1829	CA	PHE	B	126	6.834	49.695	22.055	1.00	54.13	C
ATOM	1830	C	PHE	B	126	5.525	50.182	22.688	1.00	57.79	C
ATOM	1831	O	PHE	B	126	5.141	51.334	22.460	1.00	59.99	O
ATOM	1832	CB	PHE	B	126	6.538	48.850	20.810	1.00	51.52	C
ATOM	1833	CG	PHE	B	126	7.721	48.691	19.873	1.00	49.43	C
ATOM	1834	CD1	PHE	B	126	8.650	47.685	20.086	1.00	48.93	C
ATOM	1835	CD2	PHE	B	126	7.872	49.550	18.804	1.00	48.24	C
ATOM	1836	CE1	PHE	B	126	9.721	47.531	19.226	1.00	47.28	C
ATOM	1837	CE2	PHE	B	126	8.960	49.402	17.969	1.00	46.11	C
ATOM	1838	CZ	PHE	B	126	9.882	48.401	18.174	1.00	45.91	C
ATOM	1839	N	LYS	B	127	4.843	49.346	23.505	1.00	61.28	N
ATOM	1840	CA	LYS	B	127	3.558	49.636	24.178	1.00	62.20	C
ATOM	1841	C	LYS	B	127	3.454	50.906	25.026	1.00	62.03	C
ATOM	1842	O	LYS	B	127	2.394	51.539	25.092	1.00	61.71	O
ATOM	1843	CB	LYS	B	127	3.115	48.458	25.090	1.00	64.81	C
ATOM	1844	CG	LYS	B	127	2.463	47.185	24.502	1.00	65.92	C
ATOM	1845	CD	LYS	B	127	2.082	46.311	25.702	1.00	67.81	C
ATOM	1846	CE	LYS	B	127	2.369	44.834	25.433	1.00	69.44	C
ATOM	1847	NZ	LYS	B	127	2.594	44.129	26.691	1.00	68.14	N
ATOM	1848	N	ASP	B	128	4.561	51.200	25.719	1.00	62.76	N
ATOM	1849	CA	ASP	B	128	4.736	52.380	26.554	1.00	62.70	C
ATOM	1850	C	ASP	B	128	5.573	53.412	25.794	1.00	63.56	C
ATOM	1851	O	ASP	B	128	6.638	53.838	26.251	1.00	64.23	O
ATOM	1852	CB	ASP	B	128	5.480	51.925	27.833	1.00	62.32	C
ATOM	1853	N	PHE	B	129	5.128	53.802	24.587	1.00	64.47	N
ATOM	1854	CA	PHE	B	129	5.813	54.828	23.801	1.00	65.58	C
ATOM	1855	C	PHE	B	129	5.172	56.224	23.900	1.00	66.25	C
ATOM	1856	O	PHE	B	129	4.145	56.473	23.258	1.00	67.17	O
ATOM	1857	CB	PHE	B	129	5.971	54.368	22.338	1.00	64.56	C
ATOM	1858	CG	PHE	B	129	7.424	54.230	21.907	1.00	63.61	C
ATOM	1859	CD1	PHE	B	129	8.187	55.356	21.634	1.00	64.45	C
ATOM	1860	CD2	PHE	B	129	7.979	52.977	21.775	1.00	62.93	C
ATOM	1861	CE1	PHE	B	129	9.503	55.219	21.235	1.00	64.07	C
ATOM	1862	CE2	PHE	B	129	9.291	52.837	21.378	1.00	63.56	C
ATOM	1863	CZ	PHE	B	129	10.048	53.959	21.111	1.00	64.70	C
ATOM	1864	N	ASP	B	137	17.272	62.584	24.623	1.00	55.18	N
ATOM	1865	CA	ASP	B	137	18.560	63.025	24.106	1.00	54.96	C

09609027 1302970

[illegible]

ATOM	1866	C	ASP	B	137	19.597	61.931	23.769	1.00	55.95
ATOM	1867	O	ASP	B	137	20.291	62.026	22.743	1.00	55.11
ATOM	1868	CB	ASP	B	137	19.180	63.952	25.136	1.00	53.99
ATOM	1869	N	CYS	B	138	19.669	60.900	24.656	1.00	55.99
ATOM	1870	CA	CYS	B	138	20.594	59.741	24.665	1.00	55.50
ATOM	1871	C	CYS	B	138	22.065	59.964	25.031	1.00	55.10
ATOM	1872	O	CYS	B	138	22.723	58.973	25.357	1.00	55.77
ATOM	1873	CB	CYS	B	138	20.486	58.822	23.416	1.00	53.55
ATOM	1874	SG	CYS	B	138	18.766	58.362	23.058	1.00	53.01
TER	1876		CYS	B	138					
ATOM	1877	N	ASN	C	11	51.574	13.978	45.345	1.00	51.40
ATOM	1878	CA	ASN	C	11	50.150	14.075	45.169	1.00	50.61
ATOM	1879	C	ASN	C	11	49.636	15.080	46.231	1.00	51.75
ATOM	1880	O	ASN	C	11	49.446	16.244	45.828	1.00	52.28
ATOM	1881	CB	ASN	C	11	49.486	12.671	45.271	1.00	48.14
ATOM	1881	CB	ASN	C	11	49.577	14.664	47.548	1.00	49.74
ATOM	1882	N	VAL	C	12	48.941	15.269	48.771	1.00	46.17
ATOM	1883	CA	VAL	C	12	49.317	16.681	49.255	1.00	43.47
ATOM	1884	C	VAL	C	12	48.526	17.397	49.868	1.00	42.02
ATOM	1885	O	VAL	C	12	49.032	14.271	50.044	1.00	47.02
ATOM	1886	CB	VAL	C	12	50.479	14.042	50.561	1.00	46.01
ATOM	1887	CG1	VAL	C	12	48.129	14.662	51.233	1.00	44.78
ATOM	1888	CG2	VAL	C	12	50.588	17.052	49.054	1.00	43.09
ATOM	1889	N	LYS	C	13	51.082	18.424	49.218	1.00	43.49
ATOM	1890	CA	LYS	C	13	50.370	19.321	48.980	1.00	39.49
ATOM	1891	C	LYS	C	13	49.810	20.355	48.472	1.00	35.14
ATOM	1892	O	LYS	C	13	52.643	18.424	48.986	1.00	37.77
ATOM	1893	CB	LYS	C	13	50.231	18.776	46.951	1.00	33.25
ATOM	1894	N	ASP	C	14	49.522	19.456	45.898	1.00	27.29
ATOM	1895	CA	ASP	C	14	48.042	19.262	45.991	1.00	21.51
ATOM	1896	C	ASP	C	14	47.408	20.205	45.602	1.00	20.53
ATOM	1897	O	ASP	C	14	50.101	19.142	44.565	1.00	31.10
ATOM	1898	CB	ASP	C	14	51.439	19.856	44.288	1.00	35.88
ATOM	1899	CG	ASP	C	14	52.043	20.514	45.155	1.00	37.80
ATOM	1900	OD1	ASP	C	14	51.890	19.755	43.143	1.00	37.13
ATOM	1901	OD2	ASP	C	14	47.447	18.202	46.526	1.00	16.09
ATOM	1902	N	VAL	C	15	46.073	18.207	46.562	1.00	16.75
ATOM	1903	CA	VAL	C	15	45.996	19.433	47.938	1.00	17.73
ATOM	1904	C	VAL	C	15	47.821	20.167	47.775	1.00	18.15
ATOM	1905	O	VAL	C	15	45.653	16.905	47.548	1.00	17.03
ATOM	1906	CB	VAL	C	15	44.266	16.920	48.161	1.00	15.16
ATOM	1907	CG1	VAL	C	15	45.656	15.889	46.430	1.00	17.49
ATOM	1908	CG2	VAL	C	15	46.659	19.692	48.910	1.00	17.16
ATOM	1909	N	THR	C	16	46.513	20.824	49.806	1.00	16.51
ATOM	1910	CA	THR	C	16	46.660	22.151	49.096	1.00	15.07
ATOM	1911	C	THR	C	16	45.901	23.049	49.418	1.00	16.99
ATOM	1912	O	THR	C	16	47.533	20.674	51.000	1.00	17.35
ATOM	1913	CB	THR	C	16	47.059	19.546	51.776	1.00	19.10
ATOM	1914	OG1	THR	C	16	47.615	21.848	51.734	1.00	11.74
ATOM	1915	CG2	THR	C	16	47.562	22.386	48.160	1.00	13.81
ATOM	1916	N	LYS	C	17	47.496	23.602	47.390	1.00	15.88
ATOM	1917	CA	LYS	C	17	46.197	23.789	46.541	1.00	16.97
ATOM	1918	C	LYS	C	17	45.608	24.877	46.465	1.00	17.88
ATOM	1919	O	LYS	C	17	48.702	23.598	46.505	1.00	18.13
ATOM	1920	CB	LYS	C	17	50.006	23.615	47.257	1.00	21.24
ATOM	1921	CG	LYS	C	17	51.103	23.441	46.198	1.00	24.88
ATOM	1922	CD	LYS	C	17	52.486	23.537	46.798	1.00	28.59
ATOM	1923	CE	LYS	C	17	52.730	24.883	47.284	1.00	31.31
ATOM	1924	NZ	LYS	C	17	45.682	22.736	45.880	1.00	14.39
ATOM	1925	N	LEU	C	18	44.454	22.764	45.149	1.00	11.22
ATOM	1926	CA	LEU	C	18					

Figure 8-43

ATOM	1927	C	LEU	C	18	43.333	23.111	46.047	1.00	10.78	C
ATOM	1928	O	LEU	C	18	42.612	24.032	45.691	1.00	10.08	O
ATOM	1929	CB	LEU	C	18	44.129	21.412	44.609	1.00	12.69	C
ATOM	1930	CG	LEU	C	18	42.973	21.312	43.632	1.00	15.70	C
ATOM	1931	CD1	LEU	C	18	43.151	22.220	42.429	1.00	9.04	C
ATOM	1932	CD2	LEU	C	18	42.864	19.875	43.248	1.00	15.11	C
ATOM	1933	N	VAL	C	19	43.155	22.484	47.210	1.00	11.81	N
ATOM	1934	CA	VAL	C	19	42.092	22.868	48.138	1.00	12.12	C
ATOM	1935	C	VAL	C	19	42.159	24.359	48.569	1.00	13.12	C
ATOM	1936	O	VAL	C	19	41.144	25.056	48.607	1.00	14.59	O
ATOM	1937	CB	VAL	C	19	42.041	21.868	49.328	1.00	12.63	C
ATOM	1938	CG1	VAL	C	19	40.984	22.267	50.328	1.00	11.49	C
ATOM	1939	CG2	VAL	C	19	41.661	20.496	48.835	1.00	12.48	C
ATOM	1940	N	ALA	C	20	43.362	24.909	48.821	1.00	13.02	N
ATOM	1941	CA	ALA	C	20	43.532	26.278	49.252	1.00	11.77	C
ATOM	1942	C	ALA	C	20	43.254	27.224	48.126	1.00	11.25	C
ATOM	1943	O	ALA	C	20	42.888	28.357	48.344	1.00	14.74	O
ATOM	1944	CB	ALA	C	20	44.975	26.452	49.635	1.00	10.68	C
ATOM	1945	N	ASN	C	21	43.461	26.757	46.895	1.00	15.11	N
ATOM	1946	CA	ASN	C	21	43.197	27.471	45.648	1.00	13.34	C
ATOM	1947	C	ASN	C	21	41.898	27.107	44.949	1.00	13.09	C
ATOM	1948	O	ASN	C	21	41.663	27.533	43.815	1.00	18.62	O
ATOM	1949	CB	ASN	C	21	44.318	27.149	44.717	1.00	12.84	C
ATOM	1950	CG	ASN	C	21	45.401	28.151	44.755	1.00	12.42	C
ATOM	1951	OD1	ASN	C	21	45.277	29.229	45.315	1.00	14.66	C
ATOM	1952	ND2	ASN	C	21	46.503	27.827	44.131	1.00	12.99	N
ATOM	1953	N	LEU	C	22	41.041	26.311	45.536	1.00	12.25	N
ATOM	1954	CA	LEU	C	22	39.691	26.194	45.063	1.00	12.28	C
ATOM	1955	C	LEU	C	22	38.831	27.012	45.972	1.00	12.85	C
ATOM	1956	O	LEU	C	22	39.216	27.109	47.126	1.00	17.11	O
ATOM	1957	CB	LEU	C	22	39.202	24.755	45.039	1.00	10.06	C
ATOM	1958	CG	LEU	C	22	39.745	23.906	43.936	1.00	9.08	C
ATOM	1959	CD1	LEU	C	22	39.380	22.464	44.120	1.00	8.06	C
ATOM	1960	CD2	LEU	C	22	39.124	24.394	42.666	1.00	11.26	C
ATOM	1961	N	PRO	C	23	37.706	27.649	45.629	1.00	12.49	N
ATOM	1962	CA	PRO	C	23	36.902	28.384	46.592	1.00	12.26	C
ATOM	1963	C	PRO	C	23	36.214	27.457	47.604	1.00	13.42	C
ATOM	1964	O	PRO	C	23	35.695	26.416	47.220	1.00	13.22	O
ATOM	1965	CB	PRO	C	23	35.923	29.108	45.681	1.00	13.14	C
ATOM	1966	CG	PRO	C	23	36.407	29.009	44.237	1.00	9.94	C
ATOM	1967	CD	PRO	C	23	37.094	27.667	44.292	1.00	12.73	C
ATOM	1968	N	LYS	C	24	36.216	27.796	48.898	1.00	13.54	N
ATOM	1969	CA	LYS	C	24	35.515	27.039	49.919	1.00	17.03	C
ATOM	1970	C	LYS	C	24	34.053	26.703	49.596	1.00	17.41	C
ATOM	1971	O	LYS	C	24	33.500	25.693	50.011	1.00	15.96	O
ATOM	1972	CB	LYS	C	24	35.591	27.845	51.228	1.00	17.76	C
ATOM	1973	CG	LYS	C	24	36.918	27.585	51.896	1.00	22.90	C
ATOM	1974	CD	LYS	C	24	37.423	28.782	52.700	1.00	24.73	C
ATOM	1975	CE	LYS	C	24	38.893	28.608	53.191	1.00	25.32	C
ATOM	1976	NZ	LYS	C	24	39.427	29.914	53.578	1.00	27.67	N
ATOM	1977	N	ASP	C	25	33.380	27.526	48.807	1.00	20.45	N
ATOM	1978	CA	ASP	C	25	31.969	27.349	48.579	1.00	20.93	C
ATOM	1979	C	ASP	C	25	31.690	26.924	47.164	1.00	19.35	C
ATOM	1980	O	ASP	C	25	30.617	27.146	46.603	1.00	21.38	O
ATOM	1981	CB	ASP	C	25	31.316	28.665	48.909	1.00	23.07	C
ATOM	1982	CG	ASP	C	25	31.726	29.820	48.014	1.00	28.48	C
ATOM	1983	OD1	ASP	C	25	32.736	29.755	47.329	1.00	29.48	O
ATOM	1984	OD2	ASP	C	25	31.018	30.829	48.006	1.00	35.37	O
ATOM	1985	N	TYR	C	26	32.684	26.330	46.570	1.00	17.08	N
ATOM	1986	CA	TYR	C	26	32.486	25.784	45.270	1.00	18.09	C

0060007-062900

Figure 8-44

ATOM	1987	C	TYR	C	26	32.066	24.352	45.473	1.00	20.16	C
ATOM	1988	O	TYR	C	26	32.672	23.586	46.210	1.00	20.74	C
ATOM	1989	CB	TYR	C	26	33.787	25.925	44.505	1.00	18.65	C
ATOM	1990	CG	TYR	C	26	33.779	25.389	43.087	1.00	15.43	C
ATOM	1991	CD1	TYR	C	26	32.863	25.870	42.180	1.00	14.28	C
ATOM	1992	CD2	TYR	C	26	34.687	24.394	42.740	1.00	18.66	C
ATOM	1993	CE1	TYR	C	26	32.828	25.305	40.916	1.00	18.89	C
ATOM	1994	CE2	TYR	C	26	34.680	23.853	41.457	1.00	18.57	C
ATOM	1995	CZ	TYR	C	26	33.736	24.325	40.567	1.00	17.94	C
ATOM	1996	OH	TYR	C	26	33.702	23.844	39.293	1.00	20.05	C
HETATM	1997	N	MSE	C	27	30.992	23.977	44.806	1.00	22.38	N
HETATM	1998	CA	MSE	C	27	30.472	22.643	44.960	1.00	23.82	C
HETATM	1999	C	MSE	C	27	30.902	21.790	43.796	1.00	23.07	C
HETATM	2000	O	MSE	C	27	30.675	22.180	42.659	1.00	22.78	C
HETATM	2001	CB	MSE	C	27	28.966	22.685	45.023	1.00	27.76	C
HETATM	2002	CG	MSE	C	27	28.476	23.440	46.222	1.00	33.28	C
HETATM	2003	SE	MSE	C	27	29.250	22.864	47.919	1.00	47.63	SE
HETATM	2004	CE	MSE	C	27	28.807	24.413	48.975	1.00	42.81	C
ATOM	2005	N	ILE	C	28	31.514	20.637	44.127	1.00	23.36	N
ATOM	2006	CA	ILE	C	28	31.890	19.552	43.196	1.00	24.49	C
ATOM	2007	C	ILE	C	28	30.924	18.334	43.195	1.00	25.21	C
ATOM	2008	O	ILE	C	28	30.568	17.795	44.237	1.00	24.49	O
ATOM	2009	CB	ILE	C	28	33.364	19.075	43.497	1.00	21.68	C
ATOM	2010	CG1	ILE	C	28	34.379	20.215	43.453	1.00	19.99	C
ATOM	2011	CG2	ILE	C	28	33.796	18.049	42.485	1.00	19.57	C
ATOM	2012	CD1	ILE	C	28	35.761	19.859	43.991	1.00	18.85	C
ATOM	2013	N	THR	C	29	30.508	17.846	42.017	1.00	26.46	N
ATOM	2014	CA	THR	C	29	29.637	16.688	41.888	1.00	26.80	C
ATOM	2015	C	THR	C	29	30.388	15.361	41.957	1.00	27.21	C
ATOM	2016	O	THR	C	29	31.299	15.084	41.182	1.00	26.27	O
ATOM	2017	CB	THR	C	29	28.824	16.736	40.580	1.00	25.22	C
ATOM	2018	OG1	THR	C	29	28.137	17.962	40.566	1.00	28.05	O
ATOM	2019	CG2	THR	C	29	27.773	15.659	40.545	1.00	26.26	C
ATOM	2020	N	LEU	C	30	29.980	14.498	42.878	1.00	27.91	N
ATOM	2021	CA	LEU	C	30	30.519	13.157	42.943	1.00	29.69	C
ATOM	2022	C	LEU	C	30	29.354	12.189	43.168	1.00	31.34	C
ATOM	2023	O	LEU	C	30	28.542	12.362	44.080	1.00	30.99	O
ATOM	2024	CB	LEU	C	30	31.578	13.070	44.051	1.00	25.27	C
ATOM	2025	CG	LEU	C	30	32.157	11.727	44.434	1.00	23.15	C
ATOM	2026	CD1	LEU	C	30	32.879	11.106	43.274	1.00	22.85	C
ATOM	2027	CD2	LEU	C	30	33.110	11.943	45.570	1.00	25.04	C
ATOM	2028	N	LYS	C	31	29.246	11.172	42.300	1.00	34.65	N
ATOM	2029	CA	LYS	C	31	28.335	10.045	42.533	1.00	36.49	C
ATOM	2030	C	LYS	C	31	28.910	9.150	43.620	1.00	36.03	C
ATOM	2031	O	LYS	C	31	29.741	8.287	43.370	1.00	36.42	O
ATOM	2032	CB	LYS	C	31	28.121	9.241	41.218	1.00	36.56	C
ATOM	2033	CG	LYS	C	31	27.475	9.966	40.056	1.00	39.42	C
ATOM	2034	CD	LYS	C	31	26.867	8.902	39.121	1.00	47.68	C
ATOM	2035	CE	LYS	C	31	25.930	9.427	37.990	1.00	51.31	C
ATOM	2036	NZ	LYS	C	31	24.859	8.496	37.602	1.00	51.86	N
ATOM	2037	N	TYR	C	32	28.514	9.411	44.868	1.00	38.89	N
ATOM	2038	CA	TYR	C	32	29.122	8.846	46.081	1.00	40.86	C
ATOM	2039	C	TYR	C	32	28.594	7.437	46.265	1.00	43.51	C
ATOM	2040	O	TYR	C	32	27.425	7.204	45.953	1.00	45.02	O
ATOM	2041	CB	TYR	C	32	28.707	9.747	47.229	1.00	37.67	C
ATOM	2042	CG	TYR	C	32	29.138	9.317	48.610	1.00	41.48	C
ATOM	2043	CD1	TYR	C	32	30.459	9.438	48.984	1.00	43.11	C
ATOM	2044	CD2	TYR	C	32	28.190	8.877	49.536	1.00	43.18	C
ATOM	2045	CE1	TYR	C	32	30.812	9.172	50.302	1.00	44.55	C
ATOM	2046	CE2	TYR	C	32	28.542	8.584	50.847	1.00	44.09	C

69609627 062000

Figure 8-45

ATOM	2047	CZ	TYR	C	32	29.862	8.758	51.230	1.00	45.88	C
ATOM	2048	OH	TYR	C	32	30.238	8.549	52.557	1.00	45.38	O
ATOM	2049	N	VAL	C	33	29.391	6.459	46.718	1.00	46.10	N
ATOM	2050	CA	VAL	C	33	28.866	5.097	46.885	1.00	48.63	C
ATOM	2051	C	VAL	C	33	28.323	4.935	48.307	1.00	50.48	C
ATOM	2052	O	VAL	C	33	29.088	5.086	49.265	1.00	49.75	O
ATOM	2053	CB	VAL	C	33	29.900	4.000	46.501	1.00	49.02	C
ATOM	2054	CG1	VAL	C	33	29.390	2.594	46.823	1.00	50.53	C
ATOM	2055	CG2	VAL	C	33	30.216	4.072	45.014	1.00	47.63	C
ATOM	2056	N	PRO	C	34	27.006	4.682	48.505	1.00	53.28	N
ATOM	2057	CA	PRO	C	34	26.385	4.695	49.834	1.00	55.66	C
ATOM	2058	C	PRO	C	34	27.121	3.734	50.767	1.00	58.89	C
ATOM	2059	O	PRO	C	34	27.426	2.568	50.448	1.00	59.22	O
ATOM	2060	CB	PRO	C	34	24.936	4.297	49.549	1.00	54.96	C
ATOM	2061	CG	PRO	C	34	24.701	4.825	48.139	1.00	51.80	C
ATOM	2062	CD	PRO	C	34	26.002	4.428	47.456	1.00	53.86	C
ATOM	2063	N	GLY	C	35	27.545	4.399	51.850	1.00	60.51	N
ATOM	2064	CA	GLY	C	35	28.272	3.744	52.925	1.00	62.88	C
ATOM	2065	C	GLY	C	35	29.632	3.266	52.457	1.00	63.14	C
ATOM	2066	O	GLY	C	35	29.852	2.077	52.214	1.00	64.01	O
HETATM	2067	N	MSE	C	36	30.521	4.240	52.301	1.00	62.92	N
HETATM	2068	CA	MSE	C	36	31.881	3.970	51.881	1.00	63.09	C
HETATM	2069	C	MSE	C	36	32.945	4.485	52.836	1.00	64.77	C
HETATM	2070	O	MSE	C	36	34.148	4.357	52.599	1.00	65.03	O
HETATM	2071	CB	MSE	C	36	32.115	4.582	50.531	1.00	62.61	C
HETATM	2072	CG	MSE	C	36	31.973	6.068	50.551	1.00	60.55	C
HETATM	2073	SE	MSE	C	36	33.277	6.879	49.401	1.00	61.18	SE
HETATM	2074	CE	MSE	C	36	34.541	7.346	50.777	1.00	55.15	C
ATOM	2075	N	ASP	C	37	32.430	5.163	53.863	1.00	66.73	N
ATOM	2076	CA	ASP	C	37	33.149	5.583	55.061	1.00	67.41	C
ATOM	2077	C	ASP	C	37	33.215	4.481	56.132	1.00	66.85	C
ATOM	2078	O	ASP	C	37	34.130	4.393	56.957	1.00	67.21	O
ATOM	2079	CB	ASP	C	37	32.478	6.867	55.589	1.00	69.00	C
ATOM	2080	CG	ASP	C	37	30.982	6.808	55.935	1.00	70.25	C
ATOM	2081	OD1	ASP	C	37	30.143	6.538	55.061	1.00	69.81	O
ATOM	2082	OD2	ASP	C	37	30.657	7.058	57.097	1.00	71.69	O
ATOM	2083	N	VAL	C	38	32.224	3.593	56.068	1.00	65.94	N
ATOM	2084	CA	VAL	C	38	32.091	2.461	56.960	1.00	64.55	C
ATOM	2085	C	VAL	C	38	32.395	1.200	56.170	1.00	65.94	C
ATOM	2086	O	VAL	C	38	33.340	0.521	56.584	1.00	68.33	O
ATOM	2087	CB	VAL	C	38	30.694	2.475	57.631	1.00	63.05	C
ATOM	2088	CG1	VAL	C	38	29.960	1.135	57.787	1.00	62.73	C
ATOM	2089	CG2	VAL	C	38	30.915	3.097	58.990	1.00	61.39	C
ATOM	2090	N	LEU	C	39	31.700	0.861	55.059	1.00	64.32	N
ATOM	2091	CA	LEU	C	39	31.997	-0.365	54.328	1.00	63.23	C
ATOM	2092	C	LEU	C	39	33.487	-0.412	53.952	1.00	62.57	C
ATOM	2093	O	LEU	C	39	34.084	0.647	53.713	1.00	63.24	O
ATOM	2094	CB	LEU	C	39	31.130	-0.449	53.078	1.00	62.74	C
ATOM	2095	N	PRO	C	40	34.161	-1.578	54.006	1.00	61.57	N
ATOM	2096	CA	PRO	C	40	35.608	-1.719	53.761	1.00	59.74	C
ATOM	2097	C	PRO	C	40	36.009	-1.462	52.318	1.00	57.52	C
ATOM	2098	O	PRO	C	40	35.183	-1.629	51.418	1.00	54.10	O
ATOM	2099	CB	PRO	C	40	35.861	-3.170	54.123	1.00	60.55	C
ATOM	2100	CG	PRO	C	40	34.550	-3.863	53.762	1.00	60.74	C
ATOM	2101	CD	PRO	C	40	33.546	-2.868	54.329	1.00	61.16	C
ATOM	2102	N	SER	C	41	37.282	-1.110	52.111	1.00	55.39	N
ATOM	2103	CA	SER	C	41	37.779	-0.735	50.798	1.00	56.77	C
ATOM	2104	C	SER	C	41	37.271	-1.553	49.602	1.00	56.41	C
ATOM	2105	O	SER	C	41	36.627	-0.992	48.727	1.00	56.58	O
ATOM	2106	CB	SER	C	41	39.292	-0.643	50.831	1.00	57.36	C

05600037 - 052000
0052901 - 2000060

Figure 8-46

ATOM	2107	OG	SER	C	41	39.964	1.877	50.695	1.00	60.69	N
ATOM	2108	N	HIS	C	42	37.404	-2.882	49.580	1.00	56.11	N
ATOM	2109	CA	HIS	C	42	36.947	-3.739	48.482	1.00	56.80	N
ATOM	2110	C	HIS	C	42	35.473	-3.664	48.079	1.00	56.34	C
ATOM	2111	O	HIS	C	42	35.062	-4.139	47.007	1.00	55.64	C
ATOM	2112	CB	HIS	C	42	37.301	-5.217	48.795	1.00	60.78	C
ATOM	2113	CG	HIS	C	42	36.205	-6.095	49.445	1.00	63.24	C
ATOM	2114	ND1	HIS	C	42	35.894	-6.211	50.736	1.00	63.50	N
ATOM	2115	CD2	HIS	C	42	35.244	-6.788	48.711	1.00	63.78	C
ATOM	2116	CE1	HIS	C	42	34.762	-6.882	50.802	1.00	64.65	C
ATOM	2117	NE2	HIS	C	42	34.371	-7.201	49.584	1.00	64.49	N
ATOM	2118	N	CYS	C	43	34.669	-3.175	49.027	1.00	56.27	N
ATOM	2119	CA	CYS	C	43	33.239	-3.012	48.806	1.00	56.25	C
ATOM	2120	C	CYS	C	43	32.953	-3.877	47.844	1.00	54.67	C
ATOM	2121	O	CYS	C	43	32.104	-2.006	46.959	1.00	56.77	O
ATOM	2122	CB	CYS	C	43	32.488	-2.787	50.120	1.00	57.47	C
ATOM	2123	SG	CYS	C	43	31.647	-4.253	50.786	1.00	60.51	S
ATOM	2124	N	TRP	C	44	33.695	-0.766	47.973	1.00	51.41	N
ATOM	2125	CA	TRP	C	44	33.338	0.464	47.287	1.00	47.58	C
ATOM	2126	C	TRP	C	44	34.349	0.946	46.300	1.00	46.08	C
ATOM	2127	O	TRP	C	44	33.969	1.593	45.341	1.00	46.29	O
ATOM	2128	CB	TRP	C	44	33.089	1.587	48.271	1.00	47.09	C
ATOM	2129	CG	TRP	C	44	34.199	1.801	49.301	1.00	46.63	C
ATOM	2130	CD1	TRP	C	44	34.221	1.046	50.444	1.00	47.77	C
ATOM	2131	CD2	TRP	C	44	35.261	2.660	49.225	1.00	45.55	C
ATOM	2132	NE1	TRP	C	44	35.307	1.419	51.078	1.00	47.46	C
ATOM	2133	CE2	TRP	C	44	35.948	2.361	50.389	1.00	44.86	N
ATOM	2134	CE3	TRP	C	44	35.72	3.640	48.403	1.00	42.70	C
ATOM	2135	CG2	TRP	C	44	37.422	2.956	50.754	1.00	45.49	C
ATOM	2136	CG3	TRP	C	44	36.886	4.263	48.782	1.00	43.82	C
ATOM	2137	CH2	TRP	C	44	37.597	3.925	49.920	1.00	42.91	C
ATOM	2138	N	ILE	C	45	35.615	0.635	46.539	1.00	45.14	N
ATOM	2139	CA	ILE	C	45	36.735	1.252	45.851	1.00	47.08	C
ATOM	2140	C	ILE	C	45	36.657	1.198	44.329	1.00	47.61	C
ATOM	2141	O	ILE	C	45	36.955	2.157	43.619	1.00	48.87	O
ATOM	2142	CB	ILE	C	45	38.085	0.681	46.427	1.00	47.91	C
ATOM	2143	CG1	ILE	C	45	39.316	1.515	46.123	1.00	46.35	C
ATOM	2144	CG2	ILE	C	45	38.420	-0.723	45.905	1.00	50.05	C
ATOM	2145	CD1	ILE	C	45	39.180	2.995	46.462	1.00	43.72	C
ATOM	2146	N	SER	C	46	36.158	0.077	43.850	1.00	47.61	N
ATOM	2147	CA	SER	C	46	33.969	-0.245	42.479	1.00	48.93	C
ATOM	2148	C	SER	C	46	35.166	0.685	41.995	1.00	47.26	C
ATOM	2149	O	SER	C	46	35.598	1.186	40.555	1.00	46.49	O
ATOM	2150	CB	SER	C	46	35.688	-1.728	42.427	1.00	50.90	C
ATOM	2151	OG	SER	C	46	35.093	-2.219	43.664	1.00	54.24	C
ATOM	2152	N	GLU	C	47	33.932	0.997	42.039	1.00	46.80	N
ATOM	2153	CA	GLU	C	47	33.095	2.037	41.430	1.00	45.94	C
ATOM	2154	C	GLU	C	47	33.599	3.449	41.776	1.00	43.82	C
ATOM	2155	O	GLU	C	47	33.532	4.348	40.947	1.00	43.16	O
ATOM	2156	CB	GLU	C	47	31.602	1.843	41.831	1.00	47.29	C
ATOM	2157	CG	GLU	C	47	30.478	2.752	41.246	1.00	52.00	C
ATOM	2158	CD	GLU	C	47	29.748	2.394	39.936	1.00	54.16	C
ATOM	2159	OE1	GLU	C	47	28.894	1.494	39.926	1.00	57.21	C
ATOM	2160	OE2	GLU	C	47	29.989	3.052	38.922	1.00	54.36	C
HETATM	2161	N	MSE	C	48	34.170	3.676	42.923	1.00	40.77	N
HETATM	2162	CA	MSE	C	48	34.501	4.979	43.448	1.00	40.70	C
HETATM	2163	C	MSE	C	48	35.795	5.538	42.724	1.00	37.10	C
HETATM	2164	O	MSE	C	48	35.799	6.739	42.563	1.00	39.16	O
HETATM	2165	CB	MSE	C	48	34.926	4.968	44.927	1.00	43.83	C
HETATM	2166	CG	MSE	C	48	34.667	6.334	45.551	1.00	49.60	C

Figure 8-47

HETATM	2167	SE	MSE	C	48	32.809	6.850	45.340	1.00	57.46	SE
HETATM	2168	CE	MSE	C	48	32.917	8.464	46.266	1.00	52.90	C
ATOM	2169	N	VAL	C	49	36.793	4.773	42.266	1.00	34.29	N
ATOM	2170	CA	VAL	C	49	37.955	5.271	41.388	1.00	30.22	C
ATOM	2171	C	VAL	C	49	37.372	5.680	39.997	1.00	31.03	C
ATOM	2172	O	VAL	C	49	37.936	6.572	39.365	1.00	30.17	O
ATOM	2173	CB	VAL	C	49	39.021	4.288	41.268	1.00	27.65	C
ATOM	2174	CG1	VAL	C	49	39.719	4.131	42.581	1.00	27.80	C
ATOM	2175	CG2	VAL	C	49	38.591	2.924	40.828	1.00	27.38	C
ATOM	2176	N	VAL	C	50	36.319	5.056	39.478	1.00	29.68	N
ATOM	2177	CA	VAL	C	50	35.727	5.548	38.255	1.00	29.53	C
ATOM	2178	C	VAL	C	50	34.932	6.806	38.559	1.00	28.57	C
ATOM	2179	O	VAL	C	50	35.069	7.755	37.800	1.00	30.41	O
ATOM	2180	CB	VAL	C	50	34.904	4.446	37.554	1.00	30.06	C
ATOM	2181	CG1	VAL	C	50	34.026	4.900	36.371	1.00	28.50	C
ATOM	2182	CG2	VAL	C	50	35.916	3.457	37.070	1.00	29.52	C
ATOM	2183	N	GLN	C	51	34.147	6.917	39.639	1.00	28.05	N
ATOM	2184	CA	GLN	C	51	33.421	8.148	39.945	1.00	27.55	C
ATOM	2185	C	GLN	C	51	34.267	9.336	40.379	1.00	26.77	C
ATOM	2186	O	GLN	C	51	33.957	10.480	40.061	1.00	27.78	O
ATOM	2187	CB	GLN	C	51	32.276	7.962	40.944	1.00	27.95	C
ATOM	2188	CG	GLN	C	51	31.142	7.029	40.503	1.00	31.66	C
ATOM	2189	CD	GLN	C	51	30.518	7.274	39.121	1.00	35.14	C
ATOM	2190	OE1	GLN	C	51	30.531	8.353	38.510	1.00	34.94	O
ATOM	2191	NE2	GLN	C	51	29.945	6.214	38.566	1.00	36.11	N
ATOM	2192	N	LEU	C	52	35.349	9.130	41.113	1.00	24.84	N
ATOM	2193	CA	LEU	C	52	36.290	10.188	41.316	1.00	24.73	C
ATOM	2194	C	LEU	C	52	36.914	10.560	40.004	1.00	25.82	C
ATOM	2195	O	LEU	C	52	37.061	11.752	39.750	1.00	26.91	O
ATOM	2196	CB	LEU	C	52	37.349	9.754	42.251	1.00	25.92	C
ATOM	2197	CG	LEU	C	52	36.831	9.701	43.653	1.00	27.26	C
ATOM	2198	CD1	LEU	C	52	37.880	9.090	44.510	1.00	27.86	C
ATOM	2199	CD2	LEU	C	52	36.473	11.078	44.141	1.00	27.93	C
ATOM	2200	N	SER	C	53	37.211	9.566	39.148	1.00	27.18	N
ATOM	2201	CA	SER	C	53	37.788	9.790	37.838	1.00	24.69	C
ATOM	2202	C	SER	C	53	36.859	10.558	36.918	1.00	26.00	C
ATOM	2203	O	SER	C	53	37.336	11.388	36.166	1.00	26.97	O
ATOM	2204	CB	SER	C	53	38.172	8.499	37.198	1.00	25.64	C
ATOM	2205	OG	SER	C	53	38.902	8.772	36.019	1.00	24.45	O
ATOM	2206	N	ASP	C	54	35.544	10.421	36.932	1.00	27.50	N
ATOM	2207	CA	ASP	C	54	34.743	11.292	36.113	1.00	29.13	C
ATOM	2208	C	ASP	C	54	34.719	12.679	36.663	1.00	27.20	C
ATOM	2209	O	ASP	C	54	34.826	13.616	35.906	1.00	30.75	O
ATOM	2210	CB	ASP	C	54	33.314	10.874	36.099	1.00	35.74	C
ATOM	2211	CG	ASP	C	54	33.056	9.521	35.502	1.00	43.27	C
ATOM	2212	OD1	ASP	C	54	33.871	9.016	34.694	1.00	44.80	O
ATOM	2213	OD2	ASP	C	54	31.996	8.988	35.876	1.00	47.24	C
ATOM	2214	N	SER	C	55	34.554	12.829	37.966	1.00	26.41	N
ATOM	2215	CA	SER	C	55	34.470	14.119	38.610	1.00	23.34	C
ATOM	2216	C	SER	C	55	35.676	14.964	38.382	1.00	19.99	C
ATOM	2217	O	SER	C	55	35.544	16.157	38.175	1.00	20.42	O
ATOM	2218	CB	SER	C	55	34.306	13.948	40.105	1.00	24.40	C
ATOM	2219	OG	SER	C	55	33.079	13.321	40.431	1.00	24.29	O
ATOM	2220	N	LEU	C	56	36.837	14.338	38.432	1.00	19.40	N
ATOM	2221	CA	LEU	C	56	38.082	15.062	38.245	1.00	21.98	C
ATOM	2222	C	LEU	C	56	38.333	15.488	36.797	1.00	23.22	C
ATOM	2223	O	LEU	C	56	38.922	16.543	36.512	1.00	21.76	O
ATOM	2224	CB	LEU	C	56	39.301	14.271	38.793	1.00	21.06	C
ATOM	2225	CG	LEU	C	56	39.614	14.342	40.291	1.00	19.56	C
ATOM	2226	CD1	LEU	C	56	40.647	13.313	40.678	1.00	18.16	C

00609021 062900

ATOM	2227	CD2	LEU	C	56	40.132	15.717	40.651	1.00	16.61	C
ATOM	2228	N	THR	C	57	37.873	14.624	35.881	1.00	25.77	C
ATOM	2229	CA	THR	C	57	37.991	14.906	34.462	1.00	28.23	C
ATOM	2230	C	THR	C	57	37.020	16.004	34.104	1.00	28.03	C
ATOM	2231	O	THR	C	57	37.390	16.908	33.364	1.00	31.55	C
ATOM	2232	CB	THR	C	57	37.813	13.669	33.596	1.00	30.08	C
ATOM	2233	OG1	THR	C	57	38.904	12.849	33.972	1.00	32.28	C
ATOM	2234	CG2	THR	C	57	38.044	13.945	32.109	1.00	33.98	C
ATOM	2235	N	ASP	C	58	35.831	16.009	34.675	1.00	26.77	C
ATOM	2236	CA	ASP	C	58	34.940	17.120	34.486	1.00	29.31	C
ATOM	2237	C	ASP	C	58	35.387	18.422	35.173	1.00	28.49	C
ATOM	2238	O	ASP	C	58	35.241	19.535	34.631	1.00	28.44	C
ATOM	2239	CB	ASP	C	58	33.489	16.879	34.670	1.00	36.00	C
ATOM	2240	CG	ASP	C	58	32.849	15.532	34.032	1.00	40.53	C
ATOM	2241	OD1	ASP	C	58	33.003	14.924	33.151	1.00	41.90	C
ATOM	2242	N	LEU	C	59	31.673	15.229	34.294	1.00	42.29	C
ATOM	2243	CA	LEU	C	59	35.964	18.350	36.383	1.00	26.07	C
ATOM	2244	C	LEU	C	59	36.486	19.508	37.074	1.00	21.52	C
ATOM	2245	O	LEU	C	59	37.611	20.115	36.285	1.00	19.04	C
ATOM	2246	O	LEU	C	59	37.748	21.317	36.312	1.00	20.31	C
ATOM	2247	CB	LEU	C	59	37.028	19.118	38.444	1.00	19.27	C
ATOM	2248	CG	LEU	C	59	37.519	20.223	39.377	1.00	18.52	C
ATOM	2249	CD1	LEU	C	59	36.411	21.181	39.805	1.00	14.85	C
ATOM	2250	CD2	LEU	C	59	38.147	19.538	40.574	1.00	18.90	C
ATOM	2251	N	LEU	C	60	39.399	19.348	35.553	1.00	19.17	C
ATOM	2252	CA	LEU	C	60	39.549	19.854	34.840	1.00	20.10	C
ATOM	2253	C	LEU	C	60	39.173	20.833	33.766	1.00	22.23	C
ATOM	2254	O	LEU	C	60	39.812	21.768	33.474	1.00	24.00	C
ATOM	2255	CB	LEU	C	60	40.290	18.718	34.206	1.00	18.56	C
ATOM	2256	CG	LEU	C	60	41.582	19.115	33.520	1.00	19.76	C
ATOM	2257	CD1	LEU	C	60	42.638	19.404	34.561	1.00	17.43	C
ATOM	2258	CD2	LEU	C	60	42.018	18.002	32.555	1.00	20.53	C
ATOM	2259	N	ASP	C	61	37.984	20.629	33.214	1.00	25.53	C
ATOM	2260	CA	ASP	C	61	37.471	21.478	32.157	1.00	27.32	C
ATOM	2261	C	ASP	C	61	36.950	22.809	32.666	1.00	24.92	C
ATOM	2262	O	ASP	C	61	36.768	23.738	31.883	1.00	26.04	C
ATOM	2263	CB	ASP	C	61	36.365	20.729	31.389	1.00	35.52	C
ATOM	2264	CG	ASP	C	61	36.753	19.367	30.759	1.00	45.09	C
ATOM	2265	OD1	ASP	C	61	37.808	19.241	30.086	1.00	48.21	C
ATOM	2266	OD2	ASP	C	61	35.970	18.414	30.956	1.00	49.47	C
ATOM	2267	N	LYS	C	62	36.733	22.956	33.979	1.00		

ATOM	2287	N	SER	C	64	41.606	26.540	33.393	1.00	22.26	N
ATOM	2288	CA	SER	C	64	42.458	26.748	32.268	1.00	25.03	C
ATOM	2289	O	SER	C	64	43.928	26.724	32.651	1.00	27.32	C
ATOM	2290	O	SER	C	64	44.339	27.274	33.668	1.00	29.54	C
ATOM	2291	CB	SER	C	64	41.951	28.036	31.682	1.00	27.42	C
ATOM	2292	OG	SER	C	64	42.936	28.782	30.987	1.00	33.90	O
ATOM	2293	N	ASN	C	65	44.750	26.056	31.838	1.00	29.09	N
ATOM	2294	CA	ASN	C	65	46.183	25.967	32.048	1.00	29.94	C
ATOM	2295	C	ASN	C	65	46.912	27.280	31.894	1.00	31.16	C
ATOM	2296	O	ASN	C	65	46.482	28.228	31.252	1.00	32.15	C
ATOM	2297	CB	ASN	C	65	46.770	24.950	31.088	1.00	31.52	C
ATOM	2298	CG	ASN	C	65	48.076	24.325	31.558	1.00	31.71	C
ATOM	2299	OD1	ASN	C	65	48.626	24.581	32.636	1.00	30.12	O
ATOM	2300	ND2	ASN	C	65	48.454	23.457	30.676	1.00	32.43	N
ATOM	2301	N	ILE	C	66	48.053	27.328	32.558	1.00	34.70	N
ATOM	2302	CA	ILE	C	66	48.822	28.549	32.743	1.00	38.02	C
ATOM	2303	O	ILE	C	66	50.279	28.139	32.567	1.00	39.89	C
ATOM	2304	O	ILE	C	66	50.733	27.095	33.077	1.00	40.56	C
ATOM	2305	CB	ILE	C	66	48.560	29.130	34.181	1.00	37.96	C
ATOM	2306	CG1	ILE	C	66	47.097	29.513	34.381	1.00	37.79	C
ATOM	2307	CG2	ILE	C	66	49.443	30.334	34.443	1.00	37.53	C
ATOM	2308	CD1	ILE	C	66	46.677	29.759	35.833	1.00	39.98	C
ATOM	2309	N	SER	C	67	50.960	29.038	31.828	1.00	41.75	N
ATOM	2310	CA	SER	C	67	52.349	28.856	31.397	1.00	44.33	C
ATOM	2311	C	SER	C	67	53.320	28.647	32.536	1.00	44.33	C
ATOM	2312	O	SER	C	67	54.160	27.762	32.527	1.00	44.13	C
ATOM	2313	CB	SER	C	67	52.833	30.063	30.588	1.00	45.04	C
ATOM	2314	OG	SER	C	68	52.984	31.250	31.372	1.00	50.12	O
ATOM	2315	N	GLU	C	68	53.150	29.510	33.517	1.00	46.29	N
ATOM	2316	CA	GLU	C	68	53.969	29.520	34.702	1.00	49.75	C
ATOM	2317	C	GLU	C	68	53.215	29.731	36.043	1.00	48.90	C
ATOM	2318	O	GLU	C	68	52.374	30.624	36.267	1.00	49.09	C
ATOM	2319	CB	GLU	C	68	55.066	30.581	34.479	1.00	53.81	C
ATOM	2320	CG	GLU	C	68	56.220	30.174	33.547	1.00	59.46	C
ATOM	2321	CD	GLU	C	68	57.364	29.378	34.192	1.00	63.46	C
ATOM	2322	OE1	GLU	C	68	57.165	28.736	35.239	1.00	65.40	O
ATOM	2323	OE2	GLU	C	68	58.477	29.413	33.642	1.00	65.78	C
ATOM	2324	N	GLY	C	69	53.643	28.896	30.925	1.00	46.18	N
ATOM	2325	CA	GLY	C	69	52.938	28.733	38.244	1.00	41.09	C
ATOM	2326	C	GLY	C	69	52.252	27.398	38.142	1.00	37.69	C
ATOM	2327	O	GLY	C	69	51.845	26.975	37.057	1.00	38.22	

Figure 8-50

ATOM	2347	CG	ASN	C	72	43.443	25.398	40.958	1.00	16.98	C
ATOM	2348	OD1	ASN	C	72	44.439	25.399	41.698	1.00	15.50	O
ATOM	2349	ND2	ASN	C	72	42.348	26.051	41.315	1.00	16.58	N
ATOM	2350	NA	TYR	C	73	44.626	23.493	36.878	1.00	17.45	N
ATOM	2351	CA	TYR	C	73	44.546	22.649	35.715	1.00	16.35	C
ATOM	2352	C	TYR	C	73	45.628	21.603	35.846	1.00	16.88	C
ATOM	2353	O	TYR	C	73	45.388	20.407	35.803	1.00	18.90	C
ATOM	2354	CB	TYR	C	73	44.797	23.540	34.503	1.00	14.79	C
ATOM	2355	CG	TYR	C	73	44.618	22.779	33.215	1.00	18.01	C
ATOM	2356	CD1	TYR	C	73	45.649	22.000	32.745	1.00	18.75	C
ATOM	2357	CD2	TYR	C	73	43.428	22.809	32.544	1.00	17.80	C
ATOM	2358	CE1	TYR	C	73	45.507	21.189	31.632	1.00	23.12	C
ATOM	2359	CE2	TYR	C	73	43.282	22.000	31.424	1.00	23.77	C
ATOM	2360	CZ	TYR	C	73	44.300	21.160	30.987	1.00	22.85	C
ATOM	2361	OH	TYR	C	73	44.105	20.242	29.959	1.00	27.47	C
ATOM	2362	N	SER	C	74	46.846	22.071	36.054	1.00	19.27	O
ATOM	2363	CA	SER	C	74	48.037	21.234	36.196	1.00	18.80	N
ATOM	2364	C	SER	C	74	47.939	20.205	37.316	1.00	18.49	C
ATOM	2365	O	SER	C	74	48.192	19.026	37.062	1.00	18.14	C
ATOM	2366	CB	SER	C	74	49.160	22.197	36.410	1.00	19.97	C
ATOM	2367	OG	SER	C	74	50.345	21.552	36.749	1.00	27.05	C
ATOM	2368	N	ILE	C	75	47.536	20.603	38.532	1.00	17.15	N
ATOM	2369	CA	ILE	C	75	47.360	19.670	39.640	1.00	15.78	C
ATOM	2370	C	ILE	C	75	46.266	18.688	39.303	1.00	15.56	C
ATOM	2371	O	ILE	C	75	46.392	17.487	39.540	1.00	15.90	C
ATOM	2372	CB	ILE	C	75	47.004	20.373	40.994	1.00	14.47	C
ATOM	2373	CG1	ILE	C	75	48.069	21.396	41.311	1.00	15.08	C
ATOM	2374	CG2	ILE	C	75	46.847	19.406	42.151	1.00	9.44	C
ATOM	2375	CD1	ILE	C	75	47.662	22.494	42.334	1.00	16.06	C
ATOM	2376	N	ILE	C	76	45.174	19.165	38.739	1.00	15.87	N
ATOM	2377	CA	ILE	C	76	44.072	18.254	38.540	1.00	16.45	C
ATOM	2378	C	ILE	C	76	44.423	17.278	37.416	1.00	18.42	C
ATOM	2379	O	ILE	C	76	44.407	16.107	37.479	1.00	21.96	C
ATOM	2380	CB	ILE	C	76	42.777	19.029	38.276	1.00	16.99	C
ATOM	2381	CG1	ILE	C	76	42.407	20.014	39.366	1.00	18.36	C
ATOM	2382	CG2	ILE	C	76	41.661	18.026	38.294	1.00	18.72	C
ATOM	2383	CD1	ILE	C	76	41.376	21.090	38.981	1.00	13.71	C
ATOM	2384	N	ASP	C	77	45.169	17.686	36.398	1.00	19.28	N
ATOM	2385	CA	ASP	C	77	45.673	16.806	35.340	1.00	20.35	C
ATOM	2386	C	ASP	C	77	46.477	15.616	35.867	1.00	18.75	C
ATOM	2387	O	ASP	C	77	46.259	14.474	35.483	1.00	20.55	C
ATOM	2388	CB	ASP	C	77	46.528	17.679	34.388	1.00	23.72	C
ATOM	2389	CG	ASP	C	77	46.796	17.143	32.984	1.00	27.17	C
ATOM	2390	OD1	ASP	C	77	46.195	16.148	32.611	1.00	29.11	O
ATOM	2391	OD2	ASP	C	77	47.586	17.723	32.239	1.00	31.91	N
ATOM	2392	N	LYS	C	78	47.401	15.826	36.791	1.00	18.00	C
ATOM	2393	CA	LYS	C	78	48.064	14.729	37.494	1.00	19.18	C
ATOM	2394	C	LYS	C	78	47.114	13.802	38.229	1.00	16.84	C
ATOM	2395	O	LYS	C	78	47.200	12.586	38.170	1.00	18.34	C
ATOM	2396	CB	LYS	C	78	49.017	15.288	38.533	1.00	21.80	C
ATOM	2397	CG	LYS	C	78	50.492	15.453	38.249	1.00	26.26	C
ATOM	2398	CD	LYS	C	78	50.799	16.212	36.977	1.00	33.33	C
ATOM	2399	CE	LYS	C	78	51.977	17.190	37.154	1.00	36.36	C
ATOM	2400	NZ	LYS	C	78	51.538	18.516	37.592	1.00	40.57	N
ATOM	2401	N	LEU	C	79	46.160	14.358	38.937	1.00	17.71	N
ATOM	2402	CA	LEU	C	79	45.282	13.528	39.739	1.00	19.39	C
ATOM	2403	C	LEU	C	79	44.465	12.641	38.836	1.00	19.34	C
ATOM	2404	O	LEU	C	79	44.358	11.479	39.161	1.00	22.92	O
ATOM	2405	CB	LEU	C	79	44.412	14.342	40.708	1.00	15.20	C
ATOM	2406	CG	LEU	C	79	45.179	15.238	41.695	1.00	14.54	C

Figure 8-51

ATOM	2407	CD1	LEU	C	79	44.276	15.934	42.683	1.00	15.95	C
ATOM	2408	CD2	LEU	C	79	46.119	14.401	42.497	1.00	14.50	C
ATOM	2409	N	VAL	C	80	43.974	13.115	37.594	1.00	20.79	N
ATOM	2410	CA	VAL	C	80	43.210	12.349	36.719	1.00	19.75	C
ATOM	2411	C	VAL	C	80	44.068	11.231	36.229	1.00	20.92	C
ATOM	2412	O	VAL	C	80	43.583	10.133	36.160	1.00	19.45	O
ATOM	2413	CB	VAL	C	80	42.850	13.201	35.502	1.00	20.41	C
ATOM	2414	CG1	VAL	C	80	42.103	12.364	34.477	1.00	22.80	C
ATOM	2415	CG2	VAL	C	80	41.915	14.311	35.902	1.00	19.35	C
ATOM	2416	N	ASN	C	81	45.344	11.472	35.936	1.00	24.00	N
ATOM	2417	CA	ASN	C	81	46.215	10.435	35.447	1.00	24.32	C
ATOM	2418	C	ASN	C	81	46.460	9.366	36.474	1.00	25.83	C
ATOM	2419	O	ASN	C	81	46.405	8.188	36.168	1.00	27.41	O
ATOM	2420	CB	ASN	C	81	47.505	11.049	35.027	1.00	25.29	C
ATOM	2421	CG	ASN	C	81	47.389	11.689	33.658	1.00	27.98	C
ATOM	2422	OD1	ASN	C	81	47.347	10.977	32.667	1.00	30.37	C
ATOM	2423	ND2	ASN	C	81	47.387	13.000	33.477	1.00	27.47	N
ATOM	2424	N	ILE	C	82	46.690	9.750	37.714	1.00	27.31	N
ATOM	2425	CA	ILE	C	82	46.839	8.819	38.814	1.00	27.48	C
ATOM	2426	C	ILE	C	82	45.586	7.971	39.042	1.00	29.22	C
ATOM	2427	O	ILE	C	82	45.705	6.766	39.266	1.00	32.26	O
ATOM	2428	CB	ILE	C	82	47.228	9.685	40.022	1.00	26.77	C
ATOM	2429	CG1	ILE	C	82	48.662	10.131	39.852	1.00	24.85	C
ATOM	2430	CG2	ILE	C	82	47.046	8.977	41.344	1.00	26.49	C
ATOM	2431	CD1	ILE	C	82	49.159	11.193	40.833	1.00	24.34	C
ATOM	2432	N	VAL	C	83	44.371	8.547	38.968	1.00	30.80	N
ATOM	2433	CA	VAL	C	83	43.099	7.834	39.209	1.00	29.90	C
ATOM	2434	C	VAL	C	83	42.793	6.906	38.019	1.00	30.67	C
ATOM	2435	O	VAL	C	83	42.229	5.824	38.195	1.00	29.90	O
ATOM	2436	CB	VAL	C	83	41.888	8.816	39.455	1.00	27.23	C
ATOM	2437	CG1	VAL	C	83	40.651	8.141	39.973	1.00	28.89	C
ATOM	2438	CG2	VAL	C	83	42.154	9.759	40.558	1.00	28.33	C
ATOM	2439	N	ASP	C	84	43.174	7.298	36.797	1.00	31.05	N
ATOM	2440	CA	ASP	C	84	42.971	6.473	35.629	1.00	31.24	C
ATOM	2441	C	ASP	C	84	43.761	5.196	35.686	1.00	32.41	C
ATOM	2442	O	ASP	C	84	43.233	4.156	35.291	1.00	32.47	O
ATOM	2443	CB	ASP	C	84	43.296	7.192	34.350	1.00	31.90	C
ATOM	2444	CG	ASP	C	84	42.233	8.181	33.899	1.00	36.65	C
ATOM	2445	OD1	ASP	C	84	41.105	8.177	34.417	1.00	37.73	O
ATOM	2446	OD2	ASP	C	84	42.537	8.969	33.000	1.00	40.83	C
ATOM	2447	N	ASP	C	85	44.988	5.287	36.202	1.00	31.95	N
ATOM	2448	CA	ASP	C	85	45.770	4.128	36.589	1.00	34.69	C
ATOM	2449	C	ASP	C	85	45.189	3.114	37.564	1.00	34.70	C
ATOM	2450	O	ASP	C	85	45.464	1.921	37.471	1.00	34.86	O
ATOM	2451	CB	ASP	C	85	47.030	4.593	37.248	1.00	37.43	C
ATOM	2452	CG	ASP	C	85	48.101	5.028	36.290	1.00	41.26	C
ATOM	2453	OD1	ASP	C	85	47.860	4.978	35.077	1.00	45.93	O
ATOM	2454	OD2	ASP	C	85	49.169	5.423	36.776	1.00	43.39	O
ATOM	2455	N	LEU	C	86	44.445	3.587	38.552	1.00	34.35	N
ATOM	2456	CA	LEU	C	86	43.783	2.717	39.498	1.00	34.80	C
ATOM	2457	C	LEU	C	86	42.525	2.164	38.889	1.00	34.98	C
ATOM	2458	O	LEU	C	86	42.117	1.094	39.288	1.00	36.02	O
ATOM	2459	CB	LEU	C	86	43.443	3.508	40.735	1.00	35.24	C
ATOM	2460	CG	LEU	C	86	44.591	4.321	41.331	1.00	37.43	C
ATOM	2461	CD1	LEU	C	86	45.052	5.240	42.407	1.00	38.91	C
ATOM	2462	CD2	LEU	C	86	45.728	3.422	41.825	1.00	37.75	C
ATOM	2463	N	VAL	C	87	41.886	2.866	37.939	1.00	37.37	N
ATOM	2464	CA	VAL	C	87	40.748	2.365	37.175	1.00	38.56	C
ATOM	2465	C	VAL	C	87	41.236	1.205	36.320	1.00	41.43	C
ATOM	2466	O	VAL	C	87	40.621	0.154	36.337	1.00	43.44	O

09000007-00000000

Figure 8-52

ATOM	2467	CB	VAL	C	87	40.167	3.478	36.302	1.00	36.61	C
ATOM	2468	CG1	VAL	C	87	39.054	2.945	35.450	1.00	37.46	C
ATOM	2469	CG2	VAL	C	87	39.892	4.584	37.139	1.00	35.39	C
ATOM	2470	N	GLU	C	88	42.356	1.329	35.613	1.00	45.33	N
ATOM	2471	CA	GLU	C	88	42.933	0.237	34.842	1.00	50.04	C
ATOM	2472	C	GLU	C	88	43.480	-0.856	35.761	1.00	52.28	C
ATOM	2473	O	GLU	C	88	43.503	-2.015	35.374	1.00	53.46	O
ATOM	2474	CB	GLU	C	88	44.048	0.728	33.869	1.00	52.22	C
ATOM	2475	CG	GLU	C	88	43.776	1.785	32.749	1.00	56.99	C
ATOM	2476	CD	GLU	C	88	42.784	1.451	31.610	1.00	62.14	C
ATOM	2477	OE1	GLU	C	88	42.853	0.348	31.046	1.00	66.19	O
ATOM	2478	OE2	GLU	C	88	41.926	2.286	31.266	1.00	62.89	O
ATOM	2479	N	CYS	C	89	43.930	-0.535	36.982	1.00	55.77	N
ATOM	2480	CA	CYS	C	89	44.471	-1.508	37.936	1.00	58.72	C
ATOM	2481	C	CYS	C	89	43.372	-2.333	38.578	1.00	60.22	C
ATOM	2482	O	CYS	C	89	43.624	-3.464	39.000	1.00	61.13	O
ATOM	2483	CB	CYS	C	89	45.285	-0.819	39.048	1.00	59.69	C
ATOM	2484	SG	CYS	C	89	46.103	-1.924	40.239	1.00	65.48	S
ATOM	2485	N	VAL	C	90	42.159	-1.749	38.657	1.00	61.71	N
ATOM	2486	CA	VAL	C	90	40.963	-2.396	39.210	1.00	62.70	C
ATOM	2487	C	VAL	C	90	40.453	-3.516	38.278	1.00	64.64	C
ATOM	2488	O	VAL	C	90	40.010	-4.562	38.779	1.00	65.07	O
ATOM	2489	CB	VAL	C	90	39.934	-1.260	39.622	1.00	60.49	C
ATOM	2490	CG1	VAL	C	90	38.477	-1.428	39.231	1.00	58.30	C
ATOM	2491	CG2	VAL	C	90	40.023	-1.060	41.125	1.00	58.40	C
ATOM	2492	N	LYS	C	91	40.591	-3.348	36.938	1.00	66.41	N
ATOM	2493	CA	LYS	C	91	40.281	-4.402	35.971	1.00	68.79	C
ATOM	2494	C	LYS	C	91	41.219	-5.638	36.092	1.00	70.22	C
ATOM	2495	O	LYS	C	91	40.715	-6.728	36.404	1.00	72.46	O
ATOM	2496	CB	LYS	C	91	40.233	-3.836	34.530	1.00	68.55	C
ATOM	2497	CG	LYS	C	91	39.560	-4.821	33.535	1.00	71.09	C
ATOM	2498	CD	LYS	C	91	39.779	-4.534	32.028	1.00	71.78	C
ATOM	2499	CE	LYS	C	91	39.128	-3.245	31.514	1.00	70.74	C
ATOM	2500	NZ	LYS	C	91	39.730	-2.834	30.259	1.00	70.64	N
ATOM	2501	N	SER	C	104	25.399	2.470	38.962	1.00	56.13	N
ATOM	2502	CA	SER	C	104	25.444	3.921	38.739	1.00	55.65	C
ATOM	2503	C	SER	C	104	24.850	4.688	39.939	1.00	52.95	C
ATOM	2504	O	SER	C	104	23.647	4.968	39.947	1.00	53.89	O
ATOM	2505	CB	SER	C	104	24.797	4.326	37.337	1.00	57.16	C
ATOM	2506	OG	SER	C	104	23.517	3.792	36.940	1.00	56.67	C
ATOM	2507	N	PRO	C	105	25.618	5.024	41.000	1.00	49.29	N
ATOM	2508	CA	PRO	C	105	25.119	5.676	42.224	1.00	46.42	C
ATOM	2509	C	PRO	C	105	24.631	7.146	42.171	1.00	44.43	C
ATOM	2510	O	PRO	C	105	24.768	7.791	41.134	1.00	42.75	O
ATOM	2511	CB	PRO	C	105	26.265	5.445	43.181	1.00	45.66	C
ATOM	2512	CG	PRO	C	105	27.467	5.523	42.277	1.00	46.43	C
ATOM	2513	CD	PRO	C	105	27.036	4.706	41.089	1.00	47.56	C
ATOM	2514	N	GLU	C	106	24.023	7.707	43.240	1.00	44.38	N
ATOM	2515	CA	GLU	C	106	23.436	9.055	43.238	1.00	43.85	C
ATOM	2516	C	GLU	C	106	24.414	10.202	43.420	1.00	42.61	C
ATOM	2517	O	GLU	C	106	25.293	10.113	44.289	1.00	42.69	O
ATOM	2518	CB	GLU	C	106	22.321	9.281	44.289	1.00	45.50	C
ATOM	2519	CG	GLU	C	106	20.936	8.664	44.035	1.00	46.22	C
ATOM	2520	CD	GLU	C	106	20.404	8.761	42.607	1.00	45.82	C
ATOM	2521	OE1	GLU	C	106	20.257	9.861	42.067	1.00	41.34	O
ATOM	2522	OE2	GLU	C	106	20.152	7.699	42.032	1.00	48.83	C
ATOM	2523	N	PRO	C	107	24.254	11.291	42.632	1.00	41.36	N
ATOM	2524	CA	PRO	C	107	25.096	12.486	42.637	1.00	39.50	C
ATOM	2525	C	PRO	C	107	24.873	13.318	43.850	1.00	38.28	C
ATOM	2526	O	PRO	C	107	23.767	13.685	44.226	1.00	39.34	O

09619027 062000

ATOM	2527	CB	PRO	C	107	24.680	13.288	41.434	1.00	40.28	C
ATOM	2528	CG	PRO	C	107	24.151	12.214	40.519	1.00	42.95	C
ATOM	2529	CD	PRO	C	107	23.353	11.358	41.490	1.00	41.93	C
ATOM	2530	N	ARG	C	108	26.012	13.570	44.436	1.00	35.97	C
ATOM	2531	CA	ARG	C	108	26.055	14.439	45.561	1.00	35.65	C
ATOM	2532	C	ARG	C	108	26.953	15.609	45.219	1.00	34.88	C
ATOM	2533	O	ARG	C	108	27.707	15.585	44.244	1.00	35.60	C
ATOM	2534	CB	ARG	C	108	26.617	13.701	46.756	1.00	39.40	C
ATOM	2535	CG	ARG	C	108	25.710	12.792	44.709	1.00	44.00	C
ATOM	2536	CD	ARG	C	108	25.959	12.906	49.053	1.00	48.86	C
ATOM	2537	NE	ARG	C	108	25.401	11.801	49.824	1.00	52.47	N
ATOM	2538	CZ	ARG	C	108	25.920	11.400	50.988	1.00	54.55	C
ATOM	2539	NH1	ARG	C	108	26.919	12.095	51.582	1.00	55.13	C
ATOM	2540	NH2	ARG	C	108	25.427	10.267	51.532	1.00	54.84	N
ATOM	2541	N	LEU	C	109	26.850	16.651	46.046	1.00	32.80	N
ATOM	2542	CA	LEU	C	109	27.686	17.851	45.949	1.00	31.31	C
ATOM	2543	C	LEU	C	109	28.544	17.984	47.198	1.00	27.53	C
ATOM	2544	O	LEU	C	109	28.058	17.849	48.335	1.00	29.28	C
ATOM	2545	CB	LEU	C	109	26.876	19.173	45.823	1.00	30.72	C
ATOM	2546	CG	LEU	C	109	25.837	19.411	46.844	1.00	29.50	C
ATOM	2547	CD1	LEU	C	109	25.143	20.697	45.150	1.00	31.86	C
ATOM	2548	CD2	LEU	C	109	26.433	19.432	43.347	1.00	30.24	C
ATOM	2549	N	PHE	C	110	29.841	18.247	46.995	1.00	24.61	C
ATOM	2550	CA	PHE	C	110	30.784	18.289	48.116	1.00	20.67	C
ATOM	2551	C	PHE	C	110	31.579	19.548	48.013	1.00	17.66	C
ATOM	2552	O	PHE	C	110	31.746	20.049	46.924	1.00	19.14	C
ATOM	2553	CB	PHE	C	110	31.721	17.098	48.021	1.00	23.08	C
ATOM	2554	CG	PHE	C	110	31.049	15.733	48.163	1.00	22.91	C
ATOM	2555	NH1	PHE	C	110	30.793	15.226	48.266	1.00	23.89	C
ATOM	2556	CD2	PHE	C	110	30.737	15.008	47.024	1.00	23.49	C
ATOM	2557	CE1	PHE	C	110	30.269	13.969	49.565	1.00	21.28	C
ATOM	2558	CE2	PHE	C	110	30.186	13.751	47.178	1.00	24.67	C
ATOM	2559	CZ	PHE	C	110	29.974	13.233	48.444	1.00	24.36	C
ATOM	2560	N	THR	C	111	32.071	20.116	49.084	1.00	17.78	C
ATOM	2561	CA	THR	C	111	32.961	21.249	49.978	1.00	18.25	C
ATOM	2562	C	THR	C	111	34.337	20.763	48.509	1.00	21.30	C
ATOM	2563	CB	THR	C	111	34.518	19.547	48.617	1.00	26.22	C
ATOM	2564	CG	THR	C	111	31.057	21.895	50.139	1.00	28.89	C
ATOM	2565	CD1	THR	C	111	33.780	20.989	51.199	1.00	19.58	C
ATOM	2566	CG2	THR	C	111	31.663	22.215	50.913	1.00	18.93	C
ATOM	2567	N	PRO	C	112	35.3					

Figure 8-54

ATOM	2587	CB	GLU	C	114	33.470	17.344	51.622	1.00	26.84	C
ATOM	2588	CG	GLU	C	114	32.974	18.114	52.849	1.00	31.67	C
ATOM	2589	CD	GLU	C	114	31.578	18.736	52.701	1.00	37.47	C
ATOM	2590	OE1	GLU	C	114	30.884	18.533	51.681	1.00	35.31	O
ATOM	2591	OE2	GLU	C	114	31.202	19.468	53.633	1.00	40.13	O
ATOM	2592	N	PHE	C	115	35.320	16.775	49.143	1.00	20.03	N
ATOM	2593	CA	PHE	C	115	35.606	15.979	47.971	1.00	18.15	C
ATOM	2594	C	PHE	C	115	36.997	15.397	48.157	1.00	17.33	C
ATOM	2595	O	PHE	C	115	37.214	14.205	48.013	1.00	18.05	O
ATOM	2596	CB	PHE	C	115	35.524	16.833	46.705	1.00	15.90	C
ATOM	2597	CG	PHE	C	115	35.825	16.063	45.429	1.00	17.09	C
ATOM	2598	CD1	PHE	C	115	34.861	15.299	44.845	1.00	16.21	C
ATOM	2599	CD2	PHE	C	115	37.094	16.093	44.890	1.00	18.64	C
ATOM	2600	CE1	PHE	C	115	35.193	14.558	43.744	1.00	19.14	C
ATOM	2601	CE2	PHE	C	115	37.425	15.336	43.795	1.00	18.76	C
ATOM	2602	CZ	PHE	C	115	36.463	14.570	43.217	1.00	19.41	C
ATOM	2603	N	PHE	C	116	38.010	16.167	48.509	1.00	19.36	N
ATOM	2604	CA	PHE	C	116	39.361	15.618	48.454	1.00	17.90	C
ATOM	2605	C	PHE	C	116	39.621	14.678	49.623	1.00	18.24	C
ATOM	2606	O	PHE	C	116	40.505	13.855	49.549	1.00	19.98	O
ATOM	2607	CB	PHE	C	116	40.376	16.744	48.162	1.00	16.33	C
ATOM	2608	CG	PHE	C	116	40.442	17.170	46.679	1.00	15.27	C
ATOM	2609	CD1	PHE	C	116	41.052	16.328	45.753	1.00	14.80	C
ATOM	2610	CD2	PHE	C	116	39.806	18.324	46.240	1.00	12.85	C
ATOM	2611	CE1	PHE	C	116	40.967	16.602	44.409	1.00	12.34	C
ATOM	2612	CE2	PHE	C	116	39.715	18.569	44.885	1.00	14.12	C
ATOM	2613	CZ	PHE	C	116	40.289	17.711	43.980	1.00	10.60	C
ATOM	2614	N	ARG	C	117	38.755	14.664	50.641	1.00	20.78	N
ATOM	2615	CA	ARG	C	117	38.796	13.751	51.770	1.00	21.33	C
ATOM	2616	C	ARG	C	117	38.412	12.368	51.308	1.00	20.46	C
ATOM	2617	O	ARG	C	117	39.076	11.405	51.639	1.00	21.70	O
ATOM	2618	CB	ARG	C	117	37.823	14.244	52.840	1.00	21.70	C
ATOM	2619	CG	ARG	C	117	37.838	13.513	54.177	1.00	27.63	C
ATOM	2620	CD	ARG	C	117	36.826	14.115	55.165	1.00	29.36	C
ATOM	2621	NE	ARG	C	117	37.230	15.464	55.616	1.00	32.11	N
ATOM	2622	CZ	ARG	C	117	36.411	16.535	55.565	1.00	32.37	C
ATOM	2623	NH1	ARG	C	117	35.179	16.464	55.047	1.00	32.61	N
ATOM	2624	NH2	ARG	C	117	36.836	17.701	56.025	1.00	30.98	N
ATOM	2625	N	ILE	C	118	37.342	12.263	50.540	1.00	21.91	N
ATOM	2626	CA	ILE	C	118	36.897	11.031	49.882	1.00	22.55	C
ATOM	2627	C	ILE	C	118	37.944	10.504	48.890	1.00	23.60	C
ATOM	2628	O	ILE	C	118	38.254	9.316	48.853	1.00	24.72	O
ATOM	2629	CB	ILE	C	118	35.527	11.358	49.213	1.00	22.47	C
ATOM	2630	CG1	ILE	C	118	34.467	11.506	50.293	1.00	21.67	C
ATOM	2631	CG2	ILE	C	118	35.117	10.338	48.161	1.00	21.48	C
ATOM	2632	CD1	ILE	C	118	33.164	12.169	49.825	1.00	21.12	C
ATOM	2633	N	PHE	C	119	38.544	11.402	48.103	1.00	23.86	N
ATOM	2634	CA	PHE	C	119	39.633	11.098	47.186	1.00	22.73	C
ATOM	2635	C	PHE	C	119	40.816	10.488	47.916	1.00	24.24	C
ATOM	2636	O	PHE	C	119	41.233	9.416	47.511	1.00	24.28	O
ATOM	2637	CB	PHE	C	119	40.038	12.357	46.426	1.00	15.88	C
ATOM	2638	CG	PHE	C	119	41.297	12.224	45.624	1.00	15.30	C
ATOM	2639	CD1	PHE	C	119	41.231	11.724	44.354	1.00	15.03	C
ATOM	2640	CD2	PHE	C	119	42.495	12.639	46.172	1.00	12.85	C
ATOM	2641	CE1	PHE	C	119	42.412	11.623	43.653	1.00	15.97	C
ATOM	2642	CE2	PHE	C	119	43.675	12.526	45.473	1.00	15.16	C
ATOM	2643	CZ	PHE	C	119	43.630	12.003	44.206	1.00	16.33	C
ATOM	2644	N	ASN	C	120	41.396	11.145	48.936	1.00	26.61	N
ATOM	2645	CA	ASN	C	120	42.511	10.621	49.728	1.00	27.10	C
ATOM	2646	C	ASN	C	120	42.225	9.301	50.400	1.00	28.31	C

005290 005290 005290

Figure 8-55

ATOM	2647	O	ASN	C	120	43.081	8.433	50.376	1.00	28.63	O
ATOM	2648	CB	ASN	C	120	42.959	11.550	50.783	1.00	24.50	C
ATOM	2649	CG	ASN	C	120	43.837	12.659	50.215	1.00	27.34	C
ATOM	2650	OD1	ASN	C	120	43.864	13.757	50.761	1.00	32.26	O
ATOM	2651	ND2	ASN	C	120	44.628	12.420	49.169	1.00	29.64	N
ATOM	2652	N	ARG	C	121	41.017	9.136	50.947	1.00	30.80	N
ATOM	2653	CA	ARG	C	121	40.549	7.862	51.441	1.00	35.49	C
ATOM	2654	C	ARG	C	121	40.514	6.767	50.357	1.00	36.43	C
ATOM	2655	O	ARG	C	121	40.859	5.616	50.628	1.00	38.58	O
ATOM	2656	CB	ARG	C	121	39.202	8.108	52.138	1.00	37.63	C
ATOM	2657	CG	ARG	C	121	38.534	6.865	52.651	1.00	42.24	C
ATOM	2658	CD	ARG	C	121	37.240	7.194	53.373	1.00	47.82	C
ATOM	2659	NE	ARG	C	121	36.399	6.001	53.529	1.00	51.79	N
ATOM	2660	CZ	ARG	C	121	36.788	4.912	54.233	1.00	55.38	C
ATOM	2661	NH1	ARG	C	121	38.016	4.799	54.783	1.00	57.12	N
ATOM	2662	NH2	ARG	C	121	35.928	3.904	54.446	1.00	55.34	N
ATOM	2663	N	SER	C	122	40.171	7.089	49.106	1.00	36.49	N
ATOM	2664	CA	SER	C	122	40.274	6.177	47.974	1.00	36.44	C
ATOM	2665	C	SER	C	122	41.660	5.723	47.529	1.00	37.85	C
ATOM	2666	O	SER	C	122	41.874	4.556	47.235	1.00	39.23	O
ATOM	2667	CB	SER	C	122	39.613	6.814	46.788	1.00	34.58	C
ATOM	2668	OG	SER	C	122	38.286	7.132	47.155	1.00	34.47	O
ATOM	2669	N	ILE	C	123	42.638	6.599	47.409	1.00	38.85	N
ATOM	2670	CA	ILE	C	123	43.949	6.180	46.985	1.00	43.11	C
ATOM	2671	C	ILE	C	123	44.589	5.456	48.157	1.00	46.18	C
ATOM	2672	O	ILE	C	123	45.449	4.614	47.937	1.00	47.69	O
ATOM	2673	CB	ILE	C	123	44.843	7.378	46.505	1.00	42.65	C
ATOM	2674	CG1	ILE	C	123	44.147	8.410	45.599	1.00	38.38	C
ATOM	2675	CG2	ILE	C	123	46.146	6.866	45.872	1.00	43.09	C
ATOM	2676	CD1	ILE	C	123	43.242	7.872	44.489	1.00	35.80	C
ATOM	2677	N	ASP	C	124	44.206	5.755	49.402	1.00	50.61	N
ATOM	2678	CA	ASP	C	124	44.805	5.095	50.564	1.00	54.85	C
ATOM	2679	C	ASP	C	124	44.197	3.730	50.882	1.00	54.20	C
ATOM	2680	O	ASP	C	124	44.774	2.898	51.586	1.00	54.57	O
ATOM	2681	CB	ASP	C	124	44.788	5.989	51.823	1.00	59.47	C
ATOM	2682	CG	ASP	C	124	45.794	7.151	51.915	1.00	63.36	C
ATOM	2683	OD1	ASP	C	124	45.935	7.919	50.949	1.00	63.45	O
ATOM	2684	OD2	ASP	C	124	46.414	7.295	52.988	1.00	66.94	C
ATOM	2685	N	ALA	C	125	43.039	3.460	50.281	1.00	54.57	N
ATOM	2686	CA	ALA	C	125	42.427	2.137	50.314	1.00	56.99	C
ATOM	2687	C	ALA	C	125	43.150	1.108	49.440	1.00	58.85	C
ATOM	2688	O	ALA	C	125	42.617	0.022	49.161	1.00	59.46	O
ATOM	2689	CB	ALA	C	125	40.982	2.263	49.824	1.00	56.08	C
ATOM	2690	N	PHE	C	126	44.343	1.552	48.975	1.00	60.81	N
ATOM	2691	CA	PHE	C	126	45.408	0.793	48.316	1.00	62.82	C
ATOM	2692	C	PHE	C	126	46.675	0.603	49.241	1.00	64.91	C
ATOM	2693	O	PHE	C	126	47.801	0.492	48.731	1.00	65.88	O
ATOM	2694	CB	PHE	C	126	45.715	1.476	46.898	1.00	60.15	C
ATOM	2695	CG	PHE	C	126	44.638	1.419	45.778	1.00	57.55	C
ATOM	2696	CD1	PHE	C	126	43.594	2.334	45.731	1.00	56.09	C
ATOM	2697	CD2	PHE	C	126	44.655	0.421	44.813	1.00	56.90	C
ATOM	2698	CE1	PHE	C	126	42.568	2.227	44.807	1.00	52.24	C
ATOM	2699	CE2	PHE	C	126	43.627	0.319	43.884	1.00	54.42	C
ATOM	2700	CZ	PHE	C	126	42.573	1.208	43.889	1.00	52.99	C
TER	2702		PHE	C	126						
ATOM	2703	N	ASN	D	11	47.774	44.287	38.626	1.00	52.77	N
ATOM	2704	CA	ASN	D	11	46.416	43.904	38.273	1.00	53.01	C
ATOM	2705	C	ASN	D	11	46.383	43.039	36.995	1.00	52.04	C
ATOM	2706	O	ASN	D	11	46.673	41.852	37.139	1.00	53.30	O
ATOM	2707	CB	ASN	D	11	45.488	45.136	38.154	1.00	52.37	C

09503007.062900

Figure 8-56

ATOM	2708	N	VAL	D	12	46.135	43.551	35.763	1.00	49.81	N
ATOM	2709	CA	VAL	D	12	45.936	42.823	34.490	1.00	45.10	C
ATOM	2710	C	VAL	D	12	46.697	41.529	34.194	1.00	40.73	C
ATOM	2711	O	VAL	D	12	46.109	40.477	33.958	1.00	39.20	O
ATOM	2712	CB	VAL	D	12	46.118	43.863	33.336	1.00	46.99	C
ATOM	2713	CG1	VAL	D	12	46.377	43.229	31.966	1.00	47.11	C
ATOM	2714	CG2	VAL	D	12	44.888	44.784	33.225	1.00	46.26	C
ATOM	2715	N	LYS	D	13	48.014	41.610	34.165	1.00	37.97	N
ATOM	2716	CA	LYS	D	13	48.844	40.432	34.132	1.00	36.45	C
ATOM	2717	C	LYS	D	13	48.402	39.322	35.117	1.00	36.18	C
ATOM	2718	O	LYS	D	13	48.194	38.166	34.709	1.00	37.38	O
ATOM	2719	CB	LYS	D	13	50.258	40.905	34.451	1.00	35.89	C
ATOM	2720	N	ASP	D	14	48.190	39.643	36.410	1.00	33.96	N
ATOM	2721	CA	ASP	D	14	47.703	38.684	37.372	1.00	29.22	C
ATOM	2722	C	ASP	D	14	46.220	38.409	37.305	1.00	25.55	C
ATOM	2723	O	ASP	D	14	45.799	37.316	37.647	1.00	25.36	O
ATOM	2724	CB	ASP	D	14	48.158	39.126	38.726	1.00	33.71	C
ATOM	2725	CG	ASP	D	14	48.573	38.623	39.084	1.00	41.45	C
ATOM	2726	OD1	ASP	D	14	50.178	37.858	38.316	1.00	45.64	O
ATOM	2727	OD2	ASP	D	14	50.083	38.981	40.161	1.00	44.73	O
ATOM	2728	N	VAL	D	15	45.421	39.347	36.809	1.00	22.15	N
ATOM	2729	CA	VAL	D	15	44.000	39.173	36.672	1.00	19.73	C
ATOM	2730	C	VAL	D	15	43.683	38.044	35.731	1.00	21.56	C
ATOM	2731	O	VAL	D	15	42.825	37.217	36.016	1.00	23.37	O
ATOM	2732	CB	VAL	D	15	43.294	40.462	36.234	1.00	18.49	C
ATOM	2733	CG1	VAL	D	15	41.883	40.238	35.684	1.00	17.31	C
ATOM	2734	CG2	VAL	D	15	43.093	41.327	37.450	1.00	17.77	C
ATOM	2735	N	THR	D	16	44.387	37.974	34.623	1.00	22.81	N
ATOM	2736	CA	THR	D	16	44.166	36.943	33.605	1.00	24.47	C
ATOM	2737	C	THR	D	16	44.517	35.513	34.082	1.00	21.91	C
ATOM	2738	O	THR	D	16	43.904	34.526	33.676	1.00	20.78	O
ATOM	2739	CB	THR	D	16	44.991	37.520	32.381	1.00	25.36	C
ATOM	2740	CG1	THR	D	16	44.076	38.310	31.630	1.00	28.31	O
ATOM	2741	CG2	THR	D	16	45.721	36.529	31.530	1.00	28.93	C
ATOM	2742	N	LYS	D	17	45.470	35.415	35.016	1.00	20.72	N
ATOM	2743	CA	LYS	D	17	45.958	34.179	35.596	1.00	20.21	C
ATOM	2744	C	LYS	D	17	45.019	33.719	36.683	1.00	18.63	C
ATOM	2745	O	LYS	D	17	44.754	32.526	36.783	1.00	21.04	O
ATOM	2746	CB	LYS	D	17	47.277	34.522	36.207	1.00	24.75	C
ATOM	2747	CG	LYS	D	17	48.163	33.373	36.590	1.00	29.44	C
ATOM	2748	CD	LYS	D	17	49.365	33.928	37.347	1.00	32.96	C
ATOM	2749	CE	LYS	D	17	50.423	34.474	36.422	1.00	36.20	C
ATOM	2750	NZ	LYS	D	17	51.313	35.272	37.230	1.00	39.87	N
ATOM	2751	N	LEU	D	18	44.483	34.556	37.468	1.00	16.11	N
ATOM	2752	CA	LEU	D	18	43.391	34.389	38.362	1.00	13.77	C
ATOM	2753	C	LEU	D	18	42.158	33.926	37.636	1.00	14.10	C
ATOM	2754	O	LEU	D	18	41.662	32.898	38.072	1.00	17.61	O
ATOM	2755	CB	LEU	D	18	43.070	35.599	39.180	1.00	14.87	C
ATOM	2756	CG	LEU	D	18	42.103	35.485	40.362	1.00	15.58	C
ATOM	2757	CD1	LEU	D	18	42.567	34.568	41.470	1.00	11.31	C
ATOM	2758	CD2	LEU	D	18	41.872	36.849	40.952	1.00	15.28	C
ATOM	2759	N	VAL	D	19	41.617	34.544	36.561	1.00	15.42	N
ATOM	2760	CA	VAL	D	19	40.479	34.034	35.786	1.00	13.39	C
ATOM	2761	C	VAL	D	19	40.704	32.587	35.385	1.00	14.30	C
ATOM	2762	O	VAL	D	19	39.824	31.744	35.542	1.00	13.93	O
ATOM	2763	CB	VAL	D	19	40.251	34.838	34.489	1.00	14.39	C
ATOM	2764	CG1	VAL	D	19	39.059	34.330	33.694	1.00	11.41	C
ATOM	2765	CG2	VAL	D	19	39.913	36.255	34.797	1.00	12.80	C
ATOM	2766	N	ALA	D	20	41.911	32.288	34.876	1.00	14.50	N
ATOM	2767	CA	ALA	D	20	42.319	30.924	34.543	1.00	15.90	C

09609027.062660

[illegible]

ATOM	2768	C	ALA	D	20	42.340	29.894	35.680	1.00	16.27
ATOM	2769	O	ALA	D	20	42.153	28.697	35.464	1.00	14.91
ATOM	2770	CB	ALA	D	20	43.719	30.983	33.946	1.00	16.48
ATOM	2771	N	ASN	D	21	42.543	30.396	36.914	1.00	16.20
ATOM	2772	CA	ASN	D	21	42.665	29.549	38.081	1.00	14.59
ATOM	2773	C	ASN	D	21	41.408	29.513	38.923	1.00	15.22
ATOM	2774	O	ASN	D	21	41.343	28.894	39.982	1.00	14.76
ATOM	2775	CB	ASN	D	21	43.863	30.085	38.853	1.00	15.31
ATOM	2776	CG	ASN	D	21	44.760	29.000	39.360	1.00	12.22
ATOM	2777	OD1	ASN	D	21	45.002	28.023	38.669	1.00	15.31
ATOM	2778	ND2	ASN	D	21	45.313	29.122	40.545	1.00	14.81
ATOM	2779	N	LEU	D	22	40.364	30.201	38.493	1.00	15.62
ATOM	2780	CA	LEU	D	22	39.069	30.126	39.157	1.00	15.32
ATOM	2781	C	LEU	D	22	38.172	29.811	38.319	1.00	15.81
ATOM	2782	O	LEU	D	22	38.337	29.289	37.109	1.00	18.22
ATOM	2783	CB	LEU	D	22	39.470	31.498	39.326	1.00	11.04
ATOM	2784	CG	LEU	D	22	39.203	32.454	40.210	1.00	10.12
ATOM	2785	CD1	LEU	D	22	38.580	33.801	40.004	1.00	11.85
ATOM	2786	CD2	LEU	D	22	39.108	32.071	41.671	1.00	10.74
ATOM	2787	N	PRO	D	23	37.246	28.422	38.825	1.00	16.11
ATOM	2788	CA	PRO	D	23	36.365	27.588	38.004	1.00	15.30
ATOM	2789	C	PRO	D	23	35.533	28.456	37.064	1.00	16.55
ATOM	2790	O	PRO	D	23	35.044	29.485	37.502	1.00	18.78
ATOM	2791	CB	PRO	D	23	35.474	26.944	39.027	1.00	14.03
ATOM	2792	CG	PRO	D	23	36.252	27.043	40.317	1.00	16.24
ATOM	2793	CD	PRO	D	23	36.854	28.409	40.108	1.00	15.04
ATOM	2794	N	LYS	D	24	35.319	28.105	37.785	1.00	19.22
ATOM	2795	CA	LYS	D	24	33.492	28.864	34.822	1.00	19.57
ATOM	2796	C	LYS	D	24	33.027	28.975	35.241	1.00	18.94
ATOM	2797	O	LYS	D	24	32.381	29.956	34.910	1.00	22.65
ATOM	2798	CB	LYS	D	24	34.575	28.214	33.425	1.00	20.25
ATOM	2799	CG	LYS	D	24	35.853	28.425	32.655	1.00	19.83
ATOM	2800	CD	LYS	D	24	36.049	27.261	31.683	1.00	20.33
ATOM	2801	CE	LYS	D	24	37.542	27.297	31.291	1.00	25.04
ATOM	2802	NZ	LYS	D	24	38.019	26.084	30.623	1.00	27.36
ATOM	2803	N	ASP	D	25	32.490	28.011	36.007	1.00	20.97
ATOM	2804	CA	ASP	D	25	31.146	27.984	36.585	1.00	22.24
ATOM	2805	C	ASP	D	25	31.084	28.420	36.937	1.00	20.26
ATOM	2806	O	ASP	D	25	30.092	27.177	38.714	1.00	24.64
ATOM	2807	CB	ASP	D	25	31.274	25.505	36.502	1.00	21.95
ATOM	2808	CG	ASP	D	25	31.274	25.505	37.333	1.00	26.54
ATOM	2809	OD1	ASP	D	25	32.429	25.721	37.693	1.00	28.24
ATOM	2810	OD2	ASP	D	25	30.697	24.445	37.616	1.00	29.75
ATOM	2811	N	TYR	D	26	32.109	29.038	38.591	1.00	19.65
ATOM	2812	CA	TYR	D	26	31.978	29.716	39.865	1.00	19.99
ATOM	2813	C	TYR	D	26	31.327	31.078	39.666	1.00	20.55
ATOM	2814	O	TYR	D	26	31.837	31.882	38.892	1.00	23.24
ATOM	2815	CB	TYR	D	26	33.388	29.886	40.446	1.00	18.93
ATOM	2816	CG	TYR	D	26	33.487	30.459	41.844	1.00	18.33
ATOM	2817	CD1	TYR	D	26	32.718	29.938	42.855	1.00	17.78
ATOM	2818	CD2	TYR	D	26	34.309	31.538	42.777	1.00	19.75
ATOM	2819	CE1	TYR	D	26	32.689	30.577	44.078	1.00	17.10
ATOM	2820	CE2	TYR	D	26	33.404	32.124	43.291	1.00	21.03
ATOM	2821	CZ	TYR	D	26	33.494	31.613	44.276	1.00	19.84
ATOM	2822	OH	TYR	D	26	33.553	32.163	45.538	1.00	26.79
HETATM	2823	N	MSE	D	27	30.240	31.351	40.390	1.00	20.11
HETATM	2824	CA	MSE	D	27	29.563	32.640	40.409	1.00	19.68
HETATM	2825	C	MSE	D	27	29.972	33.547	41.554	1.00	19.24
HETATM	2826	O	MSE	D	27	29.844	32.217	42.722	1.00	18.84
HETATM	2827	CB	MSE	D	27	28.030	33.478	40.470	1.00	25.00

HETATM	2828	CG	MSE	D	27	27.356	31.633	39.361	1.00	27.34	
HETATM	2829	SE	MSE	D	27	28.005	31.953	37.549	1.00	33.76	SE
HETATM	2830	CE	MSE	D	27	27.146	33.538	37.334	1.00	29.16	
ATOM	2831	N	ILE	D	28	30.503	34.700	41.191	1.00	18.26	C
ATOM	2832	CA	ILE	D	28	30.838	35.733	42.127	1.00	18.98	C
ATOM	2833	C	ILE	D	28	29.668	36.703	42.239	1.00	19.61	C
ATOM	2834	O	ILE	D	28	29.151	37.088	41.196	1.00	22.18	O
ATOM	2835	CB	ILE	D	28	32.136	36.421	41.662	1.00	15.61	C
ATOM	2836	CG1	ILE	D	28	33.234	35.398	41.469	1.00	12.73	C
ATOM	2837	CG2	ILE	D	28	32.593	37.471	42.693	1.00	15.00	C
ATOM	2838	CD1	ILE	D	28	34.487	35.969	40.818	1.00	10.07	C
ATOM	2839	N	THR	D	29	29.199	37.103	43.433	1.00	20.30	N
ATOM	2840	CA	THR	D	29	28.142	38.118	43.587	1.00	18.55	C
ATOM	2841	C	THR	D	29	28.720	39.514	43.593	1.00	18.51	C
ATOM	2842	O	THR	D	29	29.681	39.757	44.305	1.00	20.24	O
ATOM	2843	CB	THR	D	29	27.248	37.915	44.853	1.00	18.42	C
ATOM	2844	CG1	THR	D	29	26.791	36.570	44.817	1.00	20.41	C
ATOM	2845	CG2	THR	D	29	25.982	38.747	44.836	1.00	16.39	C
ATOM	2846	N	LEU	D	30	28.205	40.455	42.785	1.00	18.52	C
ATOM	2847	CA	LEU	D	30	28.610	41.845	42.783	1.00	17.78	C
ATOM	2848	C	LEU	D	30	27.305	42.598	42.724	1.00	19.35	C
ATOM	2849	O	LEU	D	30	26.420	42.245	41.946	1.00	19.98	O
ATOM	2850	CB	LEU	D	30	29.390	42.149	41.505	1.00	18.28	C
ATOM	2851	CG	LEU	D	30	29.905	43.557	41.154	1.00	15.52	C
ATOM	2852	CD1	LEU	D	30	30.720	44.170	42.241	1.00	15.62	C
ATOM	2853	CD2	LEU	D	30	30.732	43.522	39.879	1.00	17.11	C
ATOM	2854	N	LYS	D	31	27.150	43.612	40.560	1.00	21.35	C
ATOM	2855	CA	LYS	D	31	26.046	44.522	43.409	1.00	21.35	C
ATOM	2856	C	LYS	D	31	26.413	45.564	42.354	1.00	23.46	C
ATOM	2857	O	LYS	D	31	27.223	46.470	42.561	1.00	23.96	O
ATOM	2858	CB	LYS	D	31	25.702	45.148	44.722	1.00	21.22	C
ATOM	2859	CG	LYS	D	31	25.353	44.109	45.766	1.00	23.53	C
ATOM	2860	CD	LYS	D	31	24.738	44.814	46.976	1.00	28.13	C
ATOM	2861	CE	LYS	D	31	24.583	43.890	48.182	1.00	29.07	C
ATOM	2862	NZ	LYS	D	31	23.982	44.617	49.293	1.00	34.24	C
ATOM	2863	N	TYR	D	32	25.818	45.356	41.172	1.00	25.01	N
ATOM	2864	CA	TYR	D	32	26.219	46.004	39.925	1.00	25.06	C
ATOM	2865	C	TYR	D	32	25.377	47.248	39.752	1.00	26.53	C
ATOM	2866	O	TYR	D	32	24.167	47.293	40.046	1.00	27.71	O
ATOM	2867	CB	TYR	D	32	26.050	44.978	38.752	1.00	27.02	C
ATOM	2868	CG	TYR	D	32	26.196	45.465	37.336			

[illegible]

ATOM	2888	CD	PRO	D	34	22.668	49.494	38.488	1.00	27.97	C	N
ATOM	2889	N	GLY	D	35	23.756	50.780	34.117	1.00	32.89	C	N
ATOM	2890	CA	GLY	D	35	24.265	51.891	33.338	1.00	34.68	C	C
ATOM	2891	C	GLY	D	35	25.749	52.065	33.438	1.00	34.91	N	C
ATOM	2892	O	GLY	D	35	26.271	53.066	32.991	1.00	38.32	C	C
HETATM	2893	N	MSE	D	36	26.456	51.105	33.995	1.00	36.03	O	N
HETATM	2894	CA	MSE	D	36	27.910	51.084	34.060	1.00	38.11	C	C
HETATM	2895	C	MSE	D	36	28.634	51.193	32.726	1.00	38.57	C	C
HETATM	2896	O	MSE	D	36	29.741	51.717	32.594	1.00	39.99	C	C
HETATM	2897	CB	MSE	D	36	28.255	49.744	34.622	1.00	41.60	O	C
HETATM	2898	CG	MSE	D	36	28.972	49.795	35.911	1.00	45.00	C	C
HETATM	2899	SE	MSE	D	36	30.412	48.532	35.745	1.00	54.90	SE	C
HETATM	2900	CE	MSE	D	36	30.966	48.492	35.745	1.00	54.90	C	C
ATOM	2901	N	ASP	D	37	27.256	50.571	31.760	1.00	39.01	C	N
ATOM	2902	CA	ASP	D	37	28.357	50.446	30.370	1.00	37.84	C	C
ATOM	2903	C	ASP	D	37	28.125	51.687	29.525	1.00	37.29	C	C
ATOM	2904	O	ASP	D	37	29.067	52.169	28.896	1.00	40.17	O	C
ATOM	2905	CB	ASP	D	37	27.725	49.194	29.760	1.00	37.35	C	C
ATOM	2906	CG	ASP	D	37	26.258	48.854	30.083	1.00	40.62	C	C
ATOM	2907	OD1	ASP	D	37	25.560	49.672	30.709	1.00	39.43	O	O
ATOM	2908	OD2	ASP	D	37	25.813	47.752	29.705	1.00	41.13	O	O
ATOM	2909	N	VAL	D	38	26.930	52.266	29.525	1.00	36.85	O	N
ATOM	2910	CA	VAL	D	38	26.665	53.462	28.719	1.00	38.43	C	C
ATOM	2911	C	VAL	D	38	27.021	54.828	29.311	1.00	39.02	C	C
ATOM	2912	O	VAL	D	38	27.395	55.748	28.581	1.00	39.83	C	C
ATOM	2913	CB	VAL	D	38	25.212	53.466	28.717	1.00	36.75	C	C
ATOM	2914	CG1	VAL	D	38	25.086	52.227	29.566	1.00	36.24	C	C
ATOM	2915	CG2	VAL	D	38	24.981	53.482	29.175	1.00	36.31	C	C
ATOM	2916	N	LEU	D	39	26.886	54.965	30.641	1.00	39.92	C	N
ATOM	2917	C	LEU	D	39	27.031	56.231	31.341	1.00	38.96	C	C
ATOM	2918	C	LEU	D	39	28.495	56.624	31.625	1.00	41.40	C	C
ATOM	2919	O	LEU	D	39	29.397	55.777	31.589	1.00	40.82	O	C
ATOM	2920	CB	LEU	D	39	26.208	56.247	32.637	1.00	35.81	C	C
ATOM	2921	CG	LEU	D	39	24.706	56.030	32.689	1.00	34.18	C	C
ATOM	2922	CD1	LEU	D	39	24.285	56.206	34.141	1.00	33.76	C	C
ATOM	2923	CD2	LEU	D	39	23.900	56.980	31.827	1.00	31.66	C	C
ATOM	2924	N	PRO	D	40	28.807	57.926	31.852	1.00	44.17	C	N
ATOM	2925	CA	PRO	D	40	30.141	58.383	32.244	1.00	44.74	C	C
ATOM	2926	C	PRO	D	40	30.420	58.032	32.909	1.00	44.47	C	C
ATOM	2927	O	PRO	D	40	29.550	58.003	34.562	1.00	42.05	O	C
ATOM	2928	CB	PRO	D	40	30.115	59.908	32.011	1.00	45.14	C	C
ATOM	2929	CG	PRO	D	40	28.674	60.256	32.263	1.00	45.10	C	C
ATOM	2930	CD	PRO	D	40	27.934	59.092	31.603	1.00	46.22	C	C
ATOM	2931	N	SER	D	41	31.694	57.749	33.906	1.00	42.00	N	C
ATOM	2932	CA	SER	D	41	32.266	57.360	35.166	1.00	49.50	C	C
ATOM	2933	C	SER	D	41	31.724	58.115	36.365	1.00	38.61	C	C
ATOM	2934	O	SER	D	41	31.345	57.439	37.303	1.00	38.99	O	C
ATOM	2935	CB	SER	D	41	33.760	57.491	35.009	1.00	40.43	C	C
ATOM	2936	OG	SER	D	41	34.204	56.814	33.824	1.00	45.16	O	C
ATOM	2937	N	HIS	D	42	31.558	59.442	36.396	1.00	38.17	C	C
ATOM	2938	CA	HIS	D	42	31.010	60.127	37.567	1.00	36.79	C	C
ATOM	2939	C	HIS	D	42	29.633	59.688	38.668	1.00	38.51	C	C
ATOM	2940	O	HIS	D	42	29.219	59.978	39.190	1.00	39.73	O	C
ATOM	2941	CB	HIS	D	42	31.062	61.646	37.328	1.00	36.53	C	C
ATOM	2942	CG	HIS	D	42	29.988	62.146	36.370	1.00	34.40	C	C
ATOM	2943	ND1	HIS	D	42	30.070	62.275	35.063	1.00	35.82	N	C
ATOM	2944	CD2	HIS	D	42	28.694	62.443	36.749	1.00	36.22	C	C
ATOM	2945	CE1	HIS	D	42	28.872	62.607	34.629	1.00	35.92	C	C
ATOM	2946	NE2	HIS	D	42	28.050	62.680	35.644	1.00	37.56	N	C
ATOM	2947	N	CYS	D	43	28.848	58.974	37.261	1.00	40.38	C	C

ATOM	2948	CA	CYS	D	43	27.521	58.516	37.662	1.00	40.95	C
ATOM	2949	C	CYS	D	43	27.545	57.165	38.394	1.00	38.66	C
ATOM	2950	O	CYS	D	43	26.556	56.769	39.027	1.00	38.58	C
ATOM	2951	CB	CYS	D	43	26.561	58.489	36.426	1.00	43.16	C
ATOM	2952	SG	CYS	D	43	25.889	60.126	35.971	1.00	50.07	C
ATOM	2953	N	TRP	D	44	28.677	56.450	38.300	1.00	34.96	N
ATOM	2954	CA	TRP	D	44	28.763	55.094	38.789	1.00	32.27	C
ATOM	2955	C	TRP	D	44	30.055	54.754	39.486	1.00	32.35	C
ATOM	2956	O	TRP	D	44	30.010	53.891	40.349	1.00	34.30	C
ATOM	2957	CB	TRP	D	44	28.502	54.045	37.688	1.00	29.74	C
ATOM	2958	CG	TRP	D	44	29.428	54.039	36.479	1.00	25.62	C
ATOM	2959	CD1	TRP	D	44	29.034	54.685	35.340	1.00	24.56	C
ATOM	2960	CD2	TRP	D	44	30.636	53.392	36.360	1.00	24.29	C
ATOM	2961	NE1	TRP	D	44	30.006	54.462	36.497	1.00	26.97	C
ATOM	2962	CE2	TRP	D	44	30.972	53.705	35.046	1.00	26.16	C
ATOM	2963	CE3	TRP	D	44	31.442	52.536	37.072	1.00	21.05	C
ATOM	2964	CG2	TRP	D	44	32.119	53.210	34.446	1.00	23.57	C
ATOM	2965	CG3	TRP	D	44	32.600	52.058	36.490	1.00	21.72	C
ATOM	2966	CH2	TRP	D	44	32.956	52.395	35.194	1.00	23.72	C
ATOM	2967	N	ILE	D	45	31.191	55.378	39.216	1.00	31.34	N
ATOM	2968	CA	ILE	D	45	32.444	54.851	39.687	1.00	34.23	C
ATOM	2969	C	ILE	D	45	32.627	54.719	41.206	1.00	35.04	C
ATOM	2970	O	ILE	D	45	33.222	53.726	41.618	1.00	36.05	C
ATOM	2971	CB	ILE	D	45	33.586	55.584	38.980	1.00	35.62	C
ATOM	2972	CG1	ILE	D	45	34.959	54.917	39.068	1.00	36.05	C
ATOM	2973	CG2	ILE	D	45	33.716	56.959	39.592	1.00	37.86	C
ATOM	2974	CD1	ILE	D	45	35.020	53.482	38.545	1.00	36.81	C
ATOM	2975	N	SER	D	46	32.160	55.591	39.080	1.00	35.45	C
ATOM	2976	CA	SER	D	46	34.621	55.538	43.500	1.00	35.85	C
ATOM	2977	C	SER	D	46	31.651	54.443	44.213	1.00	35.51	C
ATOM	2978	O	SER	D	46	32.169	53.858	45.165	1.00	38.41	C
ATOM	2979	CB	SER	D	46	32.165	56.852	44.223	1.00	36.96	C
ATOM	2980	OG	SER	D	46	30.786	57.005	44.534	1.00	40.12	C
ATOM	2981	N	GLU	D	47	30.419	54.185	43.770	1.00	33.93	N
ATOM	2982	CA	GLU	D	47	29.656	53.051	44.230	1.00	32.65	C
ATOM	2983	C	GLU	D	47	30.197	51.773	43.648	1.00	31.56	C
ATOM	2984	O	GLU	D	47	30.216	50.761	44.339	1.00	31.25	C
ATOM	2985	CB	GLU	D	47	28.206	53.193	43.842	1.00	36.42	C
ATOM	2986	CG	GLU	D	47	27.306	51.989	44.164	1.00	45.32	C
ATOM	2987	CD	GLU	D	47	27.064	51.710	44.488	1.00	48.38	C
ATOM	2988	CE1	GLU	D	47	27.839	51.323	46.399			

ATOM	3008	O	VAL	D	50	32.438	47.921	47.699	1.00	25.08	C
ATOM	3009	CB	VAL	D	50	31.757	51.172	47.504	1.00	24.15	C
ATOM	3010	CG1	VAL	D	50	30.945	50.583	48.650	1.00	24.85	C
ATOM	3011	CG2	VAL	D	50	32.484	52.411	47.974	1.00	21.01	C
ATOM	3012	N	GLN	D	51	31.343	48.470	45.796	1.00	22.06	C
ATOM	3013	CA	GLN	D	51	30.807	47.154	45.522	1.00	22.13	C
ATOM	3014	C	GLN	D	51	31.810	46.099	45.123	1.00	20.89	C
ATOM	3015	O	GLN	D	51	31.663	44.940	45.479	1.00	21.33	C
ATOM	3016	CB	GLN	D	51	29.719	47.249	44.484	1.00	24.57	C
ATOM	3017	CG	GLN	D	51	28.496	47.999	45.018	1.00	26.12	C
ATOM	3018	CD	GLN	D	51	27.936	46.379	46.304	1.00	26.75	C
ATOM	3019	OE1	GLN	D	51	28.128	46.194	46.061	1.00	25.54	C
ATOM	3020	NE2	GLN	D	51	27.534	48.198	46.086	1.00	26.11	C
ATOM	3021	N	LEU	D	52	32.839	46.544	44.223	1.00	19.69	N
ATOM	3022	CA	LEU	D	52	33.966	45.728	44.057	1.00	20.34	C
ATOM	3023	C	LEU	D	52	34.831	45.383	45.250	1.00	20.47	C
ATOM	3024	O	LEU	D	52	35.199	44.215	45.356	1.00	23.75	C
ATOM	3025	CB	LEU	D	52	34.866	46.398	42.976	1.00	19.72	C
ATOM	3026	CG	LEU	D	52	34.402	46.541	41.509	1.00	18.02	C
ATOM	3027	CD1	LEU	D	52	35.404	47.412	40.807	1.00	14.47	C
ATOM	3028	CD2	LEU	D	52	34.217	45.177	40.844	1.00	14.93	C
ATOM	3029	N	SER	D	53	35.178	46.294	46.165	1.00	21.36	C
ATOM	3030	CA	SER	D	53	35.913	45.942	47.377	1.00	22.45	C
ATOM	3031	C	SER	D	53	35.173	44.873	48.166	1.00	22.70	C
ATOM	3032	O	SER	D	53	35.770	43.895	48.565	1.00	24.55	C
ATOM	3033	CB	SER	D	53	36.117	47.178	48.233	1.00	25.43	C
ATOM	3034	CG	SER	D	53	36.882	46.917	48.310	1.00	30.77	C
ATOM	3035	N	ASP	D	54	33.852	44.962	48.286	1.00	23.74	C
ATOM	3036	CA	ASP	D	54	33.021	44.038	49.030	1.00	25.51	C
ATOM	3037	C	ASP	D	54	33.119	42.633	48.500	1.00	22.56	C
ATOM	3038	O	ASP	D	54	33.390	41.711	49.250	1.00	22.33	C
ATOM	3039	CB	ASP	D	54	31.565	44.500	48.963	1.00	32.00	C
ATOM	3040	CG	ASP	D	54	30.624	43.913	50.019	1.00	42.23	C
ATOM	3041	OD1	ASP	D	54	30.117	42.792	49.841	1.00	45.21	C
ATOM	3042	OD2	ASP	D	54	30.364	44.607	51.018	1.00	49.94	C
ATOM	3043	N	SER	D	55	32.943	42.520	47.192	1.00	19.99	N
ATOM	3044	CA	SER	D	55	32.933	41.258	46.504	1.00	16.42	C
ATOM	3045	C	SER	D	55	34.279	40.596	46.521	1.00	14.71	C
ATOM	3046	O	SER	D	55	34.395	39.393	46.693	1.00	15.83	C
ATOM	3047	CB	SER	D	55	32.503	41.468	45.069	1.00	16.49	C
ATOM	3048	CG	SER	D	55	31.170	41.909	44.886	1.00		

ATOM	3068	CB	ASN	D	58	32.859	38.102	49.791	1.00	21.24	C
ATOM	3069	CG	ASP	D	58	32.043	39.157	50.517	1.00	26.19	C
ATOM	3070	OD1	ASP	D	58	32.458	39.665	51.572	1.00	26.83	C
ATOM	3071	OD2	ASP	D	58	30.970	39.481	49.993	1.00	30.50	O
ATOM	3072	N	LEU	D	59	35.449	37.324	48.197	1.00	19.65	N
ATOM	3073	CA	LEU	D	59	36.099	36.331	47.383	1.00	18.09	C
ATOM	3074	C	LEU	D	59	37.345	35.878	48.090	1.00	19.12	C
ATOM	3075	O	LEU	D	59	37.553	34.694	48.251	1.00	23.04	C
ATOM	3076	CB	LEU	D	59	36.392	36.893	46.028	1.00	16.75	C
ATOM	3077	CG	LEU	D	59	36.808	35.854	45.048	1.00	17.14	C
ATOM	3078	CD1	LEU	D	59	35.714	34.823	44.909	1.00	16.41	C
ATOM	3079	CD2	LEU	D	59	37.209	36.546	43.769	1.00	16.93	C
ATOM	3080	N	LEU	D	60	38.132	36.764	48.267	1.00	21.76	N
ATOM	3081	CA	LEU	D	60	39.173	36.128	44.431	1.00	21.73	C
ATOM	3082	C	LEU	D	60	39.132	35.401	50.564	1.00	24.38	C
ATOM	3083	O	LEU	D	60	40.084	34.626	50.853	1.00	25.12	C
ATOM	3084	CB	LEU	D	60	39.852	37.726	50.017	1.00	21.70	C
ATOM	3085	CG	LEU	D	60	41.196	37.710	50.670	1.00	23.77	C
ATOM	3086	CD1	LEU	D	60	42.256	37.514	49.598	1.00	22.63	C
ATOM	3087	CD2	LEU	D	60	41.446	38.985	51.425	1.00	24.99	C
ATOM	3088	N	ASP	D	61	38.005	35.386	51.224	1.00	26.63	N
ATOM	3089	CA	ASP	D	61	37.705	34.524	52.363	1.00	25.59	C
ATOM	3090	C	ASP	D	61	37.428	33.112	51.872	1.00	22.43	C
ATOM	3091	O	ASP	D	61	37.373	32.161	52.646	1.00	23.39	C
ATOM	3092	CB	ASP	D	61	36.497	35.146	53.120	1.00	33.33	C
ATOM	3093	CG	ASP	D	61	35.889	34.390	54.325	1.00	40.36	C
ATOM	3094	OD1	ASP	D	61	36.478	34.403	54.422	1.00	44.76	C
ATOM	3095	OD2	ASP	D	61	34.807	33.794	54.459	1.00	44.00	C
ATOM	3096	N	LYS	D	62	37.289	32.899	50.575	1.00	17.94	N
ATOM	3097	CA	LYS	D	62	37.048	31.574	50.058	1.00	13.29	C
ATOM	3098	C	LYS	D	62	38.344	30.855	49.757	1.00	12.68	C
ATOM	3099	O	LYS	D	62	38.308	29.692	49.387	1.00	15.69	C
ATOM	3100	CB	LYS	D	62	36.292	31.712	48.771	1.00	13.99	C
ATOM	3101	CG	LYS	D	62	35.036	32.517	48.890	1.00	16.25	C
ATOM	3102	CD	LYS	D	62	34.086	31.871	49.870	1.00	21.21	C
ATOM	3103	CE	LYS	D	62	32.997	32.898	50.166	1.00	23.50	C
ATOM	3104	NZ	LYS	D	62	32.319	33.267	48.937	1.00	30.45	C
ATOM	3105	N	PHE	D	63	39.504	31.504	49.885	1.00	12.18	N
ATOM	3106	CA	PHE	D	63	40.797	30.938	49.594	1.00	13.29	C
ATOM	3107	C	PHE	D	63	41.659	30.965	50.678	1.00	18.67	C
ATOM	3108	O	PHE	D	63	41.401	31.701	51.198			

ATOM	3128	OD1	ASN	D	65	48.695	33.551	51.752	1.00	25.73	O
ATOM	3129	ND2	ASN	D	65	47.621	33.560	53.640	1.00	22.21	N
ATOM	3130	N	ILE	D	66	49.077	29.253	50.672	1.00	15.61	N
ATOM	3131	CA	ILE	D	66	49.778	28.029	50.363	1.00	16.53	C
ATOM	3132	C	ILE	D	66	51.232	28.235	50.711	1.00	16.49	C
ATOM	3133	O	ILE	D	66	51.633	29.383	50.813	1.00	17.79	O
ATOM	3134	CB	ILE	D	66	49.594	27.623	48.869	1.00	16.19	C
ATOM	3135	CG1	ILE	D	66	50.149	28.660	47.906	1.00	16.66	C
ATOM	3136	CG2	ILE	D	66	48.115	27.329	48.611	1.00	12.63	C
ATOM	3137	CD1	ILE	D	66	50.081	28.086	46.478	1.00	18.10	C
ATOM	3138	N	SER	D	67	52.041	27.187	50.853	1.00	18.84	N
ATOM	3139	CA	SER	D	67	53.442	27.347	51.233	1.00	23.17	C
ATOM	3140	C	SER	D	67	54.005	28.078	51.214	1.00	23.34	C
ATOM	3141	O	SER	D	67	55.250	28.779	50.552	1.00	22.92	O
ATOM	3142	CB	SER	D	67	54.084	26.006	51.543	1.00	23.00	C
ATOM	3143	OG	SER	D	67	53.971	25.139	50.419	1.00	30.06	O
ATOM	3144	N	GLU	D	68	53.981	27.968	48.942	1.00	25.32	N
ATOM	3145	CA	GLU	D	68	54.755	28.626	47.914	1.00	27.08	C
ATOM	3146	C	GLU	D	68	54.045	28.401	46.597	1.00	25.08	C
ATOM	3147	O	GLU	D	68	53.391	27.373	46.403	1.00	24.26	O
ATOM	3148	CB	GLU	D	68	56.190	28.061	47.921	1.00	30.32	C
ATOM	3149	CG	GLU	D	68	56.711	27.081	46.883	1.00	40.98	C
ATOM	3150	CD	GLU	D	68	56.009	25.744	46.778	1.00	46.80	C
ATOM	3151	OE1	GLU	D	68	55.947	24.998	47.773	1.00	50.12	O
ATOM	3152	OE2	GLU	D	68	55.508	25.470	45.676	1.00	52.68	O
ATOM	3153	N	GLY	D	69	54.121	29.389	45.723	1.00	23.65	N
ATOM	3154	CA	GLY	D	69	55.784	29.192	44.320	1.00	24.45	C
ATOM	3155	CG	GLY	D	69	52.580	30.012	44.350	1.00	24.05	C
ATOM	3156	O	GLY	D	69	52.270	30.941	44.691	1.00	24.04	O
ATOM	3157	N	LEU	D	70	51.883	29.667	42.870	1.00	22.75	N
ATOM	3158	CA	LEU	D	70	50.768	30.474	42.415	1.00	23.31	C
ATOM	3159	C	LEU	D	70	49.618	30.380	43.412	1.00	21.85	C
ATOM	3160	O	LEU	D	70	49.170	29.262	43.689	1.00	23.27	O
ATOM	3161	CB	LEU	D	70	50.307	29.902	41.114	1.00	22.88	C
ATOM	3162	CG	LEU	D	70	49.652	30.850	40.145	1.00	22.31	C
ATOM	3163	CD1	LEU	D	70	49.073	29.925	39.088	1.00	24.98	C
ATOM	3164	CD2	LEU	D	70	48.576	31.722	40.710	1.00	21.90	C
ATOM	3165	N	SER	D	71	49.143	31.526	43.918	1.00	19.05	N
ATOM	3166	CA	SER	D	71	48.132	31.561	44.977	1.00	16.36	C
ATOM	3167	C	SER	D	71	47.008	32.518	44.667	1.00	15.90	C
ATOM	3168	O	SER	D	71	47.262	33.703	44.350	1.00</		

ATOM	3188	CE2	TYR	D	73	45.663	36.140	51.814	1.00	15.34	C
ATOM	3189	CZ	TYR	D	73	44.430	36.108	52.407	1.00	16.30	C
ATOM	3190	OH	TYR	D	73	44.123	37.051	53.334	1.00	22.01	C
ATOM	3191	N	SER	D	74	46.888	35.357	47.402	1.00	18.57	O
ATOM	3192	CA	SER	D	74	47.786	36.498	47.221	1.00	17.90	C
ATOM	3193	C	SER	D	74	47.420	37.417	46.121	1.00	16.44	C
ATOM	3194	O	SER	D	74	47.636	38.600	46.291	1.00	18.01	C
ATOM	3195	CB	SER	D	74	49.180	36.125	46.829	1.00	18.93	C
ATOM	3196	OG	SER	D	74	49.623	35.176	47.760	1.00	25.77	C
ATOM	3197	N	ILE	D	75	46.890	36.866	45.027	1.00	16.68	N
ATOM	3198	CA	ILE	D	75	46.470	37.645	43.893	1.00	16.88	C
ATOM	3199	C	ILE	D	75	45.256	38.493	44.244	1.00	16.78	C
ATOM	3200	O	ILE	D	75	45.237	39.693	44.204	1.00	20.42	C
ATOM	3201	CB	ILE	D	75	46.184	36.709	42.711	1.00	16.17	C
ATOM	3202	CG1	ILE	D	75	47.380	35.898	42.295	1.00	16.78	C
ATOM	3203	CG2	ILE	D	75	45.861	37.615	41.567	1.00	16.46	C
ATOM	3204	CD1	ILE	D	75	47.146	34.967	41.097	1.00	19.66	C
ATOM	3205	N	ILE	D	76	44.230	37.936	44.901	1.00	18.21	C
ATOM	3206	CA	ILE	D	76	43.023	38.678	45.220	1.00	15.41	C
ATOM	3207	C	ILE	D	76	43.340	39.669	46.286	1.00	17.60	C
ATOM	3208	O	ILE	D	76	42.870	40.796	46.215	1.00	20.17	C
ATOM	3209	CB	ILE	D	76	41.941	37.743	45.711	1.00	16.42	C
ATOM	3210	CG1	ILE	D	76	41.615	36.789	44.588	1.00	14.92	C
ATOM	3211	CG2	ILE	D	76	40.696	38.481	46.200	1.00	11.21	C
ATOM	3212	CD1	ILE	D	76	40.745	35.613	45.055	1.00	13.69	C
ATOM	3213	N	ASP	D	77	44.162	39.271	47.248	1.00	19.35	N
ATOM	3214	CA	ASP	D	77	44.561	40.150	42.217	1.00	21.27	C
ATOM	3215	C	ASP	D	77	45.241	41.436	47.858	1.00	22.57	C
ATOM	3216	O	ASP	D	77	44.924	42.515	48.376	1.00	22.07	C
ATOM	3217	CB	ASP	D	77	45.433	39.385	49.282	1.00	24.17	C
ATOM	3218	CG1	ASP	D	77	45.713	40.148	50.571	1.00	28.55	C
ATOM	3219	OD2	ASP	D	77	44.842	40.889	51.067	1.00	33.63	C
ATOM	3220	OD2	ASP	D	77	46.822	39.988	51.073	1.00	28.53	C
ATOM	3221	N	LYS	D	78	46.139	41.344	46.851	1.00	22.27	N
ATOM	3222	CA	LYS	D	78	46.692	42.534	46.222	1.00	21.32	C
ATOM	3223	C	LYS	D	78	45.654	43.318	45.471	1.00	19.56	C
ATOM	3224	O	LYS	D	78	45.786	44.524	45.417	1.00	22.75	C
ATOM	3225	CB	LYS	D	78	47.807	42.270	45.230	1.00	23.87	C
ATOM	3226	CG	LYS	D	78	49.036	41.600	45.795	1.00	30.71	C
ATOM	3227	CD	LYS	D	78	50.269	41.917	46.370	1.00	33.00	C
ATOM	3228	NE	LYS	D	78	55.817	40.799	45.004	1.00	40.	

Figure 8-65

ATOM	3248	O	ASN	D	81	44.334	48.756	48.114	1.00	28.26	O
ATOM	3249	CB	ASN	D	81	45.761	46.180	49.097	1.00	21.14	C
ATOM	3250	CG	ASN	D	81	45.684	45.257	50.278	1.00	23.73	C
ATOM	3251	OD1	ASN	D	81	44.871	45.422	51.175	1.00	31.16	C
ATOM	3252	ND2	ASN	D	81	46.490	44.231	50.357	1.00	25.26	N
ATOM	3253	N	ILE	D	82	44.340	47.414	46.280	1.00	25.02	N
ATOM	3254	CA	ILE	D	82	44.088	48.469	45.268	1.00	25.82	C
ATOM	3255	C	ILE	D	82	42.671	49.103	45.287	1.00	25.89	C
ATOM	3256	O	ILE	D	82	42.512	50.323	45.196	1.00	25.87	O
ATOM	3257	CB	ILE	D	82	44.444	48.002	43.847	1.00	23.39	C
ATOM	3258	CG1	ILE	D	82	45.885	47.557	43.751	1.00	25.26	C
ATOM	3259	CG2	ILE	D	82	44.317	49.150	42.894	1.00	23.94	C
ATOM	3260	CD1	ILE	D	82	46.185	46.717	42.500	1.00	24.24	C
ATOM	3261	N	VAL	D	83	41.595	48.324	45.443	1.00	27.50	N
ATOM	3262	CA	VAL	D	83	40.240	48.859	45.486	1.00	27.69	C
ATOM	3263	C	VAL	D	83	40.017	49.556	46.841	1.00	30.42	C
ATOM	3264	O	VAL	D	83	39.190	50.454	46.938	1.00	29.44	O
ATOM	3265	CB	VAL	D	83	39.230	47.758	45.201	1.00	23.07	C
ATOM	3266	CG1	VAL	D	83	37.910	48.384	44.868	1.00	24.95	C
ATOM	3267	CG2	VAL	D	83	39.634	47.000	43.979	1.00	23.59	C
ATOM	3268	N	ASP	D	84	40.772	49.192	47.892	1.00	32.89	N
ATOM	3269	CA	ASP	D	84	40.753	49.840	49.206	1.00	35.85	C
ATOM	3270	C	ASP	D	84	41.361	51.238	49.084	1.00	35.75	C
ATOM	3271	O	ASP	D	84	40.779	52.212	49.557	1.00	35.62	O
ATOM	3272	CB	ASP	D	84	41.531	49.029	50.294	1.00	39.03	C
ATOM	3273	CG	ASP	D	84	40.827	48.006	51.221	1.00	41.67	C
ATOM	3274	OD1	ASP	D	84	39.593	47.858	51.172	1.00	43.23	C
ATOM	3275	OD2	ASP	D	84	41.536	47.352	52.008	1.00	43.54	O
ATOM	3276	N	ASP	D	85	42.500	51.382	48.417	1.00	35.24	N
ATOM	3277	CA	ASP	D	85	43.039	52.689	48.095	1.00	39.54	C
ATOM	3278	C	ASP	D	85	42.055	53.620	47.372	1.00	40.48	C
ATOM	3279	O	ASP	D	85	41.712	54.706	47.853	1.00	42.05	O
ATOM	3280	CB	ASP	D	85	44.343	52.540	47.287	1.00	41.18	C
ATOM	3281	CG	ASP	D	85	45.534	51.871	48.001	1.00	43.42	C
ATOM	3282	OD1	ASP	D	85	45.537	51.723	49.243	1.00	41.35	O
ATOM	3283	OD2	ASP	D	85	46.465	51.488	47.276	1.00	42.78	C
ATOM	3284	N	LEU	D	86	41.518	53.157	46.238	1.00	41.90	N
ATOM	3285	CA	LEU	D	86	40.526	53.903	45.456	1.00	39.57	C
ATOM	3286	C	LEU	D	86	39.249	54.172	46.203	1.00	38.81	C
ATOM	3287	O	LEU	D	86	38.614	55.176	45.924	1.00	40.16	O
ATOM	3288	CB	LEU	D	86	40.142	53.164	44.191	1.00	36.00	C
ATOM	3289	CG	LEU	D	86	41.234	52.732	43.251	1.00	34.91	C
ATOM	3290	CD1	LEU	D	86	40.618	52.075	42.047	1.00	33.95	C
ATOM	3291	CD2	LEU	D	86	42.096	53.907	42.858	1.00	32.40	C
ATOM	3292	N	VAL	D	87	38.840	53.303	47.125	1.00	40.82	N
ATOM	3293	CA	VAL	D	87	37.680	53.589	47.958	1.00	44.87	C
ATOM	3294	C	VAL	D	87	37.965	54.754	48.933	1.00	47.95	C
ATOM	3295	O	VAL	D	87	37.085	55.580	49.176	1.00	49.04	O
ATOM	3296	CB	VAL	D	87	37.191	52.311	48.682	1.00	42.48	C
ATOM	3297	CG1	VAL	D	87	36.094	52.685	49.647	1.00	43.30	C
ATOM	3298	CG2	VAL	D	87	36.572	51.285	47.749	1.00	39.59	C
ATOM	3299	N	GLU	D	88	39.185	54.862	49.472	1.00	51.32	N
ATOM	3300	CA	GLU	D	88	39.548	55.935	50.387	1.00	55.88	C
ATOM	3301	C	GLU	D	88	39.807	57.235	49.672	1.00	57.32	C
ATOM	3302	O	GLU	D	88	39.717	58.303	50.291	1.00	59.78	O
ATOM	3303	CB	GLU	D	88	40.786	55.627	51.225	1.00	57.84	C
ATOM	3304	CG	GLU	D	88	40.534	54.935	52.572	1.00	61.46	C
ATOM	3305	CD	GLU	D	88	41.737	54.106	53.056	1.00	65.66	C
ATOM	3306	OE1	GLU	D	88	42.872	54.610	53.000	1.00	65.91	O
ATOM	3307	OE2	GLU	D	88	41.543	52.947	53.479	1.00	68.20	O

Figure 8-66

ATOM	3308	N	CYS	D	89	40.147	57.130	48.382	1.00	57.61	N
ATOM	3309	CA	CYS	D	89	40.273	58.307	47.528	1.00	58.46	C
ATOM	3310	C	CYS	D	89	38.895	58.970	47.344	1.00	58.39	C
ATOM	3311	O	CYS	D	89	38.791	60.197	47.378	1.00	58.21	O
ATOM	3312	CB	CYS	D	89	40.931	57.880	46.221	1.00	57.54	C
ATOM	3313	SG	CYS	D	89	41.341	59.181	45.038	1.00	58.90	S
ATOM	3314	N	VAL	D	90	37.809	58.179	47.271	1.00	58.70	N
ATOM	3315	CA	VAL	D	90	36.453	58.684	47.150	1.00	59.63	C
ATOM	3316	C	VAL	D	90	35.871	59.220	48.484	1.00	61.73	C
ATOM	3317	O	VAL	D	90	34.680	59.004	48.763	1.00	62.80	O
ATOM	3318	CB	VAL	D	90	35.602	57.544	46.539	1.00	58.55	C
ATOM	3319	N	SER	D	104	20.665	52.244	45.909	1.00	56.19	N
ATOM	3320	CA	SER	D	104	21.629	51.156	45.958	1.00	53.75	C
ATOM	3321	C	SER	D	104	21.476	50.204	44.750	1.00	51.69	C
ATOM	3322	O	SER	D	104	20.519	50.365	43.954	1.00	53.93	O
ATOM	3323	CB	SER	D	104	21.454	50.421	47.297	1.00	55.38	C
ATOM	3324	OG	SER	D	104	22.506	49.503	47.610	1.00	56.37	O
ATOM	3325	N	PRO	D	105	22.446	49.277	44.526	1.00	45.68	N
ATOM	3326	CA	PRO	D	105	22.366	48.292	43.470	1.00	41.30	C
ATOM	3327	C	PRO	D	105	22.138	46.887	43.955	1.00	37.99	C
ATOM	3328	O	PRO	D	105	22.529	46.478	45.049	1.00	38.93	O
ATOM	3329	CB	PRO	D	105	23.661	48.481	42.741	1.00	40.55	C
ATOM	3330	CG	PRO	D	105	24.631	48.664	43.862	1.00	42.00	C
ATOM	3331	CD	PRO	D	105	23.856	49.476	44.863	1.00	42.72	C
ATOM	3332	N	GLU	D	106	21.459	46.177	43.075	1.00	33.70	N
ATOM	3333	CA	GLU	D	106	20.971	44.880	43.417	1.00	32.02	C
ATOM	3334	C	GLU	D	106	21.976	43.812	43.085	1.00	32.36	C
ATOM	3335	O	GLU	D	106	22.715	43.942	42.111	1.00	32.37	O
ATOM	3336	CB	GLU	D	106	19.734	44.553	42.624	1.00	32.57	C
ATOM	3337	N	PRO	D	107	22.006	42.732	43.886	1.00	32.45	N
ATOM	3338	CA	PRO	D	107	22.855	41.549	43.686	1.00	31.86	C
ATOM	3339	C	PRO	D	107	22.724	40.845	42.340	1.00	29.45	C
ATOM	3340	O	PRO	D	107	21.623	40.491	41.911	1.00	29.62	O
ATOM	3341	CB	PRO	D	107	22.403	40.614	44.801	1.00	32.83	C
ATOM	3342	CG	PRO	D	107	22.040	41.574	45.904	1.00	34.59	C
ATOM	3343	CD	PRO	D	107	21.299	42.658	45.165	1.00	31.98	C
ATOM	3344	N	ARG	D	108	23.893	40.580	41.745	1.00	27.04	N
ATOM	3345	CA	ARG	D	108	23.966	39.882	40.479	1.00	24.37	C
ATOM	3346	C	ARG	D	108	25.090	38.834	40.442	1.00	22.83	C
ATOM	3347	O	ARG	D	108	26.084	39.002	41.124	1.00	21.26	O
ATOM	3348	CB	ARG	D	108	24.090	40.981	39.431	1.00	27.20	C
ATOM	3349	CG	ARG	D	108	23.924	40.490	38.015	1.00	32.52	C
ATOM	3350	CD	ARG	D	108	23.488	41.587	37.061	1.00	35.27	C
ATOM	3351	NE	ARG	D	108	23.846	41.160	35.712	1.00	38.19	N
ATOM	3352	CZ	ARG	D	108	23.536	41.872	34.627	1.00	38.97	C
ATOM	3353	NH1	ARG	D	108	22.798	43.008	34.720	1.00	34.64	N
ATOM	3354	NH2	ARG	D	108	23.995	41.398	33.454	1.00	39.61	C
ATOM	3355	N	LEU	D	109	24.984	37.734	39.681	1.00	21.95	N
ATOM	3356	CA	LEU	D	109	25.996	36.697	39.565	1.00	20.44	C
ATOM	3357	C	LEU	D	109	26.760	36.756	38.265	1.00	18.72	C
ATOM	3358	O	LEU	D	109	26.191	36.725	37.175	1.00	19.50	O
ATOM	3359	CB	LEU	D	109	25.392	35.304	39.657	1.00	21.02	C
ATOM	3360	CG	LEU	D	109	24.434	34.885	40.779	1.00	23.43	C
ATOM	3361	CD1	LEU	D	109	24.170	33.404	40.648	1.00	24.08	C
ATOM	3362	CD2	LEU	D	109	24.939	35.187	42.193	1.00	25.25	C
ATOM	3363	N	PHE	D	110	28.080	36.753	38.437	1.00	17.94	N
ATOM	3364	CA	PHE	D	110	29.031	36.804	37.333	1.00	17.25	C
ATOM	3365	C	PHE	D	110	30.013	35.649	37.346	1.00	16.87	C
ATOM	3366	O	PHE	D	110	30.417	35.198	38.404	1.00	19.49	O
ATOM	3367	CB	PHE	D	110	29.848	38.070	37.366	1.00	16.08	C

Figure 8-67

ATOM	3368	CG	PHE	D	110	28.993	39.305	37.265	1.00	18.38	C
ATOM	3369	CD1	PHE	D	110	28.573	39.743	36.029	1.00	19.11	C
ATOM	3370	CD2	PHE	D	110	28.633	39.977	38.408	1.00	16.78	C
ATOM	3371	CE1	PHE	D	110	27.802	40.874	35.946	1.00	16.73	C
ATOM	3372	CE2	PHE	D	110	27.850	41.103	38.321	1.00	18.17	C
ATOM	3373	CZ	PHE	D	110	27.445	41.553	37.081	1.00	21.53	C
ATOM	3374	N	THR	D	111	30.425	35.107	36.216	1.00	15.24	N
ATOM	3375	CA	THR	D	111	31.539	34.192	36.176	1.00	14.72	C
ATOM	3376	C	THR	D	111	32.811	34.994	36.443	1.00	12.40	C
ATOM	3377	O	THR	D	111	32.752	36.218	36.400	1.00	13.27	O
ATOM	3378	CB	THR	D	111	31.579	33.435	34.828	1.00	17.12	C
ATOM	3379	OG1	THR	D	111	31.630	34.415	33.809	1.00	17.68	O
ATOM	3380	CG2	THR	D	111	30.451	32.446	34.621	1.00	14.81	C
ATOM	3381	N	PRO	D	112	33.974	34.412	36.757	1.00	12.31	N
ATOM	3382	CA	PRO	D	112	35.219	35.126	36.935	1.00	11.10	C
ATOM	3383	C	PRO	D	112	35.594	36.046	35.783	1.00	14.02	C
ATOM	3384	O	PRO	D	112	35.884	37.215	36.011	1.00	13.17	O
ATOM	3385	CB	PRO	D	112	36.189	33.965	37.074	1.00	9.39	C
ATOM	3386	CG	PRO	D	112	35.413	32.952	37.854	1.00	7.72	C
ATOM	3387	CD	PRO	D	112	34.151	32.972	37.061	1.00	11.01	C
ATOM	3388	N	GLU	D	113	35.611	35.572	34.517	1.00	16.22	N
ATOM	3389	CA	GLU	D	113	35.905	36.456	33.395	1.00	16.17	C
ATOM	3390	C	GLU	D	113	35.026	37.679	33.272	1.00	13.99	C
ATOM	3391	O	GLU	D	113	35.508	38.761	32.985	1.00	15.09	O
ATOM	3392	CB	GLU	D	113	35.913	35.703	32.092	1.00	17.91	C
ATOM	3393	CG	GLU	D	113	34.636	34.985	31.713	1.00	19.43	C
ATOM	3394	CD	GLU	D	113	34.621	34.539	30.277	1.00	22.34	C
ATOM	3395	OE1	GLU	D	113	35.652	34.599	29.608	1.00	23.91	O
ATOM	3396	OE2	GLU	D	113	33.558	34.139	29.810	1.00	24.64	O
ATOM	3397	N	GLU	D	114	33.747	37.539	33.559	1.00	14.85	N
ATOM	3398	CA	GLU	D	114	32.837	38.649	33.596	1.00	15.81	C
ATOM	3399	C	GLU	D	114	33.063	39.567	34.769	1.00	15.50	C
ATOM	3400	O	GLU	D	114	33.085	40.783	34.557	1.00	15.87	O
ATOM	3401	CB	GLU	D	114	31.402	38.208	33.707	1.00	19.13	C
ATOM	3402	CG	GLU	D	114	30.883	37.422	32.539	1.00	21.49	C
ATOM	3403	CD	GLU	D	114	29.605	36.642	32.816	1.00	24.09	C
ATOM	3404	OE1	GLU	D	114	29.017	36.697	33.897	1.00	26.51	O
ATOM	3405	OE2	GLU	D	114	29.185	35.937	31.907	1.00	29.29	O
ATOM	3406	N	PHE	D	115	33.204	39.041	35.990	1.00	13.99	N
ATOM	3407	CA	PHE	D	115	33.464	39.892	37.125	1.00	12.83	C
ATOM	3408	C	PHE	D	115	34.753	40.667	36.905	1.00	13.21	C
ATOM	3409	O	PHE	D	115	34.827	41.855	37.193	1.00	14.99	O
ATOM	3410	CB	PHE	D	115	33.650	39.018	38.359	1.00	10.89	C
ATOM	3411	CG	PHE	D	115	33.982	39.867	39.569	1.00	11.83	C
ATOM	3412	CD1	PHE	D	115	32.951	40.361	40.344	1.00	12.60	C
ATOM	3413	CD2	PHE	D	115	35.296	40.133	39.917	1.00	14.96	C
ATOM	3414	CE1	PHE	D	115	33.251	41.093	41.480	1.00	12.59	C
ATOM	3415	CE2	PHE	D	115	35.605	40.892	41.033	1.00	13.04	C
ATOM	3416	CZ	PHE	D	115	34.560	41.373	41.810	1.00	14.57	C
ATOM	3417	N	PHE	D	116	35.833	40.025	36.477	1.00	15.07	N
ATOM	3418	CA	PHE	D	116	37.102	40.718	36.297	1.00	13.94	C
ATOM	3419	C	PHE	D	116	37.181	41.563	35.036	1.00	15.79	C
ATOM	3420	O	PHE	D	116	38.014	42.455	34.965	1.00	16.79	O
ATOM	3421	CB	PHE	D	116	38.273	39.775	36.373	1.00	13.55	C
ATOM	3422	CG	PHE	D	116	38.548	39.261	37.759	1.00	10.27	C
ATOM	3423	CD1	PHE	D	116	39.105	40.100	38.692	1.00	12.82	C
ATOM	3424	CD2	PHE	D	116	38.143	37.990	38.132	1.00	11.47	C
ATOM	3425	CE1	PHE	D	116	39.169	39.689	40.025	1.00	14.46	C
ATOM	3426	CE2	PHE	D	116	38.216	37.584	39.457	1.00	10.67	C
ATOM	3427	CZ	PHE	D	116	38.709	38.439	40.407	1.00	11.80	C

00600027 062960

Figure 8-68

ATOM	3428	N	ARG	D	117	36.361	41.405	34.011	1.00	16.57	N
ATOM	3429	CA	ARG	D	117	36.293	42.421	32.990	1.00	20.64	C
ATOM	3430	C	ARG	D	117	35.668	43.700	33.548	1.00	22.51	C
ATOM	3431	O	ARG	D	117	36.089	44.803	33.174	1.00	23.89	O
ATOM	3432	CB	ARG	D	117	35.446	41.879	31.860	1.00	26.52	C
ATOM	3433	CG	ARG	D	117	35.518	42.709	30.599	1.00	31.53	C
ATOM	3434	CD	ARG	D	117	34.496	42.146	29.640	1.00	35.05	C
ATOM	3435	NE	ARG	D	117	34.394	43.021	28.483	1.00	38.58	N
ATOM	3436	CZ	ARG	D	117	33.828	42.656	27.326	1.00	37.56	C
ATOM	3437	NH1	ARG	D	117	33.169	41.506	27.170	1.00	33.95	N
ATOM	3438	NH2	ARG	D	117	34.002	43.473	26.286	1.00	37.95	N
ATOM	3439	N	ILE	D	118	34.656	43.594	34.445	1.00	22.03	N
ATOM	3440	CA	ILE	D	118	34.052	44.753	35.121	1.00	19.63	C
ATOM	3441	C	ILE	D	118	35.047	45.368	36.086	1.00	19.88	C
ATOM	3442	O	ILE	D	118	35.183	46.586	36.085	1.00	23.21	O
ATOM	3443	CB	ILE	D	118	32.781	44.357	35.874	1.00	20.68	C
ATOM	3444	CG1	ILE	D	118	31.691	43.843	34.951	1.00	19.48	C
ATOM	3445	CG2	ILE	D	118	32.255	45.562	36.619	1.00	20.52	C
ATOM	3446	CD1	ILE	D	118	30.567	43.143	35.727	1.00	18.63	C
ATOM	3447	N	PHE	D	119	35.741	44.577	36.908	1.00	16.07	N
ATOM	3448	CA	PHE	D	119	36.853	45.059	37.683	1.00	15.72	C
ATOM	3449	C	PHE	D	119	37.853	45.894	36.880	1.00	17.75	C
ATOM	3450	O	PHE	D	119	38.208	47.006	37.267	1.00	20.22	O
ATOM	3451	CB	PHE	D	119	37.545	43.866	38.359	1.00	12.02	C
ATOM	3452	CG	PHE	D	119	38.822	44.222	39.100	1.00	13.89	C
ATOM	3453	CD1	PHE	D	119	38.760	44.766	40.389	1.00	14.47	C
ATOM	3454	CD2	PHE	D	119	40.057	44.030	38.492	1.00	10.48	C
ATOM	3455	CE1	PHE	D	119	39.944	45.148	41.032	1.00	13.14	C
ATOM	3456	CE2	PHE	D	119	41.219	44.387	39.149	1.00	10.95	C
ATOM	3457	CZ	PHE	D	119	41.163	44.965	40.405	1.00	10.47	C
ATOM	3458	N	ASN	D	120	38.349	45.343	35.779	1.00	18.18	N
ATOM	3459	CA	ASN	D	120	39.325	45.994	34.955	1.00	18.15	C
ATOM	3460	C	ASN	D	120	38.709	47.263	34.387	1.00	20.79	C
ATOM	3461	O	ASN	D	120	39.348	48.303	34.408	1.00	22.36	O
ATOM	3462	CB	ASN	D	120	39.805	45.078	33.812	1.00	18.05	C
ATOM	3463	CG	ASN	D	120	40.849	44.026	34.137	1.00	17.71	C
ATOM	3464	OD1	ASN	D	120	41.770	44.210	34.918	1.00	21.36	O
ATOM	3465	ND2	ASN	D	120	40.765	42.860	33.538	1.00	17.03	N
ATOM	3466	N	ARG	D	121	37.463	47.256	33.941	1.00	22.71	N
ATOM	3467	CA	ARG	D	121	36.824	48.438	33.431	1.00	24.59	C
ATOM	3468	C	ARG	D	121	36.703	49.523	34.494	1.00	27.41	C
ATOM	3469	O	ARG	D	121	36.971	50.683	34.192	1.00	30.49	O
ATOM	3470	CB	ARG	D	121	35.468	47.993	32.953	1.00	26.42	C
ATOM	3471	CG	ARG	D	121	34.608	49.156	32.549	1.00	33.46	C
ATOM	3472	CD	ARG	D	121	34.760	49.641	31.105	1.00	37.32	C
ATOM	3473	NE	ARG	D	121	34.149	50.962	30.882	1.00	39.99	N
ATOM	3474	CZ	ARG	D	121	32.836	51.217	31.020	1.00	39.01	C
ATOM	3475	NH1	ARG	D	121	31.955	50.306	31.426	1.00	37.27	N
ATOM	3476	NH2	ARG	D	121	32.392	52.439	30.747	1.00	40.47	N
ATOM	3477	N	SER	D	122	36.364	49.186	35.754	1.00	28.07	N
ATOM	3478	CA	SER	D	122	36.147	50.153	36.820	1.00	24.66	C
ATOM	3479	C	SER	D	122	37.455	50.758	37.250	1.00	25.38	C
ATOM	3480	O	SER	D	122	37.536	51.971	37.401	1.00	24.85	O
ATOM	3481	CB	SER	D	122	35.452	49.505	37.983	1.00	20.76	C
ATOM	3482	OG	SER	D	122	34.236	48.886	37.591	1.00	19.10	O
ATOM	3483	N	ILE	D	123	38.513	49.954	37.389	1.00	28.58	N
ATOM	3484	CA	ILE	D	123	39.853	50.468	37.718	1.00	31.03	C
ATOM	3485	C	ILE	D	123	40.396	51.464	36.684	1.00	33.54	C
ATOM	3486	O	ILE	D	123	40.998	52.471	37.040	1.00	33.54	O
ATOM	3487	CB	ILE	D	123	40.821	49.267	38.041	1.00	31.69	C

Figure 8-69

ATOM	3488	CG1	ILE	D	123	40.899	48.877	39.544	1.00	30.91	C
ATOM	3489	CG2	ILE	D	123	42.262	49.504	37.583	1.00	31.27	C
ATOM	3490	CD1	ILE	D	123	39.609	48.826	40.377	1.00	31.19	C
ATOM	3491	N	ASP	D	124	40.123	51.244	35.395	1.00	36.80	N
ATOM	3492	CA	ASP	D	124	40.562	52.125	34.333	1.00	38.72	C
ATOM	3493	C	ASP	D	124	39.846	53.455	34.353	1.00	39.18	C
ATOM	3494	O	ASP	D	124	40.487	54.491	34.186	1.00	39.94	O
ATOM	3495	CB	ASP	D	124	40.383	51.461	32.981	1.00	42.55	C
ATOM	3496	CG	ASP	D	124	40.847	52.342	31.828	1.00	47.69	C
ATOM	3497	OD1	ASP	D	124	42.058	52.554	31.646	1.00	50.62	O
ATOM	3498	OD2	ASP	D	124	39.972	52.837	31.116	1.00	51.18	O
ATOM	3499	N	ALA	D	125	38.538	53.440	34.590	1.00	39.43	N
ATOM	3500	CA	ALA	D	125	37.731	54.649	34.586	1.00	41.04	C
ATOM	3501	C	ALA	D	125	38.028	55.640	35.712	1.00	44.24	C
ATOM	3502	O	ALA	D	125	37.580	56.792	35.729	1.00	46.63	O
ATOM	3503	CB	ALA	D	125	36.289	54.232	34.688	1.00	37.89	C
ATOM	3504	N	PHE	D	126	38.795	55.189	36.693	1.00	47.55	N
ATOM	3505	CA	PHE	D	126	39.342	56.063	37.709	1.00	52.08	C
ATOM	3506	C	PHE	D	126	40.409	57.058	37.208	1.00	55.06	C
ATOM	3507	O	PHE	D	126	40.531	58.167	37.752	1.00	57.33	O
ATOM	3508	CB	PHE	D	126	39.877	55.182	38.838	1.00	51.90	C
ATOM	3509	CG	PHE	D	126	39.154	55.489	40.124	1.00	50.92	C
ATOM	3510	CD1	PHE	D	126	39.155	56.780	40.620	1.00	52.88	C
ATOM	3511	CD2	PHE	D	126	38.437	54.505	40.745	1.00	50.11	C
ATOM	3512	CE1	PHE	D	126	38.390	57.105	41.721	1.00	54.34	C
ATOM	3513	CE2	PHE	D	126	37.688	54.827	41.851	1.00	52.08	C
ATOM	3514	CZ	PHE	D	126	37.653	56.117	42.336	1.00	53.64	C
ATOM	3515	N	LYS	D	127	41.187	56.667	36.177	1.00	56.75	N
ATOM	3516	CA	LYS	D	127	42.055	57.566	35.420	1.00	57.29	C
ATOM	3517	C	LYS	D	127	41.257	58.229	34.273	1.00	58.91	C
ATOM	3518	O	LYS	D	127	41.376	57.826	33.098	1.00	60.03	O
ATOM	3519	CB	LYS	D	127	43.225	56.735	34.882	1.00	56.61	C
TER	3521		LYS	D	127						
HETATM	3522	CA	CA		1021	34.563	32.796	27.927	1.00	28.47	CA
HETATM	3523	CA	CA		1022	29.874	41.216	51.866	1.00	42.93	CA
HETATM	3524	CA	CA		1023	46.453	8.630	31.415	1.00	34.99	CA
HETATM	3525	OH2	1PE		1	18.016	39.096	31.870	1.00	54.04	O
HETATM	3526	C12	1PE		1	19.233	39.467	31.241	1.00	52.50	C
HETATM	3527	C22	1PE		1	20.344	39.764	32.285	1.00	52.87	C
HETATM	3528	OH3	1PE		1	21.455	40.455	31.657	1.00	50.81	O
HETATM	3529	C13	1PE		1	21.887	42.392	30.182	1.00	41.29	C
HETATM	3530	C23	1PE		1	20.971	41.737	31.213	1.00	45.45	O
HETATM	3531	OH4	1PE		1	23.085	42.870	30.757	1.00	37.80	O
HETATM	3532	C14	1PE		1	24.265	44.731	31.534	1.00	39.00	C
HETATM	3533	C24	1PE		1	22.866	44.120	31.391	1.00	35.49	C
HETATM	3534	OH5	1PE		1	25.158	43.676	31.917	1.00	39.07	O
HETATM	3535	C15	1PE		1	27.396	42.942	31.976	1.00	36.51	C
HETATM	3536	C25	1PE		1	26.476	44.138	32.222	1.00	37.63	C
HETATM	3537	OH6	1PE		1	26.797	41.817	32.602	1.00	37.94	O
HETATM	3538	C16	1PE		1	28.795	40.537	32.878	1.00	44.86	C
HETATM	3539	C26	1PE		1	27.405	40.589	32.251	1.00	38.90	C
HETATM	3540	OH7	1PE		1	29.817	40.999	31.987	1.00	53.59	O
HETATM	3541	O	HOH		1024	36.890	32.430	27.721	1.00	24.58	O
HETATM	3542	O	HOH		1025	35.049	30.934	29.322	1.00	27.97	O
HETATM	3543	O	HOH		1026	31.347	42.865	52.839	1.00	31.45	O
HETATM	3544	O	HOH		1027	44.819	10.251	32.056	1.00	31.08	O
HETATM	3545	O	HOH		1028	47.508	7.695	33.365	1.00	35.15	O
HETATM	3546	O	HOH		1029	48.695	9.256	30.957	1.00	29.22	O
HETATM	3547	O	HOH		1105	33.704	13.935	20.986	1.00	32.21	O
HETATM	3548	O	HOH		1106	22.707	17.800	13.006	1.00	51.74	O

00600027.006000

Figure 8-70

HETATM	3549	O	HON	1107	25.589	22.952	23.058	1.00	38.86	O
HETATM	3550	O	HON	1108	20.410	17.104	15.266	1.00	29.07	O
HETATM	3551	O	HON	1109	26.763	8.355	29.315	1.00	19.21	O
HETATM	3552	O	HON	1110	25.744	13.365	30.461	1.00	32.06	O
HETATM	3553	O	HON	1111	27.532	6.721	32.848	1.00	38.65	O
HETATM	3554	O	HON	1112	18.245	18.266	16.629	1.00	28.39	O
HETATM	3555	O	HON	1113	23.260	14.366	29.164	1.00	21.00	O
HETATM	3556	O	HON	1114	15.116	22.225	22.815	1.00	19.32	O
HETATM	3557	O	HON	1115	15.033	21.355	35.696	1.00	38.95	O
HETATM	3558	O	HON	1116	20.651	6.306	35.427	1.00	25.08	O
HETATM	3559	O	HON	1117	15.267	18.912	37.475	1.00	41.62	O
HETATM	3560	O	HON	1118	13.693	14.872	13.312	1.00	29.91	O
HETATM	3561	O	HON	1119	10.257	20.340	28.411	1.00	19.75	O
HETATM	3562	O	HON	1120	9.1034	9.246	35.269	1.00	32.81	O
HETATM	3563	O	HON	1121	6.051	17.933	33.202	1.00	21.61	O
HETATM	3564	O	HON	1122	4.997	14.576	24.993	1.00	33.94	O
HETATM	3565	O	HON	1123	0.916	19.643	30.618	1.00	37.91	O
HETATM	3566	O	HON	1124	5.906	11.136	30.408	1.00	46.39	O
HETATM	3567	O	HON	1125	6.559	5.604	30.508	1.00	37.39	O
HETATM	3568	O	HON	1126	8.033	4.439	28.006	1.00	43.67	O
HETATM	3569	O	HON	1127	5.753	3.756	33.445	1.00	43.48	O
HETATM	3570	O	HON	1128	44.059	26.360	36.277	1.00	22.42	O
HETATM	3571	O	HON	1129	34.421	31.639	20.635	1.00	57.58	O
HETATM	3572	O	HON	1130	50.215	13.426	34.211	1.00	31.74	O
HETATM	3573	O	HON	1132	22.455	45.496	39.519	1.00	46.16	O
HETATM	3574	O	HON	1133	13.246	35.686	8.764	1.00	63.66	O
HETATM	3575	O	HON	1134	34.029	21.538	54.154	1.00	48.71	O
HETATM	3576	O	HON	1135	41.505	41.139	53.266	1.00	25.89	O
HETATM	3577	O	HON	1136	14.868	40.514	8.810	1.00	46.95	O
HETATM	3578	O	HON	1138	37.977	45.274	53.726	1.00	41.75	O
HETATM	3579	O	HON	1139	10.511	41.610	30.508	1.00	54.06	O
HETATM	3580	O	HON	1140	21.928	44.651	36.769	1.00	27.65	O
HETATM	3581	O	HON	1141	9.657	38.390	31.085	1.00	36.52	O
HETATM	3582	O	HON	1142	35.556	55.905	31.455	1.00	33.05	O
HETATM	3583	O	HON	1143	52.337	31.433	47.975	1.00	42.15	O
HETATM	3584	O	HON	1144	32.915	38.699	23.494	1.00	40.84	O
HETATM	3585	O	HON	1145	29.548	21.469	24.434	1.00	44.50	O
HETATM	3586	O	HON	1146	26.181	34.331	29.823	1.00	34.71	O
HETATM	3587	O	HON	1147	39.069	5.943	33.085	1.00	53.70	O
HETATM	3588	O	HON	1148	34.970	24.222	52.427	1.00	40.12	O
HETATM	3589	O	HON	1149	59.825	24.478	43.880	1.00	40.98	O
HETATM	3590	O	HON	1150	28.412	33.531	47.673	1.00	44.44	O</

Figure 8-71

HETATM	3609	O	HOH	1173	26.042	53.508	19.228	1.00	35.35	O
HETATM	3610	O	HOH	1174	16.723	43.317	9.437	1.00	70.54	O
HETATM	3611	O	HOH	1175	11.039	27.202	31.989	1.00	35.23	O
HETATM	3612	O	HOH	1176	26.492	54.880	14.660	1.00	45.35	O
HETATM	3613	O	HOH	1177	48.739	5.603	40.080	1.00	46.72	O
HETATM	3614	O	HOH	1179	38.452	10.611	56.410	1.00	33.18	O
HETATM	3615	O	HOH	1180	25.173	41.020	50.981	1.00	37.80	O
HETATM	3616	O	HOH	1181	26.009	21.500	26.306	1.00	37.33	O
HETATM	3617	O	HOH	1185	32.901	61.354	32.974	1.00	47.36	O
HETATM	3618	O	HOH	1186	49.199	44.404	48.616	1.00	55.72	O
HETATM	3619	O	HOH	1187	28.401	31.064	46.621	1.00	25.46	O
HETATM	3620	O	HOH	1189	50.488	34.252	43.662	1.00	27.11	O
HETATM	3621	O	HOH	1190	25.015	38.231	32.413	1.00	46.20	O
HETATM	3622	O	HOH	1191	13.328	45.647	6.880	1.00	50.19	O
HETATM	3623	O	HOH	1192	9.102	28.582	30.815	1.00	28.84	O
HETATM	3624	O	HOH	1194	16.216	53.125	18.778	1.00	20.19	O
HETATM	3625	O	HOH	1195	48.924	37.778	50.511	1.00	41.81	O
HETATM	3626	O	HOH	1196	29.151	29.120	42.414	1.00	25.51	O
HETATM	3627	O	HOH	1197	10.760	56.327	24.871	1.00	25.61	O
HETATM	3628	O	HOH	1198	19.161	31.540	33.429	1.00	41.50	O
HETATM	3629	O	HOH	1201	31.584	19.545	39.778	1.00	41.14	O
HETATM	3630	O	HOH	1202	31.499	33.130	31.243	1.00	30.94	O
HETATM	3631	O	HOH	1203	33.475	31.251	32.729	1.00	30.16	O
HETATM	3632	O	HOH	1204	25.323	26.251	24.066	1.00	29.38	O
HETATM	3633	O	HOH	1205	18.912	50.780	14.345	1.00	28.88	O
HETATM	3634	O	HOH	1206	28.562	46.055	22.818	1.00	37.71	O
HETATM	3635	O	HOH	1207	31.212	15.396	37.505	1.00	38.29	O
HETATM	3636	O	HOH	1208	21.188	13.368	44.376	1.00	22.37	O
HETATM	3637	O	HOH	1209	17.682	38.715	10.160	1.00	31.02	O
HETATM	3638	O	HOH	1210	50.214	11.867	37.111	1.00	50.09	O
HETATM	3639	O	HOH	1212	28.768	41.646	47.276	1.00	22.25	O
HETATM	3640	O	HOH	1214	49.993	18.233	34.806	1.00	44.55	O
HETATM	3641	O	HOH	1215	32.815	34.522	46.504	1.00	35.13	O
HETATM	3642	O	HOH	1216	39.893	28.328	41.896	1.00	12.01	O
HETATM	3643	O	HOH	1217	15.338	26.949	28.916	1.00	11.70	O
HETATM	3644	O	HOH	1218	35.548	32.617	33.681	1.00	18.33	O
HETATM	3645	O	HOH	1219	39.368	28.656	34.414	1.00	16.49	O
HETATM	3646	O	HOH	1220	10.631	22.205	16.485	1.00	23.48	O
HETATM	3647	O	HOH	1221	38.404	33.931	29.548	1.00	20.31	O
HETATM	3648	O	HOH	1222	29.170	43.940	45.652	1.00	17.85	O
HETATM	3649	O	HOH	1223	16.493	28.977	30.383	1.00	19.55	O
HETATM	3650	O	HOH	1224	50.201	26.750	43.278	1.00	23.76	O
HETATM	3651	O	HOH	1225	38.642	25.017	49.298	1.00	24.48	O
HETATM	3652	O	HOH	1226	22.132	37.260	38.648	1.00	21.90	O
HETATM	3653	O	HOH	1227	39.985	27.256	49.971	1.00	19.31	O
HETATM	3654	O	HOH	1228	46.680	26.589	41.727	1.00	24.34	O
HETATM	3655	O	HOH	1229	45.783	30.693	47.582	1.00	25.33	O
HETATM	3656	O	HOH	1230	37.132	23.521	50.764	1.00	25.39	O
HETATM	3657	O	HOH	1231	37.666	45.416	31.269	1.00	22.37	O
HETATM	3658	O	HOH	1232	12.017	34.217	29.751	1.00	24.35	O
HETATM	3659	O	HOH	1233	26.995	45.967	27.617	1.00	23.52	O
HETATM	3660	O	HOH	1234	26.536	25.536	28.250	1.00	29.21	O
HETATM	3661	O	HOH	1235	25.412	37.399	29.161	1.00	27.51	O
HETATM	3662	O	HOH	1236	37.339	31.390	35.413	1.00	25.38	O
HETATM	3663	O	HOH	1237	49.870	32.179	49.678	1.00	25.92	O
HETATM	3664	O	HOH	1238	22.061	39.616	17.387	1.00	15.04	O
HETATM	3665	O	HOH	1239	14.228	24.366	29.787	1.00	22.47	O
HETATM	3666	O	HOH	1240	23.022	47.566	29.327	1.00	39.50	O
HETATM	3667	O	HOH	1241	21.098	32.679	17.559	1.00	35.09	O
HETATM	3668	O	HOH	1242	23.864	37.449	16.707	1.00	37.28	O

05000001 05000001

HETATM	3669	O	HOH	1243	32.934	17.639	38.491	1.00	30.00	
HETATM	3670	O	HOH	1244	30.081	39.275	47.475	1.00	27.25	
HETATM	3671	O	HOH	1245	40.219	10.507	54.210	1.00	42.36	
HETATM	3672	O	HOH	1246	20.198	57.839	14.584	1.00	26.12	
HETATM	3673	O	HOH	1247	22.701	31.034	19.118	1.00	26.32	
HETATM	3674	O	HOH	1248	50.529	25.000	51.117	1.00	16.36	
HETATM	3675	O	HOH	1249	27.308	27.122	38.575	1.00	29.98	
HETATM	3676	O	HOH	1250	41.664	46.630	31.018	1.00	29.42	
HETATM	3677	O	HOH	1251	34.271	34.271	44.099	1.00	31.98	
HETATM	3678	O	HOH	1252	28.946	26.204	44.341	1.00	51.94	
HETATM	3679	O	HOH	1253	26.643	43.795	23.560	1.00	23.03	
HETATM	3680	O	HOH	1254	52.894	25.886	44.095	1.00	33.52	
HETATM	3681	O	HOH	1255	42.339	26.613	55.952	1.00	36.97	
HETATM	3682	O	HOH	1256	48.804	2.432	50.876	1.00	36.59	
HETATM	3683	O	HOH	1257	51.244	18.531	40.805	1.00	33.51	
HETATM	3684	O	HOH	1260	49.903	39.828	48.137	1.00	44.77	
HETATM	3685	O	HOH	1261	45.720	4.638	32.384	1.00	54.41	
HETATM	3686	O	HOH	1262	32.871	29.567	30.088	1.00	39.72	
HETATM	3687	O	HOH	1263	25.890	51.315	23.775	1.00	37.61	
HETATM	3688	O	HOH	1264	11.550	26.049	31.905	1.00	33.45	
HETATM	3689	O	HOH	1266	10.689	31.547	31.432	1.00	47.94	
HETATM	3690	O	HOH	1269	26.086	-7.425	31.507	1.00	39.58	
HETATM	3691	O	HOH	1271	22.022	54.673	22.853	1.00	37.03	
HETATM	3692	O	HOH	1274	28.901	24.308	41.027	1.00	41.39	
HETATM	3693	O	HOH	1276	45.609	-2.697	31.603	1.00	49.62	
HETATM	3694	O	HOH	1277	9.649	26.708	34.475	1.00	36.02	
HETATM	3695	O	HOH	1279	21.970	8.818	36.303	1.00	45.69	
HETATM	3696	O	HOH	1280	7.956	56.039	27.031	1.00	55.41	
HETATM	3697	O	HOH	1281	15.342	17.005	12.561	1.00	55.13	
HETATM	3698	O	HOH	1284	12.862	44.437	3.810	1.00	49.95	
HETATM	3699	O	HOH	1286	34.675	64.010	47.159	1.00	47.97	
HETATM	3700	O	HOH	1287	41.049	11.857	30.681	1.00	29.94	
HETATM	3701	O	HOH	1288	34.457	19.302	55.855	1.00	47.88	
HETATM	3702	O	HOH	1289	28.546	31.433	28.564	1.00	47.71	
HETATM	3703	O	HOH	1291	33.220	60.645	39.548	1.00	52.03	
HETATM	3704	O	HOH	1292	30.910	54.312	27.471	1.00	48.06	
HETATM	3705	O	HOH	1293	23.058	27.656	32.358	1.00	45.02	
HETATM	3706	O	HOH	1294	28.377	27.872	37.772	1.00	37.72	
HETATM	3707	O	HOH	1295	17.851	13.033	47.051	1.00	31.43	
HETATM	3708	O	HOH	1297	22.435	24.151	33.420	1.00	39.38	
HETATM	3709	O	HOH	1298	29.292	20.833	37.423	1.00	52.78	
HETATM	3710	O	HOH	1299	26.196	40.554	47.655	1.00		

Figure 8-75

CONNECT 1119 1118 1120 1122
 CONNECT 1120 1119 1121 1126
 CONNECT 1121 1120
 CONNECT 1122 1119 1123
 CONNECT 1123 1122 1124
 CONNECT 1124 1123 1125
 CONNECT 1125 1124
 CONNECT 1126 1120 1127
 CONNECT 1177 1176 1874
 CONNECT 1208 1207 1209 1215
 CONNECT 1215 1208 1216
 CONNECT 1216 1215 1217 1219
 CONNECT 1217 1216 1218 1223
 CONNECT 1218 1217
 CONNECT 1219 1216 1220
 CONNECT 1220 1219 1221
 CONNECT 1221 1220 1222
 CONNECT 1222 1221
 CONNECT 1223 1217 1224
 CONNECT 1874 1177 1873
 CONNECT 1987 1986 1988 1997
 CONNECT 1997 1987 1998
 CONNECT 1998 1997 1999 2001
 CONNECT 1999 1998 2000 2005
 CONNECT 2000 1999
 CONNECT 2001 1998 2002
 CONNECT 2002 2001 2003
 CONNECT 2003 2002 2004
 CONNECT 2004 2003
 CONNECT 2005 1999 2006
 CONNECT 2065 2064 2066 2067
 CONNECT 2067 2065 2068
 CONNECT 2068 2067 2069 2071
 CONNECT 2069 2068 2070 2075
 CONNECT 2070 2069
 CONNECT 2071 2068 2072
 CONNECT 2072 2071 2073
 CONNECT 2073 2072 2074
 CONNECT 2074 2073
 CONNECT 2075 2069 2076
 CONNECT 2154 2153 2155 2161
 CONNECT 2161 2154 2162
 CONNECT 2162 2161 2163 2165
 CONNECT 2163 2162 2164 2169
 CONNECT 2164 2163
 CONNECT 2165 2162 2166
 CONNECT 2166 2165 2167
 CONNECT 2167 2166 2168
 CONNECT 2168 2167
 CONNECT 2169 2163 2170
 CONNECT 2813 2812 2814 2823
 CONNECT 2823 2813 2824
 CONNECT 2824 2823 2825 2827
 CONNECT 2825 2824 2826 2831
 CONNECT 2826 2825
 CONNECT 2827 2824 2828
 CONNECT 2828 2827 2829
 CONNECT 2829 2828 2830
 CONNECT 2830 2829
 CONNECT 2831 2825 2832

Figure 8-76

CONNECT 2891 2890 2892 2893
 CONNECT 2893 2891 2894
 CONNECT 2894 2893 2895 2897
 CONNECT 2895 2894 2896 2901
 CONNECT 2896 2895
 CONNECT 2897 2894 2898
 CONNECT 2898 2897 2899
 CONNECT 2899 2898 2900
 CONNECT 2900 2899
 CONNECT 2901 2895 2902
 CONNECT 2983 2982 2984 2990
 CONNECT 2990 2983 2991
 CONNECT 2991 2990 2992 2994
 CONNECT 2992 2991 2993 2998
 CONNECT 2993 2992
 CONNECT 2994 2991 2995
 CONNECT 2995 2994 2996
 CONNECT 2996 2995 2997
 CONNECT 2997 2996
 CONNECT 2998 2992 2999
 CONNECT 3522 3541 3542
 CONNECT 3524 3544 3545 3546
 CONNECT 3525 3526
 CONNECT 3526 3525 3527
 CONNECT 3527 3526 3528
 CONNECT 3528 3527 3530
 CONNECT 3529 3530 3531
 CONNECT 3530 3528 3529
 CONNECT 3531 3529 3533
 CONNECT 3532 3533 3534
 CONNECT 3533 3531 3532
 CONNECT 3534 3532 3536
 CONNECT 3535 3536 3537
 CONNECT 3536 3534 3535
 CONNECT 3537 3535 3539
 CONNECT 3538 3539 3540
 CONNECT 3539 3537 3538
 CONNECT 3540 3538
 CONNECT 3541 3522
 CONNECT 3542 3522
 CONNECT 3544 3524
 CONNECT 3545 3524
 CONNECT 3546 3524
 MASTER 301 0 16 19 8 0 0 27 3796 4 147 84
 END

0050007.06290

Figure 9

HETATM	4233	O	HOH	1021	36.890	32.430	27.721	1.00	24.58
HETATM	4234	O	HOH	1021	35.049	30.934	29.322	1.00	27.97
HETATM	4236	O	HOH	1022	31.347	42.865	52.839	1.00	31.45
HETATM	4238	O	HOH	1023	44.819	10.251	32.056	1.00	31.08
HETATM	4239	O	HOH	1023	47.508	7.695	33.365	1.00	35.15
HETATM	4240	O	HOH	1023	48.695	9.256	30.957	1.00	29.22

HETATM	4233	O	HOH	1021	36.890	32.430	27.721	1.00	24.58
HETATM	4234	O	HOH	1022	35.049	30.934	29.322	1.00	27.97
HETATM	4236	O	HOH	1023	31.347	42.865	52.839	1.00	31.45
HETATM	4238	O	HOH	1024	44.819	10.251	32.056	1.00	31.08
HETATM	4239	O	HOH	1025	47.508	7.695	33.365	1.00	35.15
HETATM	4240	O	HOH	1026	48.695	9.256	30.957	1.00	29.22


LINK	CA	CA	1021	O	HOH	1024
LINK	CA	CA	1021	O	HOH	1025
LINK	CA	CA	1023	O	HOH	1027
LINK	CA	CA	1023	O	HOH	1028
LINK	CA	CA	1023	O	HOH	1029

Figure 10

A. General model



B. Embodiment of the ligand head as an oligopeptide



Declaration and Power of Attorney

Page 2

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wiekowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershih (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to

John P. White, Esq. Reg. No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Full name of sole or
first joint inventor Wayne A. Hendrickson

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) Xuliang Jiang

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) Keith E. Langley

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) Rashid Syed

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) Yueh-Rong Ann Hsu

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) _____

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

SEQUENCE LISTING

<110> Hendrickson, Wayne A
Jiang, Xuliang
Langley, Keith E
Syed, Rashid
Hsu, Yueh-Rong Ann

<120> CONJUGATED LIGANDS FOR THE STIMULATION OF BLOOD CELL
PROLIFERATION BY EFFECTING DIMERIZATION OF THE RECEPTOR
FOR STEM CELL FACTOR

<130> 50950/JPW/EMW

<140> NOT YET KNOWN

<141> 2000-06-29

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 141

<212> PRT

<213> human

<400> 1

Glu	Gly	Ile	Cys	Arg	Asn	Arg	Val	Thr	Asn	Asn	Val	Lys	Asp	Val	Thr
1					5					10				15	

Lys	Leu	Val	Ala	Asn	Leu	Pro	Lys	Asp	Tyr	Met	Ile	Thr	Leu	Lys	Tyr
			20					25					30		

Val	Pro	Gly	Met	Asp	Val	Leu	Pro	Ser	His	Gln	Trp	Ile	Ser	Glu	Met
		35						40					45		

Val	Val	Gln	Leu	Ser	Asp	Ser	Leu	Thr	Asp	Leu	Leu	Asp	Lys	Phe	Ser
	50					55						60			

Asn	Ile	Ser	Glu	Gly	Leu	Ser	Asn	Tyr	Ser	Ile	Ile	Asp	Lys	Leu	Val
65					70					75				80	

Asn	Ile	Val	Asp	Asp	Leu	Val	Glu	Cys	Val	Lys	Glu	Asn	Ser	Ser	Lys
				85						90				95	

Asp	Leu	Lys	Lys	Ser	Phe	Lys	Ser	Pro	Glu	Pro	Arg	Leu	Phe	Thr	Pro
	100							105					110		

Glu Glu Phe Phe Arg Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp
 115 120 125

Phe Val Val Ala Ser Glu Thr Ser Asp Cys Val Val Ser
 130 135 140

<210> 2
 <211> 150
 <212> PRT
 <213> human

<400> 2
 Glu Glu Val Ser Glu Tyr Cys Ser His Met Ile Gly Ser Gly His Leu
 1 5 10 15

Gln Ser Leu Gln Arg Leu Ile Asp Ser Gln Met Glu Thr Ser Cys Gln
 20 25 30

Ile Thr Phe Glu Phe Val Asp Gln Glu Gln Leu Lys Asp Pro Val Cys
 35 40 45

Tyr Leu Lys Lys Ala Phe Leu Leu Val Gln Asp Ile Met Glu Asp Thr
 50 55 60

Met Arg Phe Arg Asp Asn Thr Pro Asn Ala Ile Ala Ile Val Gln Leu
 65 70 75 80

Gln Glu Leu Ser Leu Arg Leu Lys Ser Cys Phe Thr Lys Asp Tyr Glu
 85 90 95

Glu His Asp Lys Ala Cys Val Arg Thr Phe Tyr Glu Thr Pro Leu Gln
 100 105 110

Leu Leu Glu Lys Val Lys Asn Val Phe Asn Glu Thr Lys Asn Leu Leu
 115 120 125

Asp Lys Asp Trp Asn Ile Phe Ser Lys Asn Cys Asn Asn Ser Phe Ala
 130 135 140

Glu Cys Ser Ser Gln Gly
 145 150

<210> 3
 <211> 129
 <212> PRT
 <213> human

Gly Leu Arg Gly Ser Leu Thr Lys Ile Lys Gly Pro Leu Thr Met Met
65 70 75 80

Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser Cys
85 90 95

Ala Thr Gln Ile Ile Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys Asp
100 105 110

Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu
115 120 125

<210> 5

<211> 132

<212> PRT

<213> human

<400> 5

Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15

Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30

Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Tyr Met Pro Lys Lys
35 40 45

Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro
50 55 60

Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg
65 70 75 80

Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys
85 90 95

Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr
100 105 110

Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile
115 120 125

Ser Thr Leu Thr
130

<210> 6

Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys Leu Val
65 70 75 80

Asn Ile Val Asp Asp Leu Val Glu Cys Val Lys Glu Asn Ser Ser Lys
85 90 95

Asp Leu Lys Lys Ser Phe Lys Ser Pro Glu Pro Arg Leu Phe Thr Pro
100 105 110

Glu Glu Phe Phe Arg Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp
115 120 125

Phe Val Val Ala Ser Glu Thr Ser Asp Cys Val Val Ser Ser Thr Leu
130 135 140

Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu
145 150 155 160

Pro Pro Val Ala

<210> 8

<211> 164

<212> PRT

<213> MOUSE

<400> 8

Lys Glu Ile Cys Gly Asn Pro Val Thr Asp Asn Val Lys Asp Ile Thr
1 5 10 15

Lys Leu Val Ala Asn Leu Pro Asn Asp Tyr Met Ile Thr Leu Asn Tyr
20 25 30

Val Ala Gly Met Asp Val Leu Pro Ser His Cys Trp Leu Arg Asp Met
35 40 45

Val Ile Gln Leu Ser Leu Ser Leu Thr Thr Leu Leu Asp Lys Phe Ser
50 55 60

Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys Leu Gly
65 70 75 80

Lys Ile Val Asp Asp Leu Val Leu Cys Met Glu Glu Asn Ala Pro Lys
85 90 95

Asn Ile Lys Glu Ser Pro Lys Arg Pro Glu Thr Arg Ser Phe Thr Pro
100 105 110

Glu Glu Phe Phe Ser Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp
 115 120 125

Phe Met Val Ala Ser Asp Thr Ser Asp Cys Val Leu Ser Ser Thr Leu
 130 135 140

Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu
 145 150 155 160

Pro Pro Val Ala

<210> 9
 <211> 164
 <212> PRT
 <213> rat

<400> 9
 Gln Glu Ile Cys Arg Asn Pro Val Thr Asp Asn Val Lys Asp Ile Thr
 1 5 10 15

Lys Leu Val Ala Asn Leu Pro Asn Asp Tyr Met Ile Thr Leu Asn Tyr
 20 25 30

Val Ala Gly Met Asp Val Leu Pro Ser His Cys Trp Leu Arg Asp Met
 35 40 45

Val Thr His Leu Ser Val Ser Leu Thr Thr Leu Leu Asp Lys Phe Ser
 50 55 60

Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys Leu Gly
 65 70 75 80

Lys Ile Val Asp Asp Leu Val Ala Cys Met Glu Glu Asn Ala Pro Lys
 85 90 95

Asn Val Lys Glu Ser Leu Lys Lys Pro Glu Thr Arg Asn Phe Thr Pro
 100 105 110

Glu Glu Phe Phe Ser Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp
 115 120 125

Phe Met Val Ala Ser Asp Thr Ser Asp Cys Val Leu Ser Ser Thr Leu
 130 135 140

Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu

145 150 155 160

Pro Pro Val Ala

<210> 10
<211> 165
<212> PRT
<213> DOG

<400> 10
Lys Gly Ile Cys Gly Lys Arg Val Thr Asp Asn Val Lys Asp Val Thr
1 5 10 15
Lys Leu Val Ala Asn Leu Pro Lys Asp Tyr Lys Ile Ala Leu Lys Tyr
20 25 30
Val Pro Gly Met Asp Val Leu Pro Ser His Cys Trp Ile Ser Val Met
35 40 45
Val Glu Gln Leu Ser Val Ser Leu Thr Asp Leu Leu Asp Lys Phe Ser
50 55 60
Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys Leu Val
65 70 75 80
Lys Ile Val Asp Asp Leu Val Glu Cys Thr Glu Gly Tyr Ser Phe Glu
85 90 95
Asn Val Lys Lys Ala Pro Lys Ser Pro Glu Leu Arg Leu Phe Thr Pro
100 105 110
Glu Glu Phe Phe Arg Ile Phe Asn Arg Ser Ile Asp Ala Phe Lys Asp
115 120 125
Phe Glu Thr Val Ala Ser Lys Ser Ser Glu Cys Val Val Ser Ser Thr
130 135 140
Leu Ser Pro Asp Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met
145 150 155 160
Leu Pro Pro Val Ala
165